annual report sciencele global healthcare company performance summary aer aer group turnover cer new specialty medicine cer aer aer total operating profit cer adjust operating profit cer aer aer total earning share cer adjust earning share cer major pipeline dividend access pharmaceutical approval medicine index industry dow jones sustainability index content strategic report business model board role responsibilitie financial statement chairman statement board activity principal decision glaxosmithkline plc prepare ceos statement purpose value culture gaap financial performance board approach engagement investor information longterm prioritie board performance culture board committee information quarterly trend key performance indicator board committee report fiveyear record industry trend section statement product development pipeline stakeholder engagement director report product competition innovation intellectual property remuneration report performance principal risk uncertaintie trust chairmans annual statement share capital share price risk management annual report remuneration dividend group financial review remuneration policy summary financial calendar annual general meeting corporate governance financial statement tax information shareholder chairmans governance statement director statement shareholder service contact board responsibilitie law regulation corporate executive team independent auditor report group company board architecture financial statement glossary term note financial statement cautionary statement inside cover document cautionary statement forwardlooke statement nonifrs measure use number adjust nonifrs measure report performance business total report result represent group overall performance ifrs adjust result proforma growth rate nonifrs measure consider addition substitute superior information present accordance ifrs adjust result nonifrs measure define page reconciliation near ifrs measure page strategic report governance remuneration financial statement investor information business model day help improve health million people world discover develop manufacture innovative medicine vaccine consumer healthcare product operation span value chain identify performance deliver investing effectively research develop testing ground break business people execute competitively discovery regulatory approval manufacturing ability launch new product successfully commercialisation remain resilient grow sale exist portfolio key challenging year world agile maintain commercial success focus purpose strategic longterm priority trust critical success responsible central success people expert company commit use science technology science technology regulation intellectual property address health need product affordable commercialisation collaborate worldleading available modern employer public expert form strategic partnership complement commitment support trust priority cover broad exist capability range environmental social governance esg aspect commitment design help respond esg purpose strategy challenge opportunity industry society purpose improve quality human life broadly contribute sustainable help people feel well live long guide development goal particularly goal ensure healthy life action key delivery strategy promote wellbeing bring differentiate highquality need healthcare product people possible prevent value create treat disease keep people scientific delivering purpose great contribution technical knowhow talented people improve health people world include deliver billion pack medicine longterm priorities million vaccine dose billion consumer priority innovation performance trust healthcare product underpin ambition build purpose performance drive culture align value patient shareholder capital allocation focus transparency respect integrity expectation framework invest business provide shareholder courage accountability development teamwork return pay dividend share deliver billion free cash flow innovation critical improve health create financial value total expenditure billion positive contribution community turnover increase aer operate employ people cer previous year adjust basis country work directly supplier expenditure billion turnover higher pay billion corporation tax aer high cer proforma basis pay significant business employment adjust expenditure grow cer compare relate taxis aim modern employer offer broad range employee benefit include preventative pharmaceutical vaccine focus science healthcare service able attract related immune system human genetic advance retain good people technology consumer healthcare leverage scientific expertise deep consumer insight create healthcare product meet consumer demand researchbase healthcare company rely intellectual property protection help ensure reasonable return investment continue research develop new innovative medicine gsk annual report business model continue prepare future create new company year achieve important milestone early consistent strategic priority launch development organisation previous announcement start twoyear programme enable effective allocate prepare gsk separation new lead company budget share technical scientific expertise deliver new gsk new biopharma company focus specialty pipeline regardless modality medicine vaccine approach focus programme seek improve science relate immune system use human capability create efficiency global support genetic new technology new leader consumer function continue simplify focus manufacturing healthcare categoryleading power brand innovation network ensure supply chain ready launch new base science consumer insight specialty medicine rationalise portfolio track separation new standalone biopharma divestment consumer healthcare company new consumer healthcare company programme programme unique catalyst separation support build key technology infrastructure reset capability cost base company expertise necessary operate standalone company help support delivery significant value creation believe increase investment pipeline new opportunity new gsk new consumer product effective implementation twoyear healthcare programme set new company strong new gsk clear opportunity drive common foundation future performance approach science relate immune system financial benefit cost report associate converge pharmaceutical vaccine programme set page capital allocation capital allocation framework key priority capital invest business pipeline include business development vaccine capacity innovation new product improve shareholder return dividend performance cash target cover generation return dividend growth trust strict discipline return gsk annual report strategic report governance remuneration financial statement investor information chairmans statement extraordinary challenging year continue progress strategy creation new company covid pandemic dominate aspect life importance business act responsibly central business gsk exception impact feel increasingly broad range stakeholder view operationally people face huge company global health challenge deliver financial guidance year important element gsk trust priority board continue progress strategy please gsk top access medicine index environmental social governance esg testament leadership emma increasingly focus investor stakeholder management team navigate company board fully support ambitious new environmental year ensure people gsk remain focused goal climate nature new inclusion diversity purpose delivery performance target include race ethnicity management strategy announce board please continue progress board support management effort contribute company strategic goal covid include progression potential vaccine disappointing translate improved total therapeutic treatment company world lead shareholder return tsr progress reinforce infectious disease portfolio scientific expertise gsk board confidence direction company opportunity contribute meaningfully current eventual split year new company biopharma response pandemic work global institution consumer healthcare combine meaningful support well longterm preparedness planning improvement operating performance onwards provide significant opportunity create value shareholder board change board continue adapt support company strengthen biopharma pipeline remain company priority ensure effective delivery specifically new number priority continue despite committee establish oversee separation pandemic significant approval pivotal trial transformation company corporate start pipeline consist potential medicine responsibility committee take expand remit vaccine focus infectious disease oncology line great focus esg science committee immunemediate disease number asset continue provide excellent oversight direction significant launch year strategy potential change medical practice provide material value company board scientific committee charles bancroft joined board nonexecutive closely involved hal team pipeline director charlie succeed judy lewent chair audit risk committee completion annual report operational financial performance resilient cycle judy steps board agm year importantly see evidence significantly like thank enormous contribution gsk improve commercial capability execution year grateful lynn elsenhans agree drive good expansion key growth product stay board year ensure management maintain strong focus cost continuity important work corporate responsibility control cash generation pipeline committee investment continue shortterm disruption adult vaccine business reflect earning finally like thank gsk employee partner guidance year shareholder customer support unprecedented year gsk capital allocation framework focus invest pipeline new product launch vaccine supply capacity discipline business development pay share shareholder expect intend implement new distribution policy dividend year sir jonathan symond separate new company ensure chairman business competitive right capital structure capacity invest deliver growth shareholder return overall expect aggregate distribution gsk new company lower share currently pay gsk annual report ceo statement innovation healthcare impact heart purpose significant progress continue build highvalue biopharma pipeline focus vaccine specialty medicine remarkable year despite challenge continue delivery year progress gsk proud way innovation healthcare impact heart purpose company respond support patient healthcare strengthen pipeline remain priority system people deliver good financial significant progress continue performance advance strategic transformation build highvalue biopharma pipeline focus vaccine speciality medicine harness science relate progress mean high confidence ability immune system use human genetic launch new competitive standalone biopharma advanced technology consumer healthcare company achieve meaningful global impact health opportunity major approval medicine create significant value shareholder respiratory oncology hiv immunoinflammation remarkable achievement include zejula expand growth sale label ovarian cancer make potentially available group sale grow actual exchange rate aer women cabenuva world longacte constant exchange rate cer billion injectable treatment hiv allow patient testament increase focus continue injection year instead take daily pill place improve commercial execution pivotal trial start year include new speciality product drive growth sale vaccine candidate rsv virus high unmet need billion aer cer group cause thousand death hospitalisation innovative product account half year successful vaccine play significant role pharmaceutical sale ease burden start late stage trial respiratory see strong growth nucala biologic year include new longacte asthma medicine asthma trelegy inhaler asthma copd successful give month hiv new twodrug regimen dovato juluca testament patient heart double sale million oncology portfolio overall asset late stage continue grow zejula ovarian cancer significantly development transformational grow market share launch blenrep heavily patient product launch pretreate multiple myeloma patient shingrix successful believe datum positive potential vaccine shingle continue grow sale significant commercially billion despite significant disruption adult year execute business development vaccination covid pandemic see deal strengthen capability acquisition new strong consumer health performance sale antibody mrna genetic platform technologies cer proforma basis exclude brand divest review reflect underlie strength brand continue use science contribute covid portfolio response multiple front course disappoint delay vaccine develop sanofi strong performance growth driver discipline continue progress cost control allow deliver guidance year inhouse externallypartnere therapeutic importantly set pandemic total earning share look ahead potential need generation aer cer adjust covid vaccine use emerge variant earning share aer booster delight recent collaboration cer curevac research develop mrna vaccine strong cash generation free cash flow include covid billion declare dividend share expect pay gsk annual report strategic report governance remuneration financial statement investor information ceo statement continue separation preparation continue work partner longterm remain firmly track intention separate urgent global health need follow positive datum new exciting company year new gsk single dose treatment vivax strain malaria biopharma new world leader consumer healthcare file alongside partner medicine malaria venture mmv use child population disproportionately meet year target separation affect disease license candidate programme integration consumer vaccine bill melinda gates research institute substantially complete second year twoyear continue development potential use lowincome transformation investment pipeline country high burden please successfully launch new product sustain commitment important work recognise longterm competitive growth shortterm disruption access medicine index pandemic vaccine business reflect financial top seventh time row guidance set continue expect meaningful improvement performance onwards people culture people show remarkable dedication agility building trust resilience year unprecedented circumstance build trust stakeholder addition deliver include thousand employee sustainable financial return critical pandemic continue work manufacturing facility highlight need business operate responsible pandemic ensure vital medicine vaccine way life science company ensure consumer product continue reach patient consumer widespread access medicine effort mean despite challenge enter investor interest environmental social governance esg pipeline strong commercial execution issue increase significantly year believe sharp confidence high ability deliver need transition net zero economy want sustainable longterm growth post separation play protect restore people planet health november set ambitious industry lead want thank fantastic people partner environmental target netzero impact climate succeed count change netpositive impact nature prepare exciting future gsk firmly believe value inclusion diversity set aspirational target proportion ethnically diverse leader level reset gender target aim increase female representation level globally focus improve diversity clinical trial emma walmsley ensure represent medicine safe chief executive officer effective realworld patient communities gsk annual report financial performance operating performance report consumer healthcare sale grow aer cer million year largely drive turnover inclusion pfizer portfolio partly offset brand divestedunder review proforma basis sale decline proforma growth growth growth cer grow cer exclude brand divestedunder cer cer review reflect underlie strength brand pharmaceutical portfolio category strong growth ecommerce vaccine successful execution meeting evolve consumer demand consumer healthcare result pandemic corporate operating profit unallocate turnover total operating profit million compare group turnover million total operating margin reflect profit disposal horlick financial result consumer healthcare brand resultant sale share hindustan unilever increase income asset proforma disposal partly offset high remeasurement growth growth charge contingent consideration liability cer cer turnover adjust operate profit million low total operating profit aer high cer turnover increase total earning share cer proforma adjust operating profit decline adjusted operating profit primarily reflect adverse impact reduction adjust earning sale vaccine result covid pandemic share investment investment promotional product net cash operating support particularly new launch vaccine hiv activity respiratory partly offset effective cost control free cash flow include reduce promotional variable spending proforma cer growth rate calculate equivalent seven business result covid lockdown month pfizer consumer healthcare business result report pfizer include comparative period continue benefit restructuring pharmaceutical information consumer healthcare earning share turnover total eps compare strong sale performance key growth driver hiv increase eps primarily reflect net profit disposal respiratory oncology consumer healthcare offset horlick consumer healthcare brand disruption covid adult vaccination increase income asset disposal partly offset high group turnover million year aer remeasurement charge contingent consideration cer proforma basis group turnover liability high major restructuring charge oneoff cer cer exclude impact divestment benefit increase share tax profit vaccine brand divest review consumer associate innoviva healthcare adjust eps compare pharmaceutical turnover year million aer cer cer increase adjust aer cer respiratory sale aer operating profit reduction primarily result high cer million growth trelegy nucala relvar noncontrolle interest allocation consumer healthcare breo hiv sale flat aer cer million profit high investment reduce share growth juluca dovato partly offset decline tax profit associate result nonrecurre income tivicay triumeq sale establish pharmaceutical tax benefit innoviva decline aer cer million cash flow vaccine turnover decline aer cer net cash inflow operating activity year million primarily drive adverse impact covid million million free cash flow pandemic hepatitis vaccine dtpacontaine vaccine million year million synflorix bexsero divestment rabipur increase free cash flow primarily reflect increase encepur decline partly offset high sale proceed disposal intangible asset beneficial timing influenza vaccine region shingrix growth payment return rebate reduce legal payment europe china strong improved operating profit partly offset high dividend performance cervarix china noncontrolle interest increase trade receivables increase tax payment include tax disposal adverse exchange impact gsk annual report strategic report governance remuneration financial statement investor information financial performance continue total adjust result total report result represent group overall gsk encourage investor analyst rely performance single financial measure review gsk annual report include financial statement note entirety gsk use number adjust nonifrs measure report performance business adjust result gsk undertaking number boardapprove major nonifrs measure consider addition restructure programme response significant change substitute superior information present group trading environment overall strategy accordance ifrs full definition follow material acquisition cost cash noncash programme provide individual element gsk believe adjust result consider approve meet accounting recognition criterion total result provide investor analyst stakeholder helpful complementary information result charge incur number year understand well financial performance position follow initiation major restructure programme group period period allow group gsk report result year end december performance easily compare majority include month result pfizer consumer peer company measure healthcare business compare month management planning reporting purpose proforma growth rate cer calculate directly comparable similarly describe measure include equivalent seven month result period company july pfizer consumer healthcare business fully describe divestment intangible intangible significant total asset asset major transaction legal separation adjust adjust item result amortisation impairment restructure relate item cost result turnover cost sale gross profit sell general administration research development royalty income operating incomeexpense operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share intangible asset amortisation impairment divestment significant legal item amortisation impairment intangible asset goodwill proceed cost disposal associate product exclude computer software business significant legal charge net insurance recovery expense settlement litigation major restructure government investigation operate income major restructuring cost include impairment tangible royalty income item asset computer software specific boardapproved programme structural significant scale separation cost cost individual relate project exceed million additional cost prepare consumer healthcare include integration cost follow material acquisition separation transactionrelate transactionrelated accounting adjustment relate significant acquisition gsk annual report financial performance continue adjust result proforma growth growth turnover turnover cer cer turnover cost sale gross profit sell general administration research development royalty income operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share perform operating profit adjust operate profit million low cost sale aer high cer turnover increase adjust cost sale percentage turnover cer adjust operate margin flat aer percentage point low cer compare percentage point low aer percentage point proforma basis adjust cost sale low cer basis proforma basis percentage turnover percentage point adjust operating profit low cer turnover low cer compare reflect decrease cer adjust proforma operate favourable product mix pharmaceutical margin percentage point low cer contribution restructure integration saving partly basis offset adverse product mix vaccine continue adverse pricing pressure pharmaceutical reduction proforma adjust operating profit reflect adverse impact reduction sale vaccine sell general administration investment continue price pressure investment adjust sga cost percentage turnover promotional product support particularly new launch percentage point low aer offset reduce promotional variable spending percentage point low cer basis proforma basis oneoff benefit restructure postretirement benefit adjust sga cost percentage turnover continue benefit restructure tight control percentage point low cer compare ongoing cost growth adjust sga cost flat aer tax grow cer proforma basis cost reduce cer tax adjust profit amount million reflect benefit restructuring include oneoff represent effective adjusted tax rate benefit restructure postretirement benefit reduce reflect impact settlement number variable spending business tight open issue tax authority cancellation control ongoing cost partly offset increase investment government reduction corporation tax rate promotional product support noncontrolle interest research development allocation adjust earning noncontrolle interest adjust expenditure million amount million million increase turnover high aer high cer allocation primarily reflect increase allocation proforma basis adjust expenditure grow consumer healthcare profit cer primarily drive significant increase investment earning share oncology progression covid treatment adjust eps compare programme partly offset reduction aer cer cer increase adjusted investment research specialty primary operating profit reduction primarily result high care programme efficiency saving noncontrolle interest allocation consumer healthcare implementation separation preparation restructuring profit reduce share tax profit associate programme reduction variable spending result nonrecurre income tax benefit innoviva gsk annual report strategic report governance remuneration financial statement investor information longterm priority believe gsk longterm priority create last value patient consumer shareholder despite challenge operating environment deliver resilient performance strategic objective remain track innovation performance trust invest scientific technical deliver growth invest responsible company excellence develop launch effectively business commit use science pipeline new product develop people technology address health meet need patient execute competitively needs product payer consumer affordable available modern employer objective objective objective deliver innovation sale excellent prioritise spending deliver growth continue deliver ontime infull supply commercial supply chain return investment product execution successful consumer healthcare build reputation focus innovation accelerate strengthen pipeline integration include drive growth deliver progress trust commitment potential approval expect deliver synergy deliver capability building specialty pharmaceutical deliver twoyear programme prepare gsk separation new company progress progress progress strong performance new innovation strong sale performance key growth sector leading position esg index include shingrix trelegy juluca dovato drivers hiv respiratory oncology include access medicine zejula consumer healthcare reflect index major regulatory approval include resource focus therapy area market despite pandemic hiv oncology respiratory brand great potential able maintain supply extend indication portfolio advanced consumer healthcare pharmaceutical vaccine consumer include shingrix bexsero trelegy integration track million healthcare product continue ellipta benlysta annual cost saving manufacturing significant disruption accelerate pipeline pivotal billion divestment proceed achieve fda ema approve paediatric study start asset advanced specialty medicine capability dolutegravir latestage development new hire oncology join global effort develop covid establish multiple partnership programme separate gsk solution support partner develop covid solution include lead business remain track set ambitious new environmental curevac develop generation mrna sustainability goal climate nature covid vaccine vir biotechnology introduce allemployee mandatory therapeutic antibody treatment inclusion diversity training strengthen capability business development deal firstmarket launch consumer healthcare priority objective priority objective priority objective deliver innovation sale excellent continue prioritise spending deliver continue deliver ontime infull supply commercial supply chain growth return investment product execution oncology hiv vaccine continue deliver twoyear programme improve manager capability motivate accelerate strengthen pipeline prepare gsk separation focus develop care people robust commercial input include new lead company continue deliver progress trust business development build strong diverse workforce commitment new lead company culture creation new lead company continue focus performance drive remain firmly purpose lead value base track cultural change range indicator board receive regular update page principal risk principal risk patient safety product quality financial control report antibribery corruption commercial practice price nonpromotional engagement privacy research practice environment health safety environmental sustainability information security supply continuity transformation risk management framework design support longterm priority page gsk annual report culture building strong purpose performance culture inspire people power delivery longterm priority people inspire purpose help people live work pandemic make feel well live long purpose performance progress transformation programme future ready culture underpin value patient focus respect bring change personal challenge transparency integrity creation employee support period ensure new lead company critical focus employee health wellbeing service fully performance drive remain firmly accessible purpose lead value base pandemic mean flexible track cultural change range indicator get work support implement focus embed culture prioritise innovation new principle employee carry officebased work competitive edge speed agility deliver growth work place way enable orientated performance employee trust include perform well base role team personal pride purpose embed value expectation circumstance principle performance choice accountability courage development teamwork anchor drive individual collective performance progress modern employer create flexibility employee perform work check health culture range indicator make good progress addition company respect people challenging year survey see high core take pride provide access medicine response rate date main measure culture vaccine consumer product opportunity employee engagement report high score obligation build inclusive culture internally inception survey increase force good improve diversity inclusion survey improvement society focus building inclusive innovation score average performance culture include inclusion training employee alongside score show large overall improvement work evolve policy process practice question average score employee set new aspirational target gender trust score strongly average race ethnicity way work covid leader play crucial role know pandemic lead positive change culture rolemodel culture big driver close quarter employee move remote culture change continue build expertise senior work quarter continue work leader new appointment leader essential site ensure medicine vaccine everyday effectiveness global manager population healthcare product reach million patient measure annual feedback tool consumer need period year see continue improvement manager see deep connection purpose great focus score manager see highly work matter deliver priority dynamic effective people manage team move pace clear accountabilitie great connectivity care continue focus positive culture ambition long term gsk annual report strategic report governance remuneration financial statement investor information key performance indicator track progress longterm priority operate key performance indicator measure performance group level business operate key performance indicator kpi review track operating kpi internally regularly corporate executive team board provide performance datum report externally employee update progress commercial sensitivity publish datum quarter performance system align employee bonus operating kpis indicate use number adjust relevant subset indicator remuneration noninternational financial reporting standard ifrs policy reward performance executive measure report business performance describe include measure link kpi page page include adjust result free cash flow cer growth rate innovation innovation sale pharmaceutical vaccine sale product launch year bna bna consumer healthcare sale product new market year total sale pipeline value progress value product pipeline milestone achieve performance group turnover aer cer profit total operating profit aer cer adjusted operating profit aer cer total operate margin adjust operate margin free cash flow market share market share relation competitor talent succession plan key role talented employee key role succession plan place trust employee feedback employee engagement score global employee survey supply service level percentage order deliver ontime infull corporate reputation reputation index stakeholder inform public measure globally market link executive lti awards bonus page comparative information reflect sale product meet definition report externally commercial sensitivity gsk annual report industry trend operate dynamic environment shape fastchange interdependent global trend accelerate covid pandemic continue respond change environment advance strategy longterm prioritie global economy significantly affect covid covid pandemic underline centrality pandemic year economic uncertainty health security stability prosperity nation continue january global economy forecast need strengthen approach prevent identify grow impact covid containment manage future pandemic industry measure stall economy country engage key partner consider work collectively global economy face deep recession develop sustainable solution enhance pandemic preparedness strengthen global health security overall investment covid solution healthcare system economic support national lockdown global healthcare market significant longterm effect global economy government finance fiscal challenge likely global healthcare market grow year last impact national healthcare budget market worldwide pharmaceutical sale total billion outofpocket patient payment personal budget september north america remain pandemic healthcare industry centre stage large pharmaceutical market share global sale demonstrate vital role powerful force good europe represent china second large discover develop supply essential medicine individual country pharmaceutical sale represent vaccine consumer healthcare product need global sale global vaccine sale remain flat rapid solution pandemic prompt unprecedented approximately billion global consumer technological acceleration collaboration healthcare market estimate value company government regulator international billion organisation mobilise deliver novel product speed prescription medicine consumer product prove largely regulatory process scale manufacturing capacity resilient economic effect pandemic common covid dominate people live discussion trend stockpile issue longterm prescription safe effective innovation particularly vaccine dramatic increase purchase follow fall rise high public agenda industry unite demand drive few consultation lockdown common commitment apply high level rigour vaccine market impact significantly safety standard potential covidrelated solution global vaccination rate fall sharply patient unable pandemic raise question affordability visit healthcare professional rate recover lockdown equality access healthcare demand ease middle year decline pandemic license covid vaccine medicine condition worsen commentator predict widely available multistakeholder organisation economic recession suppress pharmaceutical growth covax critical help navigate challenge potential country private fund underpin significant government look secure access citizen proportion healthcare cost ensure global access pressure government global trend opportunity challenge seek domestic healthcare supply chain particularly covid solution press issue disruption change demographic international logistic system impact security supply demographic change increase demand preventive therapeutic healthcare product global population predict grow billion estimate billion virtually country experience population age proportion project double imf annual report people live city iqvia datum affluent particularly china experience world internal datum fastestever expansion middle class iqvia impact covid global pharmaceutical growth billion people project middle class quarter june worlds total united nations department economic social affair world population prospect united nations department economic social affair world population age brookings china influence global middle class october gsk annual report strategic report governance remuneration financial statement investor information industry trend continue response gsk move swiftly join global effort covid factor contribute rise demand pandemic companywide science technology healthcare include area focus vaccine portfolio resource big specialty medicine general medicine impact progress promise vaccine medicine pressure healthcare system restrain growth spending produce scale prevent treat virus line innovation priority invest develop detail launch pipeline new product meet pricing access change need patient payer consumer page price healthcare product increase pressure global health pricing strategy ensure fund highcost innovative therapy continue attract product serve broad demographic page significant attention government public advance science technology scrutiny access innovation pandemic rapid advance innovative science technology particularly intense transforming sector new advance functional genomics government long seek control healthcare crispr change possible drug expenditure particularly pharmaceutical grow discovery enable researcher pinpoint novel target population increase comorbiditie improve screen high probability success cell therapy technology escalate demand medicine vaccine consumer cell live medicine alter definition healthcare product parallel new innovative medicine profile medicine scale datum genetic library complex well target disease genomic require artificial intelligence interpret machine learn help design new experiment increase government payer increasingly cooperate likelihood success growth datum improve jurisdiction restrictive measure control healthcare ecosystem helping build virtuous cycle growth pharmaceutical expenditure case datum technology regulator purchaser lead reimbursement hurdle consequent delay harness technology track product effectiveness make innovative medicine vaccine available patient researcher build well understanding genetic control pandemic stimulate economy disease consumer use digital tool manage address environmental issue expect health determine genetic profile biden administration key priority administration covid demonstrate advanced technology plan expand federal government role covid accelerate enable innovation entire industry response propose major stimulus bill nationwide unprecedented government funding collaboration test vaccine distribution strategy rejoin world company research institutes health organization healthcare biden administration especially true rapid acceleration vaccine innovation expect seek expand access affordable care include mrna technology enable specific protein act comprehensive reform include prescription drug antigen produce bodys cell enable unlikely implement short term human immune system prevent fight disease remain intense public scrutiny cost prescription advance vaccine innovation likely implication medicine american citizen biden administration current pandemic result new range expect pay attention course term highly innovative technology mark step change prior leave office trump administration announce able fight infectious disease regulatory change address healthcare cost response notably restructure pharmaceutical rebate benefit application advanced technology central patient pharmacy counter intention proceed approach innovation priority develop international reference pricing irp mostfavoure core capability machine learn functional genomics nation pricing policy indefinitely hold pende cell therapy accelerate pace identify resolution legal challenge industry exact develop novel target medicine vaccine leadership shape impact measure finalise platform technology continue play central role implement potential significantly change example adjuvant mrna technology industry operating environment long term pursue inhouse selfamplifye mrna sam platform strategic mrna technology collaboration curevac clinical stage biotechnology company detail february announce additional new agreement curevac jointly develop generation mrna vaccine covid establish dedicated central london hub team complement collaboration focus apply crispr gene editing technology drug discovery laboratory genomics research partnership broad institute worldleading genomics centre gsk annual report industry trend continue determination control cost improve europe country implement access healthcare address outofpocket patient reform range regulatory pathway cost containment payment counter grow recognition china key change include alignment drug regulatory importance innovation early access review approval process international standard versus market restrict access improve government reimbursement innovative medicine pricing access environment continue europe market establish price evolve evidencebase assessment control process national healthcare authority continually irp instrument control cost look sharpen tool disparity access supply additionally late national reimbursement drug availability market recur topic debate list negotiation reduce price offer member state repeatedly raise concern medicine opportunity improve access innovative medicine shortage concern heighten sharply crisis phase evidence access oncology medicine pandemic company mitigate risk particular improve react quickly cooperate national authority covid create impetus great japan htas introduce april centralise procurement vaccine medicine pharmaceutical industry remain concerned use level november european commission assessment pricing control value publish pharmaceutical strategy focus improve assessment number latin american nation include patient access affordable medicine strengthen colombia mexico uruguay central american region competitive pharmaceutical industry strategy country increasingly engage hta include legislative nonlegislative proposal span consider establish strengthen exist assessment access affordability innovation competitiveness touching response legislative framework pharmaceutical aim improve health million people year company operate europe commission make product available responsible price announce plan improve crossborder preparedness sustainable business health emergency creation new agency health emergency response authority hera model get balance right responsible pricing biomedical advanced research development sustainable business fundamental innovation authority barda build reserve medicine performance trust priority set price equipment surge capacity support manufacture medicine develop market apply valuebase approach balance reward innovation access grow call transparency price development affordability aim provide truly differentiate cost public subsidy draft legislation france innovative product deliver effective health outcome italy require publication investment cost ability patient payer highcost product deliver manage unexpected supply constraint detail price value invest genetic genomic big datum jurisdiction crossborder alliance accelerate pace develop transformational valletta declaration group beneluxa initiative medicine prioritise molecule high nordic council visegrad group emerge probability success genetically validate drug candidate exert great leverage price negotiation twice likely register medicine europe emerge market irp continue investment improve productivity gain traction market investment primary lever pricing control increasingly country cooperate health technology assessment htas new hta regulation proposal aim centralise clinical assessment new medicine medical device gsk annual report strategic report governance remuneration financial statement investor information industry trend continue regulatory environment societal expectation healthcare highly regulated industry reflect public societal expectation business continue evolve time expectation product comply stringent level quality expect progress global development safety efficacy slow political economic challenge pandemic covid present number challenge concern issue grow financial community regulator industry maintain supply show increase interest corporate management essential medicine vaccine continue development environmental social governance esg risk programme new product support accelerate opportunity well foundation longterm growth development solution covid necessary rise civic protest movement aim adaptation base important regulatory effort hold company government account social initiative underway include work issue racial gender inequality novel regulatory approach encourage biopharmaceutical pandemic rise scrutiny innovation include address new technology company support employee supplier digital healthcare cell gene therapie complex clinical wide community crisis environmental trial big datum real world evidence agenda grow sense urgency pace regulator recognise need increase cooperation scale action need address climate change industry tackle pandemic increase focus degradation natural world key enablers acceleration timeline pandemic biodiversity loss deep understanding innovation regulator build exist interaction planetary health link human health supranational body international coalition response medicine regulatory authority response covid trust priority approach esg design create present opportunity challenge longterm value shareholder society potential permanent application regulatory adaptation set public commitment material issue support development approval broad range support trust priority make good progress new medicine vaccine simplification page recognise expectation regulatory process move quickly need respond accordingly parallel challenge pose covid industry outline new global approach continue prepare end transition period inclusion diversity announce ambitious new uks exit development uks future environmental goal net zero impact climate net regulatory framework medicine healthcare positive impact nature page product regulatory agency mhra independent response pandemic gsk take agile regulator peoplecentric approach include strong focus support employee supplier response gsk closely monitor relevant appropriate engage way improve regulation particularly europe china japan example scientific innovation move scope current regulation standard learn experience covid working peer engage government explore new policy process incentive support discovery delivery medicine vaccine develop emerge technology technique addition work sector realise opportunity mhra establish new enhance partnership regulator outside lead globally creation balance regulatory framework support innovation gsk annual report stakeholder engagement engage building trust broad range stakeholder interact impact business key delivering strategy ensure success long term approach enable management board understand consider stakeholder view oversight decision making explain section statement set incorporate reference strategic report summarise key stakeholder group engage issue matter response patient insight patient consumer enable matter consumer develop product well meet need differentiated product innovation base patient engage consumer need advisory board diseasespecific patient panel access reliable supply highquality safe product patient advocacy leader summit provide patient pricing healthcare product particularly outofpocket insight expense engagement support patient group disclose gskcom initiative empower patient strengthen pipeline innovative product involve medicine development maintain high standard product quality safety market research include consumer sensory lab continue valuebase approach pricing balance reward innovation access affordability investor maintain regular constructive dialogue matter investor communicate strategy performance financial performance commercial success order promote investor confidence ensure understand strategy successfully continue access capital develop pipeline engage increase importance good management esg issue ongoing communication include agm quarterly result call inperson virtual roadshow good financial performance transparent report detailed company information online business update event key pipeline onetoone meeting board member milestone senior executive institutional investor increase engagement esg matter biennial investor analyst perception study healthcare work healthcare professional hcp matter professional medical expert understand patient need ensure access product scientific information medical product administer right way responsible sale marketing practice expert engage safety efficacy differentiate innovation scientific dialogue increase understand disease management patient experience increase use digital channel deliver provide highquality balanced information personalise effective sharing information hcps medicine vaccine ensure attract retain good talent uphold collaborate clinical trial research responsible sale marketing standard hcp insight disease management patient experience inform development medicine partner partner scientific institution national health matter academia system business partner academia help find right partner accelerate potential ensure develop differentiate healthcare product medicine vaccine approval reach patient engage push science far advance collaborate outstanding scientist human health organisation globe dissemination advancement scientific knowledge establish joint venture strengthen innovation efficiency work worldleading expert biotechs university work academic institution accelerate scientific institution improve drug discovery discovery development new medicine increase productivity pipeline collaborate partner curevac mrna technology vir biotechnology new antibody therapy expand genetic genomics collaboration broad institute gsk annual report strategic report governance remuneration financial statement investor information stakeholder engagement continue government work government regulator advocate matter regulator policy encourage innovation promote investment innovation life sciences efficient management healthcare spend scientific funding collaboration patient support need medicine pricing reimbursement engage public health threat covid antimicrobial meeting regulatory body resistance amr development process ensure highquality investment preventive health strengthen health system safe new product engage government health agency work policymaker ensure postbrexit demonstrate value product patient remain sustained flow good investment capital economy talent life science innovation working government protect strengthen engage policy pricingreimbursement debate right operating environment life sciences phrma comment legislative proposal innovation launch healthcare reform participate international effort address global partnering industry government tackle amr health threat covid pandemic engage government include canada production procurement covid vaccine ngo work partner improve access healthcare matter multilateral service product advocate access medicine vaccine organisation policy environment successful sdgs target specific disease area engage universal health coverage future health system work nongovernmental organisation ngo finance global health include covid solution partner research develop product address global health challenge focus unique role global health partner collaborate ngo generic manufacturer develop product scientific expertise sustainably supply product develop country partner organisation complementary partnering strengthen health system develop capability reach create sustainable model country drive progress global health priority share risk include partnership gavi support access vaccine low low middleincome country leverage community investment programme support scientific expertise deliver great impact patient supplier work thousand supplier large small matter provide good service support prompt payment small supplier deliver reliable supply highquality safe understanding gsk policy ensure compliance product patient consumer opportunity innovate grow relationship engage regular direct engagement supplier ensure engage supplier covid support gsk strategy target pandemic understand operate financial status engage supplier thirdparty offer support necessary oversight programme conduct indepth audits engage supplier develop improvement plan participate forum pharmaceutical track progress identify area improvement supply chain initiative consumer good forum provide proactive support thirdparty ehs improve supply chain sustainability team country priority supplier locate employee involve listen employee help maintain matter strong employee engagement retain talented people purpose able difference engage great line manager regular let talk let listen event feel understand value corporate executive team senior leader inclusive diverse workplace facilitate dialogue collaboration internal communication platform deliver frequent authentic communication work council employee forum pandemic employee resource group clarify expectation manager motivate global allemployee survey survey focus care develop employee employee provide feedback line manager support employee safety mental wellbeing enable worklife balance expand commitment set aspirational target improve ethnic gender diversity leadership gsk annual report innovation year significant progress biopharma portfolio achieve substantial number new launch regulatory filing latestage research milestone consumer healthcare deliver market launch new innovation category progress strengthen biopharma fast track covid solution invest significantly strategic pipeline major approval vaccine approach partnership include immunology pivotal study start clinic therapeutic company vir biotechnology accelerate portfolio clinical study mrna technology specialist approval oncology blenrep start phase iii trial rsv curevac zejula hiv rukobia maternal rsv old adult consumer healthcare cabenuvavocabriarekamby menabcwy candidate vaccine firstmarket launch new specialty duvroq launch clinical trial innovation roll asset latestage asset andme collaboration recent innovation development new market potentially significantly change consumer healthcare read medical practice pharmaceutical vaccine approach focus science relate lifecycle innovation focus evolve increase immune system use human genetic application impact exist product key component advanced technology machine learning strengthen pipeline ensure vaccine deliver transformational medicine vaccine distinctive medicine reach protect people continue play approach enable strengthen pipeline vaccine strong role business performance specialty medicine accelerate pace significant progress biopharma discover develop deliver patient embed portfolio major gsk asset target unmet medical agile performancedriven culture encourage clear need gain regulatory approval infectious disease accountability incentivise people pursue bold portfolio receive approval hiv firstinclass research back datum strong science partner attachment inhibitor rukobia europe hire outstanding talent cuttingedge field longacte regimen cabenuva canada outside pharmaceutical industry technology datum europe license vocabria rekamby science academia time ambitious receive european regulatory approval extend use collaboration worldclass company institution vaccine infectious disease shingrix partner research access advanced technology expand use people aged crispr mrna deliver high number increase risk shingle boostrix tetanus differentiate medicine vaccine diphtheria pertussis vaccine expand indication gsk biopharma pipeline contain potential new include maternal immunisation bexsero europewide medicine candidate vaccine focus immunology label update schedule start infant strengthen diversify portfolio promising month oncology receive significant european clinical asset immunemediate disease infectious approval zejula approve expand disease oncology research target indication ovarian cancer secondly blenrep genetically validate novel target identify firstinclass antibcma bcell maturation antigen treatment collaboration consumer genetic research multiple myeloma respiratory nucala firstinclass company andme base current projection antiil biologic approve hypereosinophilic potential launch numerous new vaccine syndrome trelegy ellipta oncedaily single inhal triple medicine new indication exist asset therapy approve asthma duvroq chronic datum positive highpotential kidney diseaserelate anaemia approve japan latestage asset significantly change medical benlysta approve expand indication practice continue focus pipeline asset lupus nephritis great probability success gsk annual report strategic report governance remuneration financial statement investor information innovation continue asset enter pivotal study include fundamentally believe person live hiv covid vaccine collaboration therapeutic medicine need twodrug regimen covid antibody treatment codevelope treatment dovato juluca show vir biotechnology candidate vaccine safe effective threedrug regimen allow people live neisseria serotypes cause meningitis hiv maintain viral suppression take few hiv candidate vaccine respiratory syncytial drug lifetime virus rsv maternal immunisation dovato oncedaily singlepill contain dolutegravir successful progression pipeline ability lamivudine treatment adult live hiv fast track covid solution achieve despite disruption follow launch europe dovato international lockdown pandemic receive marketing approval treatment nave adult continue deliver trial drug thousand patient hiv japan japan australia receive approval sealedoff healthcare system assure patient switch indication quarter longterm employee safety study integrity resilience data gemini tango study show operation supply chain allow majority dovato effective number threedrug regimen clinical study remain open datum stat clinical trial demonstrate dovato effective tolerate treatment rapid initiation infectious disease diagnosis dovato include international guideline initial therapy hiv switch option gsk worldleade infectious disease portfolio medicine vaccine clinical testing reflects receive approval rukobia fostemsavir focus immunology gsk year track record firstinclass attachment inhibitor follow pioneer research method novel technologies approval europe february rukobia approve find solution disease cause bacteria viruse fast track fda breakthrough parasite information response covid therapy designation therapy provide option heavily treatmentexperienced adult hiv infection include fail current antiretroviral regimen hiv exhaust treatment option previously deliver million people world live hiv positive result week phase iii brighte study include approximately million child sub saharan africa remain affect region number viiv healthcare receive regulatory approval world case globally continues grow approximately complete longacte injectable regimen treatment new infection year people live hiv regiman contain cabotegravir rilpivirine reduce number treatment gsk long commit combatting prevent dose day year potential ultimately cure hiv limit impact extend approve canada people live hiv business manage viiv cabenuva europe vocabria cabotegravir healthcare sole global specialist hiv pharmaceutical rekambys rilpivirine company majority own gsk pfizer shionogi shareholders business underpin complementary approval align goal mission leave person live hiv provide convenient simplified treatment people live hiv advance research longacte whilst cure hiv remain viiv healthcare ultimate aim therapy september begin oneyear study portfolio approve antiretroviral medicine offer range identify evaluate approach integrate therapeutic option people live hiv include month injectable cabotegravir rilpivirine hiv treatment tivicay triumeq contain medicine dolutegravir european healthcare practice october complete widely prescribe integrase inhibitor worldwide final study visit yearlong customize study believe million people live hiv globally investigate good way implement oncemonthly hiv take dolutegravirbased regimen ensure child regimen clinical practice result indicate live hiv leave june receive high level patient preference longacte injectable food drug administration fda approval follow offer potential reduce frequency dose european medicine agency ema approval january effective daily oral threedrug regimen maintain firstever dispersible tablet formulation dolutegravir viral suppression adult live hiv tivicay child week age gsk annual report innovation continue million people newly diagnose hiv gsk maternal candidate base recombinant year focus develop effective prevention essential prefusion antigen boost preexist immune response report positive result trial vaccinate mother protective antibody investigational longacte injectable cabotegravir treatment transfer unborn child paediatric hiv acquisition interim analysis global hiv candidate harness adenovirus vector technology prevention trial network hptn study show contain rsv antigen aim induce active immunity month treatment effective extend protection infant year life superior daily preexposure prophylaxis pill prevent old adult candidate leverage recombinant prefusion hiv acquisition man result release early antigen combine adjuvant system anticipate follow outcome similarly result key ingredient successful shingle vaccine shingrix release early anticipate second hptn study enhance immune response population naturally woman show cabotegravir effective decline immune system daily oral standard care preexposure prophylaxis prep intend apply marketing authorisation promising phase iii data old adult maternal therapy regulator half rsv candidate vaccine show asset trigger robust immune response welltolerate begin shingle phase iii trial maternal candidate vaccine november launch shingrix late signal step change phase iii programme old adult february prevention shingles painful potentially phase iii study paediatric rsv candidate illness approximately people develop shingles vaccine ongoing safety immunogenicity datum lifetime vaccine address agerelate decline seronegative infant expect immunity achieve efficacy age group nonlive shingle vaccine combine meningitis specific subunit antigen adjuvant sustain approximately million people develop invasive meningococcal immune response disease imd year infant young child adolescent particularly vulnerable disease receive european approval expand use diagnose early adequate treatment start shingrix people aged patient die hour onset increase risk shingle apply broaden symptom untreate meningococcal meningitis fatal indication include adult immunodeficiency case result brain damage hearing loss immunosuppression likely contract shingle disability survivor respiratory syncytial virus rsv gsk market leader vaccine imd base innovation prioritie development novel revenue complementary portfolio bexsero prophylactic vaccine disease significant unmet marketleade meningitis vaccine menveo medical need rsv meningitis acwy vaccine help protect majority rsv leading cause low respiratory tract infection imd case pneumonia bronchiolitis infant old see publication multiple study realworld adult risk currently vaccine license protect evidence bexsero effectiveness different setting virus year estimate hospitalise include europe serogroup prevalent million underfive globally old adult public health england bexsero immunisation programme demonstrate reduction expect case gsk company develop portfolio fully vaccineeligible infant evidence lead europewide dedicated rsv candidate vaccine label update bexsero schedule start infant fast track fda candidate vaccine month tailor need vulnerable population phase trial liquid presentation menveo infant complementary maternal paediatric complete december new format aim simplify candidate vaccine old adult candidate vaccine preparation step healthcare provider vaccine target people age august begin phase iii clinical trial menabcwy pentavalent vaccine candidate vaccine build successful technology bexsero menveo favourable safety efficacy profile currently meningitis vaccine exist serogroup abcwy vaccine require vaccine few injection internal data gsk annual report strategic report governance remuneration financial statement investor information innovation continue new antibiotic amrrelate vaccine investigate therapeutic candidate vaccine aim tackle urgent threat antimicrobial resistance chronic hepatitis infection currently phase iii amr organism recognise center disease trial work chronic hepatitis focus control cdc world health organization progress therapeutic vaccine help immune system well significant negative impact global public health respond exist disease help reduce chronic disease reflect strategic commitment develop novel exacerbation slow progress hopefully improve target solution new area high medical need quality life grow number people suffer gepotidacin potential firstinclass antibiotic distinct chronic disease worldwide mechanism action phase iii study urogenital boostrix tetanus diphtheria pertussis vaccine gonorrhoea uncomplicate urinary tract infection receive approval europe expand indication datum expect half mark include maternal immunisation immunisation pregnant time infection address new mother enable mother immune system oral antibiotic year transfer antibodie help protect unborn child begin phase study candidate vaccine pertussis whooping cough expansion prevent primary recurrent softskin tissue infection support robust datum large phase randomise cause staphylococcus aureus staphylococcus aureus placebocontrolle clinical trial perform pertussis pathogen swiftly acquire antibiotic resistance multi maternal immunisation drugresistant strain threat human health rotarix vaccine rotavirus infection receive methicillinresistant strain staphylococcus european approval porcine circovirusfree presentation aureus annually cause case hospitalise patient estimate death information malaria vaccine global health progress phase study vaccine section pathogen frequently display amr clostridium difficile bacterium cause case oncology hospitalise patient lead estimate death year work oncology focus maximise patient survival discovery development transformational support antibacterial research accelerator carbx medicine portfolio oncology asset help development new drug treat clinical development individually novel combination prevent recurrent urinary tract infection cause study area focus escherichia coli coli bacteria project aim immunooncology use human immune system explore safety tolerability pharmacokinetic treat cancer portfolio asset include fimh antagonist phase study initiate blenrep dostarlimab feladilimab synthetic lethality september finish support concept mechanism work destroy enable scale drug future clinical cancerous cell lead asset area zejula nonclinical study cell therapy human tcells engineer information work amr trust target disease nyeso asset lead portfolio section lastly cancer epigenetic generegulatory system infectious disease epigenome modulate curb cancer hepatitis virus hbv chronically infect liver lead asset field type prmt inhibitor health condition include cirrhosis liver failure prmt inhibitor liver cancer despite exist treatment option start immunooncology receive regulatory approval people die hbv year europe blenrep belantamab mafodotin start phase iib study gsk firstinclass humanise antibody drug conjugate investigational antisense oligonucleotide drug bcma relapse refractory multiple myeloma multiple hbv inlicense ionis datum myeloma common blood cancer phase iia study suggest gsk currently cure blenrep antibcma potential suppress hepatitis surface antigen therapy approve provide treatment option week treatment patient relapse refractory myeloma currently limited treatment option approval follow positive result pivotal dreamm study gsk annual report innovation continue continue progress blenrep extensive clinical originally approve europe patient development programme enable advance recurrent ovarian cancer expand zejula early line treatment begin pivotal secondline indication october lateline treatment multiple myeloma study dreamm blenrep advanced ovarian cancer associate homologous combination bortezomib dexamethasone recombination deficiency pursue number dreamm blenrep combination pomalidomide clinical study zejula combination dexamethasone initiate pivotal thirdline therapy include combination therapy firstline multiple myeloma study dreamm blenrep ovarian cancer inhibitor dostarlimab monotherapy phase combination study evaluate initiation zeal trial combination pembrolizumab asset combination nirogacestat springwork nonsmall cell lung cancer strengthen pipeline investigational gamma secretase inhibitor relapse capability synthetic lethality agree broad refractory multiple myeloma combination strategic partnership ideaya bioscience oncology substudy ongoing dreamm trial focus precision medicine company dostarlimab investigational antiprogramme death lead oncology cell therapy asset tcell immunotherapy inhibitor evaluate potential letetresgene autoleucel letecel gsk treatment endometrial cancer file european genetically modify express tcell receptor tcr target regulatory approval dostarlimab monotherapy nyeso antigen present multiple cancer type secondline endometrial cancer base datum include solid tumour begin garnet trial dostarlimab phase iii study ruby registrational trial secondline advancedmetastatic synovial firstline recurrent primary advanced endometrial cancer sarcoma therapy accelerate development path combination standard care chemotherapy receive european prime fda breakthrough zejula status generation tcell immunotherapy gsk gsk transition continue progress feladilimab humanise nont cell preclinical clinical development therapy build deplete igg antibody engineer enhance tcell drive tcr platform utilise enhancement improve antitumour response activate immune costimulatory cell efficacy persistence announce strategic receptor ico study antibody collaboration biopharmaceutical company immatic combination therapy potential biotechnology enhance capability cell range tumour type patient enrolment achieve therapy work immatic identify research induce second phase iiiii gate study feladilimab develop novel adoptive cell therapy focus solid combination pembrolizumab chemotherapy tumour work complement exist relationship recurrentmetastatic head neck squamous cell carcinoma cell therapy lyell immunopharma adaptimmune expand active trial programme molecule announce new addition immuno respiratory oncology pipeline anticd gsk immune checkpoint receptor express tcell natural killer gsk extend year leadership respiratory medicine cell potential firstinclass antibody molecule continue innovation development treatment codevelope andme early begin asthma chronic obstructive pulmonary disease copd phase study asset monotherapy combination debilitate respiratory condition portfolio dostarlimab patient advance solid tumour candidate vaccine respiratory syncytial virus mention early example worldleading area zejula lead synthetic lethal asset expand launch new inhaled therapy indication approval europe firstinclass biologic nucala give broad oncedaily oral poly adpribose polymerase parp portfolio respiratory medicine industry new inhibitor firstline monotherapy maintenance treatment respiratory product portfolio compare patient platinumresponsive advanced ovarian cancer growth offset decline follow positive result phase iii prima study advairseretide moved portfolio show significant reduction disease progression period patient regardless biomarker status gsk annual report strategic report governance remuneration financial statement investor information innovation continue recognise potential medicine help priority asset patient possible work deliver lifecycle immunoinflammation innovation marketleade treatment single inhaler focus science immune system support triple therapy trelegy ellipta nucala trelegy ellipta receive development medicine immunemediate disease regulatory approval japan treatment lupus rheumatoid arthritis source adult asthma follow early positive result significant morbidity patient considerable public phase iii captain study expand trelegy elliptas health burden society emphasis reflect aim original copd indication make single inhaler triple develop immunologicalbase medicine alter course therapy approve asthma copd inflammatory disease extend leadership eosinophildriven disease nucala remain company biologic treatment approve patient hypereosinophilic benlysta specifically develop approve adult syndrome add indication severe eosinophilic paediatric systemic lupus erythematosus sle chronic asthma sea eosinophilic granulomatosis polyangiitis incurable autoimmune disease apply egpa approval follow grant fda regulatory approval geography include priority review make nucala target biologic europe china benlysta lupus nephritis treatment patient rare lifethreatening disease inflammation kidney cause sle lead apply european authorisation nucala endstage kidney disease follow positive data patient suffer chronic rhinosinusitis nasal pivotal blissln study support fda grant polyps crswnp common debilitate condition breakthrough therapy designation priority review characterise high eosinophil level cause benlysta lupus nephritis benlysta treatment difficulty breathe sleep maintain sense smell approve lupus nephritis treatment taste application follow positive result approve sle lupus nephritis pivotal synapse study nucala mark time progress otilimab phase iii study patient antiil biologic report positive phase iii data chronic systemic inflammatory condition characterise crswnp submit regulatory application pain joint swell stiffness disability study europe use nucala patient egpa follow early encourage result anti gmcsf believe nucala potential benefit antibodys phase baroque trial start phase patient copd elevate eosinophil count proof concept study otilimab treat severe phase iii copd trial ongoing pulmonary covidrelated disease recognise patient respiratory disease continue anaemia require novel therapeutic option investigational consistent intent bring new therapeutic option longacte interleukin antagonist sea move patient significant unmet medical need phase iii february develop daprodustat treatment anaemia human rhinovirus hrv common respiratory chronic kidney disease ckd receive pathogen associate flareups copd asthma regulatory approval daprodustat market duvroq replicate hrv take pik kinase japan patient anaemia ckd approval lung inhibit prevent hrvdriven follow positive result phase iii programme japan exacerbations associate patient burden gsk duvroq oral hypoxiainducible factor prolyl hydroxylase firstinclass pik inhibitor gsk start inhibitor new class drug encourage body phase study determine safety pharmacokinetic red blood cell treat anaemia associate profile ckd oral daily medicine duvroq offer great ensure focus medicine great convenience current injectionbase standard care potential terminate progression antiil receptor nearly million people japan ckdrelate severe asthma anaemia year initial datum proofofconcept study gsk commit help patient ckdlinke anaemia copd candidate vaccine show meet world robust programme evaluate primary endpoint efficacy safety daprodustat daily time week dose regimen trial evaluate wide spectrum patient ckd include patient dialysis receive hemodialysis peritoneal dialysis programme track datum expect gsk annual report innovation continue covid solution support manufacture successfully fight covid pandemic require covid vaccine february announce solution work front support production curevacs current minimise impact generation covid vaccine candidate manufacturing million dose ongoe contribute unique adjuvant technology help dialogue manufacturer support develop multiple proteinbase covid vaccine covid vaccine production simultaneously develop preventative therapeutic medicine codevelope novel mrna vaccine candidate therapeutic treatment essential patient wait partner lead healthcare company covid vaccination people vaccinate research institution central approach event variation virus vaccine partial efficacy april announce covid partnership develop covid vaccine partnership clinicalstage immunology company vir contribute pandemic adjuvant technology biotechnology identify accelerate therapeutic use adjuvant particular importance preventative antibody therapie virus pandemic reduce vaccine protein require dose allow additional dose produce month agreement vir vir protect people enable gsk antibody early treatment covid enhance immune response patient high risk hospitalisation move global phase iii trial treatment identify antibody isolate pledge supply covid pandemic adjuvant patient severe acute respiratory syndrome government institution responsible price sar virus result antibody activity standalone adjuvant adjuvanted vaccine coronaviruse include sarscov dualaction reinvest profit sale adjuvant antibody find potential block covid pandemic phase support coronavirus clear virus provide high barrier resistance achieve relate research longterm global pandemic high concentration lung ideal property treat preparedness potentially prevent covid infection result early april announce collaboration sanofi treatment study vir expect early combine sprotein covid antigen approve antibody treatment available early pandemic adjuvant technology sanofi half february cometpeak secured supply agreement canada phase study evaluate intramuscular formulation statement intent covax global initiative vir lowrisk adult mild moderate covid aim ensure equitable international distribution effective initiate covid vaccine commitment clinical development programme vir include vaccine approve available globally december evaluation subtrial national institutes announce delay development programme health accelerate covid therapeutic intervention antigen concentration address partner vaccine activ program clinical trial hospitalise start new phase study february adult covid study combination july announce collaboration medicago eli lillys cov antibody lowrisk patient mild develop covid candidate vaccine phase moderate covid expect datum clinical testing begin month vaccine combine half innovative plantbase antigen gsk adjuvant second monoclonal antibody vir gsk trial move phase iiiii clinical development collaboration vir vir november phase iii portion start march investigate potential covid treatment announce adjuvante covid vaccine ukbased agile initiative patient mild moderate collaboration february bioscience covid phase ibiia clinical trial begin enter phase testing early collaboration develop adjuvante covid follow review market medicine vaccine chinabase clover pharmaceutical pipeline product identify agent able treat stop early covid virus secondary complication started february announce new collaboration phase proof concept oscar study otilimab german biotechnology company curevac jointly treat severe pulmonary covidrelated disease develop generation mrna vaccine covid february announce result study potential multivalent approach address show primary endpoint reach statistical multiple emerge variant vaccine believe significance age efficacy analysis age important phase pandemic show potentially important clinical benefit patient year old base public health need decide expand oscar study confirm potentially important finding gsk annual report strategic report governance remuneration financial statement investor information innovation continue advanced technology partnership january announce collaboration eligo french biotech company investigate potential therapeutic application advanced technology central solution acne precise modulation skin approach significant investment microbiome composition combination crispr transformational technology change way technology bacteriophage medicine vaccine discover include human genetics genomics artificial intelligencemachine learn partnership aiml build core capability broad achieve substantial milestone establish portfolio platform technology cell therapy adjuvant london hub new collaboration human genetic recently mrnabase vaccine alter genomic hub team use biomedical information way medicine vaccine develop method advance computing platform unlock new make investment help accelerate pace mean sizeable genetic clinical datum use design develop novel medicine vaccine dedicate hub work partner lead company institution include nvidia silicon valley startup advanced technology cerebra support phd studentship covid demonstrate advanced technology university cambridge new centre medicine accelerate enable innovation entire industry provide gsk talent pipeline come unprecedented collaboration company year shape generation practitioner role research institutes gsk long history leverage establish ecosystem partner unique accelerate technological expertise achieve industry discover design medicine innovative combination partner lead vaccine high probability success company institution expert gsk adjuvant technology platform play central role vaccine innovation year form new fiveyear research adjuvant key component vaccine pipeline collaboration world lead genetics asset include rsv old adult candidate vaccine functional genomic centres broad institute cambridge drive success license shingrix vaccine massachusetts additionally december announce pandemic adjuvant technology available ahren innovation capital colead series collaboration potentially significant contribution investment adrestia therapeutic ukbase biotechnology strengthen global response covid company cuttingedge molecular biology develop progress novel vaccine technology precision medicine adrestias disease rebalancing platform bioconjugation central staphylococcus aureus use synthetic viability identify phenotypic molecular candidate vaccine adenovirusvector chad core imbalance disease basis novel drug discovery paediatric rsv asset gsk enter multiyear agreement adrestia project develop portfolio joint year agree strategic mrna technology project partner investigate human genetic collaboration clinical stage biotechnology company link disease help identify highquality curevac build relationship february genetically validate medicine agreement curevac jointly develop generation mrna vaccine covid mrna technology new genomics collaboration complement cuttingedge platform development new vaccine extend important exist gsk partnership include medicine show proof concept agreement university california establish high efficacy level covid vaccine mrna laboratory genomics research lgr stateoftheart technology potential transform vaccine development laboratory evolve advance crispr vaccine industry number genomics technology improve drug discovery enable disease enable specific protein antigen identify potential treatment enhance productivity produce bodys cell enable human immune initiate project genetic disease system prevent fight disease technology allow oncology neurodegeneration lgr discover vaccine fast produce building stateoftheart crispr library enable efficiently scale continue evolution sophistication technology transform drug discovery time strengthen original agreement curevac cover research inhouse resource automate biology ability development manufacturing commercialisation interrogate cell biology heidelberg site cellzome mrnabase vaccine monoclonal antibodie mab target infectious disease pathogen curevacs integrate collaboration andme establish help mrna platform complement gsk selfamplifye mrna identify new generation disease target validate sam vaccine capability build grow strength human genetic identify novel target mab innovation align overall focus number therapy area collaboration science immunology phase study test sam year start gskandme rabie antigen advance start phase study test clinical trial potential new immunooncology treatment sam covid model vaccine start march gsk gsk collaboration continue additional earlystage clinical study sam explore potential genetic genomic include expect start later march open target finngen altius biobank gsk annual report innovation continue pipeline overview asset development latestage pivotal phase iiiiiregistration benlysta rituximab sle letetresgeneautoleucei nyes tcr cabotegravir hiv prep vir covid daprodustat hifphi anaemia antiil antagonist asthma nucala copdnasal polyp shingrix immunocompromise vaccine blenrep bcma adc multiple myeloma bexsero infant vaccine zejula parp inhibitor ovarian lung cancer mmr vaccine dostarlimab antagonist dmmrmsih rotarix liquid vaccine bintrafusp alfa tgf trapantipdl btc menabcwy vaccine otilimab agmcsf inhibitor rsv maternal vaccine gepotidacin uuti covid medicago vaccine feladilimab icos receptor agonist hnscc rsv old adult vaccine proof concept phase ibii maturation inhibitor hiv menveo liquid vaccine hbv aso hbv rsv paediatric vaccine linerixibat ibati cholestatic pruritus pbc therapeutic hbv vaccine prmt inhibitor cancer malaria fractional dose vaccine cobolimab tsr tim antagonist nsclc shigella vaccine leucyl trna inhibitor covid sanofi vaccine tsr lag antagonist cancer time humanpom phase iib ccl inhibitor pain cdnyeso tcr cancer sting agonist cancer tgfbrnyeso tcr cancer hpgd synthase inhibitor dmd proteosome inhibitor visceral leishmaniasis crk inhibitor visceral leishmaniasis inhibitor celiac disease broadly neutralise antibody hiv mtb inhibitor type prmt inhibitor cancer ethionamide booster trpv blocker dme vir covid cancer difficile vaccine ripk psoriasis sam rabies model vaccine fimh antagonist uuti aureus vaccine maturation inhibitor hiv covid bioscience vaccine plk inhibitor viral copd exacerbation sam covid model vaccine advanced indication show asset inlicence alliance relationship otilimab covid therapy phase endometrial cancer gonorrhoea party blenrep phase iiiiii early line hbv hepatitis hnscc head neck additional indication investigation therapy multiple myeloma approve squamous cell carcinoma nsclc non gsk contribute pandemic adjuvant agent bca imll alu ryn ian iso oth mri pis covid vaccine collaboration btc biliary tract cancer copd chronic mechanism prep preexposure prophylaxis icos hnscc phase iiiii study obstructive pulmonary disease rheumatoid arthritis sle systemic lupus registrational potential dmd duchennemuscular dystrophy erythematosus synovial sarcoma dme diabetic macular edema tuberculosis uuti uncomplicated phase iii study dmmr deficient mismatch repair urinary tract infection gsk annual report strategic report governance remuneration financial statement investor information innovation continue consumer healthcare joint venture pfizer bring consumer trend particularly respiratory health category complementary brand portfolio make number increase preference natural remedy reflect globally term market share overthecounter otc trend increase consumer concern impact air medicine therapeutic oral health vitamin mineral pollution everyday health launch otrivin breathe clean supplement joint venture establish centre europe naturalsbase saline spray enable clean excellence richmond focus otc breathe washing impurity like airborne pollutant wellness weybridge oral health suzhou pollen viruse trap nose help restore nose china dedicated hub locally relevant innovation natural filtering function cough cold introduce natural ingredientbase cough relief extension theraflu deliver firstmarket launch new spain portugal liquid lozenge format innovation category total roll launch robitussin natural incorporate recent innovation new market include herbal extract aid cough relief sensodyne sensitivity gum polident cushion comfort file new invention patent application consumer increasingly take control wellbeing grant european patent multivitamin important meeting nutritional category need insight tell challenge swallow big pill represent usage barrier address deliver bestinclass innovation launch mini version power brand centrum combine deep human understanding trust science size regular pill mini deliver innovation meet need consumer platform future innovation june successfully launch voltaren arthritis pain otc prescriptionstrength nonsteroidal antiinflammatory launch number major locally relevant innovation nsaid topical gel arthritis pain help nearly million outside useurope china consumer research people osteoarthritis launch voltaren boost understand health need different arthritis pain account category growth gender build insight introduction adult topical pain relief segment genderspecific formulation caltrate lead calcium supplement china key local star brand research show consumer want vitamin mineral supplement category innovation medicine possible use ibuprofen aim increasingly health wellbee conscious paracetamolacetaminophen work different way yearold demographic risk bone treat headache muscle ache arthritis relate injury typical consumer calcium joint pain launch advil dual action supplement india gap topical formulation combine ibuprofen paracetamol gel pain relief market fastacte product provide acetaminophen single product scientifically back longlaste relief launch iodex ultragel product provide great efficacy individual component harness brand trust strong local heritage oral health continue roll pronamel intensive voltaren formulation clinically prove provide deep enamel repair launch additional market penetration affect area longlaste relief launch household try product innovation successful launch go buy year innovation indian topical gel cream category past year generate annual global retail value sale million external partnership launch sensodyne sensitivity gum new look business fuel innovation market follow introduction innovation pipeline build knowledge capability available market generate assess opportunity partnership million retail value sale launch category project diligence phase range sustainable product package device technology base nicholas hall global otc database basis consumption manufacturer price gsk annual report performance deliver guidance year offset significant impact covid adult vaccination strong sale performance key growth driver hiv respiratory oncology consumer healthcare effective cost control pharmaceutical vaccine consumer healthcare total turnover billion total turnover billion total turnover billion aer cer aer cer covid aer cer pro sale new specialty adversely impact adult forma cer cer pharmaceutical billion vaccination particular exclude brand divest aer cer shingrix launch new selfpay review strong commercial execution market china belgium strong progress joint venture key growth product include netherlands japan sweden integration launch hiv oncology strong performance europe exceed target raise respiratory reflect robust demand billion noncore accelerate digital capability germany brand divestment support enhance hcp strengthen bexsero track deliver synergy engagement strong supply profile compelling realworld million annual cost saving performance despite disruption evidence multiple setting covid pandemic strong flu sale region overall strong supply performance read read read page pharmaceutical performance remain industry leader respiratory rapid indication pharmaceutical turnover year million expansion include hypereosinophilic syndrome approval aer cer respiratory sale nucala increase uptake therapys home aer cer million growth trelegy administration option launch france spain nucala relvarbreo hiv sale flat aer japan reinforce leadership eosinophildriven disease cer million growth juluca nucala deliver billion sale growth dovato partly offset decline tivicay triumeq aer cer trelegy ellipta market new specialty product sale billion increase market share chronic obstructive pulmonary aer cer sale establish pharmaceutical disease positive early signal launch asthma decline aer cer million japan hiv twodrug regimen therapy dovato juluca double sale oncology sale million aer cer million hiv portfolio grow launch strong launch zejula blenrep strengthen cabenuva rukobia paediatric tivicay immuno commercial capability zejula parp inhibitor continue inflammation benlysta grow consistently grow market share sale increase aer cer expand market see doubledigit growth end million blenrep firstinclass antibcma treatment year benlysta indication expand multiple myeloma approve august sale include lupus nephritis million group financial review detail new specialty product comprise pharmaceutical exclude establish pharmaceutical gsk annual report strategic report governance remuneration financial statement investor information performance continue build specialty capability enter longterm partnership samsung reflect shift portfolio innovative specialty biologic access additional largescale manufacturing care product include oncology continue invest capacity supply innovative asset capacity capability area particularly quality supplement exist biopharma manufacturing network experience medical commercial team vary extent depend need partnership new hire oncology initially involve production benlysta commercial supply expect gsk specialty care roll revise incentive programme product come online sale representative country evolve approach aim drive personal accountability competitiveness strong business performance require efficient reliable allow attract retain good salesperson supply chain improve competitiveness build engagement performance sale team supply chain create logistic routetomarket implement programme uphold pharmaceutical vaccine product simplify responsible sale marketing standard manufacturing footprint central function complete divestment site verona italy transform interaction hcp patient mississauga canada announce divestment customer patient focus central successful poznan manufacturing site poland closure performance continue strengthen gsk boronia facility australia intention sell vemgal connection heighten profile healthcare india site network change expect complete professional hcp help meet patient need restriction inperson meeting place year sale team continue robust supply performance engage customer adapt interaction reflect hcp productivity level increase contribute preference local guidance online digital average rise annum past year tool enhance engagement alongside regular customer reflect progress drive operational efficiency dialogue digital solution core successful commercial digital automation technology perform launch virtual meeting educational activity strongly safety quality compliance measure continue despite pandemic ensure deliver service level measure ontime infull improve hcp want leverage data analytic shape remain quartile industry interaction example launch app maintain supply continuity service level despite sale representative combine insight multiple datum impact covid thousand manufacturing source inform action line hcps priority supply employee continue work gsk location lockdown regulatory inspection pharmaceutical china response patient insight develop site satisfactory onestop shop patient support app allow medication order directly gsk online retail giant digital transformation alibaba pharmacie app integrate resilience flexibility supply chain reflect wechat message social medium mobile payment continue investment digital datadriven app connect gsk china patient support programme organisation significant progress disease education content accelerate digital competency capability develop new way work contribute business continuity collectively measure enable maintain grow maintain productivity people share voice key market organisation work home covid restriction invest specialtyready competitive supply chain drive operational efficiency unlocked opportunity supply chain transformation progress line improve performance measure include apply shift portfolio innovative specialty care product advanced analytic drive efficiency business despite disruption cause covid introduce supply chain management manufacture new product include firstmarket launch commercial operation digital value stream map example cabenuva rukobia blenrep duvroq ongoing enable endtoend visibility supply chain enable investment facility people manufacture partnership user track specific brand site interest fuelling continue support rapid launch specialty medicine fast decision making continue harness datum learn accelerate delivery portfolio impact commercial activity commit million expand generation appropriate prescribing unlock smarter fast biopharma manufacturing facility upper merion pennsylvania interaction customer parallel accelerate development technological scientific capability people follow expansion rockville maryland biopharma manufacturing facility preparation track start commercial operation gsk annual report performance continue vaccine performance continue adjust manufacture network meet vaccine turnover decline aer cer future need include investment support growth million primarily drive adverse impact covid exist product pipeline asset pandemic hepatitis vaccine dtpacontaine vaccine prioritise investment manufacturing technology synflorix bexsero divestment rabipur digital capability investment allow transform encepur decline partly offset high sale data insight manufacture supply quality influenza vaccine region growth shingrix result improve productivity effective use sale billion aer cer work capital strong performance cervarix china quarter year site gdll vaccine performance region affect low hungary marburg germany pass food drug demand limited visit healthcare practitioners administration fda inspection fda approval point vaccination pandemic government singapore site mean strategic vaccine site stayathome directive area lockdown lift fdaapprove wellness visit vaccination rate recover paediatric digital performance vaccination near precovid level end advance goal digital adolescent adult immunisation improve slow datadriven organisation continue harness new pace backtoschool vaccination disrupt technology develop well efficient way working school university delay reverse inperson tuition businesswide example deploy robotic elongate backtoschool vaccination season automation bot vaccine organisation include adult wellness visit return prior year level manufacture quality deploy bot end support seasonal flu vaccination end increase efficiency cost saving decline late pandemic condition worsen despite shortterm impact vaccination rate remain year deliver data analytic confident demand particularly shingrix product help improve scientific productivity optimise remain key growth driver manufacturing process boost commercial performance global company commit supply vaccine worldwide growth strategy focus improve second half start digital manufacture geographic presence large vaccine market execution system production line site represent sector china currently use paper batch recording system deploy year benefit group financial review detail include operational efficiency leadtime reduction supply performance improvement compliance yield robustness system vaccine business manufacture site feed make datadriven decision manufacture country global network give strategic supply supply capability enable produce deliver improve commercial team performance million dose achieve well ontime datarich technology platform optimise numerous process infull delivery supply metric ensure critical vaccine tender allocation target marketing available patient pandemic extend awardwinne digital tool myvaccinationhub increase shingrix bexsero output follow additional help parent track children vaccination record investment supply network include bring new national market addition gsk work production capacity onstream bexsero continue health technology company philip pregnancy effort improve yield productivity throughput baby app educate parent importance expand supply capacity remain track vaccination potential reach million parent begin manufacture shingrix new facility day globe huge step forward give improve supply performance shingrix allow target audience access factual medically approve announce launch country early anticipate information partnership live brazil canada switzerland poland spain germany italy australia russia mexico internal data gsk annual report strategic report governance remuneration financial statement investor information performance continue consumer healthcare performance complete sale horlick report basis sale grow aer cer consumer health food drink brand hindustan unilever million year largely drive limited receive require regulatory approval inclusion pfizer portfolio partly offset brand agreement hindustan unilever limited sell divestedunder review distribute otc oral health brand india distribution arrangement retain brand ownership proforma basis sale decline cer grow year sell stake hindustan unilever limited cer exclude brand divestedunder review reflect transaction intend underlie strength brand portfolio sell stake appropriate time time category strong growth ecommerce successful sale enable generate great financial return execution meeting evolve consumer demand result originally anticipate pandemic meeting consumer need amid behaviour shift portfolio everyday health product give industry farreache impact covid lead position number category include pain accelerate certain consumer trend relief respiratory therapeutic oral health vitamin mineral underway trend increase supplement growth strategy base prioritise convergence digital health include rapid investment global power brand local star expansion digital commerce overall global brand concentrate key geography digital commerce business grow previous year operating model critical successful implementation outperform peer gain market strategy growth joint venture share key brand focus market continue progress roll new marketing grow ahead category example gain market operating model allow develop bestinclass lead position toothpaste amazon topical pain brand programme strategic brand market choice voltaren great stride relevant globally locally build execute improve customer experience include launch differentiate pipeline accelerate speedtomarket directtoconsumer online store chapstick heart innovation strategy innovation operate launch store acquire new model launch set practically customer sell stick ahead achieve plan datum capture conversion continue group financial review detail improve consumer experience grow party datum ahead expect leverage strong progress joint venture integration new insight business significant progress integrate business consumer healthcare joint broadly increase investment digital venture market complete legal capability business improve overall speed close enable legacy pfizer employee efficiency include accelerate digital population formally gsk leadership transformation marketing function advance role confirm market complete system capability new area supply chain cutover operate order invoice datum key enabler growth particular area focus customer market complete cutover allow well understand consumer account global sale customer smart decision create dedicated data team datum scientist innovation remain track deliver synergies million annual specialist user experience designer datum apprentice cost saving draw area build datum strategy governance process readiness network rationalisation logistic infrastructure advertising future standalone company team focus marketing meet target realise billion building datum literacy business enable extract divestment noncore brand process value datum accelerate digital ongoing thermacare include manufacturing transformation site albany georgia key divestment lift integration restriction business europe invest datarelated technology include artificial intelligence machine learn despite operate complex joint venture integration supply chain marketing team allow majority officebase team worked remotely operate efficiently accelerate speedtomarket see fast decisionmake effective meeting great collaboration focus need consumer reflect increase survey result clarity single point accountabilitie effective decisionmake rise favourability base nicholas hall global otc database basis consumption manufacturer price straight talk conversation internal data gsk annual report performance continue continue enhance digital capability literacy recognise critical importance purposedriven people launch digital commerce leadership create new virtual ninemonth academy online learn platform training module development programme senior leader playbooks plan framework resource help gsk consumer healthcare help identify sense embe core digital commerce learning behaviour personal collective purpose accelerate growth launch august employee ambition plan invest development country complete training platform people use line leader programme academy complement digital accelerator programme build capability colleague new roll europe middle east leadership role africa region follow successful launch asiapacific prioritise safety supply programme design drive sale unprecedented challenge digital commerce promote digital culture continue drive decisionmake close consumer integrate external digital expert team regional accountability supply chain trend accelerate pandemic fact accelerate approach start covid consumer proactive manage health pandemic respond agility speed change wellness vitamin mineral supplement category consumer demand uphold commitment safety big beneficiary sale vitamin priority pandemic ensure mineral supplement brand grow high teen wellbee employee continue operate cent particularly strong performance power brand manufacturing site increase safety measure centrum local star emergenc caltrate support critical production employee include china grow double digit year adjust shift pattern minimise employee overlap contact hcp significantly influence health behaviour trace protocol regionally drive support package consumer heighten result covid example grocery site lunch safe transport consumer increasingly rely doctor dentist despite operate unprecedented circumstance pharmacist trustworthy source selfcare continue deliver product matter consumer guidance expert fieldbased representative build additional capacity indemand product continue strengthen relationship hcp fall broad category product like panadol week covid outbreak accelerate adoption provide symptomatic relief immunity remote detail virtual conference roundtable boost property like emergenc see expert fieldbased representative world fully operational new way work regional perspective continue deliver world pharmacist day september partner high level service customer apac emea international pharmaceutical federation raise awareness usa challenge continue meet high level area common interest minimise impact air service customer expect cause pollution people health wellbeing develop significant growth immunity brand supply target digital campaign pharmacist key country disruption precautionary product recall creation social medium asset drive awareness address increase demand put engagement topic campaign reach place significant extra capacity internally million pharmacist engagement contract manufacturing organisation continue content seven time industry average improve supply chain resilience network partnership allow reach pharmacist continue drive culture quality improvement previously able lay foundation build additional source supply continuity build longerterm relationship finish product critical raw material leadership engagement announce plan build capacity focus quality leadership drive appointment manufacturing site civac mexico guayama puerto formal development programme increase effort rico pulogadung indonesia cape town south support employee physical mental wellbee africa streamline network close contribute positive survey score employee site sligo ireland announce closure site feel actively encourage support health wellbee carlisle cease production joint venture integration process create san jose site costa rica sale site expect new diverse consumer healthcare leadership team complete follow divestment broad industry experience legacy gsk pfizer thermacare business outside north america vesterlen business alongside talent wide fmcg sector naturprodukter dietary supplement announce improve depth talent select closure site cluj romania divestment legacy business key role nutrition business hindustan unilever include site nabha rajahmundry sonepat india gsk annual report strategic report governance remuneration financial statement investor information trust trust longterm prioritie crucial purpose enable add value shareholder society progress commit ambitious new partner launch billion form partnership well environmental sustainability goal amr action fund aiming bring prepare future pandemic net zero impact climate net novel antibiotic ensure access future covid positive impact nature patient treatment vaccine include strong performance fda ema approve age trinity challenge esg benchmark appropriate formulation tivicay industry commitment license candidate child live hiv weigh bill melinda gates foundation vaccine bill melinda week engagement gate medical research institute age covax facility continue development set new aspirational target record response gender race ethnicity employee survey engagement improve representation score level introduce mandatory inclusion diversity training employee trust priority focus broad range esg aspect external benchmarking support ability create value society djsi rank pharmaceutical industry group shareholder stakeholder particularly investor dow jones sustainability index increasingly focus company manage esg factor atmi rank access medicine index value creation risk management perspective ftsegood member ftsegood index risk management strong trust esg performance ensure remain attractive investor help cdp score cdp water cdp carbon recruit retain talent mitigate risk build trust name cdp supplier engagement leader stakeholder influence operate environment sustainalytic leading position sustainalytic stakeholder engagement msci rating trust commitment esg area vigeo eiris rank pharmaceutical sector gsk big difference set approach reporting commitment work independent party trust section report progress conduct materiality assessment identify esg issue commitment online publish detailed relevant stakeholder business information contribution sdgs esg commitment help respond challenge opportunity performance summary global compact industry broad society page communication progress global reporting initiative contribute sustainable development index sustainability accounting standard board index goal sdgs especially goal ensure healthy life assurance statement promote wellbee age gskcom esg performance summary contribution sdgs corporate responsibility committee oversee progress commitment company address evolve view expectation broad range stakeholder gsk corporate executive team senior management oversee implementation trust commitment report regularly committee page gskcom gsk materiality assessment gsk annual report trust continue science technology covid pandemic show vital importance early gsk path bharat announce product science technology innovate tackle transfer agreement malaria vaccine significant global impact disease prepare future pandemic step ensure longterm sustainable supply vaccine tafenoquine krintafelkozenis single dose radical cure new medical innovation treatment vivax malaria develop partnership commitment develop differentiate highquality medicine malaria venture prevalence vivax peak need medicine vaccine consumer healthcare child age year old present data product improve health show tafenoquine effective prevent relapse month child adolescent age use cuttingedge science technology discover develop innovative medicine vaccine consumer healthcare hiv product page include june fda approve firstever dispersible tablet develop innovation combat covid formulation dolutegravir tivicay fda approval begin produce dispersible tablet financial risk global health support rapid rollout tivicay integrase inhibitor available oncedaily tablet oral suspension child commitment improve global health impact hiv weigh week age infectious disease affect child fda pass update dose recommendation young people develop country focus approve tivicay filmcoate tablet paediatric hiv malaria tuberculosis hiv patient weigh help close work translate scientific discovery impactful gap hiv treatment option available adult solution world vulnerable patient child approval january ema appropriate transfer innovation technology grant marketing authorisation tivicay dispersible organisation right capability geographic reach tablet include update dose recommendation partner optimise development tivicay filmcoate tablet child hiv candidate medicine vaccine technologies drive publicprivate partnership clinton health access need access initiative unitaid generic manufacturer pursue early discovery global health research mylan macleod continue expedite development particularly neglect tropical disease registration market entry generic formulation paediatric establish scientific research centre focus develop dolutegravir resourcelimite setting key milestone new vaccine medicine global health research recently achieve mylan macleod submit new vaccine global health institute gvgh drug application score dolutegravir dispersible pharma unit tre canto respectively tablet tentative approval fda president emergency plan aid relief pepfar scheme mylan gskcom science global health receive tentative fda approval november tuberculosis fast generic manufacturer file short gap gsk join project accelerate new treatment originator approval generic medicine approval tuberculosis pantb collaboration aiming develop pantb regimen effective form include health security drugresistant strain work identify good possible combination medicine treatment short well commitment help world well prepare safe current standard care multidrug regimen future disease outbreak pandemic potential tackle antimicrobial resistance develop candidate vaccine phase iib trial demonstrate potential reduce pandemic preparedness active pulmonary half adult latent infection take broad approach develop covid january license vaccine bill melinda solution detail gates medical research institute continue development apply science find covid innovation believe area help improve malaria future pandemic preparedness rtss vaccine vaccine help protect child deadly form malaria falciparum join industry commitment expand global whocoordinate pilot implementation programme access covid diagnostic therapeutic vaccine lead national ministries health partnership facilitate bill melinda gates foundation collaborate path gsk ongoing ghana kenya align resource industry government malawi april gsk dispatch enable fast path current covid crisis million vaccine dose child lie foundation strong pandemic preparedness reach dose rtss far ecosystem future gsk annual report strategic report governance remuneration financial statement investor information trust continue found member trinity challenge partner major biopharmaceutical collaboration alongside google microsoft facebook company european investment bank collective vision safeguard live livelihood wellcome trust launch billion amr action fund billion people data analytic well fund aim bring novel antibiotic patient predict prevent outbreak epidemic pandemic gskcom industry covid joint communique train healthcare professional country appropriate use antibiotic address antimicrobial resistance amr amr represent grave threat global public work amr industry alliance health gsk play lead role industry response set new global limit antibiotic discharge rank large pharmaceutical company audit improve need antibiotic supply access medicine foundation amr benchmark chain include gsk factory supplier factory country track ensure factory project target priority pathogen discharge negligible conform alliance standard include pathogen deem critical urgent end currently gsk factory center disease control prevention cdc supplier factory fully compliant relate vaccine continue vaccination major pathway fight amr gskcom prepare future disease threat detail pipeline affordability availability make product affordable available develop country use innovative pricing structure people world responsible pricing strategic extend product reach page tiere pricing access programme partnership model vaccine base widelyrecognise world bank gross national income country classification high pricing uppermiddle lowermiddle lowincome country commitment improve health million tier price ceiling floor progressively decrease people year make product available tier high lowincome country responsible price sustainable business medicine lowincome country file patent medicine enforce historic patent allow generic price new product reflect value company manufacture supply generic version gsk deliver patient healthcare system wide society medicine country compare available alternative support innovation meet future healthcare need gskcom pricing access strategy average net price discount rebate product reach allowance product decrease annually past year average list commitment use access strategy reach price rise combine average net price million underserved people develop country pharmaceutical vaccine portfolio fall product average list price rise set product reach target product offer type patient support include patient reach million people assistance programme coupon copay programme commitment gavi reimbursement support help ensure appropriate access tiere pricing principle mean reserve low medicine provide prescribe medicine vaccine price organisation gavi gsk vaccine lowincome uninsure large supplier vaccine gavi underinsured medicare patient gsk supply million dose vaccine viiv healthcare patient assistance program foundation partnership allow introduce rapidly scale europe engage stakeholder develop access new vaccine take year approach ensure sustainable healthcare system reach child lowincome country confirm continue access innovative medicine example ongoing supply cervarix gavi support continue pricing zejula medicine ovarian cancer reflect effort protect girl human papillomavirus value deliver patient caregiver payer society provide pneumococcal vaccine synflorix demonstrating costeffectiveness predictable budget gavieligible country gavi country discount price reach estimate million child rotarix vaccine rotavirus reach million calculate gsk viiv healthcare product child gavieligible country year cagr calculate jan dec gavi country addition oral polio vaccine supply total exclude reach albendazole donation assess unicef polio eradication reach million people gsk annual report trust continue voluntary licensing viiv healthcare positive action launch new viiv healthcare voluntary licensing agreement allow strategy vision continue explore generic manufacturer produce sell lowcost single innovative way support peoplecentric community fix dose combination product contain dolutegravir lead intervention help meet fast track target adult generic manufacturer child end aids viiv healthcare positive action cover country adult child children fund reach people agreement large majority manufacturer million people benefit partnership medicine patent pool end million comic relief focus combat malaria people live hiv country develop contribute million project world access generic dolutegravircontaining product africa south east asia improve malaria awareness license agreement correspond prevention effort get treatment patient people live hiv antiretroviral low partnership save child amref health middleincome countries africa care international gsk invest training product donation frontline health worker work community low donate billion albendazole middleincome country train tablet include million investment approximately health worker reach million people partner save child support effort eliminate lymphatic filariasis control directly reach people health intestinal worm soiltransmitte helminth schoolage service health message programme activity child far benefit patient country world country eliminate gsk support gate ceo roundtable public health problem publicprivate collaboration train community health worker country subsaharan africa tech support global response covid donate enable community health programme year million gsk product antibiotic oral health programme reach people train product multivitamin country community health worker partnership americare direct relief ihp partnership smile train help child cleft lip map international unit medicine palate lead healthy life benefit donate humanitarian emergency response young people free surgery gskcom pricing access strategy pre postsurgery cleft care form support healthcare access contribute million community initiative include cash product donation volunteer time commitment partner improve disease employee help improve healthcare access prevention awareness access healthcare service provide support healthcare worker pandemic million people detail find gskcom exceed target reach million people gskcom prevention awareness infrastructure covid community partnership give response viivhealthcarecom positive action programme modern employer positive employee experience critical attract retain inclusion diversity motivate good people want employee commitment accelerate progress empower feel good grow include aspirational target female ethnically diverse representation senior role end engage people recognition disability confident employer commitment achieve maintain competitive lgbt indices employee engagement score believe inclusion diversity lead business survey employee annually feedback success unleash enormous potential people innovation performance trust strengthen ability respond differ need culture longterm priority record patient consumer heart agenda people take time feedback overall engagement lie fundamental commitment equity employment score jump rise survey practice support create inclusive workplace feel proud work gsk employee participate annual training programme facilitate inclusion dialogue invest leadership programme ensure leader understand health worker datum estimate base reach responsibility partner programme level funding final datum expect available april gsk annual report strategic report governance remuneration financial statement investor information trust continue corporate executive team cet member lead race ethnicity diversity council cover race ethnicity gender disability svpvp director manager employee lgbt work senior leader member black asian employee resource group minority ethnic measure progress monitor question asian employee survey participant say black authentic self gsk feel mixed respect work add new question manager feedback tool ask white employee rate action manager demonstrate commitment inclusion diversity actively respond indicate team leader score average prefer round sum datum marginally different race ethnicity total commit equality representation mean aspire increase ethnically diverse constantly strive ensure workforce reflect leader end community work hire specifically aspire specifically focus increase percentage increase percentage leader identify black leader expect monitor ethnically diverse country meet threshold ensure yearonyear growth target date expect confidentiality anonymity datum disclose employee growth identify group race ethnicity level communicate countrywide aspiration increase representation ethnically diverse support aspiration commitment equality leader satisfy threshold representation focus recruit develop provide disclosure current representation diverse talent include set appropriate ambitious set aspiration target ethnically diverse candidate early talent programme launch new global disclosure reflect gsk representation development programme accelerate difference ethnically december employee actively voluntarily diverse employee senior role disclose race ethnicity introduce policy require diverse shortlist qualified race ethnicity candidate include ethnically diverse representation define appropriately country svpvp director manager employee ethnically diverse gender american indian percentage woman management continue rise alaska native gsk proud report achieve asian important landmark global percentage female manager presently equal black african american great percentage nonmanager currently hispanic latinx senior management role native hawaiian pacific late hamptonalexander review find gsk rank islander quartile ftse company base proportion race woman board female representation white ftse sector analysis gsk rank pharmaceutical sector insufficient datum report few employee employee actively respond identify race woman management ethnicity category indicate prefer round sum datum marginally different total svpvp aspire increase representation ethnically diverse director leader end manager specifically focus increase management percentage black african american hispanic employee gender number latinx leader expect monitor male female total yearonyear growth target date expect board growth identify group management employee senior manager define company act strategic report director report regulation gsk annual report trust continue increase global gender aspiration mental health training available employee role high end importantly manager complete encourage pursue step country operate open ask help access support need enable encourage employee voluntarily self employee complete energy disclose gender identity resilience programme online training development publish fourth annual gender pay gap report platform participate covidfocuse resilience gender pay gap permanent ukbased gsk webinar virtual mindfulness session employee mean outperform national average introduce personalise digital health platform country longstanding commitment fair include subscription mental health app equal pay conduct countrybase review ensure individual selfsupport measure organisational stress market clear guidance tool support ensure pay platform focus mental health support require equity unexplainable difference detect address employee safety compensation process overall reportable injury illness rate fall disability hour work reduce signatory department international number employee drive base gsk site development charter change join organisation pandemic contribute decrease common aim ensure right freedom dignity despite extensive safety programme tragically inclusion people disability gsk sign experience employee fatality manufacture valuable pledge involve continue inv site canada road traffic accident india workplace accessibility building inclusivity skill additional workrelate fatality belgium people improve product packaging accessibility involve construction worker gsk direct develop measurable threeyear strategic disability supervision conduct extensive investigation confidence plan cause fatality ensure action lgbt reduce risk similar tragic incident occurring goal recognise global lgbt indice develop safety improvement plan consecutive year lgbt rights group stonewall strengthen exist safety practice recognise gsk global employer list approximately employee drive company business rank stonewall index help employee drive safely run driver safety employee resource group lgbt employee ally programme combine online learning practical name good gsk name good road safety activity driver place work lgbtq equality fourth year running country enrol programme human right campaign corporate equality index found member proud science alliance collective people development lgbtq network work raise bar want people develop lgbtq inclusion health life science sector career employee opportunity discuss agree development plan manager health wellbeing development employee access training resource internal development portal year redesign roll commitment lead company new virtual line leader training programme support employee health wellbeing personal development provide target development leader stage career establish leadership health wellbee accountability motivate focus care develop gsk executive team oversee covid response support purpose performance drive culture include health wellbeing engagement employee primary focus support develop strong update manager feedback tool help health safety framework align site need specific role manager need focus type certain activity provide training development manager expect complete monitor confirm covid case process involve selfassessment survey recovery workforce daily basis develop team answer question manager minimum standard return workplace provide participate employee provide clear expectation wear personal protective feedback manager rating scale equipment employee testing temperaturescreening average manager score team workplace safe possible enable employee return site commit recruit develop people start career currently people support employee work home ergonomic graduate mba programme globally advice equipment provide online training remote apprenticeship country work continue ensure sufficient employee assistance support employee dependant skcom employee engagement learn development gsk annual report strategic report governance remuneration financial statement investor information trust continue responsible business operate responsible business mean transparent living value expectation science datum deliver reliable supply employee survey show make good highquality product protect valuesdriven culture progress live value expectation issue respond swiftly transparently reduce employee agree work environment encourage environmental impact ethical behaviour face pressure meet business objective reliable supply conduct joint review commercial practice commit quality safety reliable supply antibribery corruption audit team sale force product patient consumer incentive review finding highlight strong patient focus pride working gsk review identify ensure highquality reliable supply product opportunity well embe value expectation patient consumer priority page daily work reach employee manage continuity supply especially important pandemic gsk employee complementary worker require complete living value expectation mandatory robust quality management system support continuous training annually employee improvement help maintain high standard product complementary worker complete training quality safety comply relevant regulation focus protect gsk content include topic include good manufacturing practice good antibribery corruption abac code conduct laboratory practice good pharmacovigilance practice information security privacy independent thirdparty speak good clinical practice external regulatory integrity line report concern human safety inspection carry virtually pandemic information adverse event report training help manufacture site local operating company identify manage risk appear daytoday role gsk address inspection finding minor robust process ensure corrective preventive mandatory abac training continue action plan implement timely manner employee contract worker complete training focus principle assist carry quality audits supplier employee identify mitigate abac risk audits clinical study run behalf gsk recognise report mitigate conflict interest identify area require improvement engage relevant party develop improvement plan report investigate concern track progress significant issue identify inside outside gsk raise concern speak remain unresolved choose suspend terminate independent party integrity line work party confidentially anonymously fear retaliation concern seriously review pharmacovigilance report understand formal investigation need detect assess understanding prevent adverse investigation employee breach effect drugrelate problem important policy appropriate disciplinary action evaluate safety pharmaceutical product continue work partner maintain high standard respect employee accuse misconduct safety medical governance apply rigour initiate formal investigation policy safety standard potential covid related violation relate behaviour workplace result solution employee discipline dismiss voluntarily leave receive document warning prevent manufacture distribution counterfeit instance action short document warning gsk product continue work international law take end case await enforcement agency play key role anti investigation disciplinary decision counterfeiting action china result closure location manufacture million counterfeit employee discipline breakdown type good include toothpaste brand policy violation skcom patient safety reliable supply behaviour workplace good manufacturing distribution practice ethic value mandatory training completion commitment operate ethical valuesdriven market promotional activity culture issue respond swiftly expense transparently high expectation employee live employee subject multiple allegation disciplinary action value act concern extend policy violation type fit category specify expectation party gsk annual report trust continue human right datum engagement commit respect human right commitment use datum responsibly transparently global operation continue deepen understanding improve patient scientific engagement human right impact associate activity responsible datum use improve visibility labour right risk commit datum responsibly transparently supply chain support external expert include manage datum carefully share result identify raw material commodity clinical study integrate patient insight product link modern slavery prioritise development provide healthcare professional diligence activity similar risk assessment indirect relevant accurate information need supplier progress evolve privacy approach well align membership pharmaceutical supply chain external expectation privacy design framework initiative human right labour subcommittee ensure dataowner consider privacy right start support delivery human right modern slavery activity establish specialised privacy review panel training session supplier india china assess appropriateness secondary use personal information engage stakeholder brazil well understand ensure protect individual right freedom force labour risk certification scheme associate carnauba wax tablet coating present annual code conduct train mandatory finding supplier employee globally include module privacy reinforce understand gsk personally progress priority human right area responsible correct handle personal information access healthcare research practice patient safety provide train new hire fill environment health safety privacy find key privacy role undergoes certification international relevant section report website association privacy professional require ongoing skcom human right modern slavery act statement privacy education maintain work party critical partner transcelerate consortium want ensure party work share effort create harmonised approach pharmaceutical value ethical business standard industry support exchange datum internationally party oversight tpo programme embed clinical trial transparency globally continue refine longstanding commitment datum transparency risk assessment complete tpo programme clinical study publish clinical study party identify high risk report summary result positive undergone detailed independent assessment ecovadi negative study clinical study register help ensure continuity supplier share anonymise patientlevel datum study covid pandemic conduct supplier external researcher financial check offer support supplier financial health list study datum share wwwvivliorg deteriorated example relax payment term wwwclinicalstudydatarequestcom continue work thirdparty supplier gskcom online gsk privacy notice gsk clinical study register reduce ehs risk conduct audits ehs patient scientific engagement ethic country physical visit possible virtual expand priority conduct number patient panel supplier priority supplier wide variety different disease area significant spend support significant establish process seek patient feedback design revenue andor medically critical business clinical trial provide proactive support help supplier build continue increase focus improve safety improvement plan build overall capability diverse representation clinical trial represent use range tool assess supplier management real world population term age race ethnicity gender ehs risk include use ecovadis desktop assessment approach characterise population burden site virtual audits set clear ehs requirement disease barrier access engage community supplier discontinue work supplier advocacy group provide training support consistently fail meet requirement continually staff increasingly research collaborator review ehs performance supplier internal enrolling diverse population clinical trial ehs governance oversight process read approach engage hcp code hcp engagement gskcom ethic value gskcom clinical trial diversity patient engagement engage hcp gsk annual report strategic report governance remuneration financial statement investor information trust continue environment late available datum category absolute scope emission decrease commitment net zero impact climate billion revenue represent reduction net positive impact nature billion revenue baseline year mainly set ambitious new climate nature goal reduction carbon intensity product november start report purchase update data emission milk annual report horlick reduced emission meter dose inhaler new climate goal mean aim net zero scope ellipta dry powder inhaler dpi lifecycle carbon carbon emission climate footprint time low propellantbase goal accredit caligne emission inhaler certify carbon footprint trelegy reduction target cover scope science ellipta working carbon trust recertifie carbon base target initiative join reinforce footprint ellipta product support effort commitment renewable electricity reduce promote low carbon inhaler possible impact sale fleet recognise supplier effort reduce nature goal underpin ambitious target focus environmental impact annual supplier water reduction water stewardship compliance waste environmental sustainability award winner reduction circularity include eliminate plastic api gskcom emission reduction adoption biodiversity action plan expand climate resilience analysis measurement carbon andor land use improve nature task force climaterelate financial base solution programme invest disclosure framework guideline introduce new project protect restore landuse align target relate carbon publish gskcom science base target nature approach measure new net zero target join race zero impact nature seek accredit target global campaign aim build momentum methodology finalise shift decarbonise economy ahead climate seek deliver goal take action priority summit cop impact area work key external partner include skcom new environmental approach supplier award supplier customer gskcom set carbon emission plus intensity ratio regulation target year report previous target set tonne coe scope emission gskcom new environmental approach scope emission carbon scope emission available overall value chain carbon footprint scope report emission operation scope scope emission emission supplier base logistic energy use product meter dose inhaler scope emission sale revenue tonne report progress new carbon target final year report progress scope emission target set target set fte tonne efte baseline reduce operational carbon emission scope scope emissionsbn available reduce value chain carbon emission scope revenue million tonne report billion revenue source electricity ebn revenue renewable source total energy gwh reduce scope emission energy gwh approximately compare largely transform use renewable electricity scope sbtiaccredite target aim baseline scope target commit reduce absolute purchase green certificate mean scope emission baseline electricity source renewably exceed figure expect available later interim target achieving see year treatment use propellantbase inhaler result reduction scope emission national lockdown reduce carbon footprint coe compare coe ellipta dry powder inhaler need drive salesforce carbon emission calculate accord greenhouse gas protocol continue instal improve use exist corporate accounting reporting standard revise edition gsk use marketbase scope emission reporting purpose report scope renewable energy site energy efficiency programme emission category esg performance summary continue identify opportunity reduce energy gsk ask dnv provide limited assurance isae energy scope consumption example instal new heat exchanger select scope carbon emission water waste wastewater mayenne site france transfer heat previously datum methodology report measurement provide esg performance summary kpi definition page lose chilling water use provide hot water demand site gsk annual report trust continue water join action sustainable derivative aim reduce total water use highrisk site enable trace palm oil volume set baseline mill level seven highrisk water site follow network change material use manufacture product see highrisk water vaccine site consumer derive biobase source healthcare horlick site leave network result large animalderived ambition nonanimal derive volume water water stress area remove andor sustainable alternative material operation seven remain highrisk water site time ensure efficacy safety product track achieve reduction target compromise water challenge simply volumetric reduction gskcom new responsible source good water stewardship mean reduce water biodiversity target use improve water quality minimise discharge work community stakeholder address local gskcom new environmental approach water challenge plastic site compliant water set target consumer healthcare business stewardship standard meeting target eliminate problematic unnecessary plastic reduce continue work reach plastic footprint tonne ensure package recyclable quality safety permit introduce new target related water publish gskcom join ceo water mandate join water consumer healthcare business develop design resilience coalition sustainability tool enable design new product sustainable way minimise plastic use gskcom new environmental approach example tool launch waste sustainable plasticfree toothbrush germany end site stop send continue effort reduce single use hazardous nonhazardous waste landfill companywide plastic footprint remove million single use validation year ambition complete plastic item equivalent tonne plastic half achievement exclude waste reduction programme begin end asbestos sent landfill gskcom new target relate pharmaceutical commitment ensure waste repurpose environment beneficial use site parma italy example implement initiative increase gskcom new environmental approach solid waste send incineration energy recovery pharmaceutical environment concentrate hazardous waste stream prevent commit ensure active pharmaceutical incineration tonne contaminate water ingredient apis adversely affect people programme increase waste environment key partner new project repurpose beneficial use site innovative medicine initiative imi focus reduce overall waste prioritisation risk evaluation medicine gskcom new waste reduction circularity environment premier multistakeholder project target environmental datum apis accessible stakeholder gskcom new environmental approach commit ensure api emission responsible source manufacturing include contribute carry risk assessment help antimicrobial resistance amr kept level identify highestrisk material supply chain negatively impact human health environment result assessment develop responsible carry environmental testing pharmaceutical source plan highrisk material use datum risk assessment evaluate potential committed move deforestationfree source harm use datum set safe discharge target key commodity purchase directly gsk indirectly manufacture supply chain reduce amr risk behalf early expand scope deforestationfree source policy cover soy cattlederive gskcom new target relate pharmaceutical product rubber palm oil paper packaging environment submission cdp forest cover source palm oil paper packaging paper gskcom new environmental approach packaging majority carton supply chain forest stewardship council programme endorsement forest certification pefc certify kpi definition esg performance summary exception gsk annual report strategic report governance remuneration financial statement investor information risk management gsk wellembedde risk management framework review continually board committee provide oversight framework assist risk oversight compliance council risk management framework enable gsk board year develop risk management identify evaluate manage principal risk line framework move annual quarterly upwards report longterm priority set effective hierarchy risk principal risk emerge risk external insight management compliance board enable risk oversight compliance council business promote tone establishe oversee risk dynamic way report risk culture oversee effective cascade datum drive key risk indicator enable agile escalation information internal control principal risk management strategy addition risk mitigation risk oversee cet risk owner ensure proportionate relate covid incorporate control place clear plan assign address significant risk complement pandemic risk gap business risk owner provide reporting identify manage cet risk mitigation risk oversight compliance new risk escalate standalone council board committee principal risk environmental sustainability nonpromotional gsk consider current emerge risk engagement transformation thirdparty oversight cease risk management framework emerge risk define principal risk implementation mature threeyear horizon residual risk effectively manage business adequate information impact likelihood relevant principal risk cet agree maintain emerge risk undertake investigation current principal risk include list principal risk emerge list current principal risk follow page risk assessment perform remit order significance risk definition risk management compliance board level mitigate activity page organisation risk associate propose separation cet conduct formal annual risk review consider gsk consumer healthcare business current emerge risk significant separation consumer healthcare business dependent include principal risk list review number factor outside gsk control include support extensive analysis external trend require shareholder regulatory approval favourable insight senior level interview recommendation condition public equity market public private risk management compliance board debt market change applicable law regulation risk management framework complement value certainty separation expectation speak process ensure complete propose risk associate business activity actively addition separation complete effectively identify mitigate provide reasonable assurance gsk consumer healthcare assurance material misstatement loss conduct realise expect benefit separation separation annual confirmation exercise business adversely affect gsk consumer healthcare validate key risk manage action value liquidity respective share place address gap reinforce accountability leader risk associate covid potential impact covid pandemic gsk board oversight extend audit risk trading performance principal risk committee include involvement corporate assess mitigation plan place date responsibility committee science committee report pandemic anticipate impact committee consider gsk risk strategy group performance year primarily demand address draw annual business vaccine result ongoing containment measure unit risk assurance update report strategy paper impact customer ability willingness access significant risk cet annual risk review vaccination service region anticipate government prioritisation covid vaccination programme continue impact vaccine business continue monitor situation closely continue viability statement dynamic uncertain situation ultimate severity duration impact unknown point include potential arc report impact trading result clinical trial supply continuity principal risk uncertainty employee situation change time internal control framework assurance covid pandemic material adverse impact future result group gsk annual report risk management continue risk assessment mitigation activity patient safety macro risk level unchanged remain challenge politicisation drug vaccine safety efficacy context covid provoke distrust alter public reporting restrictive privacy regulation impact manage safety datum create complication gsk exposure unchanged operational risk stabilise embed pharmacovigilance organisational efficiency offset challenge accompany fastpace development medicine vaccine covid mitigate risk apply wellestablished safety governance risk management framework ensure safeguard patient lifecycle gsk product product quality macro risk remain despite concern potential drug shortage associate covid ongoing evaluation product presence nitrosamine increase focus datum integrity requirement gsk exposure remain unchanged quality oversight process place monitor maintain strong compliance profile pandemic governance control strategy develop deploy timely completion nitrosamine assessment continue invest technology digital platform strengthen control good datum management practice financial control macro risk level increase external environment remain challenge political uncertainty increase societal expectation role auditor report increase fraud attempt challenge financial market inform mainly covid pandemic evolve political response gsk risk exposure remain stable resilience focus personnel continue implement transformational programme leverage technology centralise process strengthen control maintain effective tax treasury strategy antibribery macro risk level bribery corruption increase continued legal corruption abac framework similar develop rigorous standard aid improve technology increase enforcement focus thirdparty intermediary impact covid business gsk abac risk exposure maintain continue improve abac programme ensure appropriate control training capability building awareness raise strong monitoring use data analytic continue understand assess risk exposure money launder wide corruption mitigate exist risk commercial covid increase macrolevel risk industry gotomarket model boost practice importance different channel activity internet base consumer promote pricing connect commercialising increase risk downward price pressure international reference pricing aggressive healthcare budget control tight reimbursement gsk risk exposure level remain stable mature robust control environment continue evolve commercial practice invest new technology support virtual customer engagement maintain proportionate control training monitor employee engage healthcare organisation professional consumer healthcare improvement digital sale marketing control framework mitigate emerge risk nonpromotional macro environment nonpromotional activity scientific engagement hcp patient stable despite impact complexity dynamic nature engagement disease area treatment increase diversity engagement platform significant increase virtual engagement pandemic gsk exposure increase modernise adapt practice apply internal principle policy design mitigate risk rapidly evolve environment evolve employee training people understand risk associate nonpromotional activity conduct compliance gsk value policy local law regulation gsk annual report strategic report governance remuneration financial statement investor information risk management continue risk assessment mitigation activity privacy macro risk continue increase priority gsk market china india institute new enforce exist privacy law court ruling invalidate privacy mechanism international company rely include euus privacy shield covid highlight fragmented nature regulatory environment gsk exposure remain unchanged continue effort embed privacy framework market evolution risk mitigation business advance privacy strategy centrallydriven mitigation approach business proactively embed privacy design standard research macro risk level increase covid pandemic create continuity practice challenge particularly human subject research disruption global clinical trial programme introduce additional risk gsk exposure remain unchanged offset external impact pandemic risk mitigation action embed monitor additional business continuity measure control ongoing plan work enhance monitor culture quality continue environment macro risk level increase regulator stakeholder expectation health safety broadly new regulation control spread covid workplace ehs add significant complexity comply exist ehs regulation gsk risk exposure increase adjustment work practice enable covid control measure transition period significant organisational change factor require refocus apply ehs fundamental environmental macro risk level increase investor regulator stakeholder increasingly sustainability expect company understand reduce environmental impact value chain mitigate impact climate change operation supply chain gsk risk exposure unchanged set ambitious new environmental sustainability target implement detailed water resilience assessment increase task force climaterelate financial disclosure tcfd analysis continue monitor trend physical reputational regulatory risk climate change impact information macro risk level continue rise large multinational increase digital footprint security threat hacker sophisticated year covid add measurable increase threat target healthcare industry gsk risk exposure increase gsk cybersecurity programme continue rapid improvement control increase cyber threat intelligence capability protect critical information system include operational technology network gsk continue strengthen cybersecurity information protection capability target pharmaceutical vaccine intellectual property leverage cybersecurity party service availability mean disruption intensify supply continuity macro risk level remain high ongoing impact covid pandemic product supply potential increase protectionism country brexit uncertainty continue gsk risk exposure increase elevated risk supply issue bioscience material glass vial filter industrywide concern arise rapid ramp covid vaccine therapeutic drive increase demand component transformation macro risk level increase covid introduce uncertainty external global environment necessitate temporary measure certain country protect employment gsk risk exposure level remain unchanged transformation separation project progress plan workforce engagement priority gsk annual report risk management continue climaterelate financial disclosure provide update gsk voluntary disclosure risk extreme weather event flood wildfire accordance recommendation taskforce storm impact supply chain manufacture climaterelate financial disclosure tcfd initiative operation shortterm basis year financial stability board promote disclosure review annually address business continuity climate change risk plan scenario analysis continue inform focus consider address potential longerterm impact november commit ambitious new seven year climate change environmental sustainability goal climate nature aim net zero climate impact net positive scenario consider impact nature goal build longterm businessasusual assume little mitigation ambition reduce impact environment lead warming lowcarbon assume global temperature governance increase limit rapid board overall accountability management change legislation technology gsk principal risk include environmental scenario base internationally recognise datum sustainability support cet board set consider potential physical risk change corporate responsibility committee crc oversee gsk climate flooding water stress risk environmental sustainability principal risk progress associate transition lowcarbon economy environmental target crc support work international climate policy impact carbon pricing member cet include ceo president analysis evaluate implication gsk manufacture global affair president pharmaceutical supply chain facility supplier raw material provider attend committee meeting impact patient consumer use product year crc review approve assessment consider action gsk recommendation companys new sustainability goal mitigate adapt finding crc review contribution biopharma analysis physical transition risk show consumer business goal crc scenario likely financial risk discuss impact climate change nature loss need manage materially impact human health recognise new goal consistent business model key impact scenario company purpose strategy floodrelate disruption manufacture site regi simard president pharmaceutical supply chain supply chain member cet management responsibility environmental sustainability responsible governance water stress lead increase expenditure disruption risk oversight ensure effective framework manufacturing site supply chain place use manage risk high temperature affect quality availability business deliver commitment raw material strategy increase cost fossil fuel impact carbon trust longterm priority reduce pricing energy emission environmental impact important trust priority finding build initial assessment gain well understand climate change develop approach perform climate impact business build datum report risk scenario analysis action plan help mitigate undertake scenario analysis consider longterm longerterm risk embed sustainability strategy risk climate change additional product support environmentally sustainable decision vaccine pharmaceutical consumer internal carbon pricing capital investment pilot healthcare business mean take combination shadow price tonne reflect current good work complete developed climate practice evaluate impact governance require scenario analyse supply chain cover approximately view implementation group aim revenue stream ensure organisation asset carbon efficient time scenario base ippc representative concentration pathway iea world energy outlook new policy scenario current policy scenario sustainable development scenario datum set wwf wri water stress flood risk modelling gsk annual report strategic report governance remuneration financial statement investor information risk management continue risk management establish transformation office review environmental sustainability include climate change assess monitor progress new goal risk standalone principal risk business commitment include key performance indicator specific dedicated environmental sustainability scope carbon emission percentage enterprise risk plan place detail renewable electricity operation proportion risk management risk plan cover sale force vehicle electric vehicle expectation gsk address impact detail progress make achieve environment environment increase impact target find environment section operational resilience access energy water public response cdp climate water natural resource product questionnaire anticipate cost increase regulatory change environmental taxis step commit continue embed climate risk internal control framework establish assessment mitigation activity business environmental sustainability include appointment plan review aggregate analysis dedicate senior leader environmental sustainability identify hotspot opportunity continue ensure governance process place effective reduce value chain carbon emission bring performance reduce carbon emission energy transparency impact scenario financial water waste continue deliver manage assessment future annual report mature programme enhance include ecodesign consideration product package metric target new target net zero impact climate net positive impact nature aim deliver goal take action priority impact area work key external partner include supplier customer set target contribute goal available gskcom accredit science base target initiative set scope target line decarbonisation require global temperature increase join race zero demonstrate commitment transition low carbon economy ahead cop hold join align commitment source electricity use renewable resource join align commitment decarbonise fleet sale vehicle commit move deforestationfree source key commodity work partner roundtable sustainable palm oil rainforest alliance gsk annual report risk management continue viability statement accordance provision revision downside scenario consider gsk cash flow code gsk assess prospect company sustainability dividend fund strategy insurance provision long period month require recovery key financial ratio period go concern provision director confirm metric subject sensitivity analysis reasonable expectation gsk continue operate involve flex number main assumption underlie meet liability fall year forecast individually combination director assessment reference mitigate action realistically take avoid gsk current position prospect strategy reduce impact occurrence underlie risk board risk appetite gsk principal risk follow hypothetical downside scenario manage detailed page evaluate strategic report scenario business performance risk include key board review internal control risk management performance risk include low sale new product policy approve governance structure code great adverse impact generic competition conduct appraise approve major financing competitive launch gsk product investment licensing decision evaluate monitor possible supply manufacturing challenge performance prospect gsk focus largely improve longterm financial performance scenario external macroeconomic risk scenario delivery company business strategy reflect incremental risk business drive outside align innovation performance trust priority factor intense competition increase pricing pressure europe potential board review gsk strategy make significant capital impact material negative change macroeconomic investment decision longterm time horizon base healthcare environment multiyear assessment return capital performance company business unit market scenario principal risk scenario include severe opportunity pharmaceutical vaccine consumer assessment potential loss impact principal risk sector approach align gsk model achieve relate patient safety product quality supply chain continuity balanced growth invest high quality innovative product environmental sustainability antibribery patient consumer healthcare provider corruption consequent regulatory action fine internal external parameter fundamentally threaten operation increasingly unpredictable long time horizon gsk include potential severe impact coronavirus focus detailed bottomup plan threeyear cycle materialise supply chain disruption risk manage mitigating activity describe page plan review annually director approve business forecast show expect financial impact director believe threeyear assessment period scenario option exercise scenario evaluate viability statement appropriate align additional funding requirement assume early potential company establish business planning process exercise outstanding option hold partner balance longterm nature investment hiv business pharmaceutical vaccine consumer sector future separation consumer healthcare joint venture assessment period analysis nearterm pfizer approve board likely occur business performance realistically visible period cover viability assessment plan stress test series robust operational consider scenario conclude principal risk downside scenario board material impact viability group resultant separate review risk include potential risk associate company threeyear period assessment ongoing coronavirus pandemic consider threeyear review make certain assumption plan stress test downside scenario normal level capital recycling likely occur consider plan assume healthcare system consumer trend additional financing facility require approach normality second half vaccine respective level funding flexibility headroom business plan assume disruption result stress testing certain combination half give government prioritisation coronavirus hypothetical scenario increase funding vaccination programme resurgence late demand gsk require mitigate change pandemic expect impact adult adolescent group funding strategy light liquidity immunisation include shingrix notably strong available group base analysis director recovery contribution growth shingrix assume reasonable expectation second half stress test severe stress test company able continue potential risk principally delay business recovery operation meet liability fall threeyear period assessment gsk annual report strategic report governance remuneration financial statement investor information risk management continue impact brexit leave january brexit transition reteste certification complete period end december trade relevant marketing authorisation transfer update packaging cooperation agreement tca place secure additional warehousing product override priority prepare uks exit continue support employee obtain settle status maintain continuity supply equivalent europe comply medicine vaccine consumer healthcare product new tax custom requirement introduce new people postbrexit operating model border trade term place implement continue work closely northern ireland government expenditure date brexit preparation party effective implementation tca line projection mainly attribute set ensure life science sector continue thrive reteste medicine consumer product deliver innovation patient continue anticipate subsequent ongoing cost gsk welcome medicinal product annex tca arise brexit approximately million particular inclusion mutual recognition good year ongoing cost impact custom manufacturing practice gmp inspection duty increase logistic cost traverse new border lack agree mutual recognition batch testing cost duplicate testing release product new model conduct reteste certification continue understand technical implication medicine consumer product europe require tca implementation correspond guidance prepare meet phasedin requirement assumption underlie forecast change consequent adjustment nonfinancial information statement follow align nonfinancial reporting requirement contain section company act description business model human right policy diligence outcome create value human right summary principal risk datum engagement principal risk uncertaintie social matter party viability statement global health audit risk committee report anticorruption bribery health security nonfinancial key performance affordability availability live value expectation indicator report investigate concern employee antibribery corruption key performance indicator employee engagement environmental matter policy diversity wellbee development carbon water waste public policy code gender pay gap standard available gskcom living value expectation board diversity gsk annual report group financial review section report framework approach tax financial performance adjust item cash generation conversion financial position resource treasury policy critical accounting policy strategic report governance remuneration financial statement investor information group financial review report framework total adjust result cost ordinary course small scale restructuring group financial review discuss operate legal charge expense retain total financial performance group cash flow financial adjust result position resource result year adjust result include benefit major restructuring compare primarily result precede year programme exclude significant cost significant total result legal major restructure transaction item total report result represent group overall regard complete picture group financial performance performance present total result exclusion adjust item result adjusted gsk use number adjust nonifrs measure earning materially high low total earning report performance business adjust result particular significant impairment restructure nonifrs measure consider addition charge legal cost exclude adjusted earning substitute superior information present high total earning accordance ifrs adjust result define nonifrs measure define gsk undertake number major restructuring programme response significant change group gsk believe adjust result consider trading environment overall strategy follow material total result provide investor analyst acquisition cost cash noncash stakeholder helpful complementary information programme provide individual element understand well financial performance position approve meet accounting recognition criterion group period period allow group result charge incur number year performance easily compare majority follow initiation major restructure programme peer company measure management planning reporting purpose group initiate twoyear separation preparation directly comparable similarly describe measure programme prepare gsk separation new company lead company biopharma consumer healthcare gsk encourage investor analyst rely time time group divest noncore investment single financial measure review gsk annual report product business record profit loss include financial statement note entirety disposal adjust item notable divestment year disposal horlick consumer adjust result healthcare brand adjust result exclude follow item total result significant legal charge expense arise tax effect item settlement litigation government investigation amortisation intangible asset exclude computer software normal course materially large capitalise development cost regularly occur individual matter include certain impairment intangible asset exclude computer major legacy matter software goodwill reconciliation total adjust result provide major restructuring cost include impairment information key adjust item tangible asset computer software specific set year boardapprove programme structural set page significant scale cost individual relate gsk provide earning guidance investor community project exceed million include integration cost basis adjust result line peer company follow material acquisition expectation investor community support easy transactionrelated accounting adjustment relate comparison group performance peer gsk significant acquisition able guidance total result reliably proceed cost disposal associate product forecast certain material element total result business significant legal charge net insurance particularly future fair value movement contingent recovery expense settlement litigation consideration option give rise government investigation operate income significant adjustment drive external factor royalty income item currency movement capital market separation cost prepare separation gsk company impact enactment tax cut job act gsk annual report group financial review continue report framework continue historical record adjust item reconciliation total adjust operating profit year summarise follow total operating profit intangible asset amortisation intangible asset impairment major restructuring transactionrelate item divestment significant legal item separation cost tax reform adjust operate profit analysis impact transactionrelated item operating profit year follow novartis consumer healthcare joint venture option contingent consideration shionogiviiv healthcare include shionogi preferential dividend viiv healthcare option pfizer preferential dividend contingent consideration novartis vaccine business release fair value uplift acquire pfizer inventory adjustment transactionrelate item reconciliation total adjusted result set page explanation adjust item report noncontrolle interest viiv healthcare viiv healthcare agree pay additional future cash trading profit allocation consideration shionogi contingent future sale viiv healthcare subsidiary group performance product develop joint operating result turnover operate profit profit tax venture principally dolutegravir ifrs business include group income statement combination gsk require provide estimate portion earning allocate noncontrolle fair value contingent consideration time interest own shareholder line acquisition require update liability late respective equity shareholding pfizer shionogi estimate fair value subsequent period end shareholder include gsk entitle liability contingent consideration recognise preferential dividend determine performance balance sheet date acquisition million certain product shareholder contribute subsequent remeasurement reflect relative performance product change time operating incomeexpense adjust item proportion overall earning viiv healthcare income statement period december allocate shareholder change particular liability discount stand increase proportion sale dolutegravircontaine million posttax basis product favourable impact proportion cash payment settle contingent consideration preferential dividend allocate gsk adjust item shionogi viiv healthcare quarter base allocate shareholder base equity interest actual sale performance relevant product gsk entitle approximately total earning previous quarter payment reduce balance sheet adjust earning viiv healthcare liability record income statement remeasurement liabilitie preferential dividend cash payment shionogi viiv healthcare allocate pfizer shionogi include million operating incomeexpense liability require record fair value acquisitionrelate arrangement estimate future payment significant timing consideration acquisition shionogis interest difference charge record total shionogiviiv healthcare joint venture income statement reflect movement fair value shionogi receive equity stake viiv healthcare liability actual cash payment settle liability gsk annual report strategic report governance remuneration financial statement investor information group financial review continue report framework continue cash payment reflect cash flow statement gsk notify shionogi partly operate cash flow partly investing irrevocably give right accordingly recognise activity tax relief payment reflect liability option group balance sheet group adjust item tax charge initial value million payment relate original estimate fair shionogi irrevocably agree waive option value contingent consideration acquisition result gsk derecognise liability option shionogiviiv healthcare joint venture million group balance sheet directly equity value report investing activity cash flow statement liability million derecognise payment relate increase gsk option shionogis shareholde liability acquisition report operate cash viiv healthcare original agreement flow exercisable sixmonth window commencing movement contingent consideration payable shionogi gsk irrevocably agree waive follow exercise window sixmonth window remain option fair value value accounting purpose contingent consideration begin year free cash flow remeasurement income statement free cash flow define net cash inflow operate cash payment operate cash flow activity capital expenditure property plant cash payment invest activity equipment intangible asset contingent consideration contingent consideration end year payment net finance cost dividend pay non contingent consideration payable posttax basis control interest plus proceed sale property shionogi december million december plant equipment intangible asset dividend million expect pay year receive joint venture associate management planning reporting purpose exit right discussion presentation investment analyst pfizer request ipo viiv healthcare time rating agency free cash flow growth calculate gsk consent ipo offering report basis reconciliation net cash inflow complete month pfizer require gsk operation free cash flow set acquire shareholde original agreement gsk unconditional right long subsequent cer aer growth distribution shareholder withhold consent order illustrate underlying performance group exercise pfizer option result accordance practice discuss result term constant exchange ifrs gsk recognise liability option rate cer growth represent growth calculate balance sheet gsk notify exchange rate determine result overseas pfizer irrevocably give right accordingly company sterling remain unchanged recognise liability option group balance comparative period cer represent growth sheet initial value million constant exchange rate aer represent growth consistent revise treatment end actual exchange rate gsk recognise liability future preferential proforma growth dividend anticipate payable pfizer shionogi acquisition pfizer consumer healthcare business group balance sheet complete july closing balance liability related pfizer group present proforma growth rate cer shareholding follow turnover adjust operating profit operating profit business take account transaction proforma growth rate cer calculate compare report result pfizer option calculate apply exchange rate pfizer preferential dividend comparative period result adjust include equivalent seven month result july original agreement shionogi pfizer consumer healthcare business consolidate request gsk acquire shareholding viiv healthcare include pfizer gaap result sixmonth window commence gsk unconditional right long return capital employ subsequent distribution shareholder withhold return capital employ calculated total profit consent exercise shionogi option taxation percentage average net asset year result gsk recognise liability option net debt balance sheet note net debt calculation net debt gsk annual report group financial review continue approach tax understand responsibility pay appropriate ongoing public focus tax affair tax fully support effort ensure company multinational company include major project appropriately transparent tax affair organisation economic cooperation development manage tax important element economic oecd address tax challenge digitalisation contribution bring country operate economy gsk welcome oecds effort identify engage artificial tax arrangement longterm sustainable consensusdriven solution business commercial substance seek avoid tax tax challenge result digitalisation active use tax haven transaction fully provide relevant business input assist successful disclose tax authority zero tolerance approach delivery aim project order create long tax evasion facilitation tax evasion last stable certain business environment taxpayer government multilateral consensusbase substantial business employment presence approach ground clearly define accept principle country globe pay significant critical incentive innovate dilute tax include corporation business taxis tax associate employee time continue focus tax reform drive responsibility shareholder financially oecds base erosion profit shift bep project efficient deliver sustainable tax rate initiative fiscal state aid investigation approach look align investment strategy introduction mandatory disclosure rule output country substantial economic activity oecd bep project clarify important principle government policy promote regime tax pay profit supply chain attractive business investment activity profitmake activity take place gsk subject transparent intent available relevant tax payer taxation supply chain example include patent box research gsk support bep proposal particular development expenditure credit implementation oecds recommendation country tax risk country operate manage country report include exchange datum robust internal policy process train compliance tax authority datum validate exist programme board director audit risk information hold taxpayer support ability ensure committee responsible approve tax policy multinational group pay appropriate tax risk management arrangement wide internal leave january brexit transition control framework seek develop cooperative period end december trade relationship tax authority base mutual respect cooperation agreement tca place transparency trust appropriate provide comply new tax custom requirement constructive business input tax policy matter advocate introduce new border trade term reform support economic growth job creation place ukeu tca need patient agree december complexity group corporate tax charge million interaction continuity free trade agreement million profit tax million impact taxis fully quantifiable later million represent effective tax rate direct tax implication expect limited cash tax payment indirect tax implication significant include million year million addition example additional custom duty product cover taxis pay profit pay duty levy ukeu tca irrecoverable indirect tax cost transactional employment taxis gsk prepare additional administrative complexity tax arrangement new border adjust tax rate great britain ensure continuity supply wide rate benefit cancellation approach brexit set government reduction corporation tax rate result increase value balance sheet tax strategy set detail public policy tax asset subject material change product mix section website detail corporate tax material change tax regulation law country charge year set operate group average effective adjusted tax rate medium term expect group total tax rate low adjust tax rate mainly tax effect disposal horlick consumer healthcare brand unilever subsequent disposal share receive hindustan unilever gsk annual report strategic report governance remuneration financial statement investor information group financial review continue financial performance group turnover total result group set proforma aer growth cer growth cer growth growth turnover turnover cer turnover cost sale sell general administration research development royalty income operating incomeexpense operating profit net finance cost total operating profit share aftertax profit associate aer growth cer growth joint ventures profit taxation taxation profit taxation year profit attributable shareholder earning share earning ad adjust result group set reconciliation total result adjust result set adjusted operating profit growth proforma pro aer growth cer growth cer growth forma growth turnover turnover cer cer turnover cost sale sell general administration research development royalty income adjust gsk use number adjust nonifrs measure report operating performance business adjust result profit nonifrs measure consider addition adjust substitute superior information present profit accordance ifrs adjust result nonifrs attributable measure define page shareholders adjusted earning share gsk annual report group financial review continue financial performance continue group turnover pharmaceutical group turnover business turnover growth growth cer aer growth cer growth pharmaceutical vaccine group turnover consumer healthcare corporate unallocated turnover proforma growth group turnover geographic region growth growth cer pharmaceutical turnover growth growth europe cer international respiratory hiv immunoinflammation group turnover million year aer oncology cer proforma basis group turnover establish pharmaceuticals cer cer exclude impact divestment vaccine brand divest review consumer healthcare pharmaceutical turnover year million pharmaceutical turnover year million aer cer respiratory sales aer aer cer respiratory sales aer cer million growth trelegy nucala cer million hiv sale flat aer relvarbreo hiv sales flat aer cer cer million sale establish pharmaceutical million growth juluca dovato partly offset decline aer cer million tivicay triumeq sale establish pharmaceutical decline aer cer million vaccine turnover decline aer cer million primarily drive adverse impact end quarter additional demand relate covid pandemic hepatitis vaccine dtpacontaine covid pandemic positive impact growth vaccine synflorix bexsero divestment hiv respiratory product effect broadly reverse rabipur encepur decline partly offset high second quarter see low level new patient sale influenza vaccine region shingrix prescription europe reduce market growth europe china strong demand allergy antibiotic product international performance cervarix china europe effect continue see second half year report consumer healthcare sale grow aer cer million year largely drive sale grow aer cer continue growth inclusion pfizer portfolio partly offset brand nucala trelegy benlysta zejula hiv twodrug divestedunder review proforma basis sale decline regimen partly offset decline tivicay triumeq cer grow cer exclude brand divestedunder establish product include impact generic review reflect underlie strength brand albuterol substitute portfolio strong growth ecommerce successful europe sale decline aer cer growth execution meeting evolve consumer demand result respiratory hiv oncology offset decline establish pandemic pharmaceutical sale impact generic competition low demand antibiotic covid pandemic period approximately percentage point decline impact oneoff relenza contract comparator gsk annual report strategic report governance remuneration financial statement investor information group financial review continue financial performance continue international decline aer cer respiratory dolutegravir sale flat aer cer benlysta growth partly offset lower establish europe dolutegravir sale grow aer cer follow pharmaceutical sale include impact weak recent launch dovato combine sale twodrug allergy season generic competition avolve japan regimen million million slow market growth covid pandemic period europe growth offset decline triumeq government mandate change increase use international dolutegravir sale decline aer grow generics china cer driven tivicay tender business respiratory oncology total respiratory sale aer cer sale zejula parp inhibitor asset acquire tesaro strong growth region international respiratory sale grow million year aer aer cer include nucala aer cer drive volume growth compare prior year cer relvarbreo aer cer million blenrep treatment patient relapse refractory europe respiratory sale grow million aer multiple myeloma approve launch cer respiratory grow aer cer europe report sale million include trelegy nucala relvarbreo sale grow aer cer mainly effect prior period immunoinflammation rar adjustment sale benlysta year aer cer million include sale subcutaneous formulation sale nucala million year grow million aer cer aer cer sales aer cer million europe sale million grow aer duvroq patient anaemia chronic kidney disease cer international sale million grew launch japan report sale aer cer international region million trelegy sale aer cer million establish pharmaceutical drive growth region new asthma sale establish pharmaceutical year indication approve launch sale million aer cer aer cer million europe sale grew establish respiratory product decline aer aer cer international trelegy cer million advairseretide ventolin asthma approve japan quarter sale grew impact generic substitute europe million year flovent experience price pressure relvarbreo sales aer cer international region allergy sale impact market million year relvarbreo grow contraction generic launch japan aer cer mainly effect prior period remainder establish pharmaceutical portfolio rar adjustment europe international relvarbreo decline aer cer million lower continue grow aer cer aer demand antibiotic covid pandemic period cer respectively impact government mandate change increase hiv use generic market include japan france china hiv sale million flat aer cer strong comparator include european contract year dolutegravir franchise grow aer cer deliver sale million remain portfolio sale million total hiv sale decline aer cer reduce overall growth total hiv percentage point sale dolutegravir product million month tivicay deliver sale million aer cer triumeq sales million aer cer twodrug regimen juluca dovato deliver sale million month combined growth offset decline threedrug regimen triumeq gsk annual report group financial review continue financial performance continue vaccine follow category decline relate pandemic impact state turnover meningitis aer growth cer growth meningitis sale grow aer cer million bexsero sale decline aer cer million reflect low demand international partly offset group turnover low return rebate menveo sale decline aer grow cer million primarily drive high demand europe low return rebate partly offset low demand competitive pressure international bexsero menveo grow market share influenza fluarixflulaval sale million aer vaccine turnover cer primarily reflect robust demand growth growth region result strong government recommendation cer prioritise flu vaccination covid pandemic meningitis condition reversal prior year return influenza provision shingle establish vaccine shingle shingrix grow aer cer million primarily drive strong performance europe reflect robust vaccine turnover decline aer cer underlie demand germany launch shingrix china million primarily drive adverse impact contribute sale growth decline demand covid pandemic hepatitis vaccine dtpacontaine low adult wellness visit vaccine synflorix bexsero divestment vaccination rate partially offset strong uptake rabipur encepur decline partly offset high return growth expect sale influenza vaccine region shingrix support coadministration seasonal flu vaccination growth europe china strong programme performance cervarix china establish vaccine vaccine performance region affect low sale dtpacontaine vaccine infanrix pediarix demand limited visit healthcare practitioners boostrix decline aer cer infanrixpediarix point vaccination pandemic government sale decline aer cer million reflect stayathome directive area lockdown lift low demand unfavourable yearonyear wellness visit vaccination rate recover paediatric cdc stockpile movement supply constraint vaccination near precovid level end competitive pressure europe adolescent adult immunisation improve slow pace backtoschool vaccination disrupt boostrix sale aer cer million school university delay reverse inperson tuition primarily low vaccination rate region elongate backtoschool vaccination season hepatitis vaccine decline aer cer adult wellness visit return prior year level million adversely impact europe lower end support seasonal flu vaccination demand travel restriction competition decline late pandemic condition worsen return market synflorix sale decline aer cer million primarily low demand international supply constraint emerge market rotarix sale flat aer grow cer million reflect improve supply emerge market high demand europe partly offset low channel inventory mmrv vaccine sale grow aer cer million largely drive improved supply increase market share europe gsk annual report strategic report governance remuneration financial statement investor information group financial review continue financial performance continue consumer healthcare quarterly performance volatile year direct result covid pandemic sale proforma cer exclude brand divestedunder review turnover proforma quarter give accelerate purchase flat second quarter aer growth cer growth cer growth reverse quarter final quarter year group turnover oral health oral health sale grow aer cer million sensodyne continue outperform lowdouble digit growth reflect underlie brand strength successful innovation include sensodyne sensitivity gum strong consumer uptake traditional retail ecommerce channel gum health continue deliver double digit growth consistent trend year whilst denture care decline lowsingle digit give challenge market condition consistent prior quarter consumer healthcare turnover growth growth pain relief cer pain relief grow aer cer million oral health proforma basis sale grow midsingle digit drive pain relief successful otc switch voltaren panadol vitamin mineral supplement increase midsingle digit increase consumption respiratory health early year offset brand decline final quarter digestive health advil deliver improved performance second half year end year lowsingle digit brand divestedunder review vitamin mineral supplement vitamin mineral supplement double aer cer million proforma basis sale growth growth continue grow highteen cent consistent cer prior quarter strong performance centrum caltrate emergenc particularly strong category growth europe reflect continued consumer focus health wellness international consistent previous quarter result covid pandemic combine businesss ability proforma growth successfully quickly adapt execute deliver meet report basis sale grow aer cer consumer need million year largely drive inclusion respiratory health pfizer portfolio partly offset brand divestedunder respiratory health sale grow aer cer review million proforma basis sale decline proforma basis sale decline cer grow midsingle digit drive low cold flu season cer exclude brand divestedunder review reflect final quarter offset benefit increase underlie strength brand portfolio consumption quarter covid category strong growth ecommerce successful pandemic result robitussin contac theraflu execution meeting evolve consumer demand result decline year allergy nasal product performance pandemic mixed flonase growth lowsingle digit overall result benefit strong growth vitamin otrivin decline midsingle digit mineral supplement continue growth oral digestive health health pain relief digestive health digestive health brand grow aer cer respiratory health sale cer year million proforma basis sale decline benefit increase consumption quarter lowsingle digit growth digestive health product offset sale decline rest year decline skin health product nonstrategic particularly pronounce fourth quarter result brand smoker health product flat year historically weak cold flu season gsk annual report group financial review continue financial performance continue cost sale growth adjust sga cost flat aer grow growth growth cer proforma basis cost reduce cer cer reflect benefit restructure include oneoff total cost sale benefit restructure postretirement benefit adjust cost sale continue benefit restructuring pharmaceutical total cost sale percentage turnover consumer healthcare support function reduce variable percentage point low aer percentage point spend business result low cer term compare primarily covid lockdown tight control ongoing cost reflect lower unwind fair market value uplift particularly nonpromotional spending inventory arise completion consumer healthcare business partly offset increase investment joint venture pfizer promotional product support particularly new launch vaccine respiratory hiv exclude adjust item adjust cost sale percentage turnover flat aer research development percentage point low cer compare growth growth proforma basis adjust cost sale percentage cer turnover percentage point low cer total research development compare reflect favourable product adjust research development mix pharmaceutical contribution total expenditure million turnover restructure saving pharmaceutical vaccine aer cer include increase major integration saving consumer healthcare partly offset restructuring cost intangible impairment adjust adverse product mix vaccine continue adverse pricing expenditure million turnover high pressure pharmaceutical principally establish aer high cer proforma basis respiratory adjust expenditure grow cer compare sell general administration pharmaceutical adjust expenditure growth growth million aer cer primarily drive cer significant increase investment oncology reflect total sell general progression number key programme include blenrep administration feladilimab bintrafusp alfa progression adjust sell general covid treatment programme vir otilimab administration partly offset reduction investment research total sell general administration sga cost specialty primary care programme daprodustat percentage turnover percentage point trelegy hiv efficiency saving low aer percentage point low cer implementation development programme compare reflect low significant legal pharmaceutical vaccine separation transaction cost offset increase major restructuring cost preparation restructure programme reduction variable separation cost spending result covid lockdown exclude adjust item adjust sga adjust expenditure vaccine million cost percentage turnover percentage aer cer reflect efficiency saving point low aer percentage point implementation development programme low cer basis proforma basis adjust sga reduction variable spending result covid cost percentage turnover percentage lockdown adjust expenditure consumer healthcare point low cer compare million royalty income royalty income million million aer cer primarily reflect genericisation transderm scop consumer healthcare low sale gardasil gsk annual report strategic report governance remuneration financial statement investor information group financial review continue financial performance continue operating incomeexpense reduction proforma adjust operating profit reflect net operating income million adverse impact reduction sale vaccine million primarily reflect net profit disposal result covid pandemic investment include horlick consumer healthcare brand significant increase oncology partly asset million reversal tesaro acquisition initiation covid million embed derivative gain value programme continue price pressure principally share take prior year partly offset related establish respiratory include impact launch loss sale share hindustan unilever generic version advair february million operating income include investment promotional product support particularly new increase profit milestone income number launch vaccine hiv respiratory offset asset disposal reduce promotional variable spending business result covid lockdown oneoff partly offset accounting charge million benefit restructure postretirement million credit arise remeasurement benefit continue benefit restructure contingent consideration liability relate pharmaceutical consumer healthcare support function acquisition shionogiviiv healthcare joint venture tight control ongoing cost particularly non novartis vaccine business liability promotional spending business pfizer option pfizer shionogi preferential dividend viiv healthcare include remeasurement contingent consideration cash payment charge million million contingent shionogi company reduce balance sheet liability consideration liability shionogi primarily arise record income statement total change sale forecast exchange rate assumption contingent consideration cash payment amount unwind discount million million include cash payment shionogi million operating profit million total operating profit million compare million reflect profit disposal adjust operating profit business horlick consumer healthcare brand pharmaceutical operate profit million resultant sale share hindustan unilever aer cer turnover decrease cer increase income asset disposal partly offset operate margin percentage point low high remeasurement charge contingent aer percentage point low cer consideration liability basis primarily reflect significant increase oncology continue impact low price include exclude adjust item adjust operating impact launch generic version advair profit million low aer february investment new product support high cer turnover increase cer adjust target priority market partly offset reduced operate margin percentage point low promotional variable spending result covid aer percentage point low cer basis lockdown continue benefit restructure tight proforma basis adjust operate profit control ongoing cost low cer turnover decrease cer adjust proforma operating margin vaccine operate profit million aer percentage point low cer basis cer turnover decrease cer operating margin percentage point low aer percentage point low cer basis primarily drive negative operating leverage covid relate sale decline investment key brand gsk annual report group financial review continue financial performance continue consumer healthcare operate profit million profit tax aer cer turnover increase cer take account net finance cost share profit proforma basis operate profit million cer associate profit taxation million compare low turnover decrease cer operate margin million percentage point high aer percentage point high cer basis taxation proforma operating margin percentage point high cer basis high margin drive high normal sale growth covid current year charge synergy delivery pfizer integration rest world current year charge partially offset impact divestment increase chargecredit respect prior period target promotional investment total current taxation net finance cost total defer taxation taxation total profit finance income charge million represent effective tax rate interest income total result reflect different fair value movement tax effect adjust item include disposal horlick consumer healthcare brand unilever subsequent disposal share receive hindustan unilever tax finance expense adjust profit amount million represent interest expense effective adjust tax rate unwind discount provision remeasurement fair value movement issue relate taxation describe note finance expense lease liability financial statement taxation group continue believe finance expense adequate provision liability likely arise period open agree tax authority ultimate liability matter vary total net finance cost million compare amount provide dependent outcome million adjust net finance cost agreement relevant tax authority million compare million increase reflect low interest income overseas cash postclose noncontrolle interest divestment horlick consumer healthcare allocation total earning noncontrolle interest nutrition product india number country amount million million increase premium pay early repayment refinance bond debt primarily increase allocation consumer healthcare fair value gain interest rate swap profit million million follow comparator partly offset reduce interest expense completion new consumer healthcare joint venture low debt level refinance low rate pfizer july include unwind fair value uplift acquire inventory major restructuring cost share aftertax profit associate joint venture partly offset reduce allocation viiv healthcare share aftertax profit associate million profit million million include increase million include oneoff adjustment charge remeasurement contingent consideration liability million reflect gsk share increase tax profit innoviva primarily result nonrecurre income tax allocation adjust earning noncontrolle interest benefit amount million million increase allocation primarily reflect increase allocation consumer healthcare profit million million follow completion new consumer healthcare joint venture pfizer july partly offset reduce allocation viiv healthcare profit million million low net profit group entity noncontrolle interest primarily consumer healthcare india follow horlick consumer brand disposal gsk annual report strategic report governance remuneration financial statement investor information group financial review continue financial performance continue earning share outlook total earning share ep compare deliver strategic priority increase eps primarily reflect net profit plan continue increase investment pipeline disposal horlick consumer healthcare brand build topline momentum key growth driver largely increase income asset disposal partly offset complete readiness separation assume healthcare system high remeasurement charge contingent consideration consumer trend approach normality second half liability high major restructuring charge oneoff benefit year expect pharmaceutical revenue grow flat lowsingle increase share aftertax profit associate digit consumer healthcare revenue grow low innoviva midsingle digit exclude brand divestedunder review market growth vaccine business adjust eps compare anticipate disruption half year give aer cer cer increase adjust government prioritisation covid vaccination programme operate profit resurgence late pandemic expect reduction primarily result higher noncontrolling impact adult adolescent immunisation include shingrix interest allocation consumer healthcare profit reduce notably despite shortterm impact remain share aftertax profit associate result non confident demand product expect strong recur income tax benefit innoviva recovery contribution growth shingrix second half year expect vaccine revenue grow flat dividend lowsingle digit reflect factor guidance range board declare interim dividend result total decline mid highsingle digit cent adjust dividend year penny line dividend declare eps cer note financial statement dividend guidance include impact intend change dividend policy corporation tax rate effective gsk recognise importance dividend shareholders april announce march aim distribute regular dividend payment note post balance sheet event determine primarily reference free cash flow expectation guidance target future generate business funding investment performance dividend payment read necessary support group future growth cautionary statement forwardlooke statement board currently intends maintain dividend assumption relate guidance inside current level share subject material cover change external environment performance expectation biopharma investor update june plan set detail growth prospect financial outlook new biopharma company medium term include detailed review pipeline build recent year alongside provide detail new distribution policy reflect optimise capital structure investment priority focus deliver sustainable longterm shareholder value anticipate new policy deliver competitive attractive return inform appropriate earning payout ratio investment cycle cover free cash flow importantly expect growth potential expect aggregate distribution gsk lower present new policy implement dividend pay respect gsk annual report group financial review continue adjust item divestment intangible intangible significant adjust result reconciliation total asset asset major transaction legal separation adjust result amortisation impairment restructure relate item cost result december turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share weight average number share million divestment intangible intangible significant adjust result reconciliation total asset asset major transaction legal adjust result amortisation impairment restructure relate item result december turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share weight average number share million gsk annual report strategic report governance remuneration financial statement investor information group financial review continue adjust item continue major restructure integration total cash payment million pharmaceutical sector highly regulate million million exist combined manufacturing operation supply chain long life restructure integration programme million cycle business mean restructure programme million million major particularly involve rationalisation closure restructuring programme include settlement certain manufacturing site likely year charge accrue previous quarter million complete million relate consumer healthcare joint venture integration programme million relate major restructuring cost relate specific separation preparation restructuring programme boardapprove major restructuring programme exclude adjusted result major restructure analysis major restructuring charge business programme include integration cost follow material follow acquisition structural significant scale cost individual relate project exceed million ordinary course smallerscale restructuring pharmaceutical cost retain total adjust result vaccine total major restructuring charge incur consumer healthcare million million analyse follow corporate central function non non total major restructuring charge cash cash total cash cash total analysis major restructuring charge income major statement line follow restructure programme incl tesaro cost sale consumer sell general administration healthcare joint venture integration research development programme operating incomeexpense separation total major restructuring charge preparation restructuring benefit year major restructure programme programme billion benefit consumer combine healthcare joint venture integration billion restructuring benefit separation preparation restructuring integration programme billion programme major restructuring programme include tesaro expect cost billion period cash charge million separation preparation cash cost billion noncash cost billion programme primarily arise restructure vaccine expect deliver annual saving manufacture function build million rate saving development organisation pharmaceutical vaccine intend fully reinveste help fund target increase restructure commercial pharmaceutical commercial support new product administrative function noncash charge million completion consumer healthcare joint venture relate writedown asset site pfizer expect realise substantial cost synergies pharmaceutical supply chain generate total annual cost saving billion cash charge million consumer healthcare expect cash cost billion noncash charge joint venture programme primarily relate severance expect billion plus additional capital expenditure integration cost commercial integration consumer billion cost saving intend healthcare largely complete manufacture reinveste business support innovation integration underway growth opportunitie major restructure programme incur cash charge million relation severance cost restructure manufacturing organisation administrative function integration tesaro noncash charge million writedown disposal site gsk annual report group financial review continue adjust item continue group initiate twoyear separation million charge relate contingent consideration preparation programme prepare separation gsk shionogiviiv healthcare joint venture represent company new gsk biopharma company increase valuation contingent consideration approach focus science relate immune shionogi result million unwind discount system use genetic new technology new million primarily adjustment sale forecast leader consumer healthcare update exchange rate assumption million credit relate viiv healthcare option pfizer preferential programme aim dividend represent decrease valuation drive common approach improve capital option result adjustment multiple sale forecast allocation update exchange rate assumption align improve capability efficiency global viiv healthcare contingent consideration liability fair value support function support new gsk ifrs potential impact covid pandemic optimise supply chain product portfolio remain uncertain december include divestment noncore asset strategic assume significant impact longterm review prescription dermatology underway value liability position remain review prepare consumer healthcare operate standalone liability update future quarter company information impact pandemic available explanation accounting noncontrolling interest programme continue target delivery billion viiv healthcare set annual saving billion total cost estimate billion billion expect divestment significant legal charge item cash cost proceed anticipate divestment divestment item include gain year largely expect cover cash cost programme million arise net profit disposal horlick consumer healthcare brand transactionrelated adjustment million reversal million transactionrelated adjustment result net charge embed derivative gain value share take million million include net prior year partly offset related loss sale million accounting charge remeasurement share hindustan unilever million contingent consideration liability relate acquisition divestment item include milestone income shionogiviiv healthcare joint venture gain number asset disposal certain novartis vaccine business liability pfizer adjust item charge million million option pfizer shionogi preferential dividend viiv significant legal matter include settlement exist healthcare matter provision ongoing litigation significant legal cash payment million million chargecredit contingent consideration shionogiviiv separation cost healthcare joint venture include shionogi group start report additional cost preferential dividend prepare consumer healthcare separation viiv healthcare option pfizer preferential dividend estimate million exclude transaction cost contingent consideration novartis vaccine business release fair value uplift acquire pfizer inventory adjustment total transactionrelated charge gsk annual report strategic report governance remuneration financial statement investor information group financial review continue adjust item continue proforma growth reconciliation table set reconciliation report cer growth rate proforma cer growth rate report margin percentage proforma margin percentage adjustment include january july result pfizer report consumer proforma growth rate healthcare growth rate cer business cer group turnover adjust cost sale adjust sell general administration adjust research development adjust operate profit consumer healthcare turnover oral health pain relief vitamin mineral supplement respiratory health digestive health brand divestedunder review operate profit proforma financial information basis proforma growth rate calculate follow january july result gsk pfizer report consumer proforma result healthcare result business group turnover adjust cost sale adjust sell general administration adjust research development adjust operate profit consumer healthcare turnover oral health pain relief vitamin mineral supplement respiratory health digestive health brand divestedunder review operating profit gsk annual report group financial review continue cash generation conversion summary consolidate cash flow statement set reconciliation net cash inflow operating activity free cash flow reconciliation net cash inflow operating activity close equivalent ifrs measure free cash flow net cash inflow operating activity show net cash inflowoutflow investing activity net cash outflow financing activity increase cash bank overdraft net cash inflow operating activity purchase property plant equipment cash bank overdraft begin year purchase intangible asset increase cash bank overdraft proceed sale property plant equipment exchange adjustment proceed disposal intangible asset cash bank overdraft end year interest pay cash bank overdraft end year comprise interest receive cash cash equivalent dividend associate joint venture cash cash equivalent report asset contingent consideration pay report hold sale investing activity overdraft contribution noncontrolle interest distribution noncontrolle interest capital expenditure financial investment free cash flow cash payment tangible intangible fix asset future cash flow amount million million long term expect future cash generate disposal realise million million operation sufficient fund operate debt cash payment acquire equity investment amount servicing cost normal level capital expenditure obligation million million primarily relate exist licensing agreement expenditure arise vir biotechnology curevac sale equity restructuring programme routine outflow include investment realise million million tax pension contribution dividend subject mainly relate proceed arise sale principal risk uncertainty discuss page share hindustan unilever acquire result time time additional demand disposal horlick consumer healthcare finance acquisition include potentially acquire brand increase ownership interest viiv healthcare business minority shareholder hold option access free cash flow multiple source liquidity short longterm capital free cash flow cash generate group market financial institution need addition meeting obligation contingent consideration cash flow operation interest tax dividend pay noncontrolle interest capital expenditure property plant equipment investment appraisal capital allocation intangible asset strong framework capital allocation include board govern allocation capital business utilise consistent cash return invest free cash inflow capital croic methodology prioritise investment total cash payment shionogi relation viiv group effectively compare healthcare contingent consideration liability year return business allocate capital million million million consider impact eps recognise cash flow operating activity credit profile relevant million recognise contingent consideration pay invest cash flow payment deductible tax purpose gsk annual report strategic report governance remuneration financial statement investor information group financial review continue financial position resource property plant equipment business sciencebase technologyintensive highly asset regulate governmental authority allocate significant noncurrent asset financial resource renewal maintenance property plant equipment property plant equipment minimise risk interruption right use asset production ensure compliance regulatory standard goodwill number process use hazardous material intangible asset investment associate joint venture total cost property plant equipment investment december million net book value defer tax asset million land building represent derivative financial instrument million plant equipment million noncurrent asset asset construction million invest total noncurrent asset million new property plant equipment mainly relate large number project renewal current asset improvement expansion facility worldwide inventory site support new product development launch current tax recoverable improve efficiency exist supply chain property trade receivables mainly hold freehold new investment finance derivative financial instrument liquid resource december contractual liquid investment commitment future capital expenditure million cash cash equivalent believe property plant facility adequate asset hold sale current need total current asset observe stringent procedure use specialist skill total asset manage environmental risk activity environmental liability issue date operation modify current liability discontinue report environment note financial statement legal proceeding shortterm borrowing contingent consideration liability right use asset trade payable right use asset amount million december derivative financial instrument compare million january current tax payable decrease year reflect impact depreciation shortterm provision disposal million million respectively partly total current liability offset addition million noncurrent liability goodwill longterm borrowing goodwill increase million december corporation tax payable million defer tax liability pension postemployment benefit intangible asset provision intangible asset include cost intangible acquire derivative financial instrument party computer software net book value intangible asset december contingent consideration liabilitie million million decrease noncurrent liability primarily reflect amortisation impairment loss net total noncurrent liability reversal year million total liability net asset total equity gsk annual report group financial review continue financial position resource continue investment associate joint venture trade payable hold investment associate joint venture december trade payable carry value december million million compare million million market value december december increase primarily reflect impact million million large high customer return rebate accrual note investment innoviva inc book value financial statement trade payable december million million provision market value million note carry defer tax provision shortterm financial statement investment associate joint noncurrent provision million december venture million provision yearend investment include million million relate legal hold investment carry value dispute million million relate december million million major restructuring programme provision high value investment hold december legal dispute indemnify disposal liability curevac acquire year employee relate liability cost restructure book value december million crispr programme extent balance sheet date legal therapeutic book value million constructive obligation exist reliably estimate million lyell immunopharma inc pensions postemployment benefit book value december million account pension postemployment million investment include equity arrangement accordance ias net deficit stake company research million million pension collaboration provide access biotechnology arrangement million million development potential interest interest company unfunde postemployment liability note arise business divestment financial statement pension postemployment derivative financial instrument asset benefit hold current derivative financial asset fair value noncurrent liabilitie million million noncurrent derivative noncurrent liability amount million financial asset hold fair value million december million million majority financial instrument relate foreign exchange contract designate contingent consideration liability designate accounting hedge december contingent consideration amount million million current derivative financial asset relate december million derivative embed agreement divest horlick million million represent estimate nutritional brand unilever plc note present value amount payable shionogi relate viiv information healthcare million million represent estimate present value contingent consideration payable inventory novartis relate vaccine acquisition inventory million increase million liability shionogi include million respect preferential dividend liability preferential dividend trade receivable pfizer december million trade receivables million decrease million explanation accounting non million control interest viiv healthcare set defer tax asset total contingent consideration payable posttax defer tax asset amount million basis december million million million december expect pay year consideration payable expect pay number year derivative financial instrument liability result total estimate liability discount hold current noncurrent derivative financial liability present value posttax basis posttax discount rate fair value million million primarily relate foreign exchange contract designate shionogiviiv healthcare contingent consideration liability designate accounting hedge discount novartis vaccine contingent consideration liability discount partly partly gsk annual report strategic report governance remuneration financial statement investor information group financial review continue financial position resource continue maturity profile bond debt equivalent gbp bonds eur bond usd bond net debt cash liquid investment billion billion hold centrally december analysis cash gross debt effect hedge cash cash equivalent liquid investment follow cash cash equivalent report asset hold sale borrowing repayable year cash liquid investment borrowing repayable year gross debt fix net debt float december net debt billion compare noninterest bear billion december comprise gross debt net debt billion cash liquid investment billion include billion equivalent note swap float fix rate interest net debt decrease billion proceed rate swap horlick consumer brand disposal include share movement net debt hindustan unilever billion billion asset plus billion business asset disposal billion free cash flow partly offset cash net debt begin year divest billion dividend pay shareholder implementation ifrs billion billion additional investment net debt begin year adjust december gsk shortterm borrowing increase cash bank overdraft include overdraft lease liability repayable increasedecrease liquid investment month billion loan billion repayable increase longterm loan subsequent year net repayment shortterm loan repayment lease liability december gsk cash liquid investment debt subsidiary undertaking acquire hold follow exchange movement movement bank balance deposit net debt end year bank balance deposit report asset hold sale treasury treasury repo money market fund liquidity fund cash cash equivalent liquid investment government security gsk annual report group financial review continue financial position resource continue interest rate benchmark reform total equity interest rate benchmark reform amendment ifrs december total equity increase ias ifrs issue iasb september million december million amendment modify specific hedge accounting summary movement equity set requirement allow hedge accounting continue affect hedge period uncertainty hedge item hedge instrument affect current interest total equity beginning year rate benchmark amend result ongoing implementation ifrs interest rate benchmark reform total equity beginning year adjust december group directly expose total comprehensive income year interest rate benchmark reform hold interest rate dividend shareholder derivative reference libor mature end recognition interest consumer healthcare float rate bond mature joint venture end ordinary share issue change noncontrolle interest group closely monitor market output industry work group manage sharebase incentive plan transition new benchmark interest rate include tax sharebase incentive plan announcement libor regulator include contribution noncontrolle interest financial conduct authority fca commodity distribution noncontrolle interest future trading commission transition away total equity end year libor include gbp libor usd libor share purchase euribor sterling overnight index average rate december gsk hold million share sonia secure overnight financing rate sofr treasury share million share cost euro shortterm rate str respectively fca million million clear end long deduct retain earning seek persuade compel bank submit libor exception usd libor ordinary share repurchase period january intercontinental exchange ice benchmark administration march company expect iba fcaregulate authorise administrator ordinary share repurchase remainder libor announce consult intention cease usd libor iba intend subject confirmation million treasury share transfer follow consultation week month usd employee share ownership plan esop trust share libor setting cease end hold trust satisfy future exercise option usd libor panel cease end june awards group share option award scheme group undertake interest rate benchmark transition proportion share hold trust respect programme identify potential exposure business award rule scheme require satisfy deliver smooth transition appropriate alternative exercise market purchase issue benchmark rate new share share hold trust match option award grant december esop trust hold million million gsk share future exercise share option share award carry value million million deduct reserve market value share million million gsk annual report strategic report governance remuneration financial statement investor information group financial review continue financial position resource continue contractual obligation commitment reach agreement trustee financial commitment summarise note pension scheme additional contribution financial statement commitment assist eliminate pension deficit identify december actuarial funding valuation table follow table set contractual obligation include commitment exclude normal ongoing commitment december fall annual funding requirement approximately payment million information pension obligation total yrs yrs yrs note financial statement pension postemployment benefit loan interest loan contingent liability lease obligation contingent liability set note financial future finance charge statement contingent liability intangible asset follow table set contingent liability comprise property plant equipment discount bill performance guarantee letter credit investment item arise normal course business purchase commitment expect expire pension total total yrs yrs yrs commitment respect loan future interest payable guarantee loan disclose take account effect contingent liability derivative total enter number research collaboration normal course business provide develop new compound pharmaceutical company indemnification guarantee respect business disposal term arrangement include upfront fee legal dispute subsequently arise equity investment loan commitment fund specify provision outflow resource consider level research addition agree probable reliable estimate likely payment future milestone achieve outcome dispute include note agreement relate compound early financial statement provision stage development potential obligation provide outcome tax legal dispute milestone payment continue number year outflow resource consider probable compound successfully development reliable estimate outflow december process generally close product marketing dispute provision approval great probability success amount possible reliable estimate show intangible asset represent maximum potential outflow fund require settle pay milestone achieve include dispute possibility outflow billion relate externalised project remote discovery portfolio decrease commitment ultimate liability matter vary significantly result reduction outstanding loan amount provide dependent negotiation commitment relevant tax authority outcome litigation proceeding relevant discuss principal risk uncertainty page note financial statement legal proceeding gsk annual report group financial review continue treasury policy report sterling pay dividend sterling cash interest rate risk management flow role treasury monitor manage gsk objective minimise effective net interest cost group external internal funding requirement financial balance mix debt fix float interest rate risk support strategic objective gsk operate time policy interest rate risk management limit global basis primarily subsidiary company net float rate debt specific cap review manage capital ensure subsidiary able agree annually board operate go concern optimise return foreign exchange risk management shareholder appropriate balance debt objective minimise exposure overseas equity treasury activity govern policy approve operating subsidiary transaction risk match local annually board director recently currency income local currency cost possible october treasury management group tmg foreign currency transaction exposure arise external meeting chair chief financial officer take place internal trade flow selectively hedge gsk internal regular basis review treasury activity member trading transaction match centrally manage receive management information relate activity intercompany payment term reduce foreign currency risk treasury operation possible manage cash surplus borrow objective gsk treasury activity minimise requirement subsidiary company centrally forward posttax net cost financial operation reduce volatility contract hedge future repayment originate order benefit earning cash flow gsk use variety currency financial instrument finance operation derivative order reduce foreign currency translation exposure financial instrument manage market risk seek denominate borrowing currency operation derivative principally comprise foreign exchange principal asset cash flow primarily forward contract swap swap denominate dollar euro sterling borrowing borrowing liquid asset currency require swap currency require group purpose interest rate swap manage exposure financial risk change borrowing denominate swap foreign interest rate currency match investment overseas group asset treat hedge relevant asset forward derivative exclusively hedge purpose relation contract major currency reduce exposure underlie business activity trading group investment overseas group asset tmg speculative instrument review ratio borrowing asset major currency capital management regularly gsk financial strategy implement group counterparty risk management financial architecture support gsk strategic priority set global counterparty limit banking regularly review board manage capital investment counterpartie base longterm credit rating structure group appropriate mix debt moodys standard poor usage limit equity continue manage financial policy credit actively monitor breach limit profile particularly target shortterm credit rating report cfo immediately maintain single longterm rating consistent target addition relationship bank credit rating review regularly change rating occur gsk longterm credit rating standard poor change investment level authority limit stable outlook moodys investor service moodys appropriate banking counterparty limit review negative outlook shortterm credit rating annually standard poor moodys respectively liquidity risk management gsk policy borrow centrally order meet anticipate funding requirement cash flow forecast funding requirement monitor tmg regular basis strategy diversify liquidity source range facility maintain broad access financial market day sweep cash number global subsidiary central treasury account liquidity management purpose gsk annual report strategic report governance remuneration financial statement investor information group financial review continue critical accounting policy group consolidated financial statement prepare medicaid programme stateadministere accordance ifrs adopt pursuant regulation programme provide assistance certain poor apply european union vulnerable patient medicaid drug rebate ifrs issue international accounting standard program establish reduce state federal board iasb follow accounting policy approve expenditure prescription drug patient board describe note financial statement protection affordable care act law accounting principle policy participate provide rebate state accrual medicaid rebate calculate base specific require estimate assumption term relevant regulation patient protection affect amount asset liability revenue expense affordable care act report financial statement actual amount result differ estimate cash discount offer customer encourage prompt payment accrue time critical accounting policy relate follow area invoice adjust subsequently reflect actual turnover experience taxation note record accrual estimate sale return apply legal dispute note historical experience customer return amounts invoice marketrelate information contingent consideration note stock level wholesaler anticipate price increase pension postemployment benefit note competitor activity information judgement estimate reconciliation gross turnover net turnover area give note financial statement key pharmaceutical business follow accounting judgement estimate turnover margin margin margin respect turnover accounting policy large gross turnover business pharmaceutical market complex arrangement rebate discount marketdriven segment allowance follow briefly describe nature government arrangement existence pharmaceuticals business mandate arrangement certain indirect customer state programme customer able buy product cash discount wholesaler reduce price chargeback represent customer return difference invoice price wholesaler prior year adjustment indirect customer contractual discount price prior year item accrual estimate chargeback calculate base item term agreement historical experience total deduction product growth rate net turnover customer rebate offer key manage care marketdriven segment consist primarily manage care group purchasing organisation direct indirect medicare plan negotiate contract pricing customer arrangement require customer honour rebate chargeback mandate segment achieve certain performance target relate value consist primarily medicaid federal government product purchase formulary status predetermine market programme receive governmentmandate pricing share relative competitor accrual customer rebate chargeback rebate estimate base specific term agreement historical experience product growth rate gsk annual report group financial review continue critical accounting policy continue increase deduction governmentmandate involved significant legal proceeding state programme gross turnover net turnover respect possible reliable estimate reconciliation primarily reflect high rebate expect financial effect result chargeback respiratory product advair ultimate resolution proceeding case particular year advair account appropriate disclosure case include pharmaceutical turnover approximately total annual report provision deduction rebate return position change time respiratory portfolio include establish assurance loss result outcome respiratory product account approximately legal proceeding exceed material total deduction year provision report group financial statement balance sheet accrual rebate discount allowance return pharmaceutical vaccine business like pharmaceutical company face manage combined basis december complex product liability antitrust patent litigation total accrual amount million million investigation operation conduct governmental regulatory agency year monthly process operate monitor inventory level general counsel group head group legal wholesaler abnormal movement process use function senior vice president head global gross sale volume prescription volume base party litigation group responsible litigation datum source information receive key wholesaler government investigation routinely brief chief executive aim maintain inventory consistent level officer chief financial officer board director year year base pattern consumption significant litigation pende group basis pharmaceutical vaccine inventory governmental investigation group level wholesaler distribution channel meeting appropriate detail status significant december estimate litigation government investigation review matter approximately week turnover calculation use number claim notify information party information accuracy totally potential claim notify assessment validity verify believe sufficiently reliable claim progress settle claim recent settlement purpose level potential reimbursement insurer legal dispute meeting include assessment respect accounting policy legal dispute sufficient information available able follow briefly describe process reliable estimate potential outcome dispute determine level provision necessary external counsel assist litigation accordance requirement ias provision matter investigation assist brief contingent liability contingent asset provide board senior management follow discussion anticipate settlement cost outflow resource matter possible reliable estimate consider probable reliable estimate provision require likely outcome dispute legal expense level provision legal dispute review arise claim group adjust appropriate matter discuss note financial statement legal proceeding strategic report strategic report approve board director march iain mackay chief financial officer march gsk annual report ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn corporate governance section chairmans governance statement board corporate executive team board architecture board role responsibilitie board activity principal decision purpose value culture board approach engagement board performance board committee information board committee report section statement director report ggsskk aannnnuuaall rreeppoorrtt chairmans governance statement year governance statement explain primary education focus science objective ensure clarity give critical importance strengthen pipeline board management gsk execution strategy board benefit devote high proportion operational priority align longterm priority time understand science strategy innovation performance trust power culture testing application important board agree metric measure delivery work understand key strategic theme board annual cycle meeting ensure major strategy base theme component strategy review course complement board science thematic deep dive year focus fundamental strategy human genetic immune system covid pandemic impact dominate gain deep understanding covid vaccine live majority board different technology review run hal barron adapt operate virtually invest significant time cso support science committee scientific assess respond impact pandemic medical expert board receive regular update management board establish framework hal progress strengthen pipeline consider key area people continuity solution evolution organisation operation support corporate responsibility incredibly talented scientist science committee board consider impact covid organisation initiative treatment governance architecture solution undertake review appropriateness clear priority board enable vaccine business technology platform ensure allocation oversight responsibility innovation continue fully competitive post performance trust priority committee covid world mean meeting focus directly issue matter gsk resilience decisionmake board resilience test individually team benefit alignment board covid imperative remain fast agile committee start evident year decisionmake deeply impress progress particular change remit science management board step embrace corporate responsibility committee challenge schedule meeting january establishment transformation separation committee take place face face march board enable great focus oversight challenge detail committee meeting virtual like committee activity set later report rest organisation adjust lack physical like highlight certain key area work contact include crucial informal interaction help transformation separation committee committee build relationship trigger idea evolve think complex establish ensure board devote sufficient topic charlie bancroft joined board attention issue surround creation attend physical meeting induction far take place biopharma consumer healthcare business review entirely virtually decision physical separation corporate finance think carefully board organise listing location committee mindful virtual meeting engage spend time build separate cost base business create maintain high quality engagement operate effectively independent competitively structure cost basis please observe close quarter efficient fit purpose oversee board commitment fully align executive management restructuring programme ensure desire continuous communication sense urgency agility benefit deliver remarkable achievement desire maintain speed decision making help notwithstanding covid major programme ensure continue support management timely track execution strategic priority gsk annual report strategic report governance remuneration financial statement investor information corporate responsibility committee committee board succession plan central guide company esg agenda review pleased lynn elsenhans agree stay support management aggressive approach year stepping board execute aspect esg include agm help continuity leadership review endorse new level ambition corporate responsibility committee work separation environmental sustainability set new goal facilitate smooth transition successor current achieve net zero impact climate net positive impact covid environment nature review inclusion diversity honour lead highperforming collegiate include disclose target workforce race ethnicity unify board formal governance planning separation rebase gender diversity target begin second half include committee play key role guide overseeing building creation new board enter management response covid review critical period intention maintain continuity implication production risk scale partnering cohesion current board highly focus geographic allocation access pricing maximising value shareholder point separation convince strong commitment esg business necessity longterm value evaluation driver company benefit stakeholder busy year please jan hall believe place regard future able complete followup independent board review help improve board effectiveness science committee committee continue support conclusion review set later report oversight scientific assumption drive distinctive strategy evolve cso biopharma year company continue operate explain early guide educate board comply requirement financial report scientific perspective council corporate governance code copy code find wwwfrcorguk year cso team seek build foundation set continue strengthen pipeline look forward connect agm year organically collaboration business development update time progress thank committee review underlie scientific assumption continue support provision scientific technical assurance business development transaction critical support sir jonathan symonds board chairman march gsk annual report board board composition board diversity international experience composition gender executive male global nonexecutive female europe tenure nonexecutive ethnicity emap year black asian minority ethnic year white year year information sir jonathan symonds cbe skill experience nonexecutive chairman jon extensive international financial life science governance experience jon serve independent nonexecutive director hsbc holdings plc april age deputy group chairman august retirement board february nationality british previously chairman hsbc bank plc chief financial officer novartis partner appoint september manage director goldman sachs chief financial officer astrazeneca plc partner kpmg governance experience include role nonexecutive director chair audit committees diageo plc qinetiq group plc nonexecutive chair proteus digital health inc jon fellow institute charter accountant england wale external appointment nonexecutive director rubius therapeutics inc nonexecutive director genomics england limited previously serve chairman member european round table industry dame emma walmsley skill experience chief executive officer prior appointment gsk ceo emma ceo gsk consumer healthcare joint venture gsk novartis creation march emma join gsk age loreal work year variety role paris london new york shanghai nationality british emma previously nonexecutive director diageo plc appoint january emma hold classic modern language oxford university chief executive officer april external appointment independent director microsoft inc honorary fellow royal society chemistry iain mackay skill experience chief financial officer prior join gsk iain group finance director hsbc holdings plc position hold year charter accountant iain work asia europe hsbc age general electric schlumberger dowell price waterhouse iain previously trustee nationality british british heart foundation chair audit risk committee appoint january iain hold business study account hold honorary doctorate chief financial officer april aberdeen university scotland iain member institute chartered accountant scotland external appointment member court university aberdeen chair remuneration committee member group chair financial reporting committee hal barron skill experience chief scientific officer prior join gsk hal president calico llc california life company alphabet fund company use advanced technology increase understand lifespan biology president prior hal executive vice president head global product development chief age medical officer roche responsible product combine portfolio roche nationality american genentech genentech senior vice president development chief medical officer appoint january hal nonexecutive director chair science technology committee juno chief scientific officer president therapeutics inc march acquire celgene corporation april external appointment associate adjunct professor epidemiology biostatistics university california san francisco nonexecutive board director grail inc early cancer detection healthcare company advisory board member verily life sciences llc subsidiary alphabet inc key committee chair nomination corporate governance audit risk remuneration science corporate responsibility transformation separation gsk annual report strategic report governance remuneration financial statement investor information board continue charles bancroft skill experience independent nonexecutive director charlie wealth financial management experience global biopharma charlie retire successful career bristol myers squibb bms march age hold number leadership role commercial strategy finance begin career nationality american bms hold position increase responsibility finance organisation appoint commercial operational responsibility latin america middle east africa canada japan pacific rim country appoint chief financial officer chief financial officer executive vice president global business operation executive vice president head integration strategy business development charlie successfully steer bms period strategic transformation include recent acquisition celgene charlie serve member board colgatepalmolive company march external appointment board member kodiak sciences inc board member biovector inc advisory board member drexel university lebow college business board determine charlie recent relevant financial experience agree appropriate qualification background audit committee financial expert manvinder singh vindi banga skill experience senior independent nonexecutive vindi year commercial experience track record deliver outstanding performance highly competitive global consumerfocuse business director prior join gsk vindi spend year unilever plc role senior age position president global foods home personal care business member nationality british unilever executive board vindi sit prime minister indias council trade industry appoint september board governor indian institute management iim senior independent nonexecutive director ahmedabad vindi recipient padma bhushan india high civilian honour vindi nonexecutive director confederation british industry cbi thomson reuters corp chairman supervisory board mauser group chairman kalle gmbh senior independent director mark spencer group plc external appointments partner clayton dubilier rice director high ridge brand nonexecutive director economist newspaper limited member holdingham international advisory board board member international chamber commerce united kingdom member governing board indian school business hyderabad member global leadership council sad business school oxford member indo ceo forum chair board trustees marie curie vivienne cox cbe skill experience independent nonexecutive director vivienne wide experience business gain energy natural resource publishing sector deep understand regulatory organisation government workforce engagement director vivienne work plc year britain continental europe post include age executive vice president chief executive bps gas power renewable business nationality british alternative energy unit vivienne previously nonexecutive director group plc rio appoint july tinto plc lead independent director governments department international development vivienne appoint commander order british empire new year honour service economy sustainability external appointment senior independent director pearson plc chairman supervisory board vallourec non executive director stena advisory board member african leadership institute vice president energy institute advisory board member montrose associate chair rosalind franklin institute vice chair sad business school oxford member global leadership council patron hospice francis lynn elsenhans skill experience independent nonexecutive director lynn wealth experience run global business significant knowledge global market gsk operate age lynn serve chair president chief executive officer sunoco inc prior nationality american join sunoco president chief executive officer lynn work royal dutch appoint july shell join hold number senior role include executive vice president global manufacturing lynn previously nonexecutive director tee great houston flowserve corporation texas medical center trustee unite way great houston external appointment nonexecutive director chair governance corporate responsibility committee baker hughe company board director chair audit committee saudi aramco advisory board member johns hopkins university whiting school engineering member audit committee leadership network key committee chair nomination corporate governance audit risk remuneration science corporate responsibility transformation separation gsk annual report board continue laurie glimcher skill experience independent nonexecutive director laurie bring scientific public health expertise board deliberation wealth global publicly list pharmaceutical business experience scientific medical expert addition number senior leadership position hold harvard medical school harvard age school public health laurie serve stephen suzanne weiss dean professor nationality american medicine weill cornell medical college attend physician new york presbyterian appoint september hospitalweill cornell medical center laurie step board bristolmyer squibb bm serve year board laurie previously nonexecutive director water corporation cofounder chair scientific advisory board quentis therapeutics inc external appointment professor medicine harvard medical school ceo president attend physician danafarber cancer institute member national academy sciences national academy medicine member scientific steering committee parker institute cancer immunotherapy independent director analog devices inc member scientific advisory board repare therapeutics inc abpro therapeutic kaleido biosciences inc jesse goodman skill experience independent nonexecutive director jesse bring scientific public health expertise board deliberation wealth experience span science medicine vaccine regulation public health prove record scientific medical expert addressing press public health need academic federal sector age jesse previously serve senior leadership position food drug administration fda nationality american include recently fdas chief scientist previously deputy commissioner science appoint january public health director center biologic evaluation research cber jesse play leadership role develop fda regulatory science medical countermeasure initiative work collaboratively industry academia government global public health regulatory partner prepare respond major public health threat include emerge infectious disease disaster terrorism lead fdas response west nile virus influenza pandemic serve senior leadership team white house medical countermeasure review jesse previously member scientific advisory committee regulatory legal working group coalition epidemic preparedness innovation cepi external appointment professor medicine attend physician infectious disease georgetown university direct georgetown university center medical product access safety stewardship compass board member president united states pharmacopeia usp board member scientific counselor infectious disease center disease control prevention cdc board member intellia therapeutics inc member national academy medicine judy lewent skill experience independent nonexecutive director judy extensive knowledge global pharmaceutical industry corporate finance judy join merck serve chief financial officer age retire judy serve nonexecutive director dell inc quaker oats company motorola inc nationality american hold nonexecutive directorship purdue pharma inc napp pharmaceutical holdings limit appoint april certain mundipharma international limited company external appointment nonexecutive director thermo fisher scientific inc nonexecutive director motorola solutions inc trustee rockefeller family trust life member massachusetts institute technology corporation member american academy arts sciences business advisory board member twoxar advisory board member path inc board determine judy recent relevant financial experience agree appropriate qualification background audit committee financial expert urs rohner skill experience independent nonexecutive director urs broad business legal background extensive senior level experience multinational company age urs serve chairman number board recently credit suisse prior join nationality swiss credit suisse urs serve chairman executive board ceo prosieben appoint january prosiebensat media follow number year private practice major law firm switzerland admit bar canton zurich switzerland state new york external appointment chairman board governance nominations committee credit suisse group chairman member board trustee credit suisse research institute credit suisse foundation vicechairman govern board swiss bankers association key committee chair nomination corporate governance audit risk remuneration science corporate responsibility transformation separation gsk annual report strategic report governance remuneration financial statement investor information corporate executive team skill experience hal barron hal join gsk cet board biography page chief scientific officer president roger connor roger join cet appoint president gsk global vaccine president global vaccines addition leadership vaccine business responsible gsk global procurement organisation roger member gavi board vaccine alliance represent international federation pharmaceutical manufacturer association ifpma constituency previously president global manufacturing supply vice president office ceo corporate strategy roger join gsk astrazeneca roger hold degree mechanical manufacturing engineering queen university belfast masters manufacturing leadership cambridge university chartered accountant diana conrad diana appoint senior vice president human resource member cet senior vice president april previously senior vice president pharmaceuticals play key strategic role leader people culture agenda support human resource transformation diana join gsk canadas team hold role increase responsibility senior vice president consumer healthcare prior join gsk hold role company include capital gennum corporation zenon environmental laboratories diana honour bachelor art mcmaster university canada james ford james join cet appoint senior vice president general counsel senior vice president join gsk serve general counsel consumer healthcare general counsel global pharmaceutical vice president corporate legal act head global ethic general counsel compliance prior gsk james solicitor clifford chance dla hold law degree university east anglia diploma competition law king college qualified solicitor england wales attorney new york state bar james base london practise law live singapore hong kong james cochair base civil justice reform group director european general counsel association nick hiron nick appoint cet senior vice president global ethic compliance senior vice president responsible compliance risk management corporate security investigation nick join gsk international auditor later head audit assurance global ethic compliance combine audit function independent team common riskbase methodology nick relocate china establish governance model china business create consistent approach compliance nick fellow chartered institute management accountant sally jackson sally join cet march senior vice president global communications ceo senior vice president office responsible communication government affair global business market employee engagement group global communication ceo chief staff prior sally senior vice president office ceo cfo ceo office previously serve head investor relation join gsk sally hold degree natural science university cambridge iain mackay iain join gsk cet board biography page chief financial officer brian mcnamara brian join cet appoint ceo gsk consumer healthcare ceo gsk consumer healthcare join gsk head europe americas gsk consumer healthcare follow creation previous joint venture gsk novartis previously head novartis otc division brian begin career procter gamble brian board member consumer good forum chairman board member global selfcare federation gscf earn undergraduate degree electrical engineering union college new york mba finance university cincinnati gsk annual report corporate executive team continue skill experience luke miel luke join gsk cet president global pharmaceuticals responsible president global pharmaceuticals commercial portfolio medicine vaccine luke cochair portfolio investment board hal previously work astrazeneca executive vice president european business prior executive vice president global product portfolio strategy global medical affair corporate affair head asia roche base shanghai singapore prior hold role increase seniority roche sanofiaventis europe asia luke hold bachelor science degree biology flinder university adelaide mba macquarie university sydney david redfern david join cet chief strategy officer responsible corporate development chief strategy officer strategic planning previously senior vice president northern europe responsibility gsk pharmaceutical business region senior vice president central eastern europe join gsk david appoint chairman board viiv healthcare limited nonexecutive director aspen pharmacare holdings limited board bachelor science degree bristol university chartered accountant regis simard regis join cet president pharmaceutical supply chain president pharmaceutical responsible manufacturing supply gsk pharmaceutical product lead quality environment health safety sustainability corporate level regis join supply chain gsk site director france rise senior vice president global pharmaceutical manufacture current role previously hold senior position sony konica minolta tyco healthcare member board viiv healthcare mechanical engineer hold mba karenann terrell karenann join gsk cet chief digital technology officer responsible chief digital technology officer technology digital data analytic strategy previously work walmart chief information officer prior baxter international chief information officer daimler chrysler corporation karenann begin career general motor nonexecutive director pluralsight llc earn graduate postgraduate degree electrical engineering kettere purdue university respectively phil thomson phil join cet appoint president global affairs responsibility president global affairs group strategic approach reputation policy development stakeholder engagement global health previously phil senior vice president communication government affair phil chairman whitehall industry group board member chinabritain business council earn degree english history russian study durham university emma walmsley emma join gsk cet board biography page chief executive officer deborah waterhouse deborah appoint cet january chief executive officer ceo viiv healthcare viiv healthcare april deborah join gsk recently senior vice president primary care company business prior lead vaccines business strong track record performance specialty primary care deborah lead hiv business head hiv centre excellence pharma europe hold international role general manager australia new zealand senior vice president central eastern europe gsk annual report strategic report governance remuneration financial statement investor information board architecture enhance corporate governance framework improve effectiveness board way work support corporate executive team cet deliver transformation biopharma business plan separation consumer healthcare gsk internal control risk management arrangement describe page integral corporate governance framework board chief science committee corporate responsibility transformation executive committee separation committee officer ead ead read corporate nomination corporate audit risk committee remuneration committee executive governance committee team ead ead read role membership board committee attendance schedule board committee meeting nomination corporate corporate transformation board governance audit risk remuneration science responsibility separation total number schedule meeting member attend attend attend attend attend attend attend sir jonathan symonds emma walmsley iain mackay hal barron charle bancroft vindi banga vivienne cox lynn elsenhans laurie glimcher jesse goodman judy lewent urs rohner number adhoc meeting charles bancroft join board audit risk committee number bracket denote number meeting eligible attend gsk annual report board role responsibilitie leadership independent oversight rigorous challenge chairman nonexecutive director jonathan symond provide strong independent element board lead manage business board constructively support challenge management provide direction focus scrutinise performance meeting agree ensure clear structure effective operation deliverable board committee shape proposal strategy offer specialist advice set board agenda ensure sufficient time management allocate promote effective debate support sound letter appointment set term decision make condition directorship ensure board receive accurate timely clear devote time necessary proper information performance duty meet nonexecutive director annual expect attend meeting require basis discuss individual contribution independence statement performance training development need board consider nonexecutive director share peer feedback provide identify page independent board evaluation process assess circumstance set meet regularly nonexecutive director provision code review independently executive director continue independence commitment judy maintain dialogue shareholders lewent serve board governance company year lynn elsenhans july serve board year chairman role description available gskcom describe page chief executive officer senior independent director emma walmsley vindi banga responsible management group act sound board chairman trust business intermediary director develop group strategic direction nonexecutive director lead consideration approval board annual review chairman performance take implement agree strategy account view executive director support member cet discuss result chairman effectiveness maintain continual active dialogue review chairman shareholder respect company performance lead search appointment process make recommendation board new chairman chief executive officer role description available gskcom act additional point contact shareholder maintain understand issue concern major shareholder briefing company secretary investor relation senior independent nonexecutive director role description available gskcom company secretary secretary board board committees victoria whyte supports board committee chair annual agenda planning ensure information available board member timely fashion support chairman designing deliver board induction coordinate continue business awareness training requirement nonexecutive director undertake internal board committee evaluation request chairman advise director board practice procedure corporate governance matter chair group disclosure committee operate boardapprove appointment policy reflect board external appointment requirement code point contact shareholder corporate governance matter gsk annual report strategic report governance remuneration financial statement investor information board activity principal decision board discharge responsibility annual programme meeting paper presentation board committee focus oversight performance drive company strategic direction design facilitate effective decision make categorise awareness input andor decision aid board oversight business awareness item business consider mission critical gsk longterm success highlight area focus longterm priority link strategy board oversight execution strategy include receive discuss report pharmaceutical vaccine consumer healthcare hold joint board cet strategy day discuss plan successor business separation receive quarterly report chief executive officer ceo chief financial officer cfo chief scientific officer cso discuss scrutinise future ready plan transform biopharma consumer healthcare scrutinise approve major collaboration party develop vaccine treatment covid approve business development transaction strategic partnership party include mrna technology collaboration curevac follow review vaccine technology review approve divestment nonstrategic consumer healthcare brand performance board focus performance include evaluate ceo performance set objective set annual budget plan forwardlooke threeyear forecast annual talent succession plan review scrutinise group financial performance review risk impact covid group business performance review quarterly financial result dividend proposal earning guidance investor material result announcement confirm viability go concern statement approval statutory account science board focus science include briefing key element strategy review science technology culture strategy receive update progress key asset include impact covid receive approve appropriate number business development transaction strengthen pipeline governance board focus governance include receive report committee receive report external auditor approve appointment new nonexecutive director audit committee financial expert successor audit risk committee chair establish new committee focus transformation separation approve annual report form receive report corporate governance regulatory development company secretary report consider conclusion agree action board external evaluation set board priority review modern slavery statement gender pay gap positioning annual review board enterprise risk responsibility framework enterprisewide risk cultural receiving update cultural transformation progress transformation board consideration stakeholder impact include stakeholder reviewing board governance architecture consider report workforce engagement director discuss report annual employee survey result review stakeholder perception research mission critical item link longterm prioritie innovation performance trust culture gsk annual report board activity principal decision continue board member consider interest gsk key stakeholder decision potentially affect paper consider board committee seek highlight relevant stakeholder impact proposal consideration positive negative support duty decisionmaking process select example principal decision board consider stakeholder perspective set stakeholder group boardcommittee section principal decision decision regard stakeholder interest duty consider boardcommittee business development science committee board stakeholders science committee consider collaboration deal review business development patient consumer scientific merit business include covid opportunity covid employee investor development opportunity prior collaboration leading board review approval duty conclude transaction include longterm result strategic collaboration curevac workforce business access mrna platform capability relationship supplement gsk sam technology follow review vaccine technology consortium collaboration develop novel treatment partnership ideaya biosciences synthetic lethality emerge field precision medicine oncology collaboration vir biotechnology identify potential covid treatment option partnership sanofi medicago clover potential covid vaccine different technology arrangement consider context potential help gsk deliver transformational medicine patient commercial model audit risk committee arc stakeholder arc recommend limited sfi change china consider recommend hcp medical expert programme change board select market board change healthcare employee investor approval professional hcp engagement government regulator safeguard key stakeholder interest sale force incentive sfi programme patient consumer new programme implement china select market nonexecutive director control phase market review reflect grow shift gsk brief workshop robustness programme portfolio innovative specialty care hold arc governance arrangement present product aim increase review process enable arc end competitiveness build board meet china initial phase roll new pharmaceutical leadership sfi programme team discuss examined change mean countrys commercial policy risk management attract retain good sale compliance culture force talent china duty increase sale force longterm result accountability performance focus workforce business enhance quality dialogue relationship reputation hcps china help serve patient well arc agree robust governance arrangement underpin change include realtime monitor advanced data analytic uphold ethical valuesle approach hcp engagement gsk annual report strategic report governance remuneration financial statement investor information board activity principal decision continue boardcommittee stakeholder group principal decision decision regard stakeholder interest section duty consider boardcommittee covid solution corporate responsibility committee stakeholder committee recommend pandemic preparedness consider gsk approach hcp medical board approve proposal investment covid solution vaccine expert employee fully align purpose strategy adjuvant therapeutic price investor government area business focus supply allocation regulator non governmental organisation agree proposal commit profit multilateral organisation sale covid vaccine patient consumer pandemic investment pandemic preparedness committee please agree gsk covid solution approach principle work partnership take global approach commit access support future pandemic preparedness approach seek strike balance generate economic return reward innovation invest business act responsibly key stakeholder support global response pandemic new environmental corporate responsibility committee stakeholder committee recommend sustainability goal receive consider proposal investor employee board agree stepchange scale review develop exist government regulator pace address impact environmental sustainability target nongovernmental environment commit goal net organisation zero impact climate positive impact ambitious new target firmly multilateral organisation nature value chain align expectation environmental sustainability key stakeholder duty contribute protect group focus climate change longterm result restore healthy planet improve people damage nature workforce business health link goal action relationship community remove carbon improve biodiversity committee agree address environment reputation restore local water basin expectation positively impact demonstrate nature positive approach gsk reputation employee engagement give equity position mitigate exposure financial supply chain risk inclusion corporate responsibility committee stakeholder committee support proposal diversity receive consider proposal investor employee board agree great transparency employee government regulator report employee race ethnicity datum race ethnicity datum aspiration nongovernmental annual report accompany support aspiration organisation headline aspirational statement increase percentage leader multilateral organisation detail external disclosure identify ethnically diverse duty data specific aspirational increase global gender longterm result target delivery end aspiration workforce business relationship community increase global gender aspiration committee note environment reputation role high strategic commitment end modern employer key component trust priority strong employee experience critical attract retain key talent deliver innovation performance trust priority underpin culture broad effort area race ethnicity gender proposal consistent approach inclusion diversity focus ensure workforce reflect community work hire disclose gender diversity datum aspiration set globally gsk annual report purpose value culture board role promote gsk sustainable success year board discussion culture centre drive longterm growth shareholder add value employee experience gsk way work stakeholder strategic report page particularly backdrop covid pandemic demonstrate work achieve goal consider progress evolve gsk culture corporate governance report page explain insight reflection key external stakeholder governance arrangement support strategy audit risk corporate responsibility committee innovation performance trust priority underpin consider respective risk compliance culture aspect culture change performance line trust priority purpose gsk purpose improve quality human life help culture change complex global organisation gsk people feel well live long underpin take time sustained effort board recognise value patient focus integrity respect transparency tone drive company culture purpose value source great pride cet role model word action board management employee help attract behaviour set template employee board member retain talented individual want group seek lead example instance alongside rest contribute society strengthen relationship workforce follow key gsk training patient consumer key awareness module stakeholder help new medicine live value expectation explore gsk vaccine consumer healthcare product patient value expectation culture application consumer world operation way work culture antibribery corruption board responsible setting group culture play key role deliver high standard business inclusion diversity conduct promote longterm success unlock way people live work protect value gsk expectation courage accountability covid pandemic crucial role leader development teamwork fundamental culture play describe continue good progress evolve culture increase pace performance focus way recent race ethnicity challenge reinforce work discuss focus inclusion diversity core element culture confident work date realise board receive regular update gsk ceo cso progress promote inclusion cfo head human resource global business diversity agenda set strategic progress align strategy performance value report corporate responsibility base culture assess progress culture shift committee chair report mainly result gsk regular employee survey culture dashboard track indicator progress code conduct embody value expectation keep review board refresh regularly appoint promote right people available gskcom leadership capability corporate standard employee policy align employee engagement value expectation include longstanding speak arrangement enable employee raise way working matter confidentially anonymously fear reprisal head human resource regularly update board board audit risk committee review speak progress indicator report provide gsk global ethic compliance board support gsk culture change seek gec team speak channel report manage appoint promote right people enhance governance independent party case investigate control process uphold incentivise right gec behaviour train develop employee detail enable culture change invest reward workforce page gsk annual report strategic report governance remuneration financial statement investor information board approach engagement gsk engagement main stakeholder group key stakeholder perspective board cet include patient shareholder consumer customer strategy day employee level organisation business development analysis justification enterprise summarise page strategic report board committee evaluation way board consider key stakeholder interest remuneration policy review wide workforce discussion decision make set pay perspective holistic view board discharge duty culture succession planning update read conjunction workforce engagement director update section statement area annual governance meeting crossreference annual report annual general meeting principal decision board committee page employee survey report stakeholder rightly high expectation briefing annual strategy meeting dynamic operating environment present challenge annual budget business planning process opportunity respond prospect board corporate governance regulatory development update seeks ensure remain commercially successful meet stakeholder expectation uphold workforce reputation maintain licence operate build trust ensure identify respond expectation establish strong engagement mechanism effectively board engage stakeholder directly colleague describe key mean governance channel help communicate workforce view influence importance different stakeholder group boardroom vary depend matter consider feedback gsk global employee survey different stakeholder interest conflict require work workforce engagement director vivienne balanced judgment board cox regularly gather explain colleague view stakeholder engagement feedback help identify board outline overleaf emerge issue enable board consider gsk chairman nonexecutive director regularly activitie context relevant important meet employee group report stakeholder ensure deliver purpose advance board goal world innovative bestperforming trust healthcare company overall employee engagement score global employee survey operate key performance principal board committees cet delegate indicator publish year survey power enable build detailed understanding conduct spring backdrop impact company action plan stakeholder intensify covid crisis significant business change engagement briefing insight share resulted engagement score high board appropriate survey inception increase board primarily receive intelligence stakeholder previous survey september perspective work corporate responsibility board please improvement survey committee cover score innovation performance trust improve understand stakeholder matter priority power culture reveal follow board member encourage meet individually trend employee sentiment employee shareholder key stakeholder purpose deep connection purpose induction ongoing basis patientconsumer positive change culture encourage report board experience contribute engage productive happy relevant material workforce strong performance employee feedback board learn stakeholder view consistent key benefit general ceo board report agreement workforce contribution recognise strong support rationale monthly stakeholder perception report gsk covid response emphasis business update people business continuity solution retain focus critical innovation performance trust priority reaction gsk covid response build power culture people business continuity solution gsk annual report board approach engagement continue performance leaderdriven care people lead new performance choice initiative employee generally felt value support respected enable combination facetoface collaboration crisis help form strong digital work wave participant sign connection leader appreciate initiative officebase employee include office great regularity communication open honest worker laboratory factory need informal style onsite set new work parameter employee work manager work necessity employee flexible line objective performance requirement get job work wide team preference commitment home react leader openness sharing challenge support clear accountability pace positive flexible work pattern similar appreciation recognition management assemble right company flexibility childcare need team appropriate expertise irrespective holiday support employee health wellbeing level people company respond rapidly collaboratively fastchange issue opportunitie workforce engagement director year gsk workforce session synthesise feedback engagement director role privilege nonattribute report board meeting carry enjoy meet wide variety october chairman pleasure meet employee group different business virtually leader member gsks race ethnicity geographie employee resource group talk board plan visit agree year support ceo ambition action improve inclusion covid need creative embrace diversity widerange conversation particular technology switch virtual meeting nonetheless discuss commitment transparent meeting insightful provide helpful ethnic representation workforce leadership employee perspective progress evolution set public aspirational target focus gsk gsk culture improve ratio detail company inclusion diversity work newly publish aspiration year schedule include let talk session team develop role aim incorporate employee oncology commercial consumer annual discussion selection gsk employee healthcare marketing artificial intelligence resource group machine learn development dialogue race ethnicity employee resource please report general employee group finally observe annual senior leader virtual meet broadly supportive gsk culture change meet key benefit deliver value advantage work large company strong purpose company let talk session wellestablishe virtual employee response covid crisis receive particular support voice channel direct conversation workforce continue deal session receive briefing business challenge work remotely continue enquire head human resource include workforce datum stay resilient motivate mentally gsk survey datum insight business meeting context business wide group employee raise impact restructuring excitement opportunity let talk session follow consistent format separation company bring enable directly compare feedback gather natural trepidation understandable different part workforce year participant covid permit hope able engage represent diverse crosssection employee employee facetoface team keen hear employee meantime virtual route enabling carry time new role look forward continue provide platform company bring recent perspective compare employee view perspective boardroom gsk organisation experience introduce role explain passionate employee engagement purpose conversation vivienne cox feedback ground rule nonexecutive director manage line value expectation ensure participant comfortable express anonymised view keep group small know participant encourage share view gsk annual report strategic report governance remuneration financial statement investor information board approach engagement continue shareholder holistic view work relationship future focus audit risk committee board seeks directly engage private retail discuss remuneration policy practice proposal institutional shareholder way include regular communication agm annual governance meeting receive thoughtful incisive meeting work investor relation team question attend board member chairman sir jonathan symonds company secretary gsk external audit partner shareholder feedback share victoria whyte subsequently rest board year ceo emma walmsley cfo iain year usual annual governance meeting slide mackay give quarterly result presentation institutional available gskcom event investor analyst medium webcast teleconference annual general meeting available gskcom year agm hold register emma iain conduct continual active dialogue office covid restriction public gathering institutional shareholder performance plan broadcast agm shareholder invite join objective regular meeting emma hold ask question vote meeting electronically individual meeting major shareholder host detail find group meeting actual potential major shareholder unfortunately covid pandemic unable iain hold individual meeting group hold agm plan hold instead meeting register office close meeting attend chairman jon maintain active dialogue shareholder company secretary line minimum include fund portfolio manager see quorum shareholder meeting government governance professional enable build lockdown requirement board member join picture major shareholder insight perspective telephone ideal agm format priority gsk follow introductory meeting hold protect shareholder employee board general catchup meeting range uphold gsk governance continue provide investor comprise approximately company healthcare patient need share register write shareholder early april explain annual governance meeting arrangement encourage submit proxy vote board hold annual governance meeting response shareholder question submit advance institutional shareholder key investment industry body agm publish website propose proxy advisory firm resolution approve shareholder majority range year covid chairman host virtual event december join senior independent board keen provide channel meaningful director workforce engagement director committee chair engagement shareholder conventional gsk external audit partner share follow key gsk agm hold shareholder webcast immediately information investor meeting attend board member webcast chairman ceo give update change board committee increase shareholder able question chairman ceo cfo focus board imperative management oversight cso question lodge board increase importance corporate responsibility member answer science committee webcast offer shareholder include strong board oversight progress separation ordinarily attend agm opportunity engage transformation separation committee board shareholder join telephone online thoughtful rapid response covid focus answer give broad range question employee business usual activity potential include submit advance recording treatment vaccine webcast summary available gskcom employee feedback positive change gsk culture appear support engage productive happy workforce strong performance continue evolution gsk approach environmental social governance esg matter emphasis social esg report gsk modern employer approach include focus inclusion diversity response board organisation issue gsk annual report board performance board evaluate performance action point committee year evaluation normally carry meeting review evaluation board split externally year facilitate group appropriate mix executive non jan hall business advisory company executive director review consider report connection gsk board feel consideration discussion follow action point helpful conduct evaluation improve performance agree check progress implementation key measure consideration continue give stop agree board previous year review unnecessary task free time focus preparation priority precondition create shareholder meet chairman advance evaluation value prime importance update board operating gsk future consideration give make good use priority agree review objective scope board time virtual meeting incorporate timetable company secretary provide opportunity unstructured discussion possible advance access board committee material information board continue discuss approach separation course year interview november december conduct science committee look deepen confidential detailed virtual interview board understanding rd resource allocate select cet member company secretary gsk desire enhance root cause analysis external auditor independent remuneration adviser undertake incident issue occur seek view board effectiveness ensure avoid future meeting reflect agree discussion guideline group approach improve performance send participant include key topic board committee financial reporting council guidance review board committee focus progress board effectiveness relevant requirement embed enhance way working agree corporate governance code limit review board governance feedback participant architecture involve virtual interview committee review member conduct behalf respective review seek focus progress committee chair committee consider operate board focus continue evolve effectively maintain optimal effectiveness committee successful delivery company separation chair mindful continue prepare oral report evaluation result suggest step include update board work appropriate summary report compile discuss initially important issue highlight comment chairman ceo senior independent director chairman sid review present board december sid seek feedback chairman covered follow main area effectiveness performance director individually collectively review result effectiveness review note overall review board discuss chairman sid board organisation agenda information board dynamic challenge input future strategy development performance delivery review highlight proposal board committee well explore resolve tough question heart make board effective gsk annual report strategic report governance remuneration financial statement investor information board performance continue progress board evaluation progress conclusion board evaluation review set area focus progressachievement meeting organisation board committee presentation organise brief summary improve balance presentation discussion create key issue question address majority allot time debate time give qas discussion decision board dynamic individual contribution board committee agenda paper presentation facilitate great individual contribution create discussion evolve organised allow time board member provide time insight perspective matter critical board priority committees board committee term reference update new transformation review remit attendee board committee meeting separation committee establish board march ensure fit purpose risk exercise complete board term reference agree board committee ensure deep oversight review relevant board committee update reflect agree reallocation group enterprise risk enterprise risk oversight responsibilitie strategy performance board committee agenda organise emphasise conduct deep dive key strategic area ensure focus allocate time discuss mission critical input decision paper support management execute agree strategy reinforce focus strategic execution board knowledge board benefit great insight gsk strategy deepen board knowledge understand late scientific science theme deep dive year specifically human development genetic covid vaccine mrna technology stakeholder board align cet deliver mission critical item business board continue focus key area benefit key stakeholder focus cet strengthen pipeline growth transformation delivery gsk trust business priority externally maintain strong relationship communication information continue area focus shareholder key stakeholder seek input inform progress succession planning charles bancroft joined board arc complete appointment audit risk committee arc chair succeed judy lewent arc chair march annual report successor publish governance board approve company announce ambitious new build gsk commitment environmental social environmental sustainability goal net zero impact climate governance esg matter net positive impact nature search undertake seek successor lynn elsenhans chair corporate responsibility committee lynn agree serve year retire board detail gsk annual report board committee information board committee write term reference approve board review annually ensure comply late legal regulatory requirement reflect good practice development follow summary role committee list membership current term reference board committee available gskcom number committee meeting committee member attendance describe detail committee member skill experience include biography board page accordance frcs code board determine judy lewent charles bancroft recent relevant financial experience agree appropriate qualification background audit committee financial expert define sarbanesoxley act determine independent mean security exchange act amended board committee board committee role membership comprise report audit risk review financial reporting process integrity judy lewent chair company financial statement external internal audit charle bancroft process system internal control identification vindi banga management risk company process lynn elsenhans monitor compliance law regulation ethical laurie glimcher code practice initiate audit tender selection appointment external auditor set remuneration exercise oversight work corporate responsibility consider gsk trust priority oversight progress lynn elsenhans chair associate trust commitment reflect vivienne cox important issue responsible sustainable business jesse goodman growth oversight view interest internal external stakeholder review issue potential impact gsk business reputation science support board understand key strategic jesse goodman chair theme company strategy base laurie glimcher external transaction perform depth judy lewent review underlie scientific assumption board technical assurance undertake depth risk oversight relate risk nomination review structure size composition board sir jonathan symonds chair corporate governance appointment member board committee vindi banga appointment corporate officer make lynn elsenhans recommendation board appropriate plan judy lewent assess orderly succession executive nonexecutive urs rohner director review management succession plan ensure adequacy responsible reporting board oversee monitor corporate governance arrangement make recommendation board ensure company standard arrangement consistence exist corporate governance standard emerge good practice review company conflict interest transformation advise assist board transformation sir jonathan symonds chair separation separation company oversee associate risk charles bancroft establish separate group biopharma consumer vivienne cox march healthcare company vindi banga lynn elsenhans judy lewent urs rohner remuneration set company remuneration policy regard urs rohner chair gsk workforce remuneration gsk able recruit vindi banga retain motivate executive vivienne cox judy lewent remuneration policy regularly review ensure consistent company scale scope operation support business strategy growth plan align wide workforce help drive creation shareholder value chairman ceo responsible evaluating make recommendation board remuneration nonexecutive director gsk annual report strategic report governance remuneration financial statement investor information board committee report audit risk committee report work plan rest deliver business usual standard incorporate learning judy lewent measure take quarter process plan audit risk committee plan review committee quarter please present report ninth year approval report final chair audit risk committee please confirm effective operation finance committee committee work largely help deliver smooth second quarterly result recur structured programme activity continue provide stable reporting control understandably include impact covid platform financial year end pandemic devise programme company committee role assess effectiveness secretary agree content management internal control financial reporting committee external auditor start year adapt continue obtain regular update progress appropriate year progress breakdown strengthen information technology process activity area focus available gskcom associate infrastructure especially user access follow page aim share insight activity management appropriate mitigating technology undertake overseen committee year business control place process financial reporting control strengthen integrity gsk financial statement include annual usual committee diligent reviewing report quarterly result announcement endure key year appropriateness guidance balance focus committee committee position development external environment advise aim clear transparent financial disclosure board accordingly financial report external audit impact covid audit annual report publish company onset crisis assess covid crisis impact fully unfold external auditor discuss management report sign covid spread committee significant disruption country closely monitor potential impact audit process timetable monitor closely production result number key measure external auditor committee year take finance team present committee continue discuss insight committee please financial reporting external auditor provide use analytical tool control framework remain robust require technology help improve accelerate delivery fundamental change take target audit work adjustment ensure control framework continue significant issue committee external auditor operate effectively close quarter discuss significant issue relation financial result statement committee consider periodically adjustment quarter result include year area particular audit focus high adapt deploying finance crisis management degree alignment committee external response formation finance issue auditor area attention set management taskforce address deliver critical disclosure page areas finance organisation internal audit audit assurance team adapt deliver result time schedule assurance work account change business finance team thirdparty partner work challenge travel restriction arise covid home team regularly update committee progress agree schedule audits value review accounting consideration result assurance review covid impact result additional propose disclosure committee consider approve new way work settle adopt apply guidance issue financial anticipate opportunity report council frc effectively perform assurance activity remotely particularly audit cover end end process access technology likely apply company finance tech process gsk annual report board committee report continue sfi hcp change fundamental success continue evolution continue consider rationale test new programme strong leadership drive culture robust governance arrangement underpin incremental performance trust enforce measure change sale force incentive sfi programme governance control zero tolerance abuse healthcare care professional engagement hcp policy risk management internal control enterprise risk result gsk grow innovative specialty care gsk wellestablishe mature risk management product oncology progress build internal control framework describe specialty capability transform interaction hcp committee continue scrutinise operation limit update hcp policy framework review refinement management committee report annual report describe propose framework ensure remain fit purpose committee scrutiny recommendation board complement matter identify manage limited change sfi programme work global issue management team report cet ensure attract retain good sale force talent datum analytic key risk indicator global ethic enhance quality dialogue hcp compliance gec introduce key risk indicator kri well serve patient enterprise risk quarterly reporting believe change necessary secure growth tolerance kris risk oversight compliance council company deliver strategic priority act rocc addition risk mitigation relate covid good interest patient shareholder incorporate significant risk gec stakeholder hire datum analytic specialist enhance datum mining tool team enhance use datum analytic evolution commercial model independent business monitoring group committee consider sfi hcp policy change china support innovative product launch emerge risk help guide committee emerge risk competitiveness country discussion meet summary particular area focus rocc recent meeting share committee devote significant portion time committee member uptodate risk set robust governance arrangement underpin information change china include realtime monitoringadvance data analytic uphold ethical valuesle approach cyber security resilience gsk information protection risk hcp engagement addition nonexecutive director principal enterprise risk criticality briefing workshop hold committee business committee continue receive quarterly consideration process enable board meet update monitor closely ongoing work manage china pharmaceutical leadership team discuss continuously evolve risk relevance countrys commercial policy risk management compliance acute covid pandemic culture week result entire officebased workforce move workfromhome model addition information security rollout sfi hcp policy risk increase result increase malicious email change carefully select market safeguard key malware target gsk phishe form stakeholder interest sfi programme implement social engineering tech organisation able china select market control way successfully combat contextual detail follow clear stagegated phase step keep mitigation activity committee overseen review management committee year give committee emphasise risk unethical committee recognise covid behaviour sale team need monitor provide unique information security challenge closely comprehensive risk mitigation plan place threat create significant opportunity ongoing development programme advance security company committee seeks adopt possible good practice guideline effective compliance programme change sfi programme underpin robust internal control continue significant focus committee give associate risk know need act swiftly thing expect gsk annual report strategic report governance remuneration financial statement investor information board committee report continue internal control framework function provide independent assurance senior board recognise obligation present fair balanced management board effectiveness risk diligent assessment gsk current position management groupwide line agree assurance prospect reflect responsibility accountable plan help senior management board meet evaluate approve effectiveness gsk internal oversight advisory responsibility fulfil gsk control include financial operational compliance strategic objective build trust patient control risk management process stakeholder dual reporting line cfo committee ensure reliability financial reporting compliance law regulation internal committee receive regular report business unit control framework comprehensive enterprisewide principal risk owner gec area significant risk risk management model support board continuous group relate internal control report identification evaluation management group assess internal control environment principal risk principal risk require frc code area include enhancement strengthen control follow framework design manage risk achieve consideration report committee report annually business objective board effectiveness gsk internal control fitforpurpose framework complement corporate authority delegate committee value expectation speak process ensure board conduct robust assessment group principal risk associate business activity actively risk assessment line frc effectively control line agree risk appetite code include consideration nature extent risk believe gsk framework provide reasonable board willing achieve gsk strategic objective absolute assurance material misstatement loss board committee oversee effectiveness board mandate group rocc senior leader internal control environment risk management assist committee oversee risk management process group year internal control activity provide business approval date annual report framework risk management upward escalation gsk internal control framework risk management significant risk business unit risk board governance structure illustrate graphically gskcom structure report rocc business unit risk management compliance board rmcbs review group risk management approach responsible promote local tone discuss risk management section strategic risk culture ensure effective oversight internal report page management principal control risk management process risk explain principal risk uncertainties page group viability discuss group risk principal risk assign risk owner draw management section strategic report senior management accountable manage hisher principal risk include set implement risk mitigation plan report annually respective risk management approach progress rocc committee gec function assist rocc rmcbs gec responsible advance enterprisewide risk management develop riskbase ethically sound work practice actively promote ethical behaviour enable employee operate line value comply applicable law regulation gsk annual report board committee report continue significant issue relate financial statement consider gsk quarterly financial result announcement financial result annual report committee review significant issue management judgement determine result review management paper set key area risk action take quantify effect relevant issue judgement management appropriate accounting require address issue financial statement significant issue consider relation financial statement year end december set follow table summary financial outcomes appropriate committee external auditor discuss significant issue address committee year area particular audit focus describe independent auditor report page significant issue consider committee relation financial statement issue address committee go concern basis preparation committee consider outcome management halfyearly year end review current financial statement forecast net debt position financing facility option available group committee consider management review current longerterm impact covid pandemic outbreak pandemic year end follow consideration assessment include stress testing viability scenario sources liquidity funding forecast estimate committee confirm application go concern basis preparation financial statement continue appropriate revenue recognition include return committee review management approach time recognition revenue accrual rebate rar accrual customer return rebate pharmaceutical vaccine accrual return rebate billion december committee review basis accrual concurred management judgement amount involved full description process operate pharmaceutical vaccine business determine level accrual necessary set critical accounting policy provision legal matter include committee receive detailed report actual potential litigation internal external investigation group legal counsel number detail update investigation group commercial commercial practice practice management outlined level provision correspond disclosure consider necessary respect potential adverse litigation outcome area possible determine provision necessary december provision legal matter billion set note financial statement provision provision uncertain tax position committee consider current tax dispute area potential risk concur management judgement level tax contingency require december tax payable liability billion include provision uncertain tax position recognise group balance sheet impairment intangible asset committee review management process review testing goodwill intangible asset potential impairment committee accept management judgement intangible asset require writing result impairment charge million note financial statement intangible asset detail valuation contingent consideration committee consider management judgement necessary increase liability relation viiv healthcare pay contingent consideration result increase sale forecast unwind discount update exchange rate assumption cash payment nearly billion year december group balance sheet include contingent consideration liability billion relation viiv healthcare note financial statement contingent consideration liability detail viiv healthcare option committee review agree accounting pfizer option concur management judgement valuation option billion december gsk annual report strategic report governance remuneration financial statement investor information board committee report continue auditor reappointment committee chair regularly meet independently external auditor audit partner committee meet auditor end meeting discuss progress appropriate external auditor appointment tender december review feedback note area transition year improvement implement audit team shareholder approval current auditor committee satisfied audit annual report year end december effectiveness auditor external audit process audit tender require regulation auditor independence qualification objectivity expertise resource contractual similar obligation restrict group choice external auditor committee consider committee agree recommend company comply mandatory reappointment deloitte board forthcome agm audit process audit committee responsibility provision nonaudit service competition market authority statutory audit management operate presumption service order accountancy firm provide nonaudit services gsk effectiveness quality external audit process external auditor skill experience committee commit ensure gsk receive suitable supplier nonaudit support high quality effective external audit evaluate deloitte auditrelated matter tax service performance prior make recommendation good interest company line gsk reappointment early committee review nonaudit services policy committee ensure effectiveness performance criterion auditor objectivity independence safeguard agree management begin review preapprove external auditor provision criterion set annual report service detailed criterion judging effectiveness company policy complie frc revised deloitte external auditor base audit approach ethical standard sarbanesoxley act strategy high quality independent audit effective observe follow core policy feature engage partnership value money override responsibility external auditor nonaudit service deliver smooth thorough efficientlyexecuted audit available gskcom gsk nonaudit services policy key feature undertake review committee consider process nonaudit service competitive tender financial service provider line overall quality audit group procurement process skill independence deloitte experience external auditor suitable supplier deloitte exhibit appropriate level challenge safeguard adequate safeguard establish objectivity scepticism work independence group audit threaten deloitte length tenure take account compromise assess independence objectivity fee cap total fee payable nonaudit service recently appoint gsk auditor committee exceed annual audit fee special consider effectively assume role auditor circumstance clear advantage auditor undertake additional work committee consider feedback external prohibition gsk policy include whitelist permit nonaudit audit survey committee member financial service line relevant regulation service management team corporate business unit level list prohibit survey cover preapproval nonaudit service require preapproval set effectiveness auditor challenge table ensure service approve consistent gsk nonaudit policy permissible service process integrity deloitte ensure service fall scope service permit preapproved committee represent transparency reporting management delegation authority preapproval committee value preapprover clarity auditor communication way working committee chair cfo alignment audit group investment group financial controller system application product sap designate group quality audit team leadership financial controller skill experience audit team fee pay company auditor associate set overleaf detail given note financial statement operate profit gsk annual report board committee report continue corporate responsibility committee report audit service comparison lynn elsenhans corporate responsibility committee please present fifth report chair corporate responsibility committee committee committee important board oversight company trust priority oversee guide cet deliver longterm value shareholder society role committee committee oversee gsk trust priority company progress trust commitment audit assurance service reflect important area responsible sustainable service include tax regulatory compliance treasuryrelate service business growth oversight view interest internal external stakeholder review issue seriously impact gsk business reputation fair balanced understandable assessment need annual report fair balanced committee rolling agenda receive report understandable key compliance requirement cet member senior manager ensure action company financial statement ensure gsk annual progress gsk trust commitment consider report meet requirement wellestablishe regularly include monitor company engage document process govern coordination review effectively broad range stakeholder respond groupwide contribution publication run parallel high external expectation gsk global healthcare process follow external auditor company committee support chairman ceo general counsel president global affairs pharma committee receive summary management supply chain trust global health approach gsk annual report ensure meet invite meeting cet member attend require requirement frcs code enable committee board confirm gsk annual committee oversight principal risk relevant report fair balanced understandable area expertise responsibility product provide necessary information shareholder assess quality nonpromotional engagement supply continuity company position performance business model environmental sustainability environment health safety strategy principal risk manage member senior management ensure appropriate control place code conduct report line clear plan address gap detail risk number wellestablishe policy include page code conduct available gskcom detail confidential speak line report key activity investigate unlawful conduct focus particularly alignment group trust priority gsk purpose strategy company audit risk committee chair succession navigate challenge present covid delighted welcome charle bancroft chief purpose align motivate factor financial officer bristol myers squibb designate employee focus prove helpful financial expert charlie join committee competence relevant sector year committee undertake deep oversight company operate charlie enterprise risk relevant remit expertise work smooth transition handover involve regular report risk owner include relevant succeed committee chairman publication material advice risk highlight annual report relevant audit assurance global ethic compliance outcomes privilege serve member board chair committee oversee audit risk aspect good progress trust commitment set change company environment originally notwithstanding impact pandemic regulation governance accounting reporting pharma company continue follow company progress separation biopharma consumer business judy lewent audit risk committee chair march gsk annual report strategic report governance remuneration financial statement investor information board committee report continue key activity review include stakeholder engagement insight committee pay close attention evolve view oversight gsk covid response global health expectation company broad range key stakeholder long gsk key contribution area recent year review discuss regular report stakeholder company increase focus science ensure insight meet ensure consider issue big impact line strength strategy bear gsk reputation delivery committee oversaw company response responsible business agenda employee insight feedback covid behalf board committee discuss relation progression company management acutely aware need respond modern employer agenda result employee way balance interest key stakeholder survey sustainable gsk committee discuss gsk contribute scientific technological expertise meet directly shareholder understand issue explore decisionmake framework management concern december please engage responsible pricing model access allocation number large investor company virtual principle partnership criterion framework allow annual governance meeting include interactive gsk rapid decision consistent value session participant increasingly important work purpose strategy committee year environmental sustainability committee review committee actively look ensure gsk continue approve recommendation gsk set new ambitious delivery societal shareholder need aware goal net zero impact carbon net positive impact increase focus environmental social governance nature committee review contribution esg issue investor strongly support goal gsk pharmaceutical vaccine management approach manage esg include risk consumer healthcare business committee mitigation management continue benchmark esg discuss impact climate change nature loss performance please strong show human health recognise new goal consistent area year gsk rank second purpose strategy pharmaceutical industry dow jones sustainability index early january come access medicine index modern employer committee regular oversight company maintain strong position investor rating gsk modern employer programme sustainalytic msci vigeo eiris discussion management race ethnicity year company continue report progress committee monitor investor expectation esg gender target set disclose target report disclosure ongoing basis gsk continue workforce race ethnicity market sufficient align good practice report accordance employee datum available detail evolve sustainability accounting standard board esg company inclusion diversity agenda performance summary taskforce climaterelate financial disclosure health safety health wellbee employee extremely important gsk community committee aim operate committee formal oversight committee continue scrutinise monitor gsk employee health safety enterprise risk material trust topic relevant enterprise risk provide oversight area committee work management continue ensure commitment discussion management gsk health safety support trust priority evolve accord external performance include detailed report investigation expectation company strategy particularly gsk cause workplacerelated fatality progress creation new lead healthcare year ensure company take appropriate action company committee consider company key learning position support continue delivery trust priority committee chair succession approach end tenure board facilitate smooth transition successor agree stay board year agm subject reelection agm look forward work handing successor announce lynn elsenhans corporate responsibility committee chair march gsk annual report board committee report continue science committee report pipeline progress committee please observe progress jesse goodman hal barron gsk chief scientific officer cso science committee president drive scientific innovation significant year committee year company continue strengthen renew focus science deep level advance pipeline receive major approval support board understand company include approval new molecular entity strategy provide reassurance guidance oncology hiv chronic kidney disease deliver require lifecycle innovation key medicine area respiratory disease year committee focus broad objective encourage major development oncology pipeline include major food drug administration ensure key scientific assumption drive fda approval company strategy remain valid zejula niraparib monotherapy available provide technical assurance particularly relation firstline maintenance treatment woman advance potential transaction ovarian cancer regardless biomarker status deliver oversight research practice patient blenrep belantamab mafodotin adult patient safety enterprise risk relapse refractory multiple myeloma second renew focus committee undertake common form blood cancer deepdive strategic theme include addition viiv healthcare obtain fda approval human genetics cabenuva cabotegravir rilpivirine complete long act regimen treatment hiv infection adult artificial intelligence machine learning vaccine pipeline progress highly vaccine promise maternal rsv vaccine candidate man oncology abcwy fiveinone vaccine meningitis candidate exciting area address enter phase iii study committee year building capability business development strategic partnership area enable gsk develop system advantage collaboration world lead access human genetic datum build foundation set year committee collaboration biobank finngen continue review scientific opportunity number significant impact future discovery largescale investment business transaction development process gsk vir biotechnology committee support gsk assessment gsk response covid collaboration vir identify accelerate new antiviral committee oversaw company response develop antibody therapeutic preventative potential vaccine therapie covid response option fight covid future outbreak late include stage study underway vir result anticipate half partner vaccine adjuvant multiple company research group world include sanofi collaboration expand february advance bioscience south korea medicago canada new therapeutic influenza respiratory disease investigate generation covid vaccine pantb collaboration gsk join consortium collaboration curevac philanthropic nonprofit private sector organisation include bill melinda gates foundation accelerate develop potential therapeutic option combat development novel treatment tuberculosis covid potential future outbreak important step address current challenge collaboration vir biotechnology innovative diagnosing treat drugresistant pipeline assets gsk annual report strategic report governance remuneration financial statement investor information board committee report continue curevac partnership role helping identify critical nomination corporate governance emerge trend science medicine committee committee report believe access external innovative platform key future vaccine business jonathan symond nomination corporate governance committee gsk strategic partnership curevac provide access innovative messenger rna mrna technology rapidly please present second report chair progress platform develop new vaccine nomination corporate governance committee medicine technology expand range disease committee committee rename year reflect prevent treat potentially hasten expand role encompass corporate governance matter development manufacturing curevacs mrna technology free time board ensure deep manufacturing capability complement gsk exist focus important area expertise vaccine address significant unmet medical work nomination corporate governance committee need transform gsk close separation february build exist relationship gsk committee key priority enter collaboration curevac jointly search replacement longserve director develop generation mrna vaccine offer broad judy lewent lynn elsenhans protection variety different sarscov varient identify scientific medical expert sme enable quick response new variant potentially strengthen scientific expertise board emerge future science committee ideaya bioscience collaboration gsk partnership close skill gap ideaya synthetic lethality emerge field precision medicine oncology help achieve sustainable flow board change new treatment field synthetic lethality gsk report describe search judys successor core research area oncology make ideaya ideal chair audit risk committee arc result partner charles bancrofts appointment board charlie recently retire successful career bristol like opportunity thank judy lewent myers squibb bring wealth financial management member committee inception experience global biopharma invaluable retire board agm board gsk move stage development valuable contribution deliberation commercial handover arrangement judy charlie life sciences perspective look forward join arc chair publication annual additional scientific medical expert report describe judys report page appoint board continue committee work despite serve year judy continue develop specialist scientific support provide demonstrate characteristic independence carry board role board continue role support cso appoint korn ferry assist search lynns oversee pipeline ahead separation successor chair corporate responsibility committee gsk seek deliver generation innovative korn ferry provide gsk recruitment transformational medicine vaccine patient consultancy service signatory voluntary code conduct executive search firm gender diversity jesse goodman good practice broad selection criterion focus science committee chair potential candidate follow knowledge march experience commitment esg depth understand experience broad esg agenda ideally expectation investor area science technology address health need experience science technology progress global health potentially gain working partnership global nongovernmental organisation experience work different stakeholder group include government regulator public policy organisation make product affordable available familiar issue public access medicine ethical practice patient advocacy ideally gain life science sector gsk annual report board committee report continue modern employer ability contribute commit diversity boardroom gsk lead discussion diversity ethnicity familiarity commit equal opportunity employee set monitor high standard health level organisation board management seek safety support employee health wellbeing encourage diverse inclusive culture personal development company responsible business experience develop effective board need range balance skill culture focus organisation positive social experience knowledge ethnicity gender socialeconomic impact engagement employee supplier background independence individual customer community understand experience prepare challenge work collaboratively role responsibility organisation minimise mix need complement diversity personal environmental impact set monitoring attribute include character intellect judgement honesty environmental target safety system courage describe statement ask lynn board cet diversity target remain post year stepping committee responsible develop measurable board agm board confirm despite objective monitor progress achievement impend year service lynn continue demonstrate assist implementation board diversity policy characteristic independence carry role include gender ethnic diversity board diversity objective line measurable target give critical importance strengthen gsk pipeline set hamptonalexander parker review board increase time spend strategy achievement respectively progress science committee focus science target set consistency deep level support board understand provide diversity metric october reassurance guidance require diversity objective progress achieve search sme appoint board position exceed objective science committee entirely sme korn hold woman ferry assist appointment identify cet position meet objective follow selection criterion candidate hold woman possession scientific profile leadership combine cet exceed objective geneticsartificial intelligence immunology cellgene direct report position hold therapy woman relevant experience academia pharmaceuticalsbiotech board director meet objective board director position hold ethnic minority leadership ability add value board creation committee particularly intent closing gap new gsk biopharma company gender representation increase ethnic minority representation board cet develop strong ethical personal quality provide good fit pipeline direct report cet ethnic minority diverse board representation woman ethnic minority good progress date look forward management position illustrate announce result search diversity gsk global workforce board composition tenure diversity board seek balance composition tenure committee meet nonexecutive director present committee refresh time receive consider succession plan management benefit experience longerserve director executive director ensure diverse fresh perspective insight new appointee pipeline potential successor regularly review succession plan nonexecutive member board draw nonexecutive director wide range industry background include pharmaceutical sir jonathan symond industry vaccine consumer product nomination corporate governance committee chair healthcare medical research academia insurance march financial service wealth experience complex organisation global reach board member experience longcycle industry great assistance understand sector gsk annual report strategic report governance remuneration financial statement investor information board committee report continue transformation separation committee report jonathan symonds transformation separation committee please present report chair transformation separation committee committee meet time committee senior independent director chair audit risk remuneration corporate responsibility committee workforce engagement director invite nonexecutive director meeting save repetition board committee principal function exercise oversight future ready transformation programme particularly cost saving separation company infrastructure delivery team move project design implementation track status key risk indicator value capture technology consider optimal form separation include consumer healthcare businesss listing location implication separation committee please programme make good progress cet engagement leadership deliverable track great pride programme continue deliver plan despite covid minor adaption necessary programme provide opportunity fundamentally review structure cost base way working biopharma consumer healthcare business include consideration increase automation different service level real estate impact procurement saving accelerate digitisation revisit follow successful embed new way work outbreak pandemic committee receive report audit assurance compliance team risk related achieve successful separation committee management clear gsk remain company separation override emphasis drive line growth improve margin year look forward share progress committee pivotal role oversee guide management transformation separation gsk oversee associate risk separate group lead company biopharma consumer healthcare sir jonathan symonds transformation separation committee chair march gsk annual report section statement company director require law promote success allow build trust fully understand potential organisation benefit shareholder impact decision make stakeholder wide stakeholder include employee supplier engagement gsk main stakeholder group include community patient shareholder consumer customer employee level organisation statement align requirement set summarise page strategic report section section cza company act act indicate year director company governance architecture process address matter set section summarise page corporate governance act perform duty avoid duplication report summary explore board consider incorporate information area annual report relevant matter make principal decision contribute board consider statement focus risk delivery gsk longterm priority innovation opportunity strategically important gsk performance trust consistent group size complexity information issue factor stakeholder perform duty promote gsk success board board consider relevant complying section focus matter include listen act find location outline consider view shareholder key stakeholder board regard follow matter longterm result workforce business relationships likely consequence decision interest group employee importance develop group business long term relationship supplier customer strategic report strategic report business model strategic report business model culture business model chairmans statement modern employer industry trend ceos statement stakeholder engagement stakeholder engagement capital allocation innovation corporate governance report key performance indicator performance board activity principal decision risk management covid solution purpose value culture viability statement reliable supply board approach engagement work party audit risk committee report corporate governance report risk management nomination corporate governance board activity principal decision committee report corporate governance report purpose value culture board activity principal decision board approach engagement remuneration report board approach engagement audit risk committee report remuneration committee chair audit risk committee report statement corporate responsibility committee report director pay wider set gskcom gender pay gap report community environment reputation fairness shareholder impact group operation desire maintain reputation high aim act fairly member community environment standard business conduct company strategic report strategic report corporate governance report trust section include culture board approach engagement environment trust investor information environment health safety ethic value environmental sustainability risk page human right report investigate concern climaterelate financial disclosure antibribery corruption risk page nonfinancial information statement corporate governance report approach tax corporate responsibility committee report corporate governance report corporate responsibility committee gskcom report responsibility report datum gskcom modern slavery statement gsk annual report strategic report governance remuneration financial statement investor information director report director power determine legislation nomination corporate governance committee article association contain rule review register potential conflict authorisation appointment replacement director provide register conflict january committee director appoint ordinary resolution report board conflict appropriately member resolution board provide authorise process authorisation continue appoint board director retire operate effectively committee recommend annual general meeting follow appointment approval register conflict board subsequently approve describe note article provide director require financial statement relate party transaction seek reelection annually annual general meeting end financial year director person closely accordance code associate material interest contract director cease director significance group company bankrupt article prohibit director voting resolution cease director virtue company act concern appointment term termination article appointment independent advice suffer mental physical ill health board resolve shall cease director company agree procedure director independent legal andor financial advice company miss director meeting continuous period expense deem necessary month permission board resolve indemnification director shall cease director qualify party indemnity provision define prohibit director law company act force benefit director resign offer resign board accept offer director hold office approval signature annual report require resign board change control essential contract director conflict interest contract arrangement director duty company act individually fundamental ability business avoid situation direct operate effectively company party material indirect conflict interest possible conflict agreement effect altered terminate company article provide general power board change control follow takeover bid authorise conflict agreement director provide compensation board review new potential actual conflict loss office employment result takeover record company secretary director count provision company share plan quorum authorisation actual cause option award grant plan vest potential conflict nomination corporate governance takeover committee review register conflict annual basis detail termination provision executive director board subsequently approve service contract give version company continue basis director responsible remuneration policy available wwwgskcom inform company secretary new actual investor section potential conflict arise change circumstance affect authorisation previously give provide authorisation director absolve statutory duty promote success company actual conflict arise postauthorisation board choose exclude director receipt relevant information participation debate suspend director board resort require director resign gsk annual report director report continue content director report follow information incorporate director report purpose company act location annual report director report glaxosmithkline plc year end interest capitalise financial statement december comprise note director report publication unaudite financial information group financial review section page detail longterm incentive scheme remuneration report corporate governance report waiver emolument director applicable employee engagement waiver future emolument director applicable director statement responsibility non preemptive issue equity cash applicable investor information non preemptive issue equity cash applicable unlisted major subsidiary undertake strategic report set matter require parent company participation place applicable disclose director report consider list subsidiary strategic importance provision service control applicable strategic report shareholder section page shareholder waiver dividend financial statement note risk management objective policy shareholder waiver future dividend financial statement note likely future development company agreement control shareholder applicable research development activity business relationship director report diversity draw present accordance provision information consultation employee reliance english company law liability carbon emission director connection report shall subject section statement limitation restriction provide law approve board director march sign behalf sir jonathan symonds chairman march gsk annual report ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn remuneration section chairman annual statement annual report remuneration remuneration policy summary ggsskk aannnnuuaall rreeppoorrtt remuneration report chairman annual statement behalf remuneration committee committee performance please present remuneration report term overall performance management miss annual report remuneration annual statement agree internal budget target biopharma primarily subject advisory vote agm significantly low expect vaccine sale volume set key aspect committee work result covid pandemic disruption lockdown turn implementation remuneration policy adult vaccine include shingrix hepatitis dtpa reward management performance contain vaccine synflorix bexsero despite continue grow shingrix sale overall extraordinary challenging year group sale overall grow cer particular strong board please continue progress growth driver new specialty product respiratory company strategic goal testament increase hiv oncology drive growth sale focus place improve commercial execution cer group innovative product account despite business disruption covid half pharmaceutical sale addition robust pandemic adult vaccination especially shingrix effective cost control support delivery financial guidance year deliver group pbit target adjust eps cer internal pbit target miss result reduce low end company earning guidance set bonus outcome multiple way company begin year covid pandemic continue work response covid set begin committee please note management include contribution adjuvant determination drive deliver agree financial guidance progress potential vaccine therapeutic asset vir despite environment confirm committee biotechnology inhouse asset otilimab adjustment target measure executive review ipt outcomes director result impact covid note total remuneration preparation create exciting company post separation overall pay emma walmsley ceo iain mackay continue schedule remain track despite global cfo pay hal barron cso disruption covid increase reflect vest long term incentive award grant year join like trust set outcome context overall finally importance business operate responsibly performance highlight new ambitious industry lead environmental target climate nature innovation term innovation cso introduce work undertake introduce organisation significant progress inclusion diversity target publish recently employee strengthen biopharma pipeline exceed survey see high response rate date target major approval overall employee engagement score rise asset late stage development believe rise survey high score transformational patient business inception company top access development deal undertake strengthen medicine index seventh time row capability acquisition new antibody mrna genetic platform technology gsk annual report strategic report governance remuneration financial statement investor information remuneration outcome look ahead award relation accordance pension remuneration policy key decision committee previously report intention align committee follow current executive director pension contribution wide workforce january response bonus outcomes ceo cfo cso feedback shareholder follow determine reference performance agree review company pension arrangement financial measure group pbit committee committee reduce pension contribution assessment individual performance cso align wide employee base remarkably challenging year formulaic methodology january calculate financial performance determine payment achieve financial remuneration policy implementation target committee consider progress committee agree executive director receive executive director personal objective year salary increase align provide wide aspect company innovation performance trust workforce respective geography priority believe result overall bonus outcomes board committee continually look ensure appropriately reflect underlying performance remuneration provision support business strategy progress priority seek engage shareholder potential vest lti award third change policy believe company performance share plan psp award vest shareholder good interest change context base year performance board engage shareholder potential equally weight preagreed measure new provide oneoff additional performance incentive award product performance measure vest reflect cso aim support continuity management continue work strengthen successful delivery biopharma pipeline proactively commercialisation newly launch product equally address principal risk creation focus strong cash management generation sustainable shareholder value year reflect delivery adjust free cash flow discussion ongoing result proposal measure disappointingly company relative tsr course set ahead specific vote performance past year result agm award lapse overall vest statement annual report set level position implementation provision determine bonus lti outcomes code continue follow approach committee carefully consider director performance agm deem necessary exercise discretion address like thank shareholder input anomaly performance outcomes review include engagement ahead year agm welcome assessment performance relevant measure feedback report ahead agm wide context include company trust priority specifically look forward receive support gsk access covid government support annual report remuneration job retention scheme dividend policy maintain year company deliver financial guidance urs rohner remuneration committee chair march gsk annual report annual report remuneration glance total remuneration following show composition total remuneration pay executive director office december respect emma walmsley iain mackay hal barron usm usm usm usm usm usm usm appoint effect january fix pay salary benefit pension performance pay annual bonus ltis earn respect year performance period pay performance annual bonus financial performance lti outcome performance period end december overall vest maximum target relative new target tsr product threshold target adjust group pbit performance achieve vested adjust maximum performance target lapse free cash flow executive director shareholding audit align interest executive director share ownership sor multiple base salary shareholder require build maintain significant holding share gsk time executive emma walmsley director require continue satisfy share ownership requirement sor hold iain mackay sor month leave gsk sor month leave gsk hal barron executive director cet sor salary ceo appoint effect january executive director sor december shareholde corporate executive team member gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue total remuneration audit fix pay pay performance annual bonus vested lti awards maximum opportunity vest measure salary measure new product adjust group pbit afcf total benefit individual objective relative tsr remuneration year deferral plan pension gsk share psp award read page read page read read total remuneration audit emma walmsley iain mackay hal barron fix pay salary benefit pension total fix pay pay performance annual bonus vest lti awards dabp matching awards psp total pay performance total remuneration note detail mandatory bonus deferral defer annual bonus plan dabp set matching award cease long grant dabp emma walmsley psp vest july closing price time annual report psp figure base average share price month period december publish figure year committee specific circumstance line state principle apply clawbackmalus determine appropriate follow consideration committee recovery sum pay clawback reduction outstanding award vest level malus apply respect executive director appoint effect january gsk annual report annual report remuneration continue total remuneration audit continue follow section provide detail element total remuneration include committee implement approve remuneration policy year fix pay audit salary table provide analysis total benefit gross table set base salary executive tax receive executive director director year compare increase workforce benefit benefit base salary emma walmsley change benefit available employee emma walmsley business relate service iain mackay business travel hal barron benefit employee total benefit detail salary level provide iain mackay benefit benefit available employee remuneration reporting regulation require company business relate service add executive director total benefit calculation business travel item deem tax authority taxable benefit benefit total benefit comprise hal barron employee benefit line policy benefit available employee employee vary location role business relate service business travel business relate service provide employee assist accommodation whilst business travel enable carry role tax authority benefit deem taxable benefit individual business expense company meet total benefit tax arise item note show gross tax split area business relate service tax regulation deem taxable benefit andor business travel include travel cost executive iain mackay benefit available employee increase year director appropriate spousepartn year mainly year medical benefit compare partial year benefit include professional fee vehicle allowance associate accompany executive director gsk review methodology allocate cost certain gsk business deem taxable benefit business travel previous methodology barron business travel executive director total approximately net barron place main business move accommodation whilst business travel take effect covid international travel result reduction benefit benefit gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue fix pay audit continued pension detail change pension policy implementation addition committee determine current future executive director pension arrangement align wide workforce appropriate january executive director member pension arrangement emma walmsley pension contribution base salary matching contribution follow iain mackay january march base salary april december base salary cash supplement base salary lieu pension salary excess figure hal barron cso member plan open employee executive supplemental saving plan essp saving scheme open executive accrue benefit plan limit receive combine contribution rate essp plan core contribution plus match total base salary bonus bonus defer dabp member cash balance supplemental cash balance pension plan gsk make annual contribution base salary line senior executive member gsk cet member define contribution plan emma walmsley iain mackay eligible receive matching award salary january march salaries april december accordance term plan emma walmsley iain mackay receive cash payment lieu pension base salary excess january march cash payment lieu pension base salary excess april december line gsk define contribution pension plan rate follow table show breakdown pension value set pension remuneration figure calculate accordance methodology set large mediumsize company group account report amendment regulation remuneration regulation emma walmsley iain mackay hal barron pension remuneration value define contribution define benefit employer cash contribution total pension remuneration value detail pension value hal barron set table pension figure disclose hal barron member style define benefit plan accordance paragraph eii schedule remuneration regulation table show accrued benefit annual pension accrue date accordance regulation pension remuneration calculate increase accrue benefit adjust inflation multiply reflect fact benefit receive number year normal retirement age cash balance pension plan age additional benefit retire early accrue pension pension remuneration december december value hal barron pension value fund unfunded total gsk annual report annual report remuneration continue pay performance audit annual bonus individual annual bonus adjust group pbit objective performance target performance measure weighting follow weight adjusted group pbit performance position performance measure executive director target outcome target adjust group pbit individual objective threshold maximum performance target set target respectively adjust group pbit target outcome purpose annual bonus calculation differ adjust group pbit disclose annual report primarily target outcome number calculate apply gsk budget exchange rate actual exchange rate follow table show actual bonus earn compare bonus opportunity bonus opportunity bonus outcome financial individual total total target maximum performance objective bonus bonus bonus salary salary base salary salary salary salary emma walmsley iain mackay hal barron table provide detail delivery adjust group pbit financial performance strong financial leadership group challenging year deliver year report group sale aer cer vaccine sale impact low adult vaccination volume covid disruption partially offset growth driver respiratory hiv adjust group pbit target drive low sale delivery support effective cost control adjust eps aer cer line guidance delivery support effective cost control gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue pay performance audit continue follow table summarise performance scorecard individual objective agree committee executive director addition contribution financial performance individual objective emma walmsley continue focus progress longterm ipt priority supply chain reliability severe disruption continue robust agile commercial execution exceptional network simplification circumstance pharmaceutical vaccine sale sustained progress leadership esg global health consumer healthcare strong growth new new environmental sustainability commitment climate specialty pharmaceutical aer cer nature launch expand plan accelerate progress shingrix aer cer despite impact inclusion diversity continue quartile recognition covid disruption firstmarket launch consumer external esg rating include place access medicine healthcare index place dow jones sustainability index significant progress strengthen advance new leadership accountability train new role sustainable pipeline transformational pharmaceutical enterprise key role women senior vaccine major approval pivotal study start vice president vice president level aspiration set latestage asset development race ethnicity representation covid solution include global partnership progress purpose performance culture secondgeneration vaccine therapeutic provide accelerate covid reflect high expertise donation support local response employee engagement rate record date continue focus transformation separation plan track deliver value expectation disruption remote new competitive company consumer healthcare working launch new flexible work approach pfizer commercial integration deliver remain key leadership role preparation separation new programme track competitive company iain mackay strong financial leadership group challenging year adjust eps aer cer line deliver year report group sale aer guidance delivery support effective cost control cer vaccine sale impact low adult key leadership role preparation separation vaccination volume covid disruption partially new competitive company offset growth driver respiratory hiv strong oversight finance tech transformation extreme covid disruption hal barron strategy strengthen advancement pipeline significant progress biopharma potential new medicine vaccine candidate development organisation implement strong major product approval pivotal study start foundation single approach governance capital significant business development deal execute augment allocation pipeline include vir biotechnology curevac surface oncology employee confidence pipeline strong broad institute adrestia engagement organisation research target genetically validate continue build gsk reputation innovation target identify collaboration jointly external pipeline perception significant identify target clinical development engagement major platform medium investor advance technology capability build continue new london hub open functional genomics network nvidia collaboration key external hire new talent key role external hire malus clawback policy line disclosure guideline committee detail policy malus clawback refer recoupment committee exercise malus clawback company remuneration policy report annual report available gskcom policy committee review disclose detail exist policy recruitment remuneration recoupment committee exercise malus clawback loss office termination payment refer disclosure matter subject remuneration policy report page public report misconduct fully annual report available gskcom resolve legally permissible disclose unduly prejudice company shareholder gsk annual report annual report remuneration continue pay performance audit continue value earn longterm incentive ltis follow table set performance achieve target set company lti plan include update performance outstanding award line committee agree principle measure applicable lti awards actual performance target review adjustment appropriate ensure vest outcome reflect genuine underlie business performance result deliver line trust business priority psp award performance period end december committee review performance psp award grant executive director target set adjust free cash flow afcf target revise line disclosure annual report restate account revise phase future ready programme restructure cash payment separation cost base detailed programme separation planning undertake result target increase psp value base closing share price february closing ad price vest amount ceo cso attributable share price appreciation performance period committee exercise discretion relation vest award share price change performance achieve year december vest level set table outcome vest level performance measure relative weighting performance target outcome maximum award new product new product sale performance measure aggregate threeyear sale new performance product launch threeyear performance period precede year target vest maximum threshold adjust free line company agree principle afcf figure include adjustment cash flow number material distort item include legal settlement exchange rate performance movement special pension contribution original revise target target vest maximum threshold revise target adjust annual report note relative tsr rank tsr ranking comparator group vest performance maximum threshold median comparator group astrazeneca bristolmyers squibb eli lilly gsk johnson johnson merck novartis pfizer roche holding sanofi vest schedule base deliver vest median performance comparator group company median fall company total vest respect award gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue pay performance audit continue update performance ongoing lti awards committee review performance psp award grant executive director follow chart provide estimate vest level take account performance december actual vest level determine base performance threeyear performance period indication regard prediction final vest level afcf threshold associate vest scale psp award adjust net overall impact increase award decrease award adjustment account follow item revise phase future ready programme restructure cash payment separation cost base detailed programme separation planning undertake revise timing future ready programme divestment cancellation future ready programme divestment change target set new product innovation sale previously name new product relative tsr performance measure award psp award psp award rank rank threshold threshold maximum commercially commercially commercially median sensitive median sensitive sensitive threshold relative adjust free new relative adjust free innovation pivotal trial major regulatory tsr cash flow product tsr cash flow sale start approval milestone pipeline progress estimate vest level estimate lapsing level threshold performance award vest respect performance measure individual lti award level appear annual report set lti awards historical vest lti plan vest year adjust free new business lapse total vested grant relative tsr cash flow product diversification dabp award subject tsr performance award subject performance measure psp award lti awards dabp award respect deferral bonus psp award show table dabp award psp awards total bonus number face value award level number face value defer share award base salary share award emma walmsley share share iain mackay share share hal barron ad ad face value dabp award calculate base share price ad price closing price february day grant nilcost option executive director restrict share executive director performance condition attach dabp award reflect mandatory deferral respect annual bonus earn face value psp award calculate base share price ad price closing price february day grant conditional share base performance measure outline performance period psp award january december gsk annual report annual report remuneration continue director pay wider set internal context set executive pay important committee good understand wide workforce pay end annual basis meet human resource business leader hrbls global support function pharmaceutical viiv healthcare vaccine consumer healthcare understand perspective pay gsk remuneration package wide workforce meet hrbls year discuss current enterprisewide theme employee wide group attract recruit retain key talent support ambitious business agenda work separation biopharma consumer healthcare business inclusion diversity pay review include delivery fair pay set appropriate salary budget pension change undertake propose consultation discuss different pay levelsculture different market move key talent market handle finally vivienne cox workforce engagement director value member committee continue bring employee perspective committee discussion urs rohner remuneration committee chair remuneration structure employee element wide workforce pay comparison executive director cet pay salary market competitiveness salary company executive director cet ordinarily assess local market level competitiveness increase base salary line average role measure external market wide employee population change internal peer keep regular review scope individual role responsibility experience pension company seek provide appropriate pension executive director cet eligible benefit package align competitive receive benefit broadly line policy benefit market practice country employee vary location company operate employee base pension arrangement structure accordance executive director cet member expect retire current future executive director pension arrangement align wide workforce january annual exception sale force participate executive director cet participate plan bonus separate arrangement wide workforce participate base assessment combination stretching plan base performance business financial business personal objective financial measure measure consumer executive director require defer healthcare structure reflect priority cet bonus earn share specific business area adss appropriate year plan design reward employee collective clawback andor malus provision apply contribution business achievement separate mechanism place recognise outstanding individual performance address underperformance lti plan employee senior vice president svp vice executive director cet grant annual president level participate psp psp award performance target executive director cet period performance target period executive director require hold vested clawback andor malus provision apply award additional twoyear period svp employee director clawback andor malus provision apply manager cet receive annual share value executive director cet receive plan award restrict share share value plan award follow appointment gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue director pay wide set continue ceo pay ratio light provide supplemental ratio lower upper lti compensation exclude believe quartile median quartile provide additional view ltis form substantial financial year methodology percentage ceo total remuneration highly variable dependent business performance ceo option total remuneration exclude lti compensation pay ratio calculate actual earning financial year methodology ceo employees ceo total single figure remuneration option restate detailed report total remuneration fulltime equivalent employee total remuneration vest longterm incentive award company december calculate line percentage change remuneration ceo single figure methodology employer pension contribution employee define benefit pension emma walmsley employee cost complexity calculation instead change change future service rate agree recent actuarial funding salary valuation employee benefit reflect actual earning receive exclude annual bonus business expense produce percentile calculation option remuneration regulation wide employee population salary increase business expense exclude reimburse include annual salary review additional employee sufficiently substantial value change year promotion employee benefit significantly impact ratio unchanged previous year change benefit policy level reflect gsk continues choose option change level benefit individual received robust statistically accurate way company result change role promotion calculate ratio option available employee population consider relevant remuneration regulation decrease pay ratio comparison closely reflect economic environment low pay performance element encounter ceo bonus psp discontinuation dabp matching award receive compare historic ceo remuneration set table base salary total pay emma walmsley benefit percentile total remuneration annual bonus award maximum vest lti awards maximum salary total sir andrew witty pay benefit total remuneration annual bonus award maximum committee believe median pay ratio consistent vest lti awards maximum company pay reward progression policy base salarie employee include executive emma walmsley total remuneration include pay period january march ceo director set reference range factor include sir andrew witty receive prorata payment lieu variable bonus market practice experience performance role opportunity accordance remuneration policy supplementaladditional ratio psp dabp awards sir andrew witty grant vest april accordance term executive financial recoupment policy gsk ceo pay ratio likely vary potentially significantly time drive largely ceo variable pay outcome line reward principle ceo large portion pay base performance individual means depend gsk performance ratio increase decrease significantly committee believe senior executive significant proportion pay directly link performance gsk annual report annual report remuneration continue director pay wide set continue percentage change remuneration director allemployee share plan executive director participate hmrc approve percentage change allemployee share plan wide workforce salaryfee benefit bonus share save share reward plan employee participant share save plan save executive director month year end period emma walmsley option buy gsk share discount share price iain mackay start saving contract participant share hal barron reward plan contribute month purchase gsk nonexecutive director share company match sir jonathan symonds detail charles bancroft vindi banga dilution limit vivienne cox award plan incorporate dilution lynn elsenhans limit consistent guideline publish investment laurie glimcher association limit roll tenyear period jesse goodman plan roll tenyear period executive judy lewent share plan grant senior executive estimate dilution exist award year urs rohner december follow percentage change calculate base total remuneration table executive director total fee table nonexecutive director gsk employee share plan iain mackay join board january receive base salary year fee nonexecutive director include fee receive cash form share ad term nonexecutive director share allocation plan reduction fee usbase nonexecutive director reduction intercontinental travel fee year relate virtual attendance board committee meeting covid benefit nonexecutive director decrease significantly year reduction travel subsistence cost incur relation virtual attendance executive share plans board committee meeting covid sir jonathan symonds appoint board september charles bancroft appoint board actual limit relative importance spend pay table show total employee pay group dividend pay shareholder change total employee pay dividend pay year figure table reflect payment year impact movement exchange rate set page dividend declare respect million million increase total employee pay base employee average number people employ share repurchase company gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue director pay wide set continue external context comparator group pay relative tsr committee pay comparator group consider executive pay global pharmaceutical comparator group measure relative tsr performance primary group executive director follow european crossindustry comparator group global pharmaceutical comparator group emma walmsley roche holding linde deutsche telekom hal barron france iain mackay novartis sanofi kere sanofi abbvie lvmh astrazeneca heineken switzerland amgen anheuserbusch inbev diageo basf novartis bristolmyers squibb unilever siemens vinci roche holdings eli lilly sap christian dior adidas johnson johnson loreal inditex bayer merck astrazeneca novo nordisk bat safran pfizer airbus volkswagen reckitt benckiser abbvie amgen include remuneration benchmarking include relative tsr comparator group ceo total remuneration positioning performance graph review ceo remuneration committee follow graph set performance company reference pay global pharmaceutical group relative ftse index pharmaceutical performance comparator group tenyear period december index select comparison purpose reflect primary index gsk constituent industry operate european crossindustry group global pharmaceutical group low quartile median upper emma walmsley median quartile current position remuneration include salary expect value incentive base committee agree benchmarke methodology gsk total return gsk pharma peer ftse total return index total return index index comprise astrazeneca bristolmyers squibb eli lilly johnson johnson merck novartis pfizer roche holding sanofi gsk annual report annual report remuneration continue implementation remuneration policy fix pay pay performance salary annual bonus committee consider average increase change operation annual bonus plan award employee level executive director detail policy relation annual bonus plan consideration agree refer detail remuneration appropriate award increase line wide policy report annual report workforce ceo cfo cso ensure bonus opportunity weighting competitiveness remuneration maintain salary performance measure adjust scorecard base salary change group individual wide workforce target maximum pbit objective emma walmsley emma walmsley iain mackay iain mackay hal barron hal barron base average increase budget employee level cet set assess performance level executive directors committee consider performance company trust business priority reflect benefit group approach esg factor significant change provision benefit propose inevitably target link directly financial strategic detail policy relation benefit plan commercially sensitive committee refer detail remuneration policy consider appropriate disclose annual bonus target report page annual report year result competitive harm detail available gskcom investor section performance target usual disclose pension retrospective basis annual report table provide overview pension defer annual bonus plan dabp award arrangement ongoing executive director table provide detail mandatory deferral committee previously commit reduce exist dabp annual bonus payment executive director pension align wide associated award grant share award workforce january committee performance condition hold year determine pension contribution cso regardless continue employment align wide workforce january total bonus defer dabp award new ukbased usbased executive director pension share share ad align appropriate wide workforce appointment emma walmsley iain mackay pension contribution hal barron emma walmsley base salary matching contribution iain mackay salary accordance term plan open employee performance share plan psp award base salary lieu pension salary excess table provide detail award grant psp hal barron base salary contribution psp award essp equivalent total base salary bonus net bonus defer dabp addition salary share adss line wide workforce january combine contribution rate emma walmsley essp plans core contribution plus iain mackay match total base salary bonus net hal barron bonus defer dabp award grant february price share ad board engage shareholder potential provide oneoff additional performance incentive award cso aim support continuity management delivery biopharma pipeline proactively address principal risk creation sustainable shareholder value year discussion ongoing result proposal course set ahead specific vote agm gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue implementation remuneration policy continue lti performance measure performance measure weight lti award remain relative tsr continue measure gsk unchanged award global pharmaceutical comparator group weighting lti measure target adjust free cash flow measure grant lti measure measure weight innovation innovation sale target vest pipeline progress maximum performance relative tsr adjust free cash flow threshold innovation trust business priority innovation sale measure recognise importance set target review performance launch new product successfully drive lti measure committee consider reflect performance key commercial success company trust business priority trust priority reflect pipeline progress measure increase company approach esg factor emphasis innovation seek reward acceleration shareholding versus share ownership requirement strengthen pipeline base equally sor weight element key asset indication measure value holding salary threeyear performance period sor salary march december point allocate successful asset submeasure emma walmsley base forecast commercial value peak year sale iain mackay end performance period hal barron submeasures award vest follow share subject performance condition exclude pivotal trial start executive director sor calculation end focuses mainly phase iii registrational trial start performance period vest share include include phase start oncology director sor extent performance performance level point payout condition meet value holding threshold nil calculate posttax basis threshold hal barron ad contribute sor include investment gsk plan essp year reallocate fund plan gsk maximum stock fund major regulatory approval emma walmsley barron currently exceed sor iain mackay join board early currently performance level point payout threshold nil work satisfy sor threshold company process place ensure executive director sor continue satisfied leaving gsk include monitor nominee account maximum executive director agree term sor service contract target innovation sale pipeline progress measure nature commercially sensitive time grant end performance period provide disclosure achieve gsk annual report annual report remuneration continue remuneration governance committee role membership committee focus detail available incorporate remuneration policy reference report chairman ceo head committee set broad structure remuneration policy reward group financial controller company determine remuneration executive director secretary assisted committee year chairman corporate officer adviser committee item discuss pricewaterhousecooper llp pwc propose remuneration policy independent adviser committee appoint remuneration impact major group restructure commercial tender exercise conclude engagement shareholder consideration feedback company pwc member remuneration salary review consultant group voluntarily operate committee periodically review consider remuneration code conduct relation executive remuneration environment executive director cet approve annual consult code conduct find adjustment necessary regard remuneration wwwremunerationconsultantsgroupcom wide workforce year pwc connection item discuss committee member board director review remuneration environment include wide employee provide consulting assurance service trend executive director cet benchmarking competitiveness company line protocol agree set gsk comparator group committee chair pwc provide advice cet company secretary salary review recommendation committee satisfied advice objective independent pwc provide independent commentary executive director salary review recommendation matter consideration committee update market practice legislative requirement pwcs fee annual bonus advice year charge fix committee responsible set specific performance time material basis measure annual bonus assessment performance willis tower watson provide additional market datum item discuss committee ceo executive director cet bonus recommendation ceo bonus objective shareholder vote remuneration matter lti plan vote total vote total vote total vote withhold committee responsible approve lti plan rule change cast billion million grant assessment performance vest lti awards remuneration report executive director cet include interim award agm item discuss remuneration policy lti performance outcome vest lti awards cet agm service contract letter appointment confirmation lti grant cet table set date executive director implementation embed new pipeline progress measure service contract available review company governance area focus register office gskcom executive directors committee adhere robust remuneration governance service contract contain month notice period framework ensure alignment internal action external reportingcompliance requirement date contract effective date expiry date emma walmsley item discuss review term reference iain mackay committee evaluation annual review hal barron remuneration report proposal remuneration nonexecutive director ne letter appointment policy available view company register office confirmation group budget remuneration purpose ne expect serve board end remuneration consideration committee programme agm follow anniversary appointment agm remuneration report feedback external subject election subsequent annual reelection subject remuneration environment performance target disclosure mutual agreement expect serve incentive plan remuneration report disclosure include ceo pay ratio year normally year appointment annual governance meeting key committee message line provision code subject annual committee chair consultation employee representative reelection set pay wide workforce pay practice gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue nonexecutive director fee chairman nonexecutive director nonexecutive director fee company aim provide chairman non nonexecutive director fee apply executive director fee competitive set table pay company equivalent size complexity annum subject limit contain article association standard annual fee chairman fee supplemental fee chair audit risk committee chairman pay fee annum senior independent director take gsk share chairman fee scientific medical expert review appointment new chair chair remuneration corporate conclude remain appropriate responsibility science committee workforce engagement director nonexecutive director undertake intercontinental meet travel meeting nonexecutive director continue require invest total net fee gsk share ad implementation nonexecutive director policy follow review engagement shareholder nonexecutive director standard fee fee payable senior independent director committee chair include remuneration corporate responsibility science committee increase effect january shareholder approval remuneration policy supplemental fee introduce effect january payable workforce engagement director payment nonexecutive director pay committee chair undertake additional duty exceptional unforeseen circumstance require significant additional time commitment authorise change fee payable chair audit risk committee scientific medical expert expect increase fee payable nonexecutive director new policy period increase describe reflect time commitment role total fee audit audit table set value fee benefit receive nonexecutive director form cash share ad detail nonexecutive director share allocation plan set nonexecutive director fee pay currency sterling convert average exchange rate review time time average exchange rate update benefit comprise gross cash value travel subsistence cost incur normal course business relation attendance board committee meeting overseasbase director include travel meeting nonexecutive director fix fee fix fee emolument audit cash sharesad benefit total pay cash sharesad benefit total pay sir jonathan symonds vindi banga charles bancroft vivienne cox lynn elsenhans laurie glimcher jesse goodman judy lewent urs rohner gsk annual report annual report remuneration continue director interest share audit executive director interest share interest executive director company office person closely associate pca show table december unvested share plan interest beneficial subject total director interest interest subject performance performance march december sharesad sharesad option sharesad share emma walmsley iain mackay ad hal barron total director interest include beneficial interest unvested share plan interest subject performance balance march include sharesad award performance share plan psp defer annual bonus plan dabp vested february march respectively sell satisfy tax liability vest amount executive director shareholding versus sor outline eneficial interest include sharesad hold executive director pcas emma walmsley include share purchase glaxosmithkline share reward plan iain mackay currently participate share reward plan employee hal barron eligible participate share reward plan open employee barron beneficial interest include ad notional ad hold way investment gsk plan executive supplemental saving plan essp year barron reallocate fund plan gsk stock fund detail barron membership plan find nveste sharesad subject performance represent psp share vest subject additional twoyear hold period emma walmsley unvested ad subject performance barron represent bonus deferral describe note unvested option subject performance represent bonus deferral dabp award nilcost option describe note figure exclude share save option hold emma walmsley unvested sharesad subject performance represent unvested psp award abp table show bonus deferral subsequent reinvestment dividend dabp amount represent gross sharesad balance prior sale sharesad satisfy tax liability vest deferred annual bonus plan bonus deferral march december january shares emma walmsley iain mackay ad hal barron employee bonus deferral dabp grant nilcost option emma walmsley iain mackay follow table set detail nilcost option exercise outstanding dabp matching award follow exercise number share date market price gain exercise dabp date grant option exercise grant price exercise emma walmsley deferral award matching award respect nilcost option award dabp bonus defer executive director record remuneration annual bonus total remuneration table respect number share option include initial award reinveste dividend accrue date exercise matching element dabp award remuneration executive director record total remuneration table respect year performance period end remuneration committee grant matching award gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue director interest share audit continued nonexecutive director interest share interest nonexecutive director company office person closely associate pca show table share allocation plan nonexecutive director total director interest number sharesad beneficial dividend elect december interest reinveste december allocate march december year end year january share sir jonathan symonds vindi banga vivienne cox urs rohner ad charles bancroft lynn elsenhans laurie glimcher jesse goodman judy lewent otal director interest include beneficial interest sharesad receive fee nonexecutive director share allocation plan dividend receive sharesad plan year january convert sharesad february beneficial interest include sharesad hold nonexecutive director pcas sharesad allocate year nonexecutive director share allocation plan include dividend reinveste year director senior management information provide compensation interest director senior management group group purpose group define executive nonexecutive director members cet company secretary financial year follow table set aggregate remuneration group period serve capacity remuneration total compensation pay aggregate increase accrue pension benefit net inflation aggregate payment define contribution scheme member group award share ad company lti plan set table align interest senior management shareholder executive director cet member require build maintain significant holding share gsk time cet member require hold share equivalent multiple time base salary continue satisfy share ownership requirement minimum month leave gsk award dividend reinvestment award award share ad share ad defer annual bonus plan matching award performance share plan defer investment award share value plan notional share ad executive director eligible receive defer investment award participate share value plan gsk annual report annual report remuneration continue director senior management continue march group pcas follow interest share ad company interest award lti plan describe note financial statement employee share scheme interest march share ad own unexercised option defer annual bonus plan performance share plan defer investment award share value plan notional share executive director eligible receive defer investment award participate share value plan fee respect executive director external appointment ceo emma walmsley independent nonexecutive director microsoft corporation receive deliver cash stock option microsoft corporation defer compensation plan nonemployee director cso hal barron nonexecutive director grail inc private company earn fee payment past director audit sir andrew witty moncef slaoui left board march mutual agreement patrick vallance simon dingemans leave board march voluntary leaver vest dabp award govern remuneration policy prevail time past director leave board table reflect value defer bonus accrue dividend point release sir andrew witty date vest number share vest dabp february moncef slaoui date vest number ad vest dabp february patrick vallance date vest number share vest dabp february dabp march simon dingemans date vest number share vest dabp dabp march simon dingemans dabp award vest accordance delay vest term recoupment policy benefit gross cost predominantly simon dingemans postemployment home security payment loss office audit loss office payment gsk annual report strategic report governance remuneration financial statement investor information remuneration policy summary company remuneration policy approve gsk annual general meeting operate intend approval policy available gskcom investor section executive director remuneration policy salary provide core reward role set level appropriate secure retain high calibre individual need deliver group strategic priority operation opportunity individual role experience performance independently formal maximum limit ordinarily salary increase source datum relevant comparator group consider broadly line average increase wider determine salary level gsk workforce salary increase typically effect quarter increase higher reflect change year scope individual role responsibility experience salary adjustment reflect wide market condition salary normally pay currency executive geography individual operate director home country detail current salary level set annual report remuneration performance measure overall performance individual key consideration determine salary increase benefit level set recruit retain high calibre individual execute business strategy operation executive director base outside executive director eligible receive benefit line require travel fulfil responsibility policy employee vary location role attend board meeting subject tax include limited car allowance healthcare business travel expense life assurancedeath service provide provision accommodation reality individual pension arrangement personal financial advice represent business expense tax treatment require contractual postretirement benefit line policy travel accommodation expense include employee executive director eligible benefit business context tax liability receive overseas relocation allowance international cover company grossedup basis transferrelate benefit require executive director benefit provision tailor reflect market practice eligible participate allemployee share geography executive director base scheme share save share reward plan different policy apply current future executive subject term director base different country employee opportunity order recognise high business travel requirement formal maximum limit benefit cost fluctuate role executive director entitle car travel depend change provider cost individual exceptionally accompany spousepartn circumstance business trip benefit include expense incur detail current benefit cost set annual ordinary course business deem taxable report remuneration benefit individual performance measure gsk annual report remuneration policy summary continue executive director remuneration policy continue pension pension arrangement provide competitive level retirement income pension arrangement provide competitive level retirement new executive director receive date income appointment base salary contribution define contribution plan operation match contribution subject pension arrangement structure accordance relevant cap line implementation principle plan operate country individual likely member plan retire individual choose member base salary cash payment lieu pension pension plan cash lieu relevant pension contribution portion relevant cap contribution pay instead executive director entitle join define contribution pension plan base salary cash payment lieu pension receive cash payment lieu pension contribution contribution individual member gsk legacy define benefit plan define contribution plan alternative cash balance supplemental cash balance pension pension plan arrangement subsequently appoint plan provide annual contribution base salary board remain member plan split plan appropriate opportunity gsk plan executive supplemental saving plan policy current executive director essp core contribution salary bonus match contribution salary bonus base salary contribution define contribution plan new executive director receive match contribution subject cash balance supplemental cash balance pension relevant cap line implementation principle plan provide annual contribution base salary member plan bonus split plan appropriate base salary cash payment lieu pension gsk plan essp core contribution contribution portion relevant cap salary bonus match contribution salary bonus base salary cash payment lieu pension global contribution eligible appropriate equivalent arrangement excess january current executive director usuk arrangement role pension arrangement align performance measure new executive director arrangement follow event change plan operate similar value provide successor arrangement introduce market ess bonus defer dabp annual bonus incentivise recognise execution business strategy annual basis reward achievement stretch annual financial strategic business target delivery personal objective operation committee apply judgement make appropriate financial operational business target set start adjustment bonus outcome ensure reflect underlying year committee bonus level determine business performance clawback andor malus provision apply committee base performance target describe annual report individual objective set start year opportunity committee performance objective maximum bonus opportunity executive director assess committee salary threshold performance bonus payout financial measure nil target performance executive director require defer bonus bonus payout maximum opportunity earn share ad appropriate year defer bonus share eligible dividend equivalent performance measure date vest base combination financial target individual strategic performance objective majority bonus assess financial measure weight different measure determine year accord business priority detail include measure financial year provide annual report remuneration gsk annual report strategic report governance remuneration financial statement investor information remuneration policy summary continue executive director remuneration policy continue selection annual bonus measure annual bonus design drive achievement majority annual bonus opportunity base gsk annual financial strategic business target formal review performance stretch financial delivery personal objective target remainder bonus subject balanced scorecard strategic individual target align annual bonus financial target set reference company key objective financial year internal budget external consensus target performance incentivise recognise delivery long term business priority financial growth share plan psp increase shareholder value compare pharmaceutical company addition provide alignment shareholder interest retention element encourage longterm shareholding discourage excessive risk take operation opportunity conditional award annually vest dependent normal maximum award limit grant achievement performance condition year psp individual year set table subject additional twoyear hold period psp target set reference internal budget external salary consensus target ceo award eligible dividend equivalent date cfo vest release executive director committee adjust formulaic vest outcome performance measure ensure overall outcome reflect base combination financial share price relate underlie business performance vest period strategic performance condition align company strategic plan measure award clawback andor malus provision apply describe vest threshold performance detail include annual report performance target attach psp respect year weighting target psp award provide annual report remuneration announce annual report reduce threshold vest level tsr measure order align performance measure share ownership requirement align interest executive director minimum executive director require maintain shareholder require build maintain share ownership requirement end significant holding share gsk time year follow retirement company requirement executive director follow end second year salary ceo executive director detail policy clawbackmalus recruitment remuneration loss office termination payment refer remuneration policy report page annual report available gskcom investor section gsk annual report remuneration policy summary continue scenario future total remuneration chart opposite provide illustration future total remuneration executive director respect emma walmsley remuneration opportunity grant approve remuneration policy range potential outcome provide executive director underlie assumption set scenario base salary benefit figure base actual amount receive hal barron pension figure pension emma walmsley iain mackay base salary amounts show value psp award base relevant multiple include amount respect dividend reinveste factor fix expect maximum maximum change share price vest period share price describe increase fix exclude pay performance annual bonus pay psp award vest iain mackay expect include fix pay annual bonus assume target performance achieve psp award amount reflect vest level maximum assume annual bonus payable maximum level award psp vest maximum share price increase element maximum assume fix expect maximum maximum share price increase share price increase hal barron fix expect maximum maximum share price increase fix pay annual bonus psp share price increase gsk annual report strategic report governance remuneration financial statement investor information remuneration policy summary continue nonexecutive director remuneration policy company remuneration policy report approve wednesday gsk annual general meeting policy available investor section gskcom follow summary policy nonexecutive director fee element purpose link strategy operation chairmans fee provide inclusive flat rate fee formal maximum fee review annually set reference competitive pay review chairman performance independently source market datum company equivalent size committee responsible evaluating make recommendation board complexity subject limit contain fee payable chairman chairman participate discussion gsk article association respect fee fee pay cash chairman require invest total net fee share ad company basic fee formal maximum chairman fee review annually set reference independently source datum chairman ceo responsible evaluating make recommendation board fee payable company nonexecutive director fee pay cash director require invest total net fee share ad company share ad deliver release follow retirement board supplemental compensate nonexecutive director additional fee senior independent director committee chair scientific fee chairman take medical expert workforce engagement director role intercontinental travel additional board responsibility company authority pay additional fee equivalent undertake intercontinental travel committee chair supplement effect january nonexecutive director company require significant additional time commitment exceptional unforeseen circumstance benefit facilitate execution responsibility travel subsistence cost nonexecutive director incur normal duty require role course business relation meeting board committee matter gskhoste event overseasbase nonexecutive director include travel meeting event necessary business purpose whilst normal practice nonexecutive director accompany spouse partner meeting event cost associate meet company instance deem taxable treat benefit nonexecutive director approach recruitment remuneration follow policy principle apply role nonexecutive director chairman nonexecutive director fee level new nonexecutive director set basis exist nonexecutive director chairman company subject local law regulation fee fee set level competitive pay pay partly share company equivalent size complexity fee pay partly share event nonexecutive director different role responsibility appoint fee level benchmarke set reference comparable role company equivalent size complexity loss office chairman nonexecutive director entitle receive payment respect fee loss office retire step board gsk annual report remuneration policy summary continue operation scope remuneration policy remuneration policy policy set page policy come effect provide term annual report intend policy payment consistent shareholderapprove gsk executive nonexecutive director operate remuneration policy force time agree period year date approval company iii time relevant individual director annual general meeting company opinion committee payment committee write policy principally relation consideration individual director remuneration arrangement executive director whilst company purpose payment include take account possible recruitment replacement committee satisfy awards variable remuneration additional executive director operation relation award share ad term policy committee intend policy operate payment agree time award grant period set entirety performance share plan psp award subject consideration seek change policy period term psp plan rule award believe appropriate longterm grant committee adjust amend award success company consultation shareholder accordance provision plan rule includes seek shareholder approval general meeting make adjustment reflect oneoff corporate event committee reserve right remuneration change company capital structure payment andor payment loss office include committee minor amendment policy exercise discretion available connection regulatory exchange control tax administrative purpose payment notwithstanding line account change legislation obtain policy term payment agree shareholder approval amendment agm date company statement consideration shareholder view shareholderapprove director remuneration policy come committee engage regular dialogue shareholder effect hold annual meeting gsk large investor discuss feedback remuneration policy practice governance matter basis preparation annual report remuneration prepare annual report remuneration approve accordance company act large board director sign behalf mediumsize company group account report amendment regulation regulation accordance regulation follow part urs rohner annual report remuneration subject audit total remuneration committee chairman remuneration figure executive director include march detail element remuneration salary benefit pension annual bonus longterm incentive awards nonexecutive director fee emolument receive year director interest share include interest gsk share plan payment past director payment loss office share ownership requirement holding opinion thereon express remain section annual report remuneration subject audit page refer audit section gsk annual report ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn financial statement section director statement responsibilitie independent auditor report financial statement note financial statement financial statement glaxosmithkline plc prepare gaap ggsskk aannnnuuaall rreeppoorrtt director statement responsibilitie director responsible prepare annual report director responsible keep adequate accounting remuneration report group parent company record sufficient explain company financial statement accordance applicable law transaction disclose reasonable accuracy time regulation financial position group enable ensure group financial statement remuneration company law require director prepare financial report comply company act article statement financial year director require ias regulation responsible safeguarding prepare group consolidated financial statement asset group take reasonable step accordance international financial reporting standard prevention detection fraud irregularity ifrs adopt pursuant regulation apply european union prepare group group financial statement year end consolidated financial statement director december comprise principal statement elect comply ifrs issue international support note set financial statement accounting standard board iasb director page report parent company elect prepare parent company financial statement financial statement year end december accordance united kingdom accounting standard comprise balance sheet statement change applicable law united kingdom generally accept equity year end december support accounting practice company law director note set page approve financial statement satisfied responsibility auditor relation financial true fair view state affair statement set independent auditor report group profit loss period page prepare financial statement director financial statement year end december require include annual report publish print select suitable accounting policy apply form available website director consistently responsible maintenance integrity annual report website accordance legislation judgement accounting estimate govern preparation dissemination financial reasonable prudent statement access website available outside state group financial statement comply ifrs comparable legislation different adopt pursuant regulation current director name function apply european union ifrs issue list corporate governance section annual iasb subject material departure disclose report confirm good knowledge explain group financial statement group financial statement prepare state regard parent company financial statement accordance ifrs adopt pursuant regulation applicable accounting standard apply european union follow subject material departure disclose ifrs issue iasb true fair view explain parent company financial statement asset liabilitie financial position profit prepare financial statement go concern basis group inappropriate presume group strategic report risk section annual report parent company continue business represent management report include fair review development performance business position company group take description principal risk uncertainty face gsk annual report strategic report governance remuneration financial statement investor information director statement responsibility continue disclosure information auditor corporate governance code director office date annual report board consider glaxosmithkline plc apply confirm principle comply provision corporate governance code maintain financial report far aware relevant audit council describe corporate governance section information company auditor unaware page board consider take step ought annual report take fair balanced take director aware understandable provide information necessary relevant audit information establish company shareholder assess group position performance auditor aware information business model strategy confirmation give interpret require financial conduct authority list rule accordance provision section auditor consider director statement company act compliance relation point corporate going concern basis governance code specify review page contain information performance annual report group financial position cash flow net debt position annual report year end december borrowing facility information include treasury comprising report director remuneration risk management policy exposure market credit risk report financial statement additional information hedging activity give note financial investor approve board director statement financial instrument relate disclosure sign behalf assess principal risk matter consider connection viability statement sir jonathan symond director consider appropriate adopt go concern chairman basis accounting prepare financial statement internal control march board audit risk committee review assessment risk internal control framework operate gsk consider effectiveness system internal control operation group year cover annual report date approval board director gsk annual report independent auditor report members glaxosmithkline plc report audit financial statement opinion basis opinion opinion conduct audit accordance international standard audit isas applicable law financial statement glaxosmithkline plc parent responsibility standard describe company subsidiary group true auditor responsibility audit financial fair view state group parent statement section report company affair december group profit year end independent group parent company accordance ethical requirement relevant group financial statement properly prepare audit financial statement include accordance international accounting standard financial reporting council frc ethical standard conformity requirement company act apply list public interest entity fulfil international financial reporting standard ifrss ethical responsibility accordance adopt european union ifrss issue requirement confirm nonaudit services prohibit international accounting standard board iasb frcs ethical standard provide group parent company financial statement properly parent company note audit risk committee prepare accordance united kingdom generally report corporate governance section annual accept accounting practice include frs reduce report disclosure framework believe audit evidence obtain financial statement prepare accordance sufficient appropriate provide basis opinion requirement company act audit scope execution regard group financial statement article ias regulation structured approach audit reflect audit financial statement comprise group organise ensure audit effective risk focus audit approach group summarise follow area enable obtain consolidated balance sheet december evidence require form opinion group consolidate income statement year end parent company financial statement consolidate statement comprehensive income risk assessment audit planning group level year end central control common system group enable structure audit centrally use consolidated statement change equity year end datum analytic tool allow detailed understanding flow transaction enable focus risk consolidated cash flow statement year end assessment design target audit testing procedure risk assessment procedure consider impact note financial statement include global pandemic account balance disclosure accounting principle policy company practice addition appoint partner parent company business partner coordinate component legal entity audits country balance sheet december global business partner meet regularly relevant statement change equity year end management understand strategy matter arise note financial statement include year impact financial accounting principle policy report regular meeting member internal audit internal legal counsel global ethic financial reporting framework apply compliance team allow understand work preparation group financial statement applicable law review report enhance risk assessment international accounting standard conformity audit work perform global share service centre requirement company act ifrss significant group operational process adopt european union issue iasb cover financial reporting undertake share service financial reporting framework apply centre group audit team include senior individual preparation parent company financial statement responsible global process coordinate applicable law united kingdom accounting standard audit work share service centre scope group include frs reduce disclosure framework united audit ensure develop good understanding kingdom generally accept accounting practice endtoend view key process support material account balance class transaction disclosure group financial statement gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue evaluated effectiveness internal control application materiality financial reporting process consider define materiality magnitude misstatement implication remainder audit work financial statement make probable economic audit work execute component level individual decision reasonably knowledgeable person legal entity follow component subject change influence use materiality planning audit procedure assessment internal scope audit work evaluate result control financial report australia belgium canada work china france germany italy japan spain switzerland base professional judgement determine united kingdom united states group audit team materiality financial statement follow active dialogue audit component audit team responsible audit work parent company direction supervision group audit team group financial statement financial statement include determine work plan materiality million million million million perform accordance overall group audit basis determine benchmark materiality strategy requirement group audit instruction determine materiality consider determined component restriction overseas travel materiality metric investor total asset benchmark visit component year prior reader financial year satisfy oversight supervision statement particular appropriate perform remote review consider statutory profit tax adjust profit videoconferencing increase frequency tax revenue net cash flow length review depend significance operation risk component continue attend professional judgement planning clearance meeting component engage determined materiality local management million audit procedure undertake group level metric parent company addition perform statutory profit tax audit work group parent company financial adjust profit tax statement include limited consolidation revenue net cash inflow group result preparation financial operating activity statement certain disclosure director reconciliation statutory remuneration report litigation provision exposure profit tax adjust profit addition management entity level oversight control tax detail adjust relevant financial reporting component legal entity item section strategic report annual revenue great total group rationale give importance parent company revenue include audit scope component metric investor hold group legal entity cover audit scope subject benchmark reader financial statement investment apply conclude statutory profit profitoriente analytical procedure confirm conclusion tax primary strength significant risk material misstatement benchmark adjust profit balance sheet key aggregated financial information tax revenue net cash measure financial inflow operating activity health important internal control testing approach test internal support benchmark shareholder control financial reporting inscope entity component materiality allocate primary concern entity level control group level common system inscope component range parent company allow relevant control test centrally million payment component able place reliance control million dividend benchmark total plan efficient notwithstanding range materiality allocate asset control deficiency disclose key audit matter component audit appropriate metric prior year group financial section report mitigate control exist allow statement continue reliance control plan million million audit scope address group revenue group profit tax group total asset gsk annual report independent auditor report continue report audit financial statement continue set performance materiality level low materiality base work perform identify reduce probability aggregate uncorrected material uncertainty relate event condition undetected misstatement exceed materiality individually collectively cast significant doubt financial statement group parent company group parent company ability continue go performance materiality set group parent concern period month materiality respectively audit financial statement authorise issue determine performance materiality consider factor relation reporting group apply include corporate governance code material risk assessment include assessment add draw attention relation director statement group overall control environment consider financial statement director consider appropriate rely control number business appropriate adopt go concern basis accounting process responsibility responsibility director past experience audit indicate respect go concern describe relevant section low number correct uncorrected misstatement report identify prior period agree audit risk committee report committee audit difference excess million million difference threshold view warrant report qualitative ground report audit risk committee disclosure matter identify assess overall presentation financial statement conclusion relate go concern audit financial statement conclude director use go concern basis accounting preparation financial statement appropriate evaluation director assessment group parent company ability continue adopt go concern basis accounting include enquire management assumption go concern model evaluate group exist access source financing include undrawn commit bank facility read analyst report industry datum external information determine provide corroborative contradictory evidence relation management assumption compare forecast sale recent historical financial information test underlie datum generate prepare forecast scenario determine adequate support assumption underlie forecast evaluate group disclosure go concern requirement ias gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continued key audit matter key audit matter matter professional judgement significance audit financial statement current period include significant assess risk material misstatement fraud identify matter include great effect overall audit strategy allocation resource audit direct effort engagement team matter address context audit financial statement form opinion thereon provide separate opinion matter key audit matter description scope audit respond key audit matter valuation viiv healthcare shionogi contingent audit procedure perform consideration liability perform follow audit procedure recent year group complete number significant relate sale forecast transaction result recognition material challenge management evidence enquirie key contingent consideration liability key source individual senior leadership team commercial strategy estimation uncertainty significant liability team key personnel involve budgeting viiv healthcare shionogi contingent consideration forecasting process obtain objective evidence liability viiv ccl respect key input assumption group complete acquisition remain challenge volume assumption management interest shionogiviiv healthcare joint venture estimate sale forecast involve benchmarke market completion group recognise contingent share datum external datum total prescription consideration liability fair value expect future volume new patient prescription volume order assess payment shionogi december source contradictory evidence liability value million challenge reasonableness pricing assumption identify viiv ccl key audit matter management compare forecast return significant estimate assumption management make rebate rate product current rate assess relate sale forecast valuing viiv ccl forecast return rebate comparable sensitivity valuation input product expect change payer policy significant relate sale forecast united state certain product treatment portfolio review result clinical study undertake year forecast base management assessment management key competitor order assess expect launch date ability shift market practice corroborative contradictory management prescriber behaviour drug regimen subsequent assumption treatment product portfolio sale forecast sale volume price forecast require significant audit effort perform appropriate audit procedure benchmarke management sale forecast challenge evaluate reasonableness include report analyst consider sale forecast forecast total viiv basis individual product contingent consideration liability include viiv ccl basis disclose key source estimation uncertainty note test control key input assumption group financial statement disclosure provide valuation contingent consideration liability include note matter discuss management review control sale forecast audit risk committee report corporate treatment product portfolio value viiv ccl governance section annual report key observation communicate audit risk committee underlie sale forecast valuation reasonable line internal support datum external evidence analyst forecast satisfied sale forecast update year reflect appropriately actual performance change overall hiv treatment market approach value viiv ccl consistent prior period overall satisfied valuation liability reasonable consistent ifrs gsk annual report independent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter valuation return rebate rar accrual audit procedure perform group sell customer commercial perform follow audit procedure government mandate contract reimbursement relate management estimate rar accrual arrangement include rebate chargeback right challenge management assumption selection return certain pharmaceutical product revenue utilisation rate focus certain product recognition reflect grosstonet sale adjustment conclude accrual sensitive assumption adjustment know return rebate rar challenge include comparison historical utilisation rate accrual source significant estimation uncertainty consideration historical accuracy driver market material impact report revenue change impact ongoing generic competition significant payer channel refer macroeconomic impact covid pandemic buying group rar accrual manage healthcare supplement substantive analytical procedure organisation medicaid medicare develop independent expectation accrual balance main cause significant estimation uncertainty key segment base historical claim receive adjusted reflect market change period include utilisation rate portion total sale assessment time lag initial point sale payer channel estimate management claim receipt compare independent recording accrual utilisation assumption expectation management evaluate challenge key assumption derive accrual appropriateness management end accrual position give influence market demand factor outside control group consider historical accuracy management estimate evaluate management appropriately update time lag point sale point forecast assumption selection case exact rebate amount know group receipt actual rebate claim differ accrue claim payer channel long time lag result great accrue period great level challenge appropriateness completeness estimation uncertainty estimate period end accrual periodend adjustment liability management ongoing review estimate accrual level estimation uncertainty impact significant shift channel mix drive change competitive test key control estimation rar accrual landscape include competitor generic product launch include control associate forecast macroeconomic factor focus utilisation rate process monthend accrual review utilisation assumption product deem control level estimation uncertainty significant key observation communicate audit risk committee furthermore auditing standard presume significant fraud satisfy management estimate liability rar risk exist revenue recognition line presumption accrual year end appropriate observe prudence focus periodend adjustment management assess certain key assumption rar accrual adjustment reflect update independent expectation historical accuracy prior year management initial assumption include estimate actual rebate satisfy forecasted rar rate view present great reasonable accordance requirement ifrs opportunity fraud revenue recognition notwithstanding revenue contract customer existence internal control pharmaceuticals business million rar deduction gross revenue million result net revenue million balance sheet accrual december combine pharmaceutical vaccine business amount million pharmaceuticals return rebate disclose key source estimation uncertainty note group financial statement disclosure provide note matter discuss audit risk committee report corporate governance section annual report gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter valuation intangible asset audit procedure perform december group hold million perform follow audit procedure intangible asset include licence patent trademark relate future sale growth likelihood successful new brand name exclude goodwill computer product innovation profit margin level assessment software recoverable intangible intangible asset impairment asset rely certain assumption estimate future meet key individual senior leadership team trading performance create estimation uncertainty product category lead key personnel involve asset risk material impairment identify forecasting process discuss evaluate management sensitivity analysis key assumption review evidence support future sale growth rate profitability potential trigger event indicative assumption impairment carrying value associate asset challenge business assumption apply management result analysis perform additional audit procedure estimate sale forecast include macroeconomic certain indefinite life consumer healthcare intangible asset impact result ongoing covid pandemic acquire pfizer involve benchmarke sale forecast product key assumption apply management determine compound annual growth rate external data specific recoverable include future sale growth rate market segment profit margin level likelihood successful new evaluated independent market research corroborate expect product innovation change assumption lead category growth rate assess source impairment carry value intangible contradictory evidence asset compare forecast sale plan datum asset asset identify valuation intangible asset key internal forecast approve senior management audit matter inherent judgement involve board director estimate future cash flow year increase uncertainty bring covid assess historical accuracy management forecast pandemic associate lockdown auditing estimate include consumption datum estimate new sale require extensive audit effort challenge evaluate innovation reasonableness forecast consider event transaction occur disclosure relate intangible asset include balance sheet date reporting date affect note group financial statement matter conclusion reach carry value asset discuss audit risk committee report associate disclosure corporate governance section annual report test management review control key input assumption valuation intangible asset include control review revenue growth rate profit margin key observation communicate audit risk committee audit challenge future forecast performance consumer healthcare product include potential adverse impact covid pandemic conclude assumption underpin impairment review intangible asset reasonable accordance ifrs gsk annual report independent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter valuation uncertain tax position include transfer audit procedure perform pricing support tax specialist assess group operate numerous jurisdiction appropriateness uncertain tax provision perform open tax transfer pricing matter exposure follow audit procedure overseas tax authority rise uncertain tax assess challenge provision uncertain tax position position range possible outcome provision focus work jurisdiction group contingency management require great potential exposure high level certain judgement respect estimate tax exposure judgement require contingency order assess adequacy tax provision complex result assess management policy recognition consideration require multiple tax law regulation measurement uncertain tax position compliance guidance ifric december group record provision million respect uncertain tax position involve transfer pricing specialist review transfer pricing methodology group associate approach valuation uncertain tax position disclose key source provision estimation uncertainty note group financial statement disclosure include note involve international tax transfer pricing matter discuss audit risk committee report specialist challenge conclusion reach corporate governance section annual report management relation expect outcome financial impact consider evidence actual result recent tax authority audits enquiry thirdparty tax advice obtain tax specialist knowledge market practice relevant jurisdiction test key control preparation review report judgmental tax balance transaction include provision uncertain tax provision key observation communicate audit risk committee satisfied management estimate relation uncertain tax position relate disclosure accordance ifrs work conclude management apply consistent approach estimate uncertain tax provision judgement continue prudent appropriately record gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter system impact financial reporting audit procedure perform system group form critical component audit scope drive level reliance place group financial reporting activity impact account technology obtain assurance business process balance technology deem relevant audit base financial datum system configure automate control andor key financial identify system impact financial reporting report reside utilise specialist support key audit matter evaluation risk associate technology pervasive reliance complex technology integral testing design operation control operation key business process financial testing scope technology perform address report group control objective financial reporting risk reliance technology continue increase line include testing follow area business strategy increase use general control include user access change automation group management control importance control maintain effective key financial report system configure automate control control environment key interdependency exist ability rely control ability rely control provide assurance completeness financial datum system configure automate control accuracy relevant data migration system report test management remediation previously identify continued remediation control support scope deficiency application system risk assessment procedure include assessment implementation application system key business impact unremediated control deficiency determine area year impact audit plan relevant audit plan adjust include test additional manual business control context scope financial audit process control mitigate unaddresse risk primarily relate user access security change control group continue implement programme remediation key observation communicate audit risk committee landscape deficiency identify prior year satisfied control impact group financial extend reporting activity design operate effectively control system impact financial reporting discuss deficiency identify remediate year end mitigate audit risk committee report corporate compensating control governance section annual report management continue significant progress year remediate control deficiency relate user access change management group layer business process control mitigate risk associate control deficiencies gsk annual report independent auditor report continue report audit financial statement continue information information comprise information include annual report financial statement auditor report thereon director responsible information contain annual report opinion financial statement cover information extent explicitly state report express form assurance conclusion thereon responsibility read information consider information materially inconsistent financial statement knowledge obtain course audit appear materially misstate identify material inconsistency apparent material misstatement require determine give rise material misstatement financial statement base work perform conclude material misstatement information require report fact report regard summarise work relation area information include area specifically require report matter specifically require report responsibility report principal risk viability statement review confirmation description light knowledge set section corporate governance gather audit consider director statement material report add process support statement challenging management key draw attention respect matter judgement estimate consideration historical forecasting accuracy evaluate macroeconomic assumption consider statement align relevant provision code director remuneration report report director remuneration report audit set section opinion matter properly prepare disclosure specify company act prescribed company act opinion director remuneration report audit prepared accordance company act strategic report director report report consistent audit financial statement set section opinion matter prepare accordance applicable legal requirement prescribe company act opinion base work undertake course audit report identify material misstatement report information report consistent light knowledge understanding group audit financial statement prepare parent company environment obtain course audit accordance applicable legal requirement gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue report information responsibility report alternative performance measure apm apm measure define generally accept accounting opinion practice gaap typically include financial use calculation disclosure apm statement annual report group use apm adjust consistent group publish definition profit free cash flow constant currency growth rate policy quarterly annual report financial performance use apm group report result review assess management calculation report consistent guideline produce esma metric assess consistency group publish definition frc policy item appropriate balance use consider assess use apm statutory metric apm clear group report result consistent guideline produce definition reconciliation apm financial regulator european security market authority esma report guideline use apm frc alternative performance measure thematic review publish november consider appropriate balance use statutory metric apm addition clear definition reconciliation apm financial reporting provide dividend distribution policy consider dividend policy transparent dividend opinion dividend policy appropriately pay consistent policy outline strategic report disclose dividend pay consistent policy responsibility director auditor responsibility audit financial statement explain fully director responsibilitie statement director responsible preparation objective obtain reasonable assurance financial statement satisfy financial statement free true fair view internal control director material misstatement fraud error determine necessary enable preparation financial issue auditor report include opinion reasonable statement free material misstatement assurance high level assurance guarantee fraud error audit conduct accordance isa detect material misstatement exist prepare financial statement director misstatement arise fraud error consider responsible assess group parent material individually aggregate reasonably companys ability continue go concern disclose expect influence economic decision user take applicable matter related going concern basis financial statement go concern basis accounting director intend liquidate group parent company cease description responsibility audit operation realistic alternative financial statement locate frc website wwwfrcorgukauditorsresponsibilitie description form auditor report gsk annual report independent auditor report continue report audit financial statement continue extent audit consider audit response risk identify capable detecting irregularity include fraud result perform identify valuation return rebate accrual key audit matter irregularity include fraud instance noncompliance related potential risk fraud key audit matter law regulation design procedure line section report explain matter detail responsibility outline detect material describe specific procedure response key audit misstatement respect irregularity include fraud matter common audits isas extent procedure capable detect require perform specific procedure respond risk irregularity include fraud detailed management override identify assess potential risk relate addition procedure respond risk irregularity identify include follow identify assess risk material misstatement review financial statement disclosure test respect irregularity include fraud noncompliance support documentation assess compliance law regulation consider follow provision relevant law regulation describe nature industry sector control environment direct effect financial statement business performance include design enquire management audit risk committee group remuneration policy key driver director inhouse external legal counsel concern actual remuneration bonus level performance target potential litigation claim enquire management internal audit audit risk perform analytical procedure identify unusual committee include obtain review support unexpected relationship indicate risk material documentation concern group policy misstatement fraud procedure relate read minute meeting charge identify evaluate comply law governance review internal audit report regulation aware instance correspondence regulator noncompliance address risk fraud management override detect respond risk fraud control test appropriateness journal entry knowledge actual suspect alleged adjustment assess judgement fraud make accounting estimate indicative potential internal control establish mitigate risk relate bias evaluate business rationale significant fraud noncompliance law regulation transaction unusual outside normal course business discuss engagement team include significant component audit team involve relevant internal communicate relevant identify law regulation specialist include tax valuation pension industry potential fraud risk engagement team member specialist fraud occur significant component audit team remain alert financial statement potential indicator fraud indication fraud noncompliance law regulation audit obtain understand legal regulatory framework group operate focus report legal regulatory requirement law regulation direct effect financial statement provision company act opinion matter prescribe pension legislation tax legislation company act fundamental effect operation group include good clinical practice fda regulations general opinion director remuneration report datum protection requirement antibribery corruption audit properly prepared accordance policy foreign corrupt practice act company act opinion base work undertake course audit information give strategic report director report financial year financial statement prepare consistent financial statement strategic report director report prepared accordance applicable legal requirement gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue light knowledge understanding group director remuneration parent company environment obtain company act require report course audit identify material opinion certain disclosure director remuneration misstatement strategic report director report director remuneration report audit agreement account corporate governance statement record return list rule require review director statement report respect matter relation go concern longerterm viability corporate governance statement relate group matter require compliance provision corporate governance address code specify review auditor tenure base work undertake audit follow recommendation audit risk committee conclude follow element corporate effect january appoint governance statement materially consistent financial board director audit financial statement year statement knowledge obtain audit end december subsequent financial period director statement regard appropriateness period total uninterrupted engagement firm adopt go concern basis accounting year material uncertainty identify set consistency audit report additional report director explanation assessment group audit risk committee prospect period assessment cover audit opinion consistent additional report period appropriate set audit risk committee require provide director statement fair balanced understandable accordance isa annual report set use report board confirmation carry robust report solely parent company member assessment emerge principal risk set body accordance chapter page company act audit work undertake section annual report describe review state parent company member effectiveness risk management internal control matter require state auditor report system set page purpose full extent permit law section describe work audit risk committee accept assume responsibility set page parent company parent company member body audit work report opinion matter require report form exception parent company pass resolution accordance adequacy explanation receive accounting record section company act senior company act require report statutory auditor state opinion receive information explanation require audit adequate accounting record keep parent company return adequate audit receive branch visit parent company financial statement deloitte llp agreement accounting record return statutory auditor london united kingdom report respect matter march gsk annual report consolidated income statement year end december note turnover cost sale gross profit sell general administration research development royalty income operating incomeexpense operate profit finance income finance expense profit disposal interest associate share tax profit associate joint ventures profit taxation taxation profit taxation year profit attributable noncontrolle interest profit attributable shareholder basic earning share penny dilute earning share penny consolidate statement comprehensive income year end december profit year comprehensive incomeexpense year item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal overseas subsidiary fair value movement cash flow hedge tax fair value movement cash flow hedge reclassification cash flow hedge income statement defer tax reverse reclassification cash flow hedge item reclassify income statement exchange movement overseas net asset noncontrolle interest fair value movement equity investment tax fair value movement equity investment remeasurement lossesgain define benefit plan tax remeasurement define benefit plan comprehensive incomeexpense year total comprehensive income year total comprehensive income year attributable shareholder noncontrolle interest total comprehensive income year gsk annual report strategic report governance remuneration financial statement investor information consolidate balance sheet december note noncurrent asset property plant equipment right use asset goodwill intangible asset investment associate joint venture investment defer tax asset derivative financial instrument noncurrent asset total noncurrent asset current asset inventory current tax recoverable trade receivables derivative financial instrument liquid investment cash cash equivalent asset hold sale total current asset total asset current liability shortterm borrowing contingent consideration liability trade payable derivative financial instrument current tax payable shortterm provision total current liability noncurrent liability longterm borrowing corporation tax payable deferred tax liability pension postemployment benefit provision derivative financial instrument contingent consideration liability noncurrent liability total noncurrent liability total liability net asset equity share capital share premium account retain earning reserve shareholder equity noncontrolle interest total equity financial statement page approve board march sign behalf sir jonathan symonds chairman gsk annual report consolidate statement change equity year end december shareholder equity share share retain noncontrolle total capital premium earning reserve total interest equity december implementation ifrs implementation ifrs december adjust profit year comprehensive income year total comprehensive income year distribution noncontrolle interest contribution noncontrolle interest derecognition noncontrolle interest consumer healthcare joint venture dividend shareholder realise profit disposal equity investment share associates joint venture realise profit disposal equity investment share issue writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december report adjustment noncontrolle interest december revise implementation ifrs december adjust profit year comprehensive income year total comprehensive income year distribution noncontrolle interest change noncontrolle interest dividend shareholder recognition interest consumer healthcare realise loss disposal equity investment share issue share acquire esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december profit year comprehensive expenseincome year total comprehensive income year distribution noncontrolle interest contribution noncontrolle interest change noncontrolle interest dividend shareholder realise profit disposal equity investment share associates joint venture realise profit disposal equity investment share issue share acquire esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december analysis reserve present note movement equity gsk annual report strategic report governance remuneration financial statement investor information consolidated cash flow statement year end december note cash flow operating activity profit taxation year adjustment reconcile profit tax operating cash flow cash generate operation taxation pay net cash inflow operating activity cash flow investing activity purchase property plant equipment proceed sale property plant equipment purchase intangible asset proceed sale intangible asset purchase equity investment proceed sale equity investment contingent consideration pay purchase business net cash acquire disposal business investment associate joint venture proceed disposal interest associate increasedecrease liquid investment interest receive dividend associate joint venture equity investment net cash inflowoutflow investing activity cash flow financing activity issue share capital purchase noncontrolle interest increase longterm loan repayment shortterm note repayment ofincrease shortterm loan repayment lease liability interest pay dividend pay shareholder distribution noncontrolle interest contribution noncontrolle interest finance cash flow net cash outflow financing activity increase cash bank overdraft cash bank overdraft begin year exchange adjustment increase cash bank overdraft cash bank overdraft end year cash bank overdraft end year comprise cash cash equivalent cash cash equivalent report asset hold sale overdraft gsk annual report note financial statement presentation financial statement description business composition group gsk major global healthcare group engage list subsidiary associate opinion creation discovery development manufacture director principally affect profit net marketing pharmaceutical product vaccine overthe asset group give note principal group counter otc medicine healthrelate consumer company product gsk principal pharmaceutical product include financial period medicine follow therapeutic area respiratory hiv financial statement cover financial year immunoinflammation oncology antiviral central nervous january december comparative figure system cardiovascular urogenital metabolic antibacterial financial year january december dermatology appropriate january december compliance applicable law ifrs accounting principle policy financial statement prepare accordance financial statement prepare international accounting standard conformity historical cost convention modify revaluation certain requirement company act international item state accounting policy go financial reporting standard adopt pursuant regulation concern basis apply european union financial statement prepare accordance financial statement prepare group accounting policy approve board accordance international financial reporting standard describe note accounting principle policy issue iasb information application accounting policy include area estimation judgement give note composition financial statement key accounting judgement estimate consolidated financial statement draw sterling functional currency glaxosmithkline plc preparation financial statement conformity accordance ifrs accounting presentation financial generally accept accounting principle require management statement comprise estimate assumption affect report amount asset liability disclosure contingent consolidated income statement asset liability date financial statement consolidate statement comprehensive income report amount revenue expense consolidated balance sheet reporting period actual result differ estimate consolidated statement change equity parent company financial statement financial statement parent company consolidate cash flow statement glaxosmithkline plc prepare accordance note financial statement gaap accounting presentation company balance sheet present accounting policy give page accounting principle policy consolidation group ability exercise joint control consolidated financial statement include right net asset entity entity account joint venture group ability asset liability result cash flow exercise joint control arrangement right company subsidiary include esop trust specify asset obligation specify liability group share result net asset associate arrangement arrangement account joint joint venture operation group ability exercise group share asset liability revenue expense significant influence entity account joint operation associate result asset liability associate joint venture incorporate consolidated financial statement entity consolidate financial statement equity method accounting december year group right asset liabilitie revenue expense entity group power direct joint operation include consolidated financial relevant activity affect return group statement accordance right obligation generally control financial operating interest acquire entity consolidated date policy account subsidiary group acquire control interest sell deconsolidate date control cease gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue accounting principle policy continue transaction balance subsidiary eliminate consolidation asset liability include related profit tax take sale subsidiary goodwill overseas subsidiary associate joint product sell customer outside group venture translate sterling rate exchange relevant proportion profit transaction joint rule balance sheet date result cash flow venture joint operation associate defer overseas subsidiary associate joint venture product sell party transaction non translate sterling average rate exchange control interest record directly equity defer exchange adjustment arise open net asset tax relief unrealise intragroup profit account profit year retain overseas subsidiary extent consider recoverable associate joint venture translate sterling business combination exchange difference arise related foreign currency business combination account acquisition borrowing hedge group net investment accounting method identifiable asset liability contingent operation take separate component equity liability acquire measure fair value acquisition date translate sterling asset liability result consideration transfer measure fair value cash flow overseas subsidiary associate joint include fair value contingent consideration venture report currency hyperinflationary fair value contingent consideration liability economy adjustment material reflect reassess balance sheet date change current price level loss net monetary asset charge recognise income statement payment contingent consolidated income statement consideration reduce balance sheet liability result revenue record income statement turnover payment relate original estimate group receive revenue supply good external fair value contingent consideration acquisition customer order receive majority contract report investing activity cash flow statement gsk enter relate sale order contain single payment relate increase performance obligation delivery pharmaceutical liability acquisition date report operating vaccine consumer healthcare product average cash flow duration sale order month consideration transfer non product revenue recognise control good control interest exceed fair value net asset pass customer point control pass liability contingent liability acquire excess determine customer arrangement generally record goodwill cost effecting acquisition occur delivery customer charge income statement period product revenue represent net invoice value include fix incur variable consideration variable consideration arise goodwill capitalise separate item case sale good result discount allowance give subsidiary cost investment case accrual estimate future return rebate revenue joint ventures associate goodwill denominate recognise highly probable significant currency operation acquire reversal cumulative revenue recognise cost acquisition fair value net occur methodology assumption estimate asset acquire difference recognise directly rebate return monitor adjust regularly income statement light contractual legal obligation historical trend past experience project market condition equity subsidiary acquire uncertainty associate return rebate resolve noncontrolle interest recognise fair value revenue adjust accordingly noncontrolle interest share net asset subsidiary casebycase basis change group operate income royalty income ownership percentage subsidiary account gsk enter development marketing collaboration equity outlicence group compound product foreign currency translation party contract rise fix variable foreign currency transaction book functional consideration upfront payment development milestone currency group company exchange rate ruling salesbase milestone royalty date transaction foreign currency monetary asset income dependent achievement development liability retranslate functional currency milestone recognise highly probable rate exchange rule balance sheet date exchange significant reversal cumulative revenue difference include income statement recognise occur usually relate event occur salesbase milestone income recognise highly probable sale threshold reach gsk annual report note financial statement continue accounting principle policy continue salesbased royalty licence intellectual property certain case incur report ibnr actuarial recognise relevant product sale occur technique determine estimate addition provision legal expense arise revenue time recognition revenue claim receive dispute payment customer expect year impact material consideration group involved legal proceeding discount appropriate discount rate respect possible reliable estimate expect financial effect result value add tax sale taxis exclude revenue ultimate resolution proceeding case expenditure appropriate disclosure case include expenditure recognise respect good service provision receive supply accordance contractual term cost associate claim group provision obligation exist future liability party charge income statement respect past event incur obligation reliably estimate manufacturing startup cost validation achievement normal pension postemployment benefit production expense incur cost provide pension define benefit scheme calculate project unit credit method spread advertising promotion expenditure charge income period benefit expect derive statement incur employee service consistent advice qualified shipment cost intercompany transfer charge cost actuary sale distribution cost sale customer include pension obligation measure present value sell general administrative expenditure estimate future cash flow discount rate reflect restructuring cost recognise provide yield highquality corporate bond pension scheme asset appropriate respect direct expenditure business measure fair value balance sheet date reorganisation plan sufficiently detail cost postemployment liability calculate advanced appropriate communication similar way define benefit pension scheme spread affect undertaken period benefit expect derive research development employee service accordance advice research development expenditure charge qualified actuary service cost provide retirement income statement period incur benefit employee year cost development expenditure capitalise criterion curtailment charge operating profit year recognise asset meet usually regulatory filing actuarial gain loss effect change actuarial major market approval consider assumption recognise statement comprehensive highly probable property plant equipment income year arise research development capitalise depreciated accordance group policy group contribution define contribution plan charge income statement incur environmental expenditure environmental expenditure relate exist condition employee share plan result past current operation incentives form share provide employee current future benefit discernible charge income share option share award scheme statement group recognise liability sitebysite fair value option award calculate basis reliably estimate liability include grant date blackschole option pricing model group portion total cost portion charge income statement relevant vesting period potentially responsible party cost probable able satisfy respective share group provide finance esop trust purchase cleanup obligation recovery reimbursement company share meet obligation provide share record asset virtually certain employee exercise option award cost run esop trust charge income statement share hold legal dispute esop trust deduct reserve transfer provision anticipate settlement cost legal reserve retain earning dispute group outflow resource vest period relate share option award reflect consider probable reliable estimate ultimate proceed receivable employee exercise likely outcome respect product liability claim relate certain product provision sufficient property plant equipment history claim settlement enable management property plant equipment ppe state cost reliable estimate provision require cover purchase construction provision depreciation unasserted claim impairment financing cost capitalise cost qualifying asset construction gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue accounting principle policy continue depreciation calculate write cost residual lease applicable december value ppe exclude freehold land straightline leasing agreement transfer group substantially basis expect useful life residual value live benefit risk ownership asset treat review appropriate adjust annually normal finance lease asset purchase outright expect useful life major category ppe asset include ppe computer software capital element leasing commitment show freehold building year obligation finance lease asset hold finance leasehold land building lease term year lease depreciate basis consistent similar own plant machinery year asset lease term short interest element equipment vehicle year lease rental include income statement lease disposal ppe cost relate accumulate operating lease rental cost charge depreciation impairment remove financial income statement straightline basis lease term statement net proceed take goodwill income statement goodwill state cost impairment goodwill lease applicable january deem indefinite useful life test group recognise right use asset lease impairment annually arrangement lessee right use asset fair value interest acquire entitys own party lease agreement capitalise asset liability contingent liability exceed inception lease recognise consolidated consideration pay excess recognise immediately balance sheet gain income statement correspond liability lessor recognise lease intangible asset obligation short longterm borrowing carry intangible asset state cost provision subsequently increase reflect interest amortisation impairment lease liability reduce lease payment licence patent knowhow marketing right separately calculate discount lease liability lease acquire acquire business combination annual payment million implicit rate amortise estimate useful life generally lease available incremental borrowing exceeding year straightline basis rate lease specific adjustment time available use estimate useful life available lease annual payment determine amortisation charge account patent million incremental borrowing rate life applicable value obtain incremental borrowing rate calculate rate interest period nonexclusivity asset life review gsk able borrow similar term appropriate adjust annually similar security fund necessary obtain similar asset similar market contingent milestone payment recognise point contingent event probable development finance cost charge income statement cost incur group associate acquire produce constant periodic rate charge remain licence patent knowhow marketing right write balance obligation accounting period income statement incur criterion variable rent lease liability right recognition internallygenerate intangible asset meet use asset payment charge income usually regulatory filing major market statement incur shortterm lowvalue lease approval consider highly probable capitalise lease rental charge income acquire brand value independently fair value statement incur business acquire party brand nonlease component account separately value substantial longterm brand lease component plant equipment lease contractual legal nature sell separately separately account land building vehicle lease rest business acquire brand amortise estimate useful life year modification reassessment occur lease liability consider useful economic life indefinite right use asset remeasure cost acquire develop computer software right use asset title expect pass gsk internal use internet site external use capitalise point future depreciate basis consistent intangible fix asset software site support similar own asset case right use asset significant business system expenditure lead depreciate short useful life asset creation durable asset erp system software amortise lease term seven year computer software year gsk annual report note financial statement continue accounting principle policy continue impairment noncurrent asset investment carry value noncurrent asset review investment comprise equity investment impairment standalone basis large investment limited life fund group elect cash generating unit indication asset designate equity investment measure fvtoci impair additionally goodwill intangible asset initially record fair value plus transaction cost indefinite useful life intangible asset remeasure subsequent reporting date fair value available use test impairment annually unrealise gain loss recognise provision impairment charge income statement comprehensive income year concern disposal equity investment gain loss impairment goodwill reverse impairment loss defer comprehensive income transfer noncurrent asset reverse directly retain earning investment limited life fund change estimate determine recoverable amount measure fvtpl initially record fair value extent revise recoverable amount remeasure subsequent reporting date fair value exceed carry value exist net unrealised gain loss recognise income depreciation amortisation impairment statement recognise dividend equity investment distribution fund investment associate joint venture joint recognise income statement group right operation receive payment establish investment associate joint venture carry purchase sale investment account consolidated balance sheet group share net trade date asset date acquisition postacquisition retain profit loss goodwill arise trade receivables acquisition group recognise right asset trade receivable measure accordance liability revenue expense joint operation business model portfolio trade receivables hold group portfolio business inventory model ifrs factoring arrangement place inventory include financial statement lower collect contractual cash flow measure amortise cost cost include raw material direct labour direct cost sell contractual cash flow measure fvtpl relate production overhead net realisable value collect sell contractual cash flow measure cost generally determine basis fvtoci trade receivable measure amortise cost prelaunch inventory hold asset high carry original invoice allowance probability regulatory approval product expect credit loss point provision carry value recoverable provision reverse point expect credit loss calculate accordance high probability regulatory approval determine simplified approach permit ifrs provision matrix apply lifetime historical credit loss experience trade financial instrument receivables expect credit loss rate vary depend financial asset extent settlement trade financial asset measure amortise cost fair value receivables overdue adjust appropriate comprehensive income fvtoci fair value reflect current economic condition estimate future profit loss fvtpl measurement basis condition purpose determine credit loss rate determine reference business model customer classify grouping similar loss manage financial asset contractual cash flow pattern key driver loss rate nature characteristic financial asset financial asset business unit location type customer trade receivables month expect credit loss ecl allowance record initial recognition trade receivable determine reasonable subsequent evidence significant increase credit risk expectation recovery write firstly asset allowance increase reflect lifetime expect credit loss allowance available ecl realistic prospect recovery asset income statement write subsequent recovery amount previously provide expect credit loss recognise income statement write credit income statement longterm financial asset measure amortise cost fair value receivables discount effect material comprehensive income apart equity investment gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue accounting principle policy continue cash cash equivalent change fair value derivative designate fair value cash hold deposit account measure amortise cost hedge record income statement investment money market fund hold fair value change fair value hedge asset liability profit loss fund fail solely payment taxation principal interest sppi test current tax provide amount expect pay apply tax rate enact substantively borrowing enact balance sheet date borrowing initially record proceed receive net transaction cost borrowing subsequently defer tax provide temporary difference arise carry amortise cost difference tax basis asset liability carry proceed net transaction cost amount financial statement defer tax asset redemption recognise charge income recognise extent probable future taxable statement period relevant borrowing profit available temporary difference utilise defer tax provide temporary derivative financial instrument difference arise investment subsidiary associate derivative financial instrument manage exposure joint venture time reversal market risk principal derivative instrument temporary difference control probable gsk foreign currency swap interest rate swap foreign temporary difference reverse foreseeable exchange forward contract option group future defer tax provide rate tax hold issue derivative financial instrument trading enact substantively enact balance sheet date speculative purpose uncertain tax position identify management derivative financial asset liability include derivative judgement probable outcome embed host contract separate assume relevant tax authority knowledge host contract classify heldfortrading situation assess economic outflow measure fair value change fair value derivative probable arise provision good estimate instrument qualify hedge accounting liability estimate liability gsk apply recognise immediately income statement riskbase approach take account appropriate hedge accounting probability group able obtain compensatory adjustment international tax treaty derivative designate hedge instrument classify estimate account specific circumstance inception hedge relationship cash flow hedge net dispute relevant external advice investment hedge fair value hedge discount change fair value derivative designate cash flow time value money material balance hedge recognise comprehensive income discount current value appropriate discount rate extent hedge effective ineffective portion unwind discount record finance income recognise profit loss immediately amount defer finance expense comprehensive income reclassify income statement hedge item affect profit loss net investment hedge account similar way cash flow hedge key accounting judgement estimate prepare financial statement management require estimate judgement item gross turnover reduce rebate discount allowance recognise financial statement estimate product return give expect give assumption affect amount asset liability vary product arrangement buy group revenue expense report financial statement arrangement purchase organisation dependent actual amount result differ estimate submission claim time initial follow consider critical accounting recognition sale accrual time sale judgement key source estimation uncertainty estimate rebate discount allowance payable return base available market information turnover historical experience report group turnover million million gsk annual report note financial statement continue key accounting judgement estimate continue pharmaceuticals business large estimate complex arrangement rebate discount allowance group open tax issue number revenue pharmaceuticals turnover million authority management make judgement million recording deduction sufficient information able reliable estimate million million rebate discount outcome dispute insufficient information available allowance return balance sheet accrual rebate provision discount allowance return pharmaceutical sufficient information available estimate potential tax vaccine business manage combined basis liability gsk apply riskbased approach take december total accrual amount account appropriate probability group million million nature able obtain compensatory adjustment international accrual practicable meaningful tax treaty estimate account specific sensitivity estimate large volume variable circumstance dispute relevant external advice contribute overall rebate chargeback return inherently judgemental change substantially revenue accrual time dispute progress new fact emerge significant variability final outcome december group recognise provision group apply constraint measure variable element million respect uncertain tax position revenue revenue recognise suitably million number uncertain tax position hold cautious objective constraint ensure number jurisdiction relate highly probable significant reversal revenue practicable meaningful sensitivity estimate occur uncertainty resolve constraint apply make suitably cautious estimate input factor affect tax charge future year set assumption estimate variable consideration note taxation gsk continue believe amount estimate fully reflect adequate provision liability likely arise open final outcome amount subject change assessment open issue exist ultimate liability dependent thing type buy matter vary amount provide group product sale mix constraint apply dependent outcome negotiation relevant recognise revenue mean risk material downward tax authority necessary litigation proceeding adjustment revenue financial year low legal dispute level accrual rebate return review legal cost year million adjust regularly light contractual legal million december provision legal obligation historical trend past experience project dispute amount million million market condition market condition evaluate estimate wholesaler thirdparty analysis market research datum management make judgement sufficient internallygenerate information reasonably possible information able reliable estimate likely significant adjustment outcome dispute legal expense arise month recognise additional revenue actual outcome claim group insufficient information well cautious constrain estimate revenue available provision disclosure claim recognise highly probable significant give reversal cumulative revenue recognise occur turnover recognise year estimate provision account specific performance obligation satisfy previous period set circumstance dispute relevant external advice note turnover segment information inherently judgemental change substantially time indication level sensitivity estimate dispute progress new fact emerge detail status uncertainty involve significant future event cause assumption unresolved dispute set note legal proceeding accrual base change materially affect future result group company director take legal advice establish provision take account relevant taxation fact circumstance matter accordance tax charge year million accounting requirement respect product liability claim million december current tax payable related certain product sufficient history claim million million noncurrent corporation settlement enable management reliable tax payable million million current estimate provision require cover unasserted claim tax recoverable million million gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue key accounting judgement estimate continued group involved legal proceeding respect pension postemployment benefit possible reliable estimate judgement expect financial effect practicable surplus define benefit scheme arise meaningful range outcome result ultimate potential surplus arise commit future resolution proceeding case appropriate contribution right trustee prevent group disclosure case provide provision obtain refund surplus future consider contingent liability quantify determine necessary restrict ultimate liability legal claim vary amount surplus recognise scheme provide dependent outcome litigation surplus combine surplus million december proceeding investigation possible settlement negotiation million gsk judgement position change time amount meet requirement recoverability assurance loss result outcome estimate legal proceeding exceed provision cost provide pension postemployment report group financial statement material benefit assess basis assumption select contingent consideration management assumption include future earning income statement charge contingent pension increase discount rate expect longterm rate consideration million million return asset mortality rate disclose note december liability contingent consideration pension postemployment benefit amount million million discount rate derive rate corporate bond yield million million relate country deep market corporate acquisition shionogiviiv healthcare joint venture bond government bond yield sensitivity analysis provide note pension post employment benefit reduction discount estimate rate lead increase net pension deficit contingent consideration include consideration approximately million increase annual payable business combination record fair value pension cost approximately million similarly date acquisition fair value generally base increase discount rate lead decrease net riskadjuste future cash flow discount appropriate pension deficit approximately million decrease posttax discount rate fair value review annual pension cost approximately million regular basis annually change reflect selection different assumption affect future result income statement note contingent consideration group liabilitie new accounting requirement year group implement amendment ifrs interest rate benchmark reform phase amendment business combination issue october ifrs ias ifrs ifrs ifrs issue amendment clarifie definition business august effective january permit simplify initial assessment acquire phase amendment address issue arise set activity asset group asset implementation reform include replacement business amendment material impact benchmark alternative practical expedient result financial position group provide change contractual cash flow financial asset liability include lease liability covidrelate rent concession amendment ifrs account prospectively revise effective interest issue introduce practical expedient rate addition hedge accounting discontinue ifrs lease permit lessee elect assess solely ibor reform covidrelated concession respect rent period june lease modification amendment expect material impact amendment applicable annual reporting period begin result financial position group june early application permit gsk annual report note financial statement continue exchange rate group use average exchange rate prevail period translate result cash flow overseas subsidiary joint venture associate sterling period end rate translate net asset entity currency influence translation relevant exchange rate average rate period end rate euro euro yen yen turnover segment information operating segment report base financial information provide chief executive officer responsibilitie corporate executive team cet gsk report result segment pharmaceutical pharmaceutical vaccine consumer healthcare individual member cet responsible segment group management reporting process allocate intragroup profit product sale market sale record profit analysis present basis corporate unallocated turnover cost include result certain consumer healthcare product hold sale number market order meet antitrust approval requirement cost corporate function revenue recognise year performance obligation satisfy previous period total million million include million million impacting turnover arise change prior year estimate rar return rebate accrual million million milestone income million million royalty income recognise current year turnover segment pharmaceutical vaccine consumer healthcare segment turnover corporate unallocated turnover pharmaceutical turnover therapeutic area respiratory hiv immunoinflammation oncology establish pharmaceutical vaccine turnover category meningitis influenza shingle establish vaccine gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue turnover segment information continue operation pharmaceutical vaccine business sale wholesaler approximately million million million million million million million million million respectively allocate finalcustomer discount wholesalers gsk review presentation consumer healthcare product january adopt revise detailed disclosure category sale closely align consumer healthcare industry standard definition comparative information revise consistent basis revise revise consumer healthcare turnover category oral health pain relief vitamin mineral supplement respiratory health digestive health brand divestedunder review segment profit pharmaceutical pharmaceutical pharmaceutical include vaccine consumer healthcare segment profit corporate unallocated cost reconcile item segment profit operating profit operating profit finance income finance cost profit disposal interest associate share aftertax profit associate joint ventures profit taxation taxation profit taxation year reconcile item segment profit operating profit comprise item specifically allocate segment profit include impairment amortisation intangible asset major restructuring cost include impairment tangible asset computer software transactionrelate adjustment relate significant acquisition proceed cost disposal associate product business significant legal charge expense settlement litigation government investigation operate income royalty income item separation cost depreciation amortisation segment pharmaceutical pharmaceutical pharmaceutical include vaccine consumer healthcare segment depreciation amortisation corporate unallocated depreciation amortisation reconcile item segment depreciation amortisation total depreciation amortisation total depreciation amortisation gsk annual report note financial statement continue turnover segment information continue ppe intangible asset goodwill impairment segment pharmaceutical pharmaceutical pharmaceutical include vaccine consumer healthcare segment impairment corporate unallocated impairment reconcile item segment impairment total impairment total impairment ppe intangible asset impairment reversal segment pharmaceutical pharmaceutical pharmaceutical include vaccine consumer healthcare segment impairment reversal corporate unallocated impairment reversal reconcile item segment impairment reversal total impairment reversal total impairment reversal net operating asset segment pharmaceutical pharmaceutical pharmaceutical include vaccine consumer healthcare segment net operating asset corporate unallocated net operating asset net operating asset net debt investment associate joint venture derivative financial instrument current defer taxation asset hold sale exclude cash cash equivalent net asset pharmaceutical segment include shionogiviiv healthcare contingent consideration liability million million pfizer option million million gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue turnover segment information continue geographical information regard group country domicile turnover location customer rest world external turnover noncurrent asset location subsidiary rest world noncurrent asset noncurrent asset location exclude amount relate investment defer tax asset derivative financial instrument pension asset amount receivable insurance contract certain noncurrent receivables operating incomeexpense fair value remeasurement equity investment disposal business asset fair value remeasurement contingent consideration recognise business combination remeasurement viiv healthcare option liability preferential dividend remeasurement consumer healthcare option liability fair value adjustment derivative financial instrument incomeexpense disposal business asset include net profit disposal horlick consumer healthcare nutritional brand subsidiary india bangladesh million reflect reversal million embed derivative gain value share take prior year partly offset related million loss share hindustan unilever limit include fair value remeasurement loss acquisition consideration divestment gsk consumer healthcare limited india subsequent disposal operating income include increase profit milestone income number asset disposal profit disposal rabie tickborne encephalitis vaccine million gain arise increase value share hindustan unilever limit subsequently receive million include fair value movement relate derivative fair value remeasurement contingent consideration recognise business combination include million related acquisition shionogiviiv healthcare joint venture million relate vaccine acquisition novartis fair value movement relate hedging contract gsk annual report note financial statement continue operating profit follow item include operate profit employee cost note advertising distribution cost depreciation property plant equipment impairment property plant equipment net reversal depreciation right use asset impairment right use asset amortisation intangible asset impairment intangible asset net reversal impairment property plant equipment hold sale net reversal impairment intangible asset hold sale net reversal impairment goodwill allocate disposal group net reversal net foreign exchange lossesgain inventory cost inventory include cost sale writedown inventory reversal prior year writedown inventory shortterm lease charge lowvalue lease charge variable lease payment operate lease rental minimum lease payment contingent rent sublease payment fee payable company auditor associate relation group reversal prior year writedown inventory principally arise reassessment usage demand expectation prior inventory expiration net foreign exchange gain include net loss million million gain nil arise reclassification exchange liquidation disposal overseas subsidiary include operate profit major restructuring charge million million million note major restructuring cost fee payable company auditor associate audit parent company consolidate financial statement include attestation sarbanesoxley act audit company subsidiary total audit service taxation compliance audit relate assurance service service total auditrelated nonaudit service assurance service provide auditor relate agree procedure assurance service outside statutory audit requirement addition fee pay auditor respect gsk pension scheme audit service fee million million nil pay auditor respect audits certain company subsidiary acquire year gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue employee cost wage salary social security cost pension postemployment cost include augmentation note cost sharebase incentive plan severance cost integration restructuring activity increase wage salary include impact movement exchange rate group provide benefit employee commensurate local practice individual country include market healthcare insurance subsidise car scheme personal life assurance cost sharebase incentive plan analyse follow share value plan performance share plan share option plan cash settle plan average monthly number person employ group include director year number number number manufacturing sell general administration research development average monthly number group employee exclude temporary contract staff number group employee end financial year give financial record compensation director senior management member cet aggregate follow wage salary social security cost pension postemployment cost cost sharebase incentive plan information remuneration director give section annual report remuneration label audit page gsk annual report note financial statement continue major restructuring cost pharmaceutical sector highly regulate manufacture operation supply chain long lifecycle business mean restructure programme particularly involve rationalisation closure manufacturing site likely year complete major restructuring cost relate specific boardapprove major restructuring programme include integration cost follow material acquisition structural significant scale cost individual relate project exceed million exist combined restructure integration programme incorporate previous major change programme pharmaceutical restructure programme restructure integration programme follow novartis transaction programme substantially complete july boardapprove major restructure programme design significantly improve competitiveness efficiency group cost base saving deliver primarily supply chain optimisation reduction administrative cost february board approve major restructuring plan generate synergies integration pfizer consumer healthcare business gsk consumer healthcare business january board approve twoyear separation preparation programme prepare separation gsk company total restructuring cost million incur follow area restructure cost prepare separation gsk company restructure follow integration pfizer consumer healthcare business gsk consumer healthcare continue implementation restructure programme start july simplify operating model improve resource allocation pharmaceutical consumer healthcare supply chain continue transformation central function include gsk technology platform interface deliver great digital synergy simplification application staff reduction analysis cost charge operating profit programme follow increase provision major restructuring programme note provision reverse unused note impairment loss recognise noncash charge cash cost provision reversal million million million reflect provision release mainly combine restructure integration programme asset impairment million noncash charge million principally comprise fix asset writedown manufacturing facility accelerate depreciation asset life shorten supply chain manufacturing network result major restructuring programme charge settle cash include site closure cost consultancy project management cost analysis major restructuring charge programme follow cash noncash total separation preparation programme consumer healthcare joint venture integration programme major restructuring programme include tesaro combine restructure integration programme cash noncash total consumer healthcare joint venture integration programme major restructuring programme include tesaro combine restructure integration programme gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue major restructuring cost continue analysis major restructuring charge income statement line follow cost sale sell general administration research development operate expense finance income finance income arise financial asset measure amortise cost financial asset measure fair value profit loss net gain arise forward element forward contract net investment hedge relationship finance expense finance expense arise financial liability amortise cost derivative fair value profit loss net loss arise financial instrument mandatorily measure fair value profit loss retranslation loan reclassification hedge comprehensive income unwind discount provision finance expense arise lease liability finance expense finance expense arise derivative fair value profit loss relate swap interest expense figure finance expense arise lease liability relate interest arise finance lease previous leasing standard ias originally report finance expense finance expense include million charge interest relate historical income tax settlement gsk annual report note financial statement continue associate joint venture group share aftertax profit loss associate joint venture set share aftertax profit associate share aftertax lossesprofit joint venture december group hold significant associate innoviva inc summarise income statement information respect innoviva set group share aftertax profit associate comprehensive income include profit million comprehensive income nil respect innoviva result innoviva include summarise income statement information represent estimate earning innoviva relevant period base publicly available information balance sheet date innovivas turnover arise royalty income gsk relation relvarbreo ellipta anoro ellipta trelegy ellipta sale turnover profit taxation total comprehensive income aggregate financial information respect gsk share associate undertaking joint venture set share turnover share aftertax loss share comprehensive income share total comprehensive incomeexpense group sale associate joint venture nil million million gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue taxation group tax charge sum total current defer tax expense taxation charge base profit year current year charge rest world current year charge chargecredit respect prior period current taxation defer taxation gsk payment million corporation tax hmrc amount corporation tax include business taxis bear gsk year defer tax credit reflect origination current year expense offset taxable profit future period probable relate primarily unwind defer tax liability intangible asset recognition current year tax loss reversal temporary difference include uplift tax carrying value certain consumer healthcare brand result acquisition novartis interest consumer healthcare joint venture significant prior year credit reflect impact settlement number open issue tax authority period follow table reconciles tax charge calculate statutory rate group profit tax actual tax charge year reconciliation taxation group profit profit tax statutory rate taxation difference overseas taxation rate benefit intellectual property incentive credit fair value remeasurement nontaxable option tax loss benefit recognise permanent difference disposal acquisition permanent difference reassessment prior year estimate change tax rate tax chargetax rate gsk substantial business presence country globe impact difference overseas taxation rate arise profit earn country tax rate high statutory rate significant belgium germany india japan adverse impact partly offset benefit intellectual property incentive patent box belgian patent income deduction regime provide reduce rate corporation tax profit earn qualifying patent claim incentive manner intend relevant statutory regulatory framework change tax rate include credit relation reduction corporation tax rate cancel india tax treatment dividend change effect april credit partly reverse expense future benefit provide enact corporation tax rate permanent difference disposal acquisition reflect tax impact disposal horlick consumer healthcare brand unilever subsequent disposal share receive hindustan unilever group tax rate influence reassessment open issue tax authority jurisdiction reassessment prior year estimate include current defer tax future tax charge effective tax rate affect factor acquisition disposal restructuring location activity tax regime reform resolution open matter continue bring tax affair date world gsk annual report note financial statement continue taxation continue tax item charge equity statement comprehensive income current taxation sharebase payment define benefit plan fair value movement cash flow hedge fair value movement equity investment defer taxation sharebase payment define benefit plan fair value movement cash flow hedge fair value movement equity investment total creditcharge equity statement comprehensive income item charge statement comprehensive income tax sharebase payment issue relate taxation integrate nature group worldwide operation involve significant investment research strategic manufacture limited number location consequential crossborder supply route numerous endmarket line current oecd guideline base transfer pricing policy arm length principle different tax authority seek attribute profit activity undertake jurisdiction potentially result double taxation group open item jurisdiction concern matter deductibility particular expense tax treatment certain business transaction gsk apply risk base approach determine transaction likely subject challenge probability group able obtain compensatory adjustment international tax treaty calculation group total tax charge necessarily involve degree estimation judgement respect certain item tax treatment finally determine resolution reach relevant tax authority appropriate formal legal process december group recognise provision million respect uncertain tax position million decrease recognise provision drive reassessment estimate utilisation provision uncertain tax position follow settlement number open issue tax authority jurisdiction whilst ultimate liability matter vary amount provide dependent outcome agreement relevant tax authority litigation appropriate group continue believe appropriate provision period open agree tax authority provision defer tax liability million december million respect taxation payable remittance profit certain overseas subsidiary whilst aggregate unremitte profit balance sheet date approximately billion billion majority unremitted profit subject tax include withhold tax repatriation legislation relate company distribution provide exemption tax overseas profit subject certain exception defer tax provide temporary difference million million arise unremitted profit management ability control future reversal consider reversal probable continue focus tax reform expect future year drive oecds project address tax challenge arise digitalisation economy result significant change establish tax principle increase tax authority dispute turn adversely affect gsk effective tax rate result high cash tax liability gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue taxation continue movement defer tax asset liability pension share accelerate post option net capital intangible contingent intragroup employment tax award temporary allowance asset consideration profit benefit loss scheme difference total january exchange adjustment creditcharge income statement creditcharge statement comprehensive income equity acquisition disposal credit utilisation december exchange adjustment chargecredit income statement creditcharge statement comprehensive income equity acquisition disposal credit utilisation december defer tax liability provide relation intangible asset predominately relate temporary difference arise asset liability acquire historic business combination acquisition disposal include defer tax liability million relate pfizer consumer healthcare business acquisition million relate tesaro acquisition group continue recognise defer tax asset future obligation respect contingent consideration amount payable minority shareholder payment tax deductible point time payment deferred tax asset recognise intragroup profit arise intercompany inventory eliminate consolidated account intragroup profit eliminate individual entity tax return temporary difference arise reverse point time inventory sell externally defer tax asset million million recognise tax loss relate trading loss defer tax asset recognise probable future taxable profit available utilise loss support product level forecast net temporary difference include accrue expense tax deduction available pay basis defer tax asset liability recognise balance sheet follow defer tax asset defer tax liability unrecognised unrecognised defer tax defer tax tax loss asset tax loss asset unrecognised tax loss trading loss expire year year available indefinitely december capital loss expire available indefinitely december gsk annual report note financial statement continue earning share pence pence pence basic earning share dilute earning share basic earning share calculate divide profit attributable shareholder weight average number share issue period deduct share hold esop trust treasury share trustee waive right dividend share hold esop trust diluted earning share calculate adjust weight average number share basic calculation assume conversion potentially dilutive share potentially dilutive share form employee share scheme exercise price average market price gsk share period performance condition attach scheme meet balance sheet date number share calculate basic diluted earning share reconcile weight average number share issue million million million basic dilution share option award dilute dividend dividend total dividend total dividend total share dividend share dividend share dividend paidpayable penny pay penny pay pence interim july july july second interim october october october interim january january january fourth interim april april april total ifrs interim dividend recognise financial statement pay declare gsk normally pay dividend quarter quarter relate quarter declare financial statement recognise dividend pay fourth interim dividend second interim dividend amount recognise year follow dividend shareholder gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue property plant equipment plant land equipment asset building vehicle construction total cost december implementation ifrs december adjust exchange adjustment addition business combination addition capitalise borrowing cost disposal writeoff reclassification transfer asset hold sale cost december exchange adjustment addition business combination addition capitalise borrowing cost disposal writeoff reclassification transfer asset hold sale cost december depreciation december implementation ifrs december adjust exchange adjustment charge year disposal writeoff transfer asset hold sale depreciation december exchange adjustment charge year disposal writeoff transfer asset hold sale depreciation december impairment december implementation ifrs december adjust exchange adjustment disposal writeoff impairment loss reversal impairment transfer asset hold sale impairment december exchange adjustment disposal writeoff impairment loss reversal impairment transfer asset hold sale impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december gsk annual report note financial statement continue property plant equipment continue weight average interest rate capitalise borrowing cost year disposal writeoff year include number asset nil net book value long use business impairment loss principally arise decision rationalise facility calculate base fair value cost disposal fair value cost disposal valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy calculation determine net present value project riskadjuste posttax cash flow relevant asset cash generating unit apply discount rate group posttax weight average cost capital wacc adjust appropriate specific segment country currency risk asset continue group generally assess associate cash generating unit value use basis value use calculation posttax cash flow include impact future uncommitted restructuring plan improvement impairment indicate pretax cash flow calculation expect materially different result test reperforme pretax cash flow pretax discount rate group wacc equivalent pretax discount rate approximately net impairment loss charge cost sale million million million million sga million million include million million arise major restructuring programme reversal impairment arise subsequent review impaired asset condition gave rise original impairment deem long apply reversal credit cost sale million million computer software reclassify asset construction intangible asset ready use right use asset land plant building equipment vehicle total net book value january exchange adjustment addition business combination addition depreciation disposal impairment reclassification net book value december exchange adjustment addition depreciation disposal impairment reclassification net book value december total cash outflow lease amount million significant lease commitment lease commence yearend analysis lease liability set note net debt gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue goodwill cost january exchange adjustment addition business combination note transfer tofrom asset hold sale cost december net book value january net book value december goodwill allocate group segment follow pharmaceutical vaccine consumer healthcare net book value december recoverable amount cash generating unit assess fair value cost disposal model fair value cost disposal calculate discount cash flow approach posttax discount rate apply project riskadjuste posttax cash flow terminal value discount rate base group wacc cash generating unit integrate operation large part group discount rate adjust appropriate specific segment country currency risk valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy detail relate discount cash flow model impairment test pharmaceutical vaccine consumer healthcare cash generating unit follow valuation basis fair value cost disposal key assumption sale growth rate profit margin terminal growth rate discount rate taxation rate determination assumption growth rate internal forecast base internal external market information margin reflect past experience adjust expect change terminal growth rate base management estimate future longterm average growth rate discount rate base group wacc adjust appropriate taxation rate base appropriate rate region period specific project cash flow year terminal growth rate discount rate terminal growth rate discount rate pharmaceutical vaccines consumer healthcare terminal growth rate exceed longterm project growth rate relevant market reflect impact future generic competition account new product launch goodwill monitor impairment segmental level case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment relate goodwill consumer healthcare cash generating unit comprise collection small cash generating unit include brand indefinite live carry value billion billion detail indefinite life brand give note intangible asset gsk annual report note financial statement continue intangible asset licence patent computer amortise indefinite life software brand etc brand total cost january exchange adjustment capitalise development cost capitalise borrowing cost addition business combination addition disposal asset writeoff transfer asset hold sale reclassification cost december exchange adjustment capitalise development cost addition business combination addition disposal asset writeoff transfer asset hold sale reclassification cost december amortisation january exchange adjustment charge year disposal asset writeoff transfer asset hold sale amortisation december exchange adjustment charge year disposal asset writeoff transfer asset hold sale amortisation december impairment january exchange adjustment impairment loss reversal impairment disposal asset writeoff transfer asset hold sale impairment december exchange adjustment impairment loss reversal impairment disposal asset writeoff transfer asset hold sale reclassification impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december weight average interest rate capitalise borrowing cost year net book value computer software include million million internally generate cost carry value december intangible asset impairment charge reversed year follow impairment reversal million million patent expiry date group significant asset relevant set page gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue intangible asset continue amortisation impairment loss net reversal charge income statement follow amortisation net impairment loss cost sale sell general administration research development licence patent amortise brand etc include large number acquire licence patent knowhow agreement marketing right market use development note acquisition disposal give detail addition business combination year book value large individual item follow tesaro asset meningitis portfolio dolutegravir benlysta lamisil merck asset bms asset fluarixflulaval okairos stiefel trade tesaro asset comprise zejula currently market monotherapy combination therapie meningitis portfolio include menveo bexsero man abcwy menjugate lamisil move licence patent amortise brand etc follow decision start amortisation gsk divest breathe right brand year indefinite life brand comprise portfolio consumer healthcare product primarily acquire acquisition sterling winthrop inc block drug company inc cns inc novartis consumer healthcare business pfizer consumer healthcare business book value major brand follow advil voltaren centrum caltrate otrivin preparation robitussin nexium fenistil chapstick emergenc theraflu panadol lamisil sensodyne breathe right gsk annual report note financial statement continue intangible asset continue brand consider indefinite life give strength durability brand level marketing support brand relatively similar stable profitable market sector similar risk profile size diversification market share mean risk marketrelated factor cause reduction live brand consider relatively low group aware material legal regulatory contractual competitive economic factor limit useful life accordingly amortise brand test annually impairment amortise intangible asset test indicator impairment arise testing apply fair value cost disposal methodology generally posttax cash flow forecast terminal value calculation discount rate equal group posttax wacc adjust appropriate specific segment country currency risk valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy main assumption include future sale price volume growth product contribution future expenditure require maintain product marketability registration relevant jurisdiction exchange rate assumption base past experience review management budget strategic planning cycle change market condition sale erosion competition terminal growth rate apply management estimate future longterm average growth rate relevant market case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment intangible asset investment associate joint venture joint joint ventures associates total ventures associates total january exchange adjustment addition disposal distribution receive net fair value movement comprehensive income movement profitloss tax recognise consolidated income statement december group hold significant associate december innoviva inc december group own million share innoviva biopharmaceutical company list nasdaq innoviva partner gsk development long act beta agonist vilanterol currently receive royalty income sale product contain component relvarbreo ellipta anoro ellipta economic interest royalty pay gsk sale trelegy ellipta remain economic interest royalty hold theravance biopharma inc group hold common stock investment innoviva market value million december million summarise balance sheet information base information publish post balance sheet date respect innoviva set december december noncurrent asset current asset current liability noncurrent liability net asset carry value group investment innoviva analyse follow interest net asset associate goodwill fair value adjustment carry value december gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue investment investment investment designate investment designate investment measure measured measured measured fvtoci fvtpl fvtoci fvtpl january addition net fair value movement comprehensive income net fair value movement profit loss disposal settlement december investment comprise noncurrent equity investment record fair value balance sheet date investment trade active market fair value determine reference relevant stock exchange quote bid price investment fair value estimate management reference relevant available information include current market value similar instrument recent financing round discount cash flow underlie net asset net fair value movement include impact exchange loss million comprehensive income nil profit loss loss million million respectively investment include list investment million million gsk elect designate majority equity investment measure fair value comprehensive income fvtoci significant investment hold december curevac group hold common stock crispr therapeutics group hold lyell immunopharma inc group hold andme inc group hold turn point therapeutics inc group hold investment fair value december million million million million million million million million million respectively investment include equity stake company gsk research collaboration company provide access biotechnology development potential interest june gsk issue note exchangeable option note holder time maturity note june share hold gsk theravance biopharma inc exchange note gsk expect deliver share option certain circumstance deliver cash combination theravance biopharma shares cash theravance biopharma share measure fvtoci fair value december million disposal equity investment measure fvtoci accumulate fair value movement reclassify fair value reserve retain earning investment fair value million million dispose year cumulative gain investment tax million million certain investment investment fund limited live investment acquire intention sell measure fair value profit loss fvtpl addition disposal investment measure fvtpl include acquisition share hindustan unilever limited merger gsk indian list consumer healthcare entity hindustan unilever subsequent divestment share noncurrent asset amount receivable insurance contract pension scheme surplus receivables amount receivable insurance contact hold cash surrender value movement profit loss receivables million million million million classified financial asset million million classify fair value profit loss remain balance million million expect credit loss allowance immaterial december gsk annual report note financial statement continue inventory raw material consumable work progress finish good trade receivable trade receivables net loss allowance accrue income prepayment interest receivable employee loan advance receivables trade receivables include nil nil associate joint ventures receivables include nil nil associate joint venture loss allowance january exchange adjustment charge year subsequent recovery amount provide utilise december total trade receivables balance million million consider credit impair million million expect credit loss allowance apply purchase originated credit impair receivables million million million million classified financial asset nil nil classify fair value profit loss remain balance million million expect credit loss allowance million million recognise december charge report profit loss year discussion credit risk practice refer note gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue cash cash equivalent cash bank hand shortterm deposit addition nil million cash cash equivalent report asset hold sale note asset hold sale cash cash equivalent include billion billion available general use restriction apply subsidiary hold restriction include exchange control taxis repatriation asset hold sale property plant equipment right use asset lease liability goodwill intangible inventory cash cash equivalent noncurrent asset disposal group transfer asset hold sale expect carry amount recover principally disposal sale consider highly probable hold low carrying fair value cost sell include asset hold sale inventory write fair value cost sell million million valuation methodology significant input base observable market datum valuation classify level fair value hierarchy intangible asset million transfer intangible year intangible asset hold sale remain december million impairment exchange movement asset divest year asset hold sale december primarily comprise disposal group thermacare acquire pfizer consumer healthcare business divest meet antitrust requirement disposal group horlick consumer healthcare nutritional product india number country divestment disposal group complete gsk annual report note financial statement continue trade payable trade payable wage salary social security viiv healthcare option payable defer income customer return rebate accrual accrual trade payable include million million associate joint ventures group provide limited supplier financing arrangement certain customer amount involve december material revenue recognise year include deferred income january million million customer return rebate accrual provide group point sale respect estimate rebate discount allowance payable customer include million million respect pharmaceutical vaccine fully describe group financial review accrual time sale actual amount pay base claim time initial recognition sale amount estimate fully reflect final outcome subject change dependent thing type buy group product sale mix level accrual review adjust quarterly light historical experience actual amount pay change arrangement future event cause assumption accrual base change affect future result group pfizer option shareholding viiv healthcare currently exercisable pfizer request ipo viiv healthcare time gsk consent ipo offering complete month pfizer require gsk acquire shareholding liability option hold gross redemption basis derive internal valuation viiv healthcare business utilise discount forecast future cash flow multiplesbase methodology table show indicative basis income statement balance sheet sensitivity pfizer option reasonably possible change key assumption increasedecrease financial liability lossgain income statement increase sale forecast decrease sale forecast cent appreciation dollar cent depreciation dollar cent appreciation euro cent depreciation euro explanation accounting viiv healthcare set gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue net debt list exchange current asset liquid investment cash cash equivalent cash cash equivalent report asset hold sale shortterm borrowing commercial paper bank loan overdraft draw bank facility euribor euro medium term note london stock exchange euro medium term note london stock exchange libor medium term note new york stock exchange euribor euro medium term note london stock exchange euro medium term note london stock exchange lease liability longterm borrowing medium term note new york stock exchange libor medium term note new york stock exchange euribor euro medium term note london stock exchange euro medium term note london stock exchange medium term note new york stock exchange medium term note new york stock exchange medium term note new york stock exchange euro medium term note london stock exchange exchangeable medium term note new york stock exchange medium term note new york stock exchange euro medium term note london stock exchange medium term note new york stock exchange medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange medium term note new york stock exchange medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange medium term note new york stock exchange euro medium term note london stock exchange medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange medium term note new york stock exchange euro medium term note london stock exchange longterm borrowing lease liability net debt gsk annual report note financial statement continue net debt continue current asset liquid investment classify financial asset amortise cost december include treasury note government bond effective interest rate liquid investment december approximately approximately liquid investment balance december earn interest float rate million million liquid investment balance december earn interest fix rate nil million balance report cash cash equivalent original maturity month effective interest rate cash cash equivalent december approximately approximately cash cash equivalent december earn interest float fix rate amount million million respectively million million noninterest bearing holding amount million million gsk policy credit quality cash cash equivalent set note financial instrument relate disclosure shortterm borrowing gsk billion billion commercial paper programme million million issue december billion billion gsk billion euro commercial paper programme newly establish nil issue december gsk billion threeyear commit facility billion billion day commit facility year commit facility agree september extend year september day commit facility agree september facility undrawn december weight average interest rate commercial paper borrowing december weight average interest rate current bank loan overdraft december average effective preswap interest rate note classify shortterm december rate reflect upcoming maturity libor coupon note zero coupon euribor note september longterm borrowing yearend gsk longterm borrowing billion billion billion billion fall year average effective preswap interest rate note issue december approximately approximately longterm borrowing repayable year carry interest effective rate repayment date range pledge asset group hold pledge investment treasury note par value million million million million security irrevocable letter credit issue group behalf respect group selfinsurance activity provision respect selfinsurance include provision legal dispute discuss note provision lease liability maturity analysis discount lease liability recognise group balance sheet follow rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total lease liability gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue pension postemployment benefit pension postemployment cost pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme analyse fund define benefithybrid pension scheme unfunded define benefit pension scheme unfunded postretirement healthcare scheme define benefit scheme define contribution pension scheme cost define benefit pension postretirement healthcare scheme charge income statement follow cost sale sell general administration research development gsk entity operate pension arrangement cover group material obligation provide pension retire employee arrangement develop accordance local practice country concern pension benefit provide state scheme define contribution scheme retirement benefit determine value fund arise contribution pay respect employee define benefit scheme retirement benefit base employee pensionable remuneration length service pension cost define benefit scheme accounting purpose calculate project unit credit method certain country pension benefit provide unfunded basis administer trustee company formal independent actuarial valuation group main plan undertake regularly normally year remeasurement movement year recognise statement comprehensive income discount rate derive rate corporate bond yield country deep market corporate bond government bond yield discount rate select reflect term expect benefit payment project inflation rate pension increase longterm prediction base yield gap longterm indexlinke fix interest gilt mortality rate determine adjust sap standard mortality table reflect recent scheme experience rate project reflect improvement life expectancy line cmi projection longterm rate improvement year male female mortality rate calculate pri white collar table adjust reflect recent experience rate project allow future improvement life expectancy gsk annual report note financial statement continue pension postemployment benefit continue average life expectancy assume individual age project apply individual age follow male female male female year year year year current project asset fund scheme generally hold separately administer trust specific asset proportion general fund insurance contract asset invest different class order maintain balance risk return investment diversify limit financial effect failure individual investment physical asset allocation strategy plan adjusted returnseeke asset liabilitymatche asset returnseeke asset liabilitymatche assets buyin insurance contract purchase cover substantially obligation plan december value insurance contract million million asset allocation plan currently set returnseeke asset liabilitymatche asset pension plan expose risk arise estimate market value plan asset decline investment return reduce estimate value plan liability increase line agree mix returnseeke asset generate future return liabilitymatche asset well match future pension obligation group define overall longterm investment strategy plan investment broad range asset main market risk asset hedge portfolio credit risk interest rate longterm inflation equitie property currency bank counterparty risk plan liability series future cash flow relatively long duration ias basis cash flow sensitive change expect longterm inflation rate discount rate corporate bond yield curve increase longterm inflation correspond increase liability increase discount rate correspond decrease liabilitie interest rate risk credit rate risk partially hedge target base accounting measure plan liability plan interest rate inflation hedge strategy place target base economic measure plan liability furthermore plan currently hedge portion equity exposure stagger maturity profile define benefit pension scheme operate benefit glaxo wellcome employee smithkline beecham employee remain separate scheme close new entrant subsequent employee entitle join define contribution scheme addition group operate number postretirement healthcare scheme principal follow period consultation impact employee announce december define benefit plan closed future accrual effective march result post closure accrue benefit active participant revalue line inflation rpi legacy glaxo wellcome plan cpi legacy smithkline beecham plan subject relevant cap arrangement cap pay increase addition define benefit plan participant active april receive define pension contribution effect closure define contribution enhancement result cost million announce september cash balance pension plan closed future accrual january change result credit million june september amendment retiree healthcare plan result credit million group apply follow financial assumption assess define benefit liability rest world rate increase future earning discount rate expect pension increase cash balance creditconversion rate inflation rate sensitivity analysis detail effect change assumption provide analysis provide reflect assumption change material impact result group gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue pension postemployment benefit continue amount record income statement statement comprehensive income year end december relation define benefit pension postretirement healthcare scheme follow postretirement pension benefit rest world group group amount charge operating profit current service cost past service costcredit net interest incomecost gain settlement expense remeasurement gainslosse record statement comprehensive income postretirement pension benefit rest world group group amount charge operating profit current service cost past service costcredit net interest incomecost gain settlement expense remeasurement loss record statement comprehensive income postretirement pension benefit rest world group group amount charge operating profit current service cost past service costcredit net interest incomecost gain settlement expense remeasurement gainslosse record statement comprehensive income amount include past service cost include million million million augmentation cost arise major restructuring programme charge million relation impact closure define benefit scheme future accrual past service cost include charge million relation estimate impact guarantee minimum pension gmp equalisation gmp minimum pension entitlement member scheme elect contract state earning relate pension scheme high court ruling require equalisation benefit earn include gmp order address gender inequality arise gmp different man woman past service credit million reflect closure cash balance pension plan january amendments retiree healthcare plan result credit million past service cost postretirement benefit gsk annual report note financial statement continue pension postemployment benefit continue summarise balance sheet presentation group define benefit pension scheme postretirement benefit set table recognise noncurrent asset pension scheme surplus recognise asset hold sale postretirement benefit recognise pension postemployment benefit pension scheme deficit postretirement benefit event plan windup gsk believe pension scheme rule provide company right refund surplus asset follow settlement plan liability result net surplus define benefit pension scheme recognise fair value asset liability define benefit pension scheme aggregate datum define benefit pension scheme group follow rest world group december equity list unlisted multiasset fund property list unlisted corporate bond list unlisted government bond list insurance contract liabilitiesasset fair value asset present value scheme obligation net surplusobligation include noncurrent asset include pension postemployment benefit actual return plan asset multiasset fund comprise investment pool investment vehicle invest range asset class increase diversification growth portfolio value fund asset class quote market price million million asset category comprise cash mark market value derivative position indexlinke gilt hold repo programme include government bond relate loan million december million nil deduct asset gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue pension postemployment benefit continue rest world group december equity list unlisted multiasset fund property list unlisted corporate bond list unlisted government bond list insurance contract liabilitiesasset fair value asset present value scheme obligation net surplusobligation include noncurrent asset include pension postemployment benefit actual return plan asset rest world group december equity list unlisted multiasset fund property list unlisted corporate bond list unlisted government bond list insurance contract asset fair value asset present value scheme obligation net surplusobligation include noncurrent asset include pension postemployment benefit actual return plan asset gsk annual report note financial statement continue pension postemployment benefit continue postretirement pension benefit rest world group group movement fair value asset asset january exchange adjustment interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution benefit pay asset december exchange adjustment addition business combination interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution benefit pay asset december exchange adjustment addition business combination interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution benefit pay asset december group special funding contribution pension scheme million million nil nil nil million scheme gsk reach revise agreement trustee pension scheme additional contribution eliminate pension deficit identify scheme december actuarial funding valuation base funding agreement additional contribution eliminate pension deficit expect million include note commitment fund commitment supersede previous agreement contribution base government bond yield curve approach select discount rate rate choose include allowance expect investment return reflect asset mix scheme employer contribution include special funding contribution estimate approximately million respect define benefit pension scheme million respect postretirement benefit gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue pension postemployment benefit continue postretirement pension benefit rest world group group movement define benefit obligation obligation january exchange adjustment service cost past service costcredit interest cost settlement curtailment remeasurement scheme participant contribution benefit pay obligation december exchange adjustment addition business combination service cost past service cost interest cost settlement curtailment remeasurement scheme participant contribution benefit pay obligation december exchange adjustment disposal service cost past service cost interest cost settlement curtailment remeasurement scheme participant contribution benefit pay obligation december define benefit pension obligation analyse follow fund unfunded liability postretirement healthcare scheme assess assumption pension scheme assumption future medical inflation grade december postretirement healthcare scheme obligation million million million postretirement benefit unfunded gsk annual report note financial statement continue pension postemployment benefit continue movement net define benefit liability follow january exchange adjustment addition business combination service cost past service cost interest cost settlement curtailment remeasurement return plan asset exclude amount include interest gain change demographic assumption lossgain change financial assumption experience gainslosse employer contribution expense december remeasurement include postretirement benefit detailed gain change demographic assumption lossgain change financial assumption experience gain define benefit pension obligation analyse membership category follow active retire defer postretirement benefit obligation analyse membership category follow active retired defer weight average duration define benefit obligation follow year year year pension benefit postretirement benefit gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue pension postemployment benefit continue sensitivity analysis effect change assumption benefit obligation annual define benefit pension post retirement cost detailed information determine take account duration liability overall profile plan membership increase decrease discount rate decreaseincrease annual pension cost increasedecrease annual postretirement benefit cost decreaseincrease pension obligation decreaseincrease postretirement benefit obligation increase decrease decreaseincrease annual pension cost increasedecrease annual postretirement benefit cost decreaseincrease pension obligation decreaseincrease postretirement benefit obligation increase decrease inflation rate increasedecrease annual pension cost increasedecrease pension obligation year increase life expectancy increase annual pension cost increase annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation increase rate future healthcare inflation increase annual postretirement benefit cost increase postretirement benefit obligation gsk annual report note financial statement continue provision legal major employee restructure relate dispute programme provision provision total january exchange adjustment charge year reverse unused unwind discount utilise reclassification movement transfer pension obligation december settle year settle year december legal dispute group potential settlement discussion number group involve substantial number legal dispute amount provide dispute include notification possible claim set base current assessment progress note legal proceeding provision legal dispute estimate million provide dispute include amount relate product liability antitrust december settle year government investigation contract termination self december expect million insurance million provision legal dispute reimburse party discussion net charge year million include reversal legal issue note legal proceeding estimate insurance recovery primarily relate provision product liability case commercial dispute major restructuring programme government investigation group major restructuring programme progress combined restructuring discount provision increase million integration programme substantially complete increase million discount calculate major restructure programme consumer riskadjuste project cash flow riskfree rate healthcare joint venture integration programme return separation preparation programme programme respect product liability claim relate certain product focus primarily simplify supply chain process provision sufficient history claim rationalise group manufacture network restructuring settlement enable management reliable pharmaceutical commercial operation integrate estimate provision require cover unasserted claim pfizer consumer healthcare business prepare ultimate liability matter vary amount separation gsk new company provide dependent outcome litigation restructure provision primarily include severance cost proceeding investigation possible settlement management formal decision eliminate negotiation certain position communicate nature group business number group employee affect appropriate consultation matter subject negotiation litigation procedure complete appropriate provision year litigation proceeding include staff severance payment pay immediately appeal procedure year reach resolution pension augmentation arise staff redundancie outofcourt settlement discussion million million charge protract indemnify dispute result provision year transfer pension obligation provision charge correspond receivable million relate define benefit plan million relate define contribution scheme show note pension postemployment benefit gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue provision continue employee relate provision give nature provision amount likely employee relate provision include obligation certain settle year medical benefit disabled employee spouse provision december provision benefit include provision insurance provision amount million million employee million million number benefit reflect variety provision severance cost provision include vehicle insurance regulatory matter jubilee awards longservice benefit contingent consideration liability consideration certain acquisition include amount contingent future event development milestone sale performance group provide fair value contingent consideration follow shionogi viiv novartis healthcare vaccine total january remeasurement income statement cash payment operate cash flow cash payment invest activity december remeasurement income statement cash payment operate cash flow cash payment invest activity movement december remeasurement income statement cash payment operate cash flow cash payment invest activity december contingent consideration payable december million million expect pay year consideration payable acquisition shionogiviiv healthcare joint venture novartis vaccine business expect pay number year result total estimate liability discount present value show shionogiviiv healthcare contingent consideration liability discount novartis vaccine contingent consideration liability discount commercialise product pipeline asset shionogiviiv healthcare novartis vaccine contingent consideration liability calculate principally base forecast sale performance specify product live product table show indicative basis income statement balance sheet sensitivity reasonably possible change key input valuation contingent consideration liability shionogi shionogi viiv novartis viiv novartis healthcare vaccine healthcare vaccine increasedecrease financial liability lossgain income statement increase sale forecast decrease sale forecast increase discount rate decrease discount rate increase probability milestone success decrease probability milestone success cent appreciation dollar cent depreciation dollar cent appreciation euro cent depreciation euro explanation accounting viiv healthcare set gsk annual report note financial statement continue noncurrent liability accrual defer income payable payable include number employeerelate liability include employee saving plan contingent liability december contingent liability gsk present obligation result past event comprise guarantee discount bill item arise normal course business amount million million contingent liability arise group present obligation arise past event december million million financial asset pledge collateral contingent liability provision outcome tax legal dispute probable group suffer outflow fund possible reliable estimate outflow december dispute provision possible reliable estimate potential outflow fund require settle dispute possibility outflow remote description significant legal dispute group party set note legal proceeding commitment contractual obligation commitment contract provide financial statement intangible asset property plant equipment investment purchase commitment pension interest loan future finance charge lease commitment related intangible asset include milestone payment dependent successful clinical development meeting specify sale target represent maximum pay milestone unlikely achieve amount riskadjuste discount increase intangible commitment mainly attributable number new collaboration include curevac ideaya bioscience surface oncology gsk reach agreement trustee pension scheme additional contribution eliminate pension deficit identify december actuarial funding valuation payment million table include commitment exclude normal ongoing annual funding requirement approximately million group commitment principally relate revenue payment licence alliance commitment respect future interest payable loan disclose take account effect interest rate swap gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue share capital share premium account share ordinary share premium number share capital issue fully pay january issue employee share scheme december issue employee share scheme ordinary share acquire esop trust december issue employee share scheme ordinary share acquire esop trust december december december number share issuable employee share scheme number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme gsk annual report note financial statement continue movement equity retain earning reserve amount million december million million loss million million million relate associate joint venture cumulative translation exchange equity follow net translation exchange include non total retain fair value control translation earning reserve interests exchange january exchange movement overseas net asset december report adjustment exchange movement overseas net asset december revise exchange movement overseas net asset reclassification exchange movement liquidation disposal overseas subsidiary december exchange movement overseas net asset reclassification exchange movement liquidation disposal overseas subsidiary december analysis comprehensive income equity category follow non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal overseas subsidiary fair value movement cash flow hedge reclassification cash flow hedge income expense tax fair value movement cash flow hedge item reclassify income statement exchange movement overseas net asset noncontrolle interest fair value movement equity investment tax fair value movement equity investment remeasurement loss define benefit plan tax remeasurement loss define benefit plan comprehensive expenseincome year non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal overseas subsidiary fair value movement cash flow hedge reclassification cash flow hedge income expense tax fair value movement cash flow hedge item reclassify income statement exchange movement overseas net asset noncontrolle interest fair value movement equity investment tax fair value movement equity investment remeasurement gain define benefit plan tax remeasurement gain define benefit plan comprehensive expenseincome year gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue movement equity continue non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge fair value movement cash flow hedge reclassification cash flow hedge income expense tax fair value movement cash flow hedge defer tax reverse reclassification cash flow hedge item reclassify income statement exchange movement overseas net asset noncontrolle interest fair value movement equity investment tax fair value movement equity investment remeasurement gain define benefit plan tax remeasurement gain define benefit plan comprehensive incomeexpense year information net investment hedge provide note financial instrument relate disclosure analysis reserve follow esop trust fair value cash flow share reserve hedge reserve reserves total january exchange adjustment transfer retain earning year disposal equity investment net fair value movement year writedown share hold esop trust december exchange adjustment transfer retain earning year disposal equity investment net fair value movement year ordinary share acquire esop trust writedown share hold esop trust december exchange adjustment transfer retain earning year disposal equity investment net fair value movement year ordinary share acquire esop trust writedown share hold esop trust december reserve include nondistributable merger premerger reserve amount million december million million reserve include capital redemption reserve create result share buyback programme amount million december million million gsk annual report note financial statement continue noncontrolle interest total noncontrolle interest includes follow individually material noncontrolle interest noncontrolle interest individually material viiv healthcare gsk hold viiv healthcare subgroup give rise material noncontrolle interest summarise financial information respect viiv healthcare subgroup follow turnover profit taxation comprehensive incomeexpense total comprehensive income noncurrent asset current asset total asset current liability noncurrent liability total liability net liability net cash inflow operating activity net cash outflow investing activity net cash outflow financing activity decreaseincrease cash bank overdraft year financial information relate viiv healthcare group standalone basis impact grouprelate adjustment primarily relate recognition preferential dividend profit taxation million million million state charge preferential dividend payable gsk shionogi pfizer charge million million million remeasurement contingent consideration payable consideration expect pay number year follow amount attributable viiv healthcare group include gsk financial statement share profit year attributable noncontrolle interest dividend pay noncontrolle interest noncontrolle interest consolidate balance sheet gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue noncontrolle interest continue consumer healthcare joint venture gsk hold consumer healthcare subgroup give rise material noncontrolle interest summarise financial information respect consumer healthcare subgroup follow turnover profit taxation comprehensive expense total comprehensive incomeexpense noncurrent asset current asset total asset current liability noncurrent liability total liability net asset net cash inflow operating activity net cash inflowoutflow investing activity net cash outflow financing activity increase cash bank overdraft yearperiod financial information relate consumer healthcare joint venture standalone basis year end december period formation july december impact grouprelate adjustment classification cash pooling account group company outside consumer healthcare joint venture major restructuring charge follow amount attributable consumer healthcare joint venture include gsk financial statement share profit yearperiod attributable noncontrolle interest dividend pay noncontrolle interest noncontrolle interest consolidate balance sheet gsk annual report note financial statement continue related party transaction december gsk own million share innoviva inc biopharmaceutical company list nasdaq gsk begin recognise innoviva associate september royalty gsk innoviva year million million december balance payable gsk innoviva million million loan million medicxi venture remain gsk december loan index venture life jersey repay year gsk increase investment kurma biofund fcpr million apollo therapeutic llp million investment medicxi venture million joint venture agreement qura therapeutics llc group obligation fund joint venture million quarter april june agreement extend second fiveyear period april gsk joint venture partner commit additional financial support million december outstanding liability qura million cash distribution receive investment medicxi venture million index venture jersey million aggregate compensation director cet give note employee cost acquisition disposal detail acquisition disposal significant subsidiary associate joint venture business give business acquisition gsk complete small business acquisition acquire pfizer biotech corporation taiwan pfizer consumer healthcare business previously recognise consumer healthcare joint venture september non cash consideration million represent goodwill million cash million asset acquire million noncontrolling interest million net liability million total net asset acquire intangible asset property plant equipment inventory trade receivables cash cash equivalent trade payable noncontrolle interest goodwill noncash consideration settlement promissory note total consideration business disposal april gsk complete divestment horlick consumer healthcare nutrition product india number country exclude bangladesh unilever merger gsk indian list consumer healthcare entity hindustan unilever indian list public company gsk receive equity stake hindustan unilever million cash gsk dispose equity stake hindustan unilever divestment bangladesh closed june total cash consideration receive million cash divest disposal india bangladesh consumer healthcare entity million gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue acquisition disposal continue profit disposal business year million calculate follow horlick divestment total consideration cash consideration receivable include currency forward purchase adjustment equity investment hindustan unilever limited total net asset dispose goodwill intangible asset property plant equipment inventory cash cash equivalent net liabilitiesasset total cost transaction cost derivative reclassification exchange comprehensive income total gain disposal exposure share price movement embed agreement merge gsk indian list consumer healthcare entity hindustan unilever limited divestment horlick nutrition product india number country recognise derivative signing agreement completion transaction million record cost table derecognition derivative asset largely reflect fair value gain recognise income statement prior period associates joint ventures year gsk investment associate million million pay cash cash flow associate joint business business venture acquisition disposal investment cash consideration receivedpaid net defer consideration transaction cost cash cash equivalent acquireddiveste cash inflowoutflow gsk annual report note financial statement continue acquisition disposal continue business acquisition pfizer consumer healthcare business acquisition pfizer consumer healthcare business complete july gsk pfizer contribute respective consumer healthcare business new consumer healthcare joint venture noncash transaction gsk acquire pfizer consumer healthcare business return share joint venture gsk equity interest majority control joint venture pfizer equity interest group control consumer healthcare joint venture consolidate group financial statement number territory legal completion acquisition occur regulatory constraint consumer healthcare joint venture obtain control majority business territory july consolidate net asset business date case entitle benefit trading business delay territory noncontrolle interest consumer healthcare joint venture calculate apply proportionate goodwill method represent pfizer share net asset joint venture exclude goodwill goodwill billion expect deductible tax purpose recognise goodwill represent potential synergy arise combine acquire business gsk exist business value workforce acquire total transaction cost recognise acquisition amount million acquisition july sale billion arise pfizer consumer healthcare business include group turnover business acquire beginning year estimate group turnover approximately billion high business integrate group exist activity practicable identify impact group profit period tesaro inc january gsk acquire tesaro inc oncology focus biopharmaceutical company cash consideration billion billion order strengthen group pharmaceutical pipeline transaction cost amount million goodwill billion expect taxdeductible recognise goodwill represent potential synergy arise combine acquire business gsk exist business value workforce acquire acquisition january december sale billion arise tesaro business include group turnover business integrate group exist activity practicable identify impact group profit period fair value asset acquire business combination include goodwill set table amount relate pfizer consumer healthcare business acquisition provisional subject change pfizer consumer healthcare business tesaro net asset acquire intangible asset property plant equipment right use asset inventory trade receivables asset include cash cash equivalent trade payable net defer tax liability liabilitie term loan noncontrolle interest goodwill total consideration settle share gsk consumer healthcare joint venture cash consideration pay fair value investment joint venture convert subsidiary total consideration gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue acquisition disposal continue noncontrolle interest million represent pfizer share fair value pfizer consumer healthcare business exclude goodwill total noncontrolle interest initially recognise consolidated statement change equity million include pfizer share book value gsk consumer healthcare business disposal gsk number business disposal net cash consideration receive year million profit disposal business year million calculate follow total cash consideration receivable net subsidy payable net asset dispose goodwill intangible asset property plant equipment inventory cash cash equivalent net asset transaction cost reclassification exchange comprehensive income noncontrolle interest divest transaction sign complete gain embed derivative transaction sign complete transaction cost total profit disposal transaction sign complete december december gsk agree divest horlick consumer healthcare nutrition brand unilever plc form merger glaxosmithkline consumer healthcare limit hindustan unilever limited total consideration value approximately billion glaxosmithkline consumer healthcare limited public company list national stock exchange nse bombay stock exchange bse gsk hold stake follow merger glaxosmithkline consumer healthcare limit hindustan unilever limited public company list nse bse gsk million hindustan unilever limited share group enter forward foreign exchange contract relation transaction contract value billion designate cash flow hedge foreign exposure arise transaction contract value billion designate net investment hedge inr eur asset addition exposure share price movement forward purchase share hindustan unilever limited recognise embed derivative embed derivative asset position fair value million december million associate joint venture year gsk investment million associate joint venture million pay cash cash flow associate joint business business venture acquisition disposal investment cash consideration paidreceive net defer consideration receive transaction cost cash cash equivalent acquireddiveste cash outflowinflow gsk annual report note financial statement continue business acquisition business acquisition business disposal gsk number small business disposal year net cash consideration million cash flow associate associate joint joint business venture venture disposal investment disposal cash consideration net defer consideration receive cash inflowoutflow adjustment reconcile profit tax operating cash flow profit tax tax profit share aftertax profit associate joint venture finance expense net finance income depreciation amortisation intangible asset impairment asset write profit sale business profit sale intangible asset profit sale investment associate profit sale equity investment gain novartis consumer healthcare joint venture option hedge business acquisition cost change work capital decrease inventory increase trade receivables increase trade payable increasedecrease receivables contingent consideration pay note noncash increase contingent consideration liability increase payables increasedecrease pension provision sharebase incentive plan fair value adjustment cash generate operation gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue reconciliation net cash flow movement net debt net debt previously report implementation ifrs net debt begin year adjust increase cash bank overdraft increasedecrease liquid investment increase longterm loan repayment shortterm note repayment ofincrease shortterm loan repayment lease liability debt subsidiary undertaking acquire exchange adjustment noncash movement movement net debt net debt end year january profit reclass december exchange loss ification cash flow analysis change net debt liquid investment cash cash equivalent cash cash equivalent ahfs overdraft debt year commercial paper europeanu medium term note bank facility lease liability debt year europeanu medium term note bank facility lease liability net debt analysis change liability finance activity debt year debt year derivative financial instrument finance item interest payable total liability financing activity ifrs january implement debt profit reclass december ation exchange acquire loss ification cash flow analysis change liability finance activity debt year debt year derivative financial instrument finance item interest payable total liability financing activity information significant change net debt note net debt gsk annual report note financial statement continue financial instrument relate disclosure objective gsk treasury activity minimise facility undrawn december gsk posttax net cost financial operation reduce volatility consider level commit facility adequate give benefit earning cash flow gsk use variety current liquidity requirement financial instrument finance operation derivative repayment additional bank facility agree financial instrument manage market risk support transaction complete remain active operation derivative principally comprise foreign exchange december june billion draw forward contract swap swap support acquisition novartis remain stake borrowing liquid asset currency require group consumer healthcare joint venture billion repay purpose interest rate swap november billion repay manage exposure financial risk change interest rate financial instrument reduce uncertainty gsk billion euro medium term note programme foreign currency transaction interest payment december billion note issue programme group billion derivative exclusively hedge purpose billion note issue december relation underlie business activity trade shelf registration gsk borrowing mature date speculative instrument capital management option own pfizer viiv healthcare gsk financial strategy support group strategic exercisable review liquidity requirement gsk consider priority regularly review board gsk manage sufficient financing option available capital structure group appropriate mix option exercise debt equity market risk capital structure group consist net debt interest rate risk management billion note net debt total equity objective gsk treasury activity minimise include item relate noncontrolle interest effective net interest cost balance mix debt fix billion consolidated statement change float rate time equity total capital include provide noncontrolle interest billion group main interest rate risk arise borrowing investment float rate refinance mature fix group continue manage financial policy credit rate debt change interest rate affect future profile particularly target shortterm credit rating cash flow fair value financial instrument policy maintain single longterm rating consistent interest rate risk management limit net target group longterm credit rating float rate debt specific cap review agree standard poor stable outlook moodys annually board investor service moodys negative outlook group shortterm credit rating standard majority debt issue fix interest rate poor moodys respectively change float rate interest significantly affect group net interest charge include liquidity risk management borrowing interest rate swap place gsk policy borrow centrally order meet anticipate remove impact associate periodic repricing funding requirement strategy diversify liquidity shortterm borrowing include bank facility expose source range facility maintain broad access risk future change market interest rate financial market majority cash liquid investment december gsk billion borrowing repayable year hold billion cash interest rate benchmark reform cash equivalent liquid investment billion interest rate benchmark reform amendment ifrs hold centrally gsk access shortterm finance ias ifrs issue iasb september billion billion commercial paper amendment modify specific hedge accounting programme million million issue requirement allow hedge accounting continue december billion billion gsk affect hedge period uncertainty access shortterm finance billion euro hedge item hedge instrument affect current commercial paper programme newly establish interest rate benchmark amend result nil issue december gsk billion ongoing interest rate benchmark reform threeyear commit facility billion billion december group directly expose day commit facility year commit facility interest rate benchmark reform hold interest rate agree september extend year derivative reference libor mature end september day commit facility float rate bond mature agree september end gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue group closely monitor market output group consider maximum credit risk december industry work group manage million december transition new benchmark interest rate include million total group financial announcement libor regulator include asset exception investment comprise financial conduct authority fca commodity equity investment bear equity risk credit future trading commission transition away risk detail group total financial libor include gbp libor usd libor assets december gsk great concentration euribor sterle overnight index average rate credit risk billion legal general sonia secure overnight financing rate sofr investment management class gbp liquidity fund aaaaaa euro shortterm rate str respectively fca billion legal general investment clear end long management class gbp liquidity fund aaaaaa seek persuade compel bank submit libor change estimation technique exception usd libor significant assumption current reporting intercontinental exchange ice benchmark administration period assess loss allowance financial asset iba fcaregulate authorise administrator amortise cost adoption ifrs start libor announce consult intention reporting period cease libor iba intend subject confirmation follow consultation week month treasuryrelate credit risk libor setting cease end gsk set global counterparty limit gsk bank libor panel cease end june investment counterpartie base longterm credit rating moodys standard poor usage group undertake interest rate benchmark transition limit actively monitor programme identify potential exposure business deliver smooth transition appropriate alternative gsk actively manage exposure credit risk reduce benchmark rate surplus cash balance possible gsk strategy regionalise cash management concentrate foreign exchange risk management cash centrally possible table set group objective minimise exposure overseas credit exposure counterpartie rate liquid operating subsidiary transaction risk match local investment cash cash equivalent derivative currency income local currency cost possible foreign currency transaction exposure arise external gross asset position derivative contract internal trade flow selectively hedge gsk internal consider purpose table isda trading transaction match centrally intercompany agreement risk net position payment term manage reduce foreign currency risk counterparty table set group possible gsk manage cash surplus financial asset liability offset basis borrowing requirement subsidiary company centrally december million cash categorise forward contract hedge future repayment hold unrated subinvestment grade rate counterpartie originate currency low bbbbaa million cash transit order reduce foreign currency translation exposure remain exposure concentrate overseas bank group seek denominate borrowing currency local cash management investment purpose include principal asset cash flow primarily million nigeria hold united bank africa zenith denominate dollar euro sterling borrowings bank stanbic ibtc bank million halk bank swap currency require million btv austria million banco itau brazil million banco nacion panama million borrowing denominate swap foreign hatton national bank sri lanka million hua nan currencies match investment overseas group assets bank taiwan million banco popular puerto treat hedge relevant asset forward rico million bank balance deposit hold contract major currency reduce exposure bbbbaa rate counterpartie million hold group investment overseas asset net bbbbaa rate counterpartie include balance investment hedge section note detail deposit million hdfc bank india million credit risk state bank india bank local credit risk risk counterparty default investment purpose contractual obligation result financial loss group gsk measure expect credit loss cash cash arise cash cash equivalent favourable equivalent function individual counterparty credit rating derivative financial instrument hold bank financial associate month default rate expect credit loss institution credit exposure wholesale retail cash cash equivalent thirdparty financial customer include outstanding receivables derivative deem immaterial loss experienced gsk annual report note financial statement continue financial instrument relate disclosure continue credit rating assign standard poor moodys respectively opinion rating agency differ gsk assign low rating counterparty local rating agency fitch datum source available rating convert global rating equivalent standard poor moodys publish conversion table credit rating form basis assessment expect credit loss treasuryrelate balance hold amortise cost bank balance deposit government security bbba aaaaaa aaaa bbbbaa unrated total bank balance deposit treasury treasury repo money market fund liquidity fund government security party financial derivative total bbba aaaaaa aaaa bbbbaa unrated total bank balance deposit treasury treasury repo money market fund liquidity fund government security party financial derivative total gsk centrally manage cash reserve amount new customer subject credit vetting process billion december available exist customer subject review annually month include billion cash manage vetting process subsequent review involve obtain group viiv healthcare own subsidiary information include customer status government billion cash manage group gsk consumer private sector entity audit financial statement credit bureau healthcare own subsidiary group invest report debt rating agency moodys standard poor centrally manage liquid asset bank deposit aaaaaa report payment performance history trade reference rate treasury treasury repo money market fund industry credit group bank reference aaaaaa rate liquidity fund trade receivables consist amount large number wholesale retail credit risk customer spread diverse industry outside customer account geographical area ongoing credit evaluation perform group trade receivable balance financial condition account receivable appropriate credit insurance purchase factor line pharmaceutical company arrangement place group sell product small number wholesaler addition hospital pharmacie physician information obtain proportional level group sale large wholesaler amount exposure consider information evaluate approximately sale quantitatively credit score qualitatively judgement pharmaceutical vaccine business conjunction customer credit requirement december group trade receivable determine credit limit wholesaler total million trade receivables group customer segment million group expose concentration similar loss pattern assess credit risk credit risk respect wholesaler receivables financial asset assess individually encounter financial difficulty materially historical forwardlooking information consider adversely affect group financial result determine appropriate expect credit loss allowance group credit risk monitoring activity relate group believe credit risk provision wholesaler include review quarterly financial require excess allowance expect credit loss information standard poor credit rating development note trade receivables gsk internal risk rating establishment periodic review credit limit gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue credit enhancement follow method assumption estimate group use credit enhancement include factor fair value significant financial instrument credit insurance minimise credit risk trade measure fair value balance sheet receivables group december million companyowne life insurance policy base cash million trade receivables insure surrender value order protect receivables loss credit risk default insolvency bankruptcy receivables payable include option carry amortise cost approximate carry group entity assess credit risk private customer determine credit insurance require liquid investment approximate carry factoring arrangement manage locally entity cash cash equivalent carry amortise cost mitigate risk arise large credit risk approximate carry concentration factoring arrangement nonrecourse longterm loan base quote market price level fair value financial asset liability exclude lease fair value measurement case european liability medium term note approximate carry table present carry amount case fix rate borrowing float rate bank fair value group financial asset liability loan exclude lease liability december shortterm loan overdraft commercial paper december approximate carry short fair value financial asset liability include maturity instrument price receive sell asset pay transfer liability orderly transaction market participant measurement date follow method assumption measure fair value significant financial instrument carry fair value balance sheet investment equity investment trade active market determine reference relevant stock exchange quote bid price equity investment determine reference current market value similar instrument recent financing round discount cash flow underlie net asset trade receivable carry fair value base invoice interest rate swap foreign exchange forward contract swap option base present value contractual cash flow option valuation model market source datum exchange rate interest rate balance sheet date cash cash equivalent carry fair value base net asset value fund contingent consideration business acquisition divestment base present value expect future cash flow gsk annual report note financial statement continue financial instrument relate disclosure continue carry fair carry fair value value value value note financial asset measure amortise cost noncurrent asset trade receivables liquid investment cash cash equivalent item asset hold sale financial asset measure fair value comprehensive income fvtoci investment designate fvtoci trade receivables financial asset mandatorily measure fair value profit loss fvtpl investment noncurrent assets trade receivables hold trading derivative designate effective hedge relationship ade cash cash equivalent derivative designate effective hedging instrument fair value movement comprehensive income ade total financial asset financial liability measure amortise cost borrowing exclude obligation lease liability bond designate hedge relationship bond bank loan overdraft commercial paper borrowing total borrowing exclude lease liability trade payable provision noncurrent liability item asset hold sale financial liability mandatorily measure fair value profit loss fvtpl contingent consideration liability hold trading derivative designate effective hedge relationship ade derivative designate effective hedging instrument fair value movement comprehensive income ade total financial liability exclude lease liability net financial asset financial liability exclude lease liability valuation methodology measure fair value table describe categorise trade receivables noncurrent asset trade payable provision noncurrent liability contingent consideration liability item asset hold sale reconcile relevant note page december cash cash equivalent table include million report asset hold sale note asset hold sale gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue fair value investment gsk share december employee share ownership plan esop trust hold gsk share carry value million million market value million million base quote market price share hold esop trust satisfy future exercise option award employee incentive scheme carry value low cost expect proceed share recognise deduction reserve december gsk hold treasury share cost million million deduct retain earning financial instrument hold fair value follow table categorise group financial asset liability hold fair value valuation methodology apply determine fair value possible quote price active market level price available asset liability classify level provide significant input valuation model base observable market datum significant input valuation model base observable market datum instrument classified level investment classify level table comprise equity investment unlisted entity group enter research collaboration investment emerge life science company level level level total december financial asset fair value financial asset measure fair value comprehensive income fvtoci investment designate fvtoci trade receivables financial asset mandatorily measure fair value profit loss fvtpl investment noncurrent asset trade receivable hold trading derivative designate effective hedge relationship cash cash equivalent derivative designate effective hedging instrument fair value movement oci financial liability fair value financial liability mandatorily measure fair value profit loss fvtpl contingent consideration liability hold trading derivative designate effective hedging relationship derivative designate effective hedging instrument fair value movement oci level level level total december financial asset fair value financial asset measure fair value comprehensive income fvtoci investment designate fvtoci trade receivables financial asset mandatorily measure fair value profit loss fvtpl investment noncurrent asset trade receivable hold trading derivative designate effective hedge relationship cash cash equivalent derivative designate effective hedging instrument fair value movement oci financial liability fair value financial liability mandatorily measure fair value profit loss fvtpl contingent consideration liability hold trading derivative designate effective hedging relationship derivative designate effective hedging instrument fair value movement oci gsk annual report note financial statement continue financial instrument relate disclosure continue movement year financial instrument measure level valuation method present january net loss recognise income statement net gain recognise comprehensive income settlement contingent consideration liability settlement contingent consideration receivables addition disposal settlement transfer level movement december net loss million million attributable level financial instrument recognise income statement include net loss million million respect financial instrument hold end year loss million million report operating income gain nil million report finance income charge million million arise remeasurement contingent consideration payable acquisition shionogiviiv healthcare joint venture million million arise remeasurement contingent consideration payable acquisition novartis vaccine business net gain million million attributable level financial instrument report comprehensive income fair value movement equity investment include net gain million net gain million respect financial instrument hold end year net gain million net gain million arise prior transfer level equity investment transfer level valuation methodology result list recognise stock exchange year net gain loss include impact exchange movement financial liability measure level valuation method december include million million respect contingent consideration payable acquisition shionogiviiv healthcare joint venture consideration expect pay number year vary line future performance specify product movement certain foreign currency include million million respect contingent consideration acquisition novartis vaccine business consideration expect pay number year vary line future performance specify product achievement certain milestone target movement certain foreign currency sensitivity analysis balance provide note contingent consideration liability trade receivables noncurrent asset item asset hold sale scope ifrs follow table reconcile financial instrument trade receivables noncurrent asset item asset hold sale fall scope ifrs relevant balance sheet amount financial asset predominantly noninterest earn nonfinancial instrument include tax receivables pension surplus balance prepayment outside scope ifrs non non amortise financial financial amortise financial financial fvtpl fvtoci cost instrument instrument total fvtpl fvtoci cost instrument instrument total trade receivable note noncurrent asset note item asset hold sale note trade receivables include trade receivables million million group portfolio business model ifrs factoring arrangement place million million hold sell contractual cash flow measure fvtpl million million hold collect sell contractual cash flow measure fvtoci million million hold collect contractual cash flow measure amortise cost december item asset hold sale include million trade receivables measure amortise cost gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue trade payable provision noncurrent liability contingent consideration liability item asset hold sale scope ifrs follow table reconcile financial instrument trade payable provision noncurrent liability contingent consideration liability item asset hold sale fall scope ifrs relevant balance sheet amount financial liability predominantly noninterest bear accrue wage salary include financial liability nonfinancial instrument include payment account tax social security payable provision arise contractual obligation deliver cash financial asset outside scope ifrs non non amortise financial financial amortise financial financial fvtpl cost instrument instrument total fvtpl cost instrument instrument total trade payable note provision note noncurrent liability note contingent consideration liability note item asset hold sale note derivative financial instrument hedge programme derivative economic hedging purpose speculative investment classify hold trading designate effective hedging instrument present current asset liability expected settle month end reporting period classified noncurrent group follow derivative financial instrument fair value fair value asset liability asset liabilitie noncurrent cash flow hedge interest rate swap contract principal nil million net investment hedge cross currency swap principal nil million current cash flow hedge interest rate swap contract principal million million net investment hedge cross currency swap principal million nil cash flow hedge foreign exchange contract principal million million net investment hedge foreign exchange contract principal million million derivative designate effective hedging instrument noncurrent embed derivative current foreign exchange contract principal million million embed derivative derivative classify hold trading total derivative instrument fair value hedge december december group designate fair value hedge gsk annual report note financial statement continue financial instrument relate disclosure continue net investment hedge december certain foreign exchange contract designate net investment hedge respect foreign currency translation risk arise consolidation group net investment european euro singaporean sgd japanese jpy foreign operation show table carry value bond include million million designate hedging instrument net investment hedge cash flow hedge group enter forward foreign exchange contract designate cash flow hedge enter hedge foreign exchange exposure arise cash flow euro denominate coupon payment relate note issue group european medium term note programme buyout novartis noncontrolle interest consumer healthcare joint venture divestment horlick nutrition brand take place refinance exist debt maturity group manage cash flow interest rate risk floatingtofixed interest rate swap addition group carry balance reserve arise prehedge fluctuation longterm interest rate pricing bond issue prior year current year balance reclassify finance cost life bond foreign exchange risk current year group designate certain foreign exchange forward contract swap cash flow net investment hedge foreign exchange derivative financial asset liability present line derivative financial instrument asset liability consolidate balance sheet follow table detail foreign exchange forward contract swap outstanding end report period information relate hedge item notional value foreign exchange forward contract swap absolute total outstanding position balance sheet date hedge effectiveness determined inception hedge relationship periodic prospective effectiveness assessment ensure economic relationship exist hedge item hedging instrument group enter hedge relationship critical term hedge instrument match exactly term hedge item qualitative assessment effectiveness perform change circumstance affect term hedge item critical term long match exactly critical term hedge instrument group use hypothetical derivative method assess effectiveness main source hedge ineffectiveness hedging relationship effect counterparty group credit risk fair value foreign exchange forward contract swap reflect fair value hedge item attributable change foreign exchange rate ineffectiveness roll cash flow hedge divestment mention source ineffectiveness emerge hedging relationship ineffectiveness record cash flow hedge amount gain million loss million ineffectiveness record net investment hedge nil include table borrowing bond notional value million swap fix interest rate eur debt cross currency interest rate swap notional carry average foreign value value hedge instrument exchange rate currency cash flow hedge foreign exchange contract buy foreign currency month eur gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue notional carry average foreign value value hedge instrument exchange rate currency net investment hedge foreign exchange contract sell foreign currency month eur month sgd month jpy borrowing include cross currency interest rate swap month eur month eur cumulative balance cash periodic change value flow hedge reserveforeign calculate hedge currency translation reserve ineffectiveness continue hedge hedge item cash flow hedge variability cash flow highly probable forecast transaction variability cash flow foreign exchange exposure arise euro denominate coupon payment relate debt issue net investment hedge net investment foreign operation balance cash flow hedge reserve arise hedge relationship hedge accounting long apply average foreign notional carry exchange rate currency value value hedge instrument cash flow hedge foreign exchange contract buy foreign currency month eur months eur sell foreign currency month inrgbp month inrsgd net investment hedge foreign exchange contract sell foreign currency month eur month sgd month inr month jpy borrowing include cross currency interest rate swap month eur month eur gsk annual report note financial statement continue financial instrument relate disclosure continue cumulative balance cash periodic change value flow hedge reserveforeign calculate hedge currency translation reserve ineffectiveness continue hedge hedge item cash flow hedge variability cash flow highly probable forecast transaction variability cash flow foreign exchange exposure arise euro denominate coupon payment relate debt issue net investment hedge net investment european foreign operation balance cash flow hedge reserve arise hedge relationship hedge accounting long apply follow table detail effectiveness hedge relationship amount reclassify hedging reserve profit loss reclassify profit loss line item hedge hedge profit future cash line item hedge ineffectiveness loss flow gainslosse gainslosse hedge long hedge reclassification recognise recognise ineffectiveness expect item affect adjustment reserve profit loss include occur profit loss include cash flow hedge variability cash flow highly probable forecast transaction operate operate income income expense expense variability cash flow foreign exchange exposure arise finance finance euro denominate coupon payment relate debt issue income income expense expense net investment hedge net investment foreign operation finance finance income income expense expense follow table detail effectiveness hedge relationship amount reclassify hedging reserve profit loss reclassify profit loss line item hedge hedge profit future cash line item hedge ineffectiveness loss flow gainslosse gainslosse hedge long hedge reclassification recognise recognise ineffectiveness expect item affect adjustment reserve profit loss include occur profit loss include cash flow hedge variability cash flow highly probable forecast transaction operate operate income income expense expense variability cash flow foreign exchange exposure arise finance finance euro denominate coupon payment relate debt issue income income expense expense net investment hedge net investment foreign operation finance finance income income expense expense gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue interest rate risk group manage cash flow interest rate risk floatingtofixed interest rate swap quarterly interval difference fix contract rate float rate interest amount calculate reference agree notional principal amount exchange interest rate swap contract exchange float rate interest fix interest designate cash flow hedge hedge variability interest cash flow associate float rate debt relate note issue group european medium term note programme interest rate swap interest payment loan occur simultaneously accumulate equity reclassify profit loss period float rate interest payment affect profit loss critical term interest rate swap contract correspond hedged item qualitative assessment effectiveness perform expect value interest rate swap contract value correspond hedge item systematically change opposite direction response movement underlie interest rate main source ineffectiveness hedge relationship effect group credit risk fair value interest rate swap contract reflect fair value hedge item attributable change interest rate source ineffectiveness emerge hedging relationship follow table provide information interest rate swap contract outstanding related hedge item december december interest rate swap contract asset liability present line derivative financial instrument asset liability consolidate balance sheet change fair value average notional recognise fair value contract fix principal hedge asset rate value ineffectiveness liability hedge instrument year year change value balance cash flow hedge calculate reserve hedge continue ineffectiveness hedge hedge item variable rate borrowing change fair value average notional recognise fair value contract fix principal hedge asset rate value ineffectiveness liability hedge instrument year year change value balance cash flow hedge calculate reserve hedge continue ineffectiveness hedge hedge item variable rate borrowing gsk annual report note financial statement continue financial instrument relate disclosure continue follow table detail effectiveness hedge relationship amount reclassify hedging reserve profit loss reclassify profit loss line item hedge profit future cash line item hedge hedge loss flow gainslosse ineffectiveness hedge long hedge reclassification recognise recognise ineffectiveness expect item affect adjustment reserve profit loss include occur profit loss include cash flow hedge variability cash flow finance finance income income expense expense prehedge longterm interest rate finance finance income income expense expense reclassify profit loss line item hedge profit future cash line item hedge hedge loss flow gainslosse ineffectiveness hedge long hedge reclassification recognise recognise ineffectiveness expect item affect adjustment reserve profit loss include occur profit loss include cash flow hedge variability cash flow finance finance income income expense expense prehedge longterm interest rate finance finance income income expense expense offset financial asset liability financial asset liability offset net report balance sheet legally enforceable right offset recognise amount intention settle net basis realise asset settle liability simultaneously arrangement meet criterion offset allow related amount offset certain circumstance bankruptcy termination contract follow table set financial asset liability offset subject enforceable master netting arrangement similar agreement offset december december column net show impact group balance sheet offset right exercise gross financial financial liability net financial relate asset asset asset amount net liability offset liability offset december financial asset trade receivables derivative financial instrument financial liability trade payable derivative financial instrument gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue gross financial financial liability net financial relate asset asset asset amount net liability offset liability offset balance december financial asset trade receivables derivative financial instrument financial liability trade payable derivative financial instrument amount meet criterion offset balance sheet settle net certain circumstance principally relate derivative transaction isda international swap derivative association agreement party option settle amount net basis event default party presently legally enforceable right offset amount offset balance sheet present separately table debt interest rate repricing table follow table set exposure group interest rate debt include commercial paper maturity analysis fix rate debt state contractual maturity float rate debt interest rate repricing date purpose table debt define class borrowing lease liability total debt total float fix rate debt year year year year year year great year total original issuance profile fix rate interest float rate interest gsk annual report note financial statement continue financial instrument relate disclosure continue sensitivity analysis table illustrate estimate impact income statement equity result hypothetical market movement foreign exchange interest rate relation group financial instrument range variable choose sensitivity analysis reflect management view change reasonably possible oneyear period foreign exchange sensitivity group operate internationally primarily expose foreign exchange risk relation sterling movement dollar euro japanese yen foreign exchange risk arise translation financial asset liability functional currency entity hold base group net financial asset liability december weaken strengthen sterling currency variable hold constant illustrate table table exclude financial instrument expose group foreign exchange risk risk fully hedge financial instrument increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposure cent appreciation dollar cent appreciation euro yen appreciation yen increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposure cent depreciation dollar cent depreciation euro yen depreciation yen equity impact show foreign exchange sensitivity relate derivative nonderivative financial instrument hedge group net investment european euro foreign operation cash flow hedge foreign exchange exposure arise euro denominate coupon payment relate note issue group european medium term note programme increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposure cent appreciation euro increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposure cent depreciation euro gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue table present group sensitivity weakening strengthen sterle relevant currency base composition net debt show note adjust effect foreign exchange derivative net debt affect future foreign currency cash flow increasedecrease increasedecrease net debt net debt impact foreign exchange movement net debt cent appreciation dollar cent appreciation euro yen appreciation yen increasedecrease increasedecrease net debt net debt impact foreign exchange movement net debt cent depreciation dollar cent depreciation euro yen depreciation yen interest rate sensitivity group expose interest rate risk outstanding borrowing investment change interest rate affect future cash flow fair value financial instrument majority debt issue fix interest rate change float rate interest significantly affect group net interest charge majority cash liquid investment earn float rate interest table hypothetically show group sensitivity change interest rate relation sterling dollar euro float rate financial asset liabilitie interest rate applicable float rate financial asset liability increase basis point assume variable remain constant estimate group finance income increase approximately million million decrease basis point movement interest rate deem material effect equity increasedecrease increasedecrease income income income statement impact interest rate movement basis point increase sterling interest rate basis point increase dollar interest rate basis point increase euro interest rate gsk annual report note financial statement continue financial instrument relate disclosure continue contractual cash flow nonderivative financial liability derivative instrument follow table provide analysis anticipate contractual cash flow include interest payable group non derivative financial liability undiscounte basis purpose table debt define class borrowing lease liability interest calculate base debt hold december take account future issuance float rate interest estimate prevail interest rate balance sheet date cash flow foreign currency translate spot rate december finance trade payable charge interest lease lease liability debt debt liability liabilitie net debt total december year year year year year year great year gross contractual cash flow finance trade payable charge interest lease lease liability debt debt liability liabilitie net debt total december year year year year year year great year gross contractual cash flow table provide analysis anticipate contractual cash flow group derivative instrument exclude equity option rise cash flow embed derivative material undiscounted cash flow cash flow foreign currency translate spot rate december gross cash flow foreign exchange contract present purpose table practice group use standard settlement arrangement reduce liquidity requirement instrument cash flow interest rate swap show table significant gross cash inflow gross cash ouflow gross cash inflow gross cash outflow foreign foreign foreign foreign cross exchange cross exchange cross exchange cross exchange currency forward currency forward currency forward currency forward interest rate contract interest rate contract interest rate contract interest rate contract swap swap swap swap swap swap swap swap year year gross contractual cash flow gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue employee share scheme gsk operate employee share scheme include share value plan award grant employee acquire share ad glaxosmithkline plc cost year vest period performance share plan award grant employee acquire share ad glaxosmithkline plc cost subject achievement group specify performance target grant restrict share award replace grant option employee cost scheme readily equate potential gain employee group operate saving relate share option scheme option grant employee acquire share glaxosmithkline plc discount price grant restrict share award normally exercisable end threeyear vest performance period award normally grant employee acquire share ad glaxosmithkline plc circumstance settle cash grant savingsrelate share option scheme normally exercisable year save accordance practice majority option savingsrelate share option scheme grant price market price ruling date grant option historical share option scheme grant market price ruling date grant total charge sharebase incentive plan million million million million million million arise share value plan note employee cost detail glaxosmithkline share award scheme share value plan share value plan share award grant certain employee cost award vest half year performance criterion attach fair value award determine base closing share price day grant deduct expect future dividend yield duration award share weight ad weight number share ad issuable number fair value number fair value january award grant award exercise award cancel december award grant award exercise award cancel december award grant award exercise award cancel december performance share plan performance share plan share award grant director senior executive cost percentage award vest base performance group define measurement period dividend reinveste period award grant performance condition base equally weight measure threeyear performance period adjust free cash flow tsr new product performance award grant performance condition base measure threeyear performance period adjust free cash flow tsr new product performance pipeline progress fair value award determine base closing share price day grant tsr performance element adjust likelihood condition meet assess time grant award million share weight fair value million ad weight fair value december outstanding award million share million ad gsk annual report note financial statement continue employee share scheme continue share option savingsrelate option purpose value savingsrelated option arrive sharebased payment charge blackschole option pricing model assumption model follow grant grant grant riskfree interest rate dividend yield volatility expect life year year year savingsrelate option grant price include discount share option share option savingsrelate option outstanding scheme share scheme ad share option scheme weight weight weight number exercise number exercise number exercise price price price december range exercise price option outstanding year end weight average market price exercise year weight average remain contractual life year option million share grant year savingsrelate share option scheme weight average fair value december million savingsrelate share option exercisable share option ad option exercisable expire exercise july change effective exercise price outstanding option year employee share ownership plan trust group sponsor employee share ownership plan esop trust acquire hold share glaxosmithkline plc satisfy award employee incentive plan option grant employee share option scheme trustee esop trust purchase share finance provide group way loan contribution cost run esop trust charge income statement share hold esop trust deduct reserve amortise value proceed receivable employee exercise transfer retain earning trustee waive right dividend share hold esop trust share hold share award scheme number share nominal value carry value market value share hold share option scheme number share nominal value carry value market value gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue principal group company follow represent principal subsidiary country incorporation group december equity share capital entity wholly own group percentage interest show company incorporate principal country operation state england glaxo group limited block drug company inc glaxo operation limited corixa corporation glaxosmithkline capital plc glaxosmithkline capital inc glaxosmithkline consumer healthcare holdings limited glaxosmithkline consumer healthcare holding llc glaxosmithkline consumer healthcare trading limited glaxosmithkline consumer healthcare glaxosmithkline consumer trading services limited glaxosmithkline holdings americas inc glaxosmithkline export limited glaxosmithkline llc glaxosmithkline finance plc human genome sciences inc glaxosmithkline holdings limited gsk consumer health inc glaxosmithkline research development limit consumer healthcare llc glaxosmithkline service unlimited gsk equity investment limited glaxosmithkline limited stiefel laboratories inc setfirst limit tesaro inc smithkline beecham limited viiv healthcare company viiv healthcare finance limit viiv healthcare limited viiv healthcare limited europe glaxosmithkline biological belgium glaxosmithkline australia pty ltd australia glaxosmithkline sante grand public sas france glaxosmithkline consumer healthcare australia pty ltd australia laboratoire glaxosmithkline france glaxosmithkline brasil limitada brazil viiv healthcare sas france glaxosmithkline consumer healthcare ulcglaxosmithkline soin glaxosmithkline consumer healthcare gmbh germany sante aux consommateurs sri canada glaxosmithkline gmbh germany glaxosmithkline inc canada gsk vaccines gmbh germany biomedical corporation quebec canada glaxosmithkline consumer healthcare srl italy consumer healthcare canada ulcpf soin sante sri canada glaxosmithkline spa italy glaxosmithkline limited china hong kong gsk vaccines srl italy sinoamerican tianjin smith kline french laboratories ltd china viiv healthcare srl italy wyeth pharmaceutical ltd china pfizer consumer manufacturing italy srl italy glaxosmithkline asia pvt limited india gsk service poland glaxosmithkline pharmaceuticals limited india glaxosmithkline trading services limited republic ireland glaxosmithkline consumer healthcare japan japan glaxosmithkline healthcare russia glaxosmithkline japan glaxosmithkline spain glaxosmithkline pakistan limited pakistan laboratorios viiv healthcare spain glaxo wellcome manufacturing pte ltd singapore gsk consumer healthcare switzerland glaxosmithkline korea limited republic korea glaxosmithkline llaclari sanayi ticaret turkey directly hold whollyowne subsidiary glaxosmithkline plc subsidiary associate list principally affect figure group financial statement glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline llc whollyowne finance subsidiary company company fully unconditionally guarantee security issue glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline llc page complete list subsidiary undertaking associate joint venture form financial statement gsk annual report note financial statement continue legal proceeding group involve significant legal administrative dolutegravirtivicaytriumeqdovatojuluca proceeding principally product liability intellectual property viiv healthcare receive patent challenge letter tax antitrust consumer fraud governmental investigation hatchwaxman act cipla reddys labs significant matter tax matter apotex triumeq tivicay letter lupin describe group make provision mylan triumeq letter sandoz tivicay viiv proceeding regular basis summarise note healthcare list patent fda orange book tivicay accounting principle policy note triumeq patent cover molecule dolutegravir provision note describe disclosure expire october second patent claim crystal proceeding provision legal expense form dolutegravir expire december incur provision relate legal claim charge letter challenge laterexpire crystal form patent sell general administration cost group generic company allege crystal believe information seek plaintiff form patent invalid claim crystal form patent know meaningful respect legal invalid infringe propose product proceeding number factor include viiv healthcare file patent infringement suit limit stage proceeding entitlement generic company party appeal decision clarity theory liability matter mylan laurus successor damage govern law reddys labs resolve case december group aggregate provision defendant consolidate single case legal dispute include tax matter describe district court district delaware trial date note taxation million set assurance loss result outcome september viiv healthcare receive paragraph legal proceeding exceed material letter cipla relate dovato challenge provision report group financial crystal form patent november viiv healthcare file statement happen material suit cipla district court district adverse impact result operation group delaware trial date set reporting period judgement incur settlement enter january viiv healthcare receive paragraph letter lupin relate juluca challenging crystal form intellectual property patent patent relate combination intellectual property claim include challenge validity dolutegravir rilpivirine expire january enforceability group patent product february viiv healthcare file suit lupin process assertion noninfringement patent additionally june cipla send viiv patent loss case result loss healthcare paragraph letter relate juluca patent protection product issue consequence july viiv healthcare file suit cipla federal loss significant decrease sale court delaware court set trial date product materially affect future result operation february viiv healthcare file patent infringement group litigation bictegravir gilead sciences inc coreg gilead district court district delaware gsk initiate suit teva induce canadian federal court viiv healthcare allege gilead infringement patent relate use carvedilol coreg triple combination hiv drug contain hiv integrase decrease mortality cause congestive heart failure inhibitor bictegravir infringe viiv healthcare patent cover june case proceed jury trial district dolutegravir compound include dolutegravirs court district delaware jury return verdict unique chemical scaffold canada viiv gsk favour award gsk lose profit reasonable healthcare seek financial redress injunctive royalty total award million march relief jury trial case set january trial judge rule posttrial motion file teva canadian matter fourday summary trial issue find substantial evidence trial support infringement hold january april jurys find induce infringement overturning jury court rule gilead bictegravir compound infringe award gsk appeal october divide panel viiv healthcare canadian patent viiv healthcare court appeal federal circuit reverse appeal district court rule reinstate jury award gsk favour december teva file petition rehear viiv healthcare commence action france banc court grant tevas petition germany japan south korea australia gilead rehear threemember panel issue original alleging gilead biktarvy infringe certain viiv decision oral argument take place february healthcares hiv integrase inhibitor patent infringement await court rule trial german action set april gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue legal proceeding continue kivexa longpende group action allege seroxat june biogaran commence proceeding france cause severe discontinuation symptom conclude seek revocation french supplementary protection july trial court enter judgement certificate spc cover kivexa trial date set group favour award cost case action involve discontinuationtype claim resolve product liability ppi litigation group currently defendant number product group defendant ongoing proton pump inhibitor liability lawsuit ppi litigation plaintiff allege use ppis cause bodily injury include acute kidney injury avandia chronic kidney disease endstage renal failure january avandia product liability case january approximately prevacidhr settle remain class action bring personal injury lawsuit approximately nexiumhr thirdparty payer action assert claim case pende company nearly racketeer influence corrupt organization act rico pende multidistrict litigation mdl proceed state consumer protection law december district new jersey manufacturers ppi circuit court appeal reverse summary name codefendants mdl group file judgement grant favour group remand motion dismiss case mdl court thirdparty payer case district court trial date rule motion ppi bellwether trial set set november addition mdl case small seroxatpaxil paxil number case pende state court seroxatpaxil paroxetine product liability matter involve zantac general type allegation use paxil group contact regulatory pregnancy cause congenital malformation persistent authority detection nnitrosodimethylamine pulmonary hypertension autism paxil treatment ndma zantac ranitidine product base information cause patient commit suicidal violent act iii available time correspondence regulator group fail warn patient experience certain group decision suspend release distribution symptom discontinue seroxatpaxil treatment supply dose form zantac market pende group reach agreement settle majority outcome ongoing test investigation claim relate use paxil pregnancy precautionary action group decision initiate january lawsuit remain pende voluntary pharmacyretail level recall zantac product additional action pende canada globally begin pende claim april european medicine agency ema case case canada concern recommend suspension ranitidine medicine allegation patient take paroxetine paxil commit follow publication emas recommendation attempt commit suicide act violence dolin company communicate decision reenter market case involve suicide man allegedly take generic fda request manufacturer withdraw paroxetine manufacture mylan conclude favour ranitidine product market group leave pende matter group name defendant approximately canada remain case largely dormant personal injury claim involve zantac class action pende canadian action carmichael group allege economic injury thirdparty payer class action file motion summary judgement base statute file federal court outside limitation deny group appeal rule class action pende group canada oral argument take place december july class action israel appellate court reverse low court decision grant summary judgement group favour plaintiff file application leave appeal supreme court canada briefing application complete january party await rule gsk annual report note financial statement continue legal proceeding continue february product liability litigation sale marketing regulation assign multidistrict litigation mdl status southern group marketing promotion pharmaceutical district florida august group file motion vaccine product subject certain governmental dismiss mdl claim base innovator liability investigation private lawsuit bring litigant preemption deficiency pleading december theory law court grant group motion innovator gsk korea proceeding fair trade law liability generic defendant motion preemption august gsk korea indict koreas motion defendant deficiency pleading monopoly regulation fair trade law relation additionally january court grant brand government tender hpv cervarix pcv synflorix defendant partial motion preemption dismiss plaintiff vaccine prosecutor allege claim seek refund otc zantac product court gsk korea action allow plaintiff replead master complaint employee interfere tender process attempt cure deficiency pleading plaintiff national immunisation programme straw bidder file notice appeal relate decision innovator liability generic preemption employee charge individual capacity prosecutor relation matter addition class action litigation march number wholesaler codefendant proceedings department justice doj send group notice civil korea fair trade commission commence investigation open allegation false claim act investigation gsk korea matter gsk violation group relate zantac june korea cooperate authority matter doj serve civil investigative demand group proceeding ongoing formalizing request document day new mexico attorney general file lawsuit multiple sfo secdoj anticorruption enquiry defendant include group allege violation state previously report follow resolution investigation consumer protection false advertising statute fraud office sfo securities claims exchange commission sec department justice doj group commercial operation zofran number country include china sfo request january group defendant product additional information group thirdparty liability case involve zofran case pende state adviser engage company course court rest pende transfer investigation initiate chinas ministry public security multidistrict litigation mdl proceeding district sec doj investigate matter massachusetts case allege child suffer birth february sfo announce closed defect mother ingestion zofran andor generic investigation confirm take ondansetron pregnancyrelate nausea vomit action group sec notify group plaintiffs assert group sell zofran know march terminate investigation unsafe pregnant woman fail warn risk matter doj likewise inform illegally market zofran offlabel use pregnant woman group close investigation zofran bellwether trial set october recommendation action accordingly matter party continue await ruling court conclude motion exclude general causation expert group motion summary judgement case set trial preemption motion group defendant propose class action canada gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue legal proceeding continue antitrustcompetition december trial judge grant plaintiff class certain governmental action private lawsuit certification motion certify class direct purchaser bring group allege violation competition group file rule motion court appeal antitrust law circuit challenge class certification decision april court appeal vacate low court competition market authority investigation grant class certification remand issue february competition market low court analysis authority cma issue decision fine group million infringement competition act october district court hear argument connection agreement settle patent dispute plaintiff renew motion class certification remand group enter potential supplier await court decision generic paroxetine formulation commercial corporate group appeal competition appeal tribunal group historically name defendant cat deliver initial judgement uphold fine certain case allege violation security law march refer certain question law employee retirement income security act erisa european union court justice ecj january securitieserisa class action stiefel ecj issue judgement endorse criterion february group reach settlement principle cma levy fine matter return respect claim bring security cat entry final judgement exchange commission sec group relate lamictal group acquisition stiefel laboratories inc purport class purchaser file suit district sec file motion entry final judgement april court district new jersey allege group effectively dismiss case matter teva pharmaceuticals unlawfully conspire delay generic conclude claim bring private litigant martinolich competition lamictal result overcharge remain pende federal court florida matter purchaser enter allegedly anticompetitive plaintiff stiefel employee allege stiefel reverse payment settlement resolve patent infringement officer director violate erisa federal state litigation separate count accuses group monopolise security law induce stiefel employee sell share market employee stock plan stiefel greatly undervalue price disclose employee stiefel sell group post balance sheet event intention increase corporation tax rate effective april announce budget march defer taxis measure appropriate rate substantively enact balance sheet date overall effect propose change corporation tax rate apply defer tax balance december increase defer tax asset approximately million gsk annual report company balance sheet gaap include frs reduce disclosure framework december note fix asset investment current asset trade receivables cash bank total current asset short term borrowing trade payable total current liability net current asset total asset current liability provision liability noncurrent liability net asset capital reserve share capital share premium account reserves retain earning january profitloss year change retain earning equity shareholder fund financial statement page approve board march sign behalf sir jonathan symonds chairman glaxosmithkline plc register number company statement change equity year end december share share premium retain total capital account reserve earning equity january loss total comprehensive expense attributable shareholder distribution receive glaxosmithkline consumer healthcare holdings limit total comprehensive income year dividend shareholder share issue employee share scheme treasury share transfer esop trust december profit total comprehensive income attributable shareholder dividend shareholder share issue employee share scheme treasury share transfer esop trust december gsk annual report strategic report governance remuneration financial statement investor information note company balance sheet gaap include frs reduce disclosure framework presentation financial statement accounting principle policy description business preparation balance sheet conformity glaxosmithkline plc parent company gsk major generally accept accounting principle require management global healthcare group engage creation estimate assumption affect report discovery development manufacture marketing amount asset liability disclosure contingent pharmaceutical product include vaccine overthecounter asset liability date balance sheet actual otc medicine healthrelate consumer product amount differ estimate preparation financial statement balance sheet prepare accordance financial statement prepare company accounting policy approve board historical cost convention modify include revaluation describe note policy consistently certain financial instrument go concern basis apply state prepared accordance financial reporting standard key accounting judgement estimate reduce disclosure framework accounting key accounting judgement estimate require presentation company act december current year comparative figure december accounting policy permit section company act foreign currency transaction income statement company present foreign currency transaction record exchange annual report rate ruling date transaction foreign currency asset company include group financial statement liability translate rate exchange ruling glaxosmithkline plc publicly available balance sheet date follow exemption requirement ifrs dividend pay receive apply preparation financial statement dividend pay receive include financial accordance frs statement period relate dividend paragraph ifrs sharebase actually pay receive payment expenditure ifrs financial instrument disclosure expenditure recognise respect good service receive supply accordance contractual term paragraph ifrs fair value measurement provision obligation exist future liability paragraph ias presentation financial statement respect past event comparative information requirement respect obligation reliably estimate paragraph ia investment subsidiary company paragraph investments subsidiary company hold cost ias presentation financial provision impairment include capital contribution statement relation movement contingent consideration ias statement cash flow impairment investment carry value investment review impairment paragraph ias accounting policy change indication investment accounting estimate error impair assessment method compare paragraph ias relate party disclosure carry value investment share requirement ia disclose related party group valuation basis overall market capitalisation transaction enter member impairment charge recognise income statement group year concern accounting convention standard sharebase payment balance sheet prepare historical issuance company subsidiary grant cost convention complie applicable accounting company share represent additional capital standard contribution company subsidiarie additional investment subsidiary result correspond increase shareholder equity additional capital contribution base fair value grant issue allocate underlying grant vest period gsk annual report note company balance sheet gaap include frs reduce disclosure framework continue taxation financial guarantee current tax provide amount expect pay liability relate guarantee issue company apply tax rate enact substantively behalf subsidiary initially recognise fair value enact balance sheet date amortise life guarantee defer tax provide liability method operate profit temporary difference arise tax basis asset fee relate audit liability carry amount financial company charge operate profit statement defer tax asset recognise dividend extent consider recoverable future director declare interim dividend result taxable profit dividend year penny line dividend defer tax measure average tax rate detail note group financial expect apply period temporary statement dividend difference expect realise settle defer tax liability asset discount fix asset investment share glaxosmithkline service unlimited share glaxosmithkline holding limited share glaxosmithkline holdings limited share glaxosmithkline consumer healthcare holdings limited shares glaxosmithkline mercury limited capital contribution relate sharebased payment contribution relate contingent consideration share glaxosmithkline consumer healthcare holding limit receive dividend specie group reorganisation prior acquisition pfizer consumer healthcare business trade receivables amount year corporation tax recoverable amount owe group undertaking amount year amount owe group undertaking gsk annual report strategic report governance remuneration financial statement investor information note company balance sheet gaap include frs reduce disclosure framework continue shortterm borrowing billion borrowing december relate balance facility take june finance buyout noncontrolle interest consumer healthcare joint venture hold novartis loan repay trade payable amount year creditor contingent consideration payable amount owe group undertaking company guarantee debt issue subsidiary company receive fee aggregate company outstanding guarantee billion debt instrument billion amount subsidiary company relation guarantee fee recover life bond disclose trade receivable note provision liability january charge year utilise december provision relate number legal dispute company currently involve noncurrent liability contingent consideration payable contingent consideration relate payable acquisition novartis vaccine portfolio current year liability include trade payable detail note group financial statement contingent consideration liability gsk annual report note company balance sheet gaap include frs reduce disclosure framework continue share capital share premium account share premium ordinary share account number share capital issue fully pay january issue employee share scheme ordinary share acquire esop trust december issue employee share scheme ordinary share acquire esop trust december december december number share issuable employee share scheme number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme retain earning reserve profit glaxosmithkline plc year million million loss dividend pay million million effect million treasury share transfer subsidiary company million distribution receive share subsidiary company million retain earning december stand million million million unrealise million dividend shareholder pay realise profit company december amount million million reserve include capital redemption reserve reserve reflect historical contribution share company issue satisfy share option award grant employee subsidiary company group company page complete list subsidiary associate joint venture significant shareholding form financial statement gsk annual report ssttrraatteeggicic erepporotrt ggoovveerrnnaannccee nadn dre rmeumnuernaetiroantion ffiinnaanncciaial stattaetmemenetsnt iinnvveessttoor ninfoformrmataiotnion investor information section quarterly trend pharmaceutical turnover vaccine turnover year record product development pipeline product competition intellectual property principal risk uncertainty share capital control dividend financial calendar annual general meeting tax information shareholder shareholder service contact law regulation group company glossary term ggsskk aannnnuuaall rreeppoorrtt financial record quarterly trend unaudite analysis group result provide quarter sterle financial year income statement total month report proforma report report report report cer cer cer cer cer cer turnover pharmaceutical vaccine consumer healthcare corporate unallocated turnover total turnover cost sale sell general administration research development royalty income operating incomeexpense operating profit net finance cost share aftertax profitslosse associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder basic earning share penny dilute earning share penny income statement adjust total turnover cost sale sell general administration research development royalty income operating profit net finance cost share aftertax profitslosse associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder adjust earning share penny calculation adjust result describe gsk annual report strategic report governance remuneration financial statement investor information financial record continue quarterly trend quarterly trend continue unaudite analysis group result provide quarter sterle financial year income statement total month report proforma report report report report cer cer cer cer cer cer turnover pharmaceutical vaccine consumer healthcare corporate unallocated turnover total turnover cost sale sell general administration research development royalty income operating incomeexpense operating profit net finance cost share aftertax profitslosse associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder basic earning share penny dilute earning share penny income statement adjust total turnover cost sale sell general administration research development royalty income operating profit net finance cost share aftertax profitslosse associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder adjust earning share penny calculation adjust result describe gsk annual report financial record continued pharmaceutical turnover therapeutic area total europe international growth growth growth growth therapeutic areamajor product cer cer cer cer respiratory ellipta product anoro ellipta arnuity ellipta incruse ellipta relvarbreo ellipta trelegy ellipta nucala hiv dolutegravir product tivicay triumeq juluca dovato epzicomkivexa selzentry rukobia immunoinflammation benlysta oncology zejula blenrep pharmaceutical exclude establish product establish pharmaceutical establish respiratory seretideadvair flixotideflovent ventolin avamysveramyst respiratory dermatology augmentin avodart imigranimitrex lamictal seroxatpaxil valtrex pharmaceuticals gsk annual report strategic report governance remuneration financial statement investor information financial record continue pharmaceutical turnover therapeutic area total europe international growth growth growth growth therapeutic areamajor product cer cer cer cer respiratory ellipta product anoro ellipta arnuity ellipta incruse ellipta relvarbreo ellipta trelegy ellipta nucala hiv dolutegravir product tivicay triumeq juluca dovato epzicomkivexa selzentry immunoinflammation benlysta oncology zejula pharmaceutical exclude establish product establish pharmaceutical establish respiratory seretideadvair flixotideflovent ventolin avamysveramyst respiratory dermatology augmentin avodart imigranimitrex lamictal seroxatpaxil valtrex pharmaceuticals gsk annual report financial record continue vaccine turnover total europe international growth growth growth growth major product cer cer cer cer meningitis bexsero menveo influenza fluarix flulaval shingle shingrix establish vaccine infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix vaccine represent growth actual exchange rate cer represent growth constant exchange rate vaccine turnover total europe international growth growth growth growth major product cer cer cer cer meningitis bexsero menveo influenza fluarix flulaval shingle shingrix establish vaccine infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix vaccine represent growth actual exchange rate cer represent growth constant exchange rate gsk annual report strategic report governance remuneration financial statement investor information financial record continue year record record financial performance provide analysed accordance current reporting practice information include year record prepare accordance ifrs adopt european union ifrs issue international accounting standard board group turnover geographic region europe international group turnover segment pharmaceutical vaccine consumer healthcare segment turnover corporate unallocated turnover pharmaceutical turnover respiratory hiv immunoinflammation oncology establish pharmaceutical vaccine turnover meningitis influenza shingle establish vaccine revise revise revise revise consumer healthcare turnover oral health pain relief vitamin mineral supplement respiratory health digestive health subtotal brand divestedunder review gsk annual report financial record continue year record continue financial result total turnover operate profit profit taxation profit taxation pence pence pence pence pence basic earning share dilute earning share million million million million million weight average number share issue basic diluted financial result adjust turnover operate profit profit taxation profit taxation pence pence pence pence pence adjust earning share return capital employ return capital employ calculated total profit taxation percentage average net asset year gsk annual report strategic report governance remuneration financial statement investor information financial record continue year record continue balance sheet noncurrent asset current asset total asset current liability noncurrent liability total liability net asset shareholder equity noncontrolle interest total equity number employee europe international manufacturing sell administration research development geographic distribution employee table base location gsk subsidiary company number employee number permanent employ staff end financial period exclude employee employ manage gsk contract basis exchange rate guide holder ad follow table set period indicate information exchange rate dollar sterling report bank england buy rate average rate year calculate average buy rate day year average mar feb jan dec nov oct sep high low buying rate march gsk annual report financial record continue year record continue divestment intangible intangible significant adjust result reconciliation total asset asset major transaction legal separation adjust result amortisation impairment restructure relate item cost result december turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share weight average number share million divestment intangible intangible significant adjust result reconciliation total asset asset major transaction legal adjust result amortisation impairment restructure relate item result december turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share weight average number share million gsk annual report strategic report governance remuneration financial statement investor information financial record continue year record continue divestment intangible intangible significant adjust result reconciliation total asset asset major transaction legal adjust result amortisation impairment restructure relate item result december turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost profit disposal associate share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share weight average number share million divestment intangible intangible significant adjust result reconciliation total asset asset major transaction legal tax adjust result amortisation impairment restructure relate item reform result december turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost profit disposal associate share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share weight average number share million gsk annual report financial record continue year record continue divestment intangible intangible significant adjust result reconciliation total asset asset major transaction legal adjust result amortisation impairment restructure relate item result december turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share weight average number share million gsk annual report strategic report governance remuneration financial statement investor information pipeline product competition pharmaceutical vaccine product development pipeline key nlicense alliance relationship party nda new drug application exception rituximab own biogen inc approve iiv healthcare global specialist hiv company submit gsk pfizer inc shionogi limited shareholder phase valuation clinical pharmacology usually conduct responsible developing deliver hiv medicine volunteer contribute pandemic adjuvant covid phase etermination dose initial evaluation efficacy vaccine collaboration conduct small number patient bla biological licence application phase iii arge comparative study compound versus placebo maa marketing authorisation application europe andor establish treatment patient establish clinical benefit safety maa ndabla regulatory review milestone show table achieve future filing date include list oncology asset useu regulatory approvalssubmission advance indication clinic list achieve regulatory review milestone compound mechanism action indication phase maa ndabla oncology zejula poly adpribose polymerase parp inhibitor maintenance ovarian cancer approve oct apr niraparib prima maintenance ovarian cancer iii combination dostarlimab maintenance non small cell lung cancer iii nsclc blenrep adc target bcell maturation antigen multiple myeloma approve aug aug belantamab dreamm mafodotin multiple myeloma iii multiple myeloma iii dostarlimab antiprogramme cell death protein receptor dmmrmsih endometrial cancer submit mar dec antibody dmmr solid tumour submit dec endometrial cancer iii feladilimab icos receptor agonist cell depletion relapsedmetastatic head neck iiiii squamous cell carcinoma hnscc bintrafusp alfa transform growth factor beta tgf trap biliary tract cancer btc iiiii immune checkpoint inhibitor letetresgene engineer tcr tcell target nyeso synovial sarcoma autoleucel pivotal cobolimab antitcell immunoglobulin mucin domain nonsmall cell lung cancer nsclc tsr tim antibody protein arginine methyltransferase prmt solid tumour haematological malignancy iii inhibitor antilymphocyte activation gene lag cancer tsr antibody type protein arginine methyltransferase cancer type prmt inhibitor sting cytosolic dna pathway agonist cancer antagonist cancer engineer tcr tcells coexpresse cda cancer cell surface receptor target nyeso engineer tcr tcell coexpresse cancer dntgfrii cell surface receptor target nyeso hiv infectious disease rukobia hiv attachment inhibitor hiv infection approve feb jul fostemasavir cabenuva hiv integrase strand transfer inhibitor non hiv infection approve dec jan vocabria nucleoside reverse transcriptase inhibitor nnrti cabotegravir longacte regiman rilpivirine cabotegravir hiv integrase strand transfer inhibitor longacte hiv preexposure prophylaxis iii gepotidacin triazaacenaphthylene bacterial type topoisomerase uncomplicate urinary tract infection uuti iii inhibitor gonorrhea gsk annual report pipeline product competition continue pharmaceutical vaccine product development pipeline continue achieve regulatory review milestone compound mechanism action indication phase maa ndabla hiv infectious disease continue vir antispike protein antibody covid iiiii leucyl trna synthetase inhibitor tuberculosis hbv antisense hepatitis hiv maturation inhibitor hiv infection crk inhibitor visceral leishmaniasis hiv attachment inhibitor hiv infection hiv maturation inhibitor hiv infection fimh antagonist uncomplicate urinary tract infection uuti proteasome inhibitor visceral leishmaniasis mtb cholesterol dependent inhibitor tuberculosis ethionamide booster tuberculosis vir antispike protein antibody covid immunoinflammation benlysta lymphocyte stimulator monoclonal lupus nephritis approve jun dec antibody submit benlysta rituximab lymphocyte stimulator monoclonal systemic lupus erythematosus iii antibody cluster differentiation monoclonal antibody otilimab granulocyte macrophage colony rheumatoid arthritis iii stimulate factor inhibitor covid relate acute pulmonary disease ccl inhibitor osteoarthritis pain rip kinase inhibitor psoriasis respiratory trelegy fluticasone glucocorticoid agonist longacte asthma approve jan sep furoate vilanterol beta agonist muscarinic umeclidinium acetylcholine antagonist submit nucala interleukin antagonist hypereosinophilic syndrome approve soct asep submit nasal polyposis submit soct ssep useu copd iii interleukin antagonist asthma iii longacte pik beta inhibitor viral copd exacerbation pharmaceutical daprodustat prolyl hydroxylase inhibitor anaemia associated chronic renal disease jnda jnda approve jun iii row linerixibat ileal bile acid transporter ibat inhibitor cholestatic pruritus pbc primary biliary cholangitis hematopoietic prostaglandin duchenne muscular dystrophy synthase hpgds inhibitor trpv channel blocker diabetic macular edema dme transglutaminase inhibitor celiac disease gsk annual report strategic report governance remuneration financial statement investor information pipeline product competition continue pharmaceutical vaccine product development pipeline continue achieve regulatory review milestone compound vaccine type indication phase maa ndabla vaccine shingrix recombinant protein adjuvante herpe zoster prophylaxis immunocompromise approve jul sep submit rotarix live attenuate pcv porcine circovirus rotavirus prophylaxis approve feb free variation iii bexsero recombinant protein meningococcal disease prophylaxis infant iii mmr live attenuate measle mump rubella prophylaxis iii man abcwy recombinant protein conjugate meningococcal abcw disease prophylaxis iii adolescent rsv recombinant protein respiratory syncytial virus prophylaxis pregnant iii woman population prevent respiratory syncytial virus low respiratory tract illness infant month life transfer maternal antibodie recombinant protein adjuvante respiratory syncytial virus prophylaxis old adult iii population replicationdefective recombinant respiratory syncytial virus prophylaxis paediatric viral vector population malaria recombinant protein adjuvante malaria prophylaxis plasmodium falciparum generation fractional dose menveo conjugate liquid formulation meningococcal acw disease prophylaxis adolescent shigella bioconjugate tetravalent shigella diarrhoea prophylaxis therapeutic hbv primeboost viral vector vaccine treatment chronic hepatitis infection aim iii sequentially administrate functional cure controlling resolve infection adjuvante recombinant protein reduce need treatment difficile recombinant protein adjuvante active immunization prevention primary difficile disease prevention recurrence sam rabies model selfamplifye mrna rabie prophylaxis aureus recombinant protein bioconjugate active immunization prevention primary adjuvante recurrent softskintissue infection cause aureus covid recombinant protein adjuvante covid iiiii plantderive viruslike particles vaccine medicago covid vaccine recombinant protein adjuvante covid sanofi covid vaccine recombinant protein nanoparticle covid iii bioscience adjuvante sam covid selfamplifye mrna covid model gsk annual report pipeline product competition continue pharmaceutical product competition intellectual property major patent expiry date product compound indication competitor brand respiratory anoro ellipta umeclidinium bromide copd stiolto respimat vilanterol trifenatate utibronultibro nce nce breezhaler duaklir genuair device device bevespi aerosphere formulation formulation brimica genuair arnuity ellipta fluticasone furoate asthma beclazone pulmicort budesonide nce nce asmanex alvesco device device formulation formulation avamysveramyst fluticasone furoate rhinitis dymista xhance nasonex fluticasone flixotideflovent fluticasone propionate asthmacopd beclazone pulmicort expire expire budesonide diskus device diskus device asmanex alvesco expire hfadevice hfadevice incruse ellipta umeclidinium bromide copd spiriva handihaler respimat yupelri nce nce braltus seebri breezhaler bretaris device device genuair formulation formulation nucala mepolizumab severe eosinophilic asthma egpa xolair cinqair expire expire hypereosinophilic syndrome fasenra dupixent relvarbreo ellipta fluticasone furoate asthmacopd symbicort foster vilanterol trifenatate budesonideformetrol nce nce sirdupla dulera device device formulation formulation seretideadvair salmeterol xinafoate asthmacopd symbicort foster expire expire fluticasone propionate budesonideformetrol diskus device diskus device sirdupla dulera expire hfadevice hfadevice trelegy ellipta fluticasone furoate copd trimbow vilanterol trifenatate breztri aerosphere nce nce umeclidinium bromide trixeo aerosphere enerzair breezhaler device device formulation formulation ventolin hfa albuterol sulphate asthmacopd generic company expire hfadevice hfadevice antiviral valtrex valaciclovir genital herpe coldsore shingles prevymis valacyclovir expire expired valcyte central nervous system lamictal lamotrigine epilepsy bipolar disorder vimpat trokendi expire expire inovelon imigranimitrex sumatriptan migraine zomig maxalt relpax expire expire seroxatpaxil paroxetine depression anxiety trintellix aplenzin viibryd expire expire disorder zoloft cardiovascular urogenital avodart dutasteride benign prostatic hyperplasia harnal vesomni urorec expire expire antibacterials augmentin amoxicillinclavulanate common bacterial generic product expire potassium infection generic competition commence include supplementary protection certificate grant multiple country patent term extension grant data exclusivity expire gsk annual report strategic report governance remuneration financial statement investor information pipeline product competition continue pharmaceutical product competition intellectual property continue major patent expiry date product compound indication competitor brand oncology zejula niraparib ovarian cancer lynparza rubraca nce nce blenrep belantamab mafodotin relapsedrefractory multiple sarclisa xpovio myeloma immunoinflammation benlysta benlysta belimumab systemic lupus erythematosus lupkynis lupus nephritis hiv juluca dolutegravir rilpivirine hivaids descovy genvoya odefsey biktarvy nce nce dovato dolutegravir lamivudine hivaids descovy genvoya odefsey biktarvy nce nce selzentrycelsentri maraviroc hivaids isentress intelence prezista nce nce tivicay dolutegravir hivaid isentress prezista symtuza reyataz nce nce biktarvy triumeq dolutegravir lamivudine hivaids descovy genvoya abacavir odefsey biktarvy nce nce vaccine product competition intellectual property major patent expiry date product compound indication competitor brand bexsero meningococcal groupb meningitis group prevention trumenba vaccine boostrix diphtheria tetanus acellular diphtheria tetanus acellular adacel expire expire pertussis pertussis booster vaccination infanrix hexapediarix diphtheria tetanus pertussis prophylaxis diphtheria pentacel pediacel expire expired polio hepatitis haemophilus tetanus pertussis polio pentaxim pentavac influenzae type hepatitis haemophilus hexaxim hexyon influenzae type vaxeli cervarix hpv virus like human papilloma virus gardasil silgard particle vlp type adjuvant mpl aluminium hydroxide fluarix tetra split inactivated influenza seasonal influenza prophylaxis intenza flumist qiv antigens virus subtype vaxigrip qiv subtype fluzone qiv fluzone high dose flulaval split inactivated influenza seasonal influenza prophylaxis vaxigrip mutagrip antigens virus subtype fluzone influvac subtype aggripal fluad intenza flumist menveo meningococcal group meningitis group nimenrix menactra conjugate vaccine prophylaxis prepandrix derive split inactivated pandemic influenza aflunov vepacel influenza virus antigen prophylaxis adjuvant priorix priorix tetraab live attenuate measle mump measle mump rubella mmr mmrvaxpro expire expire varilrixb rubella varicella vaccine chickenpox prophylaxis proquad varivax rotarix human rotavirus rix strain rotavirus prophylaxis rotateq synflorix conjugate pneumococcal prophylaxis invasive prevenar prevnar polysaccharide disease pneumonia acute otitis medium shingrix zoster vaccine herpe zoster zostavax recombinant adjuvante shingle note financial statement legal proceeding include supplementary protection certificate grant multiple country patent term extension grant relate compoundsindication measle mump rubella vaccineprophylaxis relate compound varicella vaccine gsk annual report pipeline product competition continue consumer healthcare product competition brand product application market competition oral health sensodyne toothpaste toothbrushe relief dentinal hypersensitivity global colgate sensitive prorelief pronamel mouth rinse pronamel additionally protect colgatepalmolive acid erosion elmex colgatepalmolive oral procter gamble parodontax toothpaste dailymedicate help stop prevent global colgate total gum health corsodyl mouthwash gel spray bleed gum treat colgatepalmolive prevent gingivitis oral gum enamel repair crest gum detoxify procter gamble polident denture adhesive denture improve retention comfort global fixodent kukident poligrip cleanser wipe denture clean denture procter gamble corega steradent reckitt benckiser aquafresh toothpastes toothbrushes aids prevention dental cavity global colgate colgatepalmolive mouthwash maintain healthy tooth gum crest procter gamble fresh breath oralb procter gamble pain relief panadol tablet caplet infant paracetamolbase treatment global aspirin bayer panadol cold syrup headache joint pain fever cold tylenol johnson johnson flu symptoms nurofen reckitt benckiser voltaren topical gel nonsteroidal diclofenac base global salonpas hisamitsu antiinflammatory aspirin bayer tylenol johnson johnson nurofen reckitt benckiser advil tablets caplet gel caplet ibuprofen base treatment canada brazil tylenol tylenol tylenol children nonrespiratory liquid fill suspension headache toothache backache colombia mexico motrin motrin childrens johnson range drop children menstrual cramp muscular johnson aleve aleve bayer pain minor pain arthritis vitamin mineral supplement centrum tablet gummie vitamin supplement global nutralite infinitus cheongkwanjung capsule chewables byhealth nature herbalife swisse caltrate tablet gummie calcium supplement global citracal bayer oscal nature soft chew private label emergenc powder gummie immune support dietary canada airborne reckitt benckiser supplement zicam church dwight nature pharmavite sambucol healthcare brand international esterc american health respiratory health otrivin nasal spray nasal decongestant germany netherlands afrin bayer nasivin proctor gamble norway russia sweden tyzine johnson johnson theraflu hot liquids tablet syrup cold flu relief russia poland tylenol cold flu johnson johnson mucinex reckitt benckiser lemsip reckitt benckiser advil respiratory tablet allergy relief cold flu tylenol cold flu johnson johnson cold flu advil relief lemsip mucinex reckit benckiser respiratory allergy flixonaseflonase nasal spray tablet allergy relief china ireland claritin bayer allegra sanofi piriton zyrtec johnson johnson robitussin syrup tablet coughcold canada singapore mucinex reckitt benckiser philippines australia dimetapp foundation consumer healthcare digestive health zovirax topical cream lip care treat prevent global compeed johnson johnson abreva nonmedicate patch onset cold sore carmex carma labs blistex blistex incorporate retail label chapstick lip balm protect moisturise prevent global blistex burt bee carmex carma labs soothe chap lip eos nivea beiersdorf vaseline unilever eno effervescent immediate relief antacid global estomazil hypermarca gelusil tums chewable tablet immediate relief antacid alkaseltzer bayer gaviscon reckitt benckiser rolaids sanofi nicorette lozenge gum treatment nicotine withdrawal global nicorette johnson johnson nicoderm nicotinell transdermal patch aid smoking reduction niquitin perrigo australia cessation gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertainty outline principal risk uncertaintie relevant manufacturing testing approval distribution sale gsk business financial condition operation market pharmaceutical vaccine consumer healthcare affect performance ability achieve objective product affect cost product development risk believe cause actual time require reach market likelihood result differ materially expect historical result successfully uninterrupted basis board oversight extend audit risk rule regulation change government interpretation committee include involvement corporate evolve business activity develop nature responsibility committee science committee particular risk alter change certain regulatory committee consider gsk risk strategy regime substantial alteration failure address draw annual business unit comply applicable law regulation materially risk assurance update report strategy paper adversely affect financial result significant risk corporate executive team cet similarly global business expose litigation annual risk review government investigation include limited product year develop risk management liability litigation patent antitrust litigation sale framework move annual quarterly upwards report marketing litigation litigation government investigation principal risk enable risk include related provision unfavourable oversight compliance council oversee risk outcome increase related cost insurance dynamic way continue evolve report new premium materially adversely affect emerge risk external environmental insight financial result report datum drive key risk indicator detail status uncertainty enable agile risk management strategy addition significant unresolved dispute potential litigation set risk mitigation relate covid incorporate note legal proceeding significant risk complement pandemic risk identify manage global issue management regulation require discussion mitigation activity team report cet company take address principal risk uncertaintie description principal risk require comply broad range law summary activity manage risk regulation apply research development business list order significance patient safety risk definition collect information safety efficacy failure appropriately collect review follow report product human clinical development gain human safety information hsi include adverse event comprehensive information realworld use product potential source act relevant finding market safety information obtain timely manner ongoing safety surveillance activity external party analyse publiclyavailable clinical trial result datum risk impact variety source increase volume safety ability effectively collect manage analyse safety datum set variable complex global regulation information associate product enable conduct present new evolving challenge conduct robust safety signal detection activity turn ensure pharmacovigilance example collect sensitive decision base uptodate riskbenefit health information develop robust product safety profile profile product appropriate measure ensure adherence increasingly stringent global safeguard patient consumer effectively privacy regulation remain vigilant threat manage risk patient safety activity cyberattack repercussion harm patient lead reputational damage productrelate litigation governmental result covid pandemic gsk safety investigation regulatory action include fine penalty organisation party quickly effectively loss product marketing authorisation adopt new way working impact patient safety urgent need effective treatment context prevention covid political discourse licence operate depend compliance global develop treatment prevention increase regulatory pharmacovigilance requirement fully accountable governmental public scrutiny industry ensure safeguard patient comply global regulation development regulatory measure safety augment pharmacovigilance capability efficacy medicine vaccine environment party continue seek innovative solution undermine regulatory governmental public trust automation machine learning improve patient medicine treat covid turn negatively safety management efficient reliable influence healthcare decision disease lead accurate data collection interrogation reputational damage product liability lawsuit gsk annual report principal risk uncertainty continue patient safety continue mitigating activity propose action discuss regulatory authority chief medical officer cmo accountable patient include update prescribing information safety enterprise risk human safety matter collaboration communicate healthcare provider restrict product head global safety support business prescribingavailability help assure safe use carry unitspecific cmos crossenterprise safety governance clinical trial certain case appropriate board oversee implementation control framework stop clinical trial withdraw product market include risk management global safety board embed change central local safety subsidiary business unitspecific product safety board ensure department increase support core pharmacovigilance human safety address proactively activity thirdparty vendor operating model product lifecycle test pandemic area improvement global policy management human safety information identify term vendor flexibility capacity adapt require employee immediately report issue relate quickly operational capacity second half safety product thirdparty oversight framework year impact patient safety implement ensure party risk encounter human safety new safety signal management tool leveraged automation information identify train appropriately possible case processing prepare integration pfizer consumer healthcare safety database safety information product source refine global pharmacovigilance collect process report analyse follow organisation deliver additional efficiency include focus compliance global regulation information allow advance innovation automation detect safety signal product timely action information change product riskbenefit profile product quality risk definition gsk increasingly new technology enhance failure gsk contractor supplier ensure manufacture testing product example continue deploy new electronic documentation system appropriate control governance quality product advance laboratory information management tool development threat cyberattack remain key risk integrity compliance good manufacturing practice good product quality datum audit trail distribution practice regulation commercial clinical significant change take place gsk implement trial manufacture distribution activity new organisational alignment strategy change compliance term gsk product licence assess quality organisation sure support regulatory activity quality procedure governance facilitate strategy risk impact ensure unintended consequence increase failure ensure product quality far reach product quality risk implication patient consumer safety product launch mitigating activity delay drug shortage product recall extensive global network quality compliance regulatory legal financial consequence professional site senior management level align materially adversely affect gsk reputation financial business unit provide oversight assist result delivery quality performance operational compliance context management oversight accomplish external environment product quality remain hierarchy quality council independent chief product challenge quality officer global product quality office oversee product quality risk company european medicine agency ema implement new set requirement ema regulation develop implement single quality cover license medical device effective management system define quality standard new annex guidance manufacture sterile system business associate pharmaceutical medicinal product release gsk prepare vaccine consumer healthcare product clinical trial implement set requirement material system broad scope applicable product lifecycle mature reviewing manufacturing process product commercial supply augment consolidation identify risk presence nitrosamine impurity numerous regulatory requirement market comply update regulatory requirement work world assure meet external expectation product continue necessary mitigate quality market supply system base identify risk internationallyrecognise principle ich pharmaceutical quality system framework gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertaintie continue product quality continue quality management system routinely update ensure product incident committee process place keep pace evolve external regulatory environment investigate product issue recommendation new scientific understanding product remediation activity include necessary recall process drive continually improve product protect patient consumer establish operational deployment quality management system complaint process ensure gsk respond appropriately make policy procedure simple understand product quality issue raise patient customer implement adopt innovative tool independent function review triage allegation non userfriendly experience staff member regularly train compliance misconduct receive formal informal regulatory expectation learning inspection speak channel global disciplinary enforcement exist procedure ensure continue maintenance procedure apply breach standard current good manufacturing practice standard initiate appropriate follow investigation implement riskbase approach assess leverage key risk indicator support risk management manage party supplier provide material activity provide gsk corporate executive team finish product contract manufacturer risk oversight compliance council integrate product expect comply gsk standard assessment product quality performance regularly audit provide assurance financial control report risk definition treasury group deal daily high value transaction failure comply current tax law incur significant foreign exchange cash management transaction loss treasury activity failure report accurate transaction involve market volatility counterparty risk financial information compliance accounting standard group effective tax rate reflect location applicable legislation activity value generate determine risk impact jurisdiction profit arise applicable tax rate noncompliance exist new financial reporting higher low statutory rate disclosure requirement change recognition income reflect regime encourage innovation investment expense expose gsk litigation regulatory provide tax incentive change action materially adversely affect financial affect gsk tax rate addition worldwide nature result current global pandemic significant operation mean crossborder supply route change short notice failure comply change necessary ensure supply medicine numerous substance application law govern transfer pricing country result conflict claim tax authority dividend tax credit intellectual property profit tax individual country lead materially adversely affect financial result double taxation profit tax country complexity tax regulation mean inconsistent application treasury policy transactional occasionally disagree tax authority technical settlement error counterparty default lead interpretation particular area tax law tax charge significant loss include financial statement good estimate tax context liability pende audits tax authority require law jurisdiction publicly expect continued focus tax reform drive disclose financial result event materially initiative oecd address tax affect group financial result regulator routinely review challenge arise digitalisation economy financial statement list company compliance domestic initiative world result new revise exist accounting regulatory requirement significant change establish tax principle believe comply appropriate regulatory increase tax authority dispute regardless merit requirement concern financial statement outcome costly divert management attention disclosure material information include transaction adversely impact reputation relationship key relate business restructuring acquisition stakeholder divestiture subject investigation potential noncompliance accounting disclosure requirement lead restatement previously report result significant penalty gsk annual report principal risk uncertainty continue financial control report continue mitigate activity counterparty exposure subject define limit approve financial result review approve regional board credit rating individual counterpartie management review gsk group financial corporate compliance officer operate independently controller chief financial officer cfo allow treasury oversee treasury role manage counterparty financial controller cfo assess evolution risk line agree policy detail mitigation business time evaluate performance plan treasury risk find page note significant judgement review confirm senior financial instrument relate disclosure management technical organisational transformation newly gsk manage tax risk robust internal policy acquire activity external risk covid process train compliance programme seek pandemic integrate risk assessment appropriate maintain open constructive relationship tax authority control review apply worldwide monitor government debate tax policy maintain control environment design identify material key jurisdiction understand share error financial reporting disclosure design inform point view potential future change operating effectiveness key financial reporting control tax law relevant provide pragmatic constructive regularly review management test external business input tax policy maker directly party minimum standard control set place industry trade body include advocate reform finance location irrespective size review support economic growth job creation management monitor independently provide need patient key stakeholder submit assurance control key financial report significant tax decision tax governance board disclosure process operate effectively global meet quarterly senior gsk finance finance risk management control centre excellence employee provide extra support significant transformation tax affair manage global basis team tax system deployment managementstructural professional lead global head tax work closely reorganisation add operational resource ensure business daytoday basis global tax team process control maintain change suitably qualified role perform support introduce additional risk mitigation amend training need provide date technical programme timeline system upgrade optimise delivery advice line responsibility disclosure committee reporting board review submit tax return accord statutory time limit gsk quarterly result annual report consultation engage proactively tax authority seek ensure tax legal advisor year determine affair current enter continuous audit programme necessary disclose publicly information group advance pricing agreement appropriate stock exchange announcement uptodate arrangement provide longterm certainty tax late development financial reporting requirement authority gsk tax treatment business work external auditor legal advisor base disclosure relevant fact seek resolve treasury management group meets regularly seek difference interpretation tax legislation tax ensure liquidity interest rate counterparty foreign currency authority cooperative manner exceptional case transaction foreign currency translation risk resolve dispute formal proceeding manage line conservative approach detail associate risk strategy policy adopt board gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertainty continue antibribery corruption abac risk definition appropriate control place transaction abac risk comprise subrisk area payment party train awareness raise strong monitoring plan continue pre bribery public official gsk posttransaction abac diligence increase bribery commercial nonpublic entity gsk capabilitie business monitoring oversight red bribery party act behalf gsk flag resolution party review control accountability government official continue assess gsk employee receive andor request bribe andor understand money launder risk exposure undue personal benefit mitigate exist risk corruptionnoncompliance law regulation code conduct value expectation relate money launder facilitation tax evasion commitment zero tolerance bribery corruption partiesclientspartner integral mitigate risk light complexity risk impact geographic breadth risk constantly evolve failure mitigate risk expose group oversight activity datum reinforce workforce associate persons governmental investigation regulatory gsk clear expectation acceptable behaviour action civil criminal liability compromise maintain regular communication centre group ability supply product certain government local market contract addition failure prevent bribery corruption abac programme build good class principle substantial implication gsk reputation subject ongoing review development provide credibility senior leader erode investor confidence basis seek manage risk governance risk management lead example programme comprise legal financial penalty toplevel commitment board leadership context datum analytic programme create embe local key risk overall environment abac remain challenging indicator enable target intervention risk management country hold individual corporation activity accountable increase employer duty care programme underpin global abac policy divergence legislation increase political protectionism write standard address commercial social inequality pricing pressure make compliance practice rise abac risk addition hard society hold corporation high standard programme mandate enhance control interaction technology provide rapid anonymous avenue government official business development dissemination previously confidential information transaction control abac policy establish damage false report diligence requirement engagement party enforcement action penalty increase dedicated team responsible implementation globe focus use thirdparty intermediary evolution abac programme response propose legislation require business carry development internal external environment diligence potential human right relate abac team continually work group environmental impact operation supply chain enterprise address improve control monitor impose legal standard care addition impact requirement team work complement covid business include disruption independent oversight assurance audit manufacture supply chain importexport travel assurance independent business monitoring team etc increase risk bribery corruption issue identify oversight assurance exercise supportive aspect external environment include investigation identify area specific increase transparency collaboration enforcement intervention market continuously improve authority aim reduce bribery corruption programme globally advance technology provide well periodically provide mandatory abac training employee platform streamline process detect potential issue relevant party accordance role mitigate activity responsibility risk face enterprisewide abac programme design continually benchmark abac programme ensure compliance abac policy mitigate risk large multinational company use external bribery corruption build business standard expertise internal insight drive improvement value expectation form comprehensive practical approach compliance flexible evolve nature formal informal speak channel available report business misconduct noncompliance allegation noncompliance review triaged central investigation team programme governance provide enterprise risk allocate investigation appropriate management oversee gsk abac governance board include representation key functional area gsk annual report principal risk uncertainty continue commercial practice price risk definition commit ethical responsible failure engage commercial activity consistent commercialisation product support purpose letter spirit law industry regulation improve quality human life enable people group requirement relate sale promotion feel well live long accomplish purpose medicine vaccine appropriate interaction engage healthcare community way provide healthcare professionalsorganisation patient legitimate important information medicine vaccine transparent transfer value pricing competition promote approve product seek ensure antitrust regulation commercial practice include hcp globally access information need trade channel activity tender business patient consumer fact product risk impact require product prescribe recommend failure engage commercial activity consistent manner provide maximum healthcare benefit letter spirit law industry regulation commit communicate information relate group requirement relate sale promotion approve product responsible legal ethical manner medicine vaccine appropriate interaction mitigate activity healthcare professional hcp organisation patient strategic objective design ensure achieve legitimate transparent transfer value purpose continue strive new product launch pricing competition antitrust regulation commercial competitive resourced effectively ensure practice include trade channel activity business healthy proportion group sale come new product tender materially adversely affect ability innovation deliver strategy long term priority additionally result incomplete awareness riskbenefit profile establish new product meet price expectation product possibly suboptimal treatment patient patient consumer hcp payer shareholder consumer governmental investigation regulatory action community able maintain strong global business legal proceeding bring group governmental remain relevant need patient consumer private plaintiff result government value behaviour provide guide lead sanction criminal andor financial penalty practice decision constantly strive right thing find misalign value result deliver quality product sustain reliable supply meet reputational harm dilute trust establish external customer need seek ensure action stakeholder reflect gsk value behaviour purpose context gsk act enhance improve policy continue evolve business operation operate standard application datum analytic channel globally highly regulate extremely competitive activity develop policy support strong biopharma industry peer significant growth consumer healthcare internet channel digital product innovation technical advance intensify price marketing activity artificial intelligencepowere tool competition consumer healthcare marketplace improve oversight gsk website partner classic retail pharmacy increasingly improve control framework report adverse online platform face similarly robust competition event digital space upgrade customer service challenge environment achieve strategic objective policy standard govern commercial activity continue develop commercially viable new product undertake carry behalf deliver additional use exist product address implement train relevant employee support need patient consumer hcp payer evolution activity commercial activity common pharmaceutical vaccine consumer worldwide conform high ethical regulatory industry healthcare company embrace opportunity standard local standard differ global one evolve digital landscape face uncertain market apply stringent standard condition global covid pandemic acquire company joint venture partner differ global continue downward price pressure major market standard remediate legacy policy implement revision align develop new pharmaceutical vaccine consumer healthcare product costly lengthy uncertain process consumer healthcare business harmonise policy candidate product fail stage include procedure guide regional global commercial investment significant economic human resource practice process clarify applicable standard competitor product pricing strategy potential operation market operate failure develop commercially successful product deliver reduce number export hub additional use exist product materially complement specific control framework activity adversely affect ability achieve gsk strategic china develop specific promotion code objective enable responsible business growth employee behaviour train employee new code gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertainty continue commercial practice continue gsk pharmaceuticals consumer healthcare vaccine target approach implement business adopt internal control framework market support comprehensive training support assessment management risk business unit control monitoring framework ensure alignment risk management compliance board manage risk gsk valuesbase approach hcp engagement incountry business activity oversee commercial allow fair market value payment gsk activity monitor programme continue expert practitioner speak innovative medicine improve framework culture compliance vaccine country north america europe process asia pacific restrict time period product promotional material activity review lifecycle control training ensure appropriate oversight approve accord policy standard market permit report payment conduct accordance local law regulation individual hcp commitment transparency requirement seek ensure material activity responsible disclosure fairly represent group product service consumer consumer healthcare key driver development healthcare deploy new copy approval tool improve ethical code global selfcare federation setting control important promotional activity necessary principle promotion healthcare practitioner event misconduct discipline employee pharmacy staff include termination contract claw remuneration senior management gsk commit comply applicable sanction law regulation deploy programme enable continue evolve incentive programme management sanction risk programme lead gsk pharmaceutical vaccine sale representative well finance system control include recognise reward individual effort specialty care limit policy procedure train example cap variable pay element representative awareness screen monitor risk reporting compensation evaluate basis individual sale nonpromotional engagement risk definition context failure engage nonpromotional activity nonpromotional engagement diverse activity direct consistent external regulation internal policy healthcare professional patient payer gsk value scientific engagement healthcare stakeholder aim improve patient care professional patient include communication relate exchange provision knowledge use gsk medicine associate disease areas appropriate medicine vaccine relate disease non conduct interaction iii legitimacy transparency promotional engagement external stakeholder group interaction vital gsk researchbase healthcare company necessary scientific medical advance expect risk impact nonpromotional activity scientifically sound control place risk result reputational accurate conduct ethically transparently compliant damage governmental regulatory investigation applicable code law regulation non real perceive disguised promotion include promotional engagement largely unregulated offlabel priorauthorisation promotion real measure risk take root sound value principle perceive provision medical advice criminal investigation base decision make train communication monitor penalty civil litigation competitor complaint affect key manage risk enable appropriate financial result reduce trust general public engagement patient healthcare professional payer regulator government time failure engage fully appropriately result reputational damage patient harm financial loss gsk annual report nonpromotional engagement continue mitigating activity covid result significant increase virtual chief medical officer cmo oversees nonpromotional engagement external expert advisory board engagement enterprise risk owner patient advocacy patient engagement congresse modernized practice apply internal gsk code practice key internal policy non principle policy rapidly change grow promotional engagement activity activity include environment evolve employee training scientific interaction support medical people understand risk associate nonpromotional disease education advice seek scientific communication activity conduct compliance gsk value research disease awareness general public policy local law regulation training launch revise code practice support extended party support nonpromotional activity revise standard operating procedure order ensure understand comply risk agile innovative organisation mitigation ensure nonpromotional activity appear promotion continue build effective management monitoring system apply key risk indicator manage nonpromotional engagement privacy risk definition mitigate activity failure collect secure use destroy personal group chief compliance officer chair information accordance datum privacy law lead privacy governance board oversee gsk overall harm individual financial stress prejudice gsk datum privacy operating model gsk business area fine operational financial reputational appoint risk owner accountable overseeing privacy risk support privacy leader business risk impact country datum privacy law require datum protection noncompliance datum privacy law globally lead officer dpo appoint gsk appoint single harm individual gsk damage trust dpo represent support specific gsk individual community business partner country country privacy advisor government authority chief compliance officer gsk enterprise risk owner country increase enforcement power ero ero appoint delegate risk owner datum protection authority allow impose global privacy officer gpo daytoday accountability significant fine impact crossborder datum flow temporarily design implement control framework ban datum process new country law gpo colead crossfunctional privacy centre individual right bring collective legal action excellence global privacy counsel company like gsk failure comply datum privacy law support privacy officer privacy counsel multiple context country privacy advisor familiar local privacy datum privacy legislation diverse limited harmonisation regulation simplification challenge multinational standardise gsk evolve initial control framework implement approach compliance datum privacy law general data protection regulation government enforce compliance datum privacy law comprehensive privacy control framework base global rigorously focus ethical use personal privacy principle common global privacy landscape information grow compliance datum global framework deploy country exhibit privacy law increase volume datum need comprehensive framework base factor process advance technology like robust local privacy legislation establish datum protection workforce protection effective privacy control research authority gsk footprint country covid pandemic create unique challenge start preparation involve resource educate additionally new datum privacy law enforcement activity employee remain undeployed country gsk court decision like court justice european footprint union ruling schrems create uncertainty privacy centre excellence responsible international data transfer potential localisation requirement operate improve centralised global privacy control framework continuously assess provide relevant proportionate control aid nondeploye market gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertainty continue pprriivvaaccyy ccoonnttiinnuueedd monitor new change law adapt privacy continuously improve process issue framework accordingly identification report handling monitor privacy centre excellence involve new business deploy comprehensive training programme drive development opportunity early stage ensure great awareness accountability manage personal appropriate diligence perform right step information entire organisation take onboarde splitting business unit certify key gsk privacy network role accredit international privacy association research practice risk definition integrity governance datum essential success research practice risk failure adequately conduct stage datum lifecycle include design generation ethical sound preclinical clinical research addition recording management analysis report storage failure engage scientific activity retrieval datum govern legislation consistent letter spirit law industry regulatory requirement datum support document group requirement comprise follow subrisk core component stage pipeline progression nonclinical laboratory research human subject research decision make form content regulatory datum integrity care welfare treatment animal human submission publication patent filing poor datum integrity biological sample management datum disclosure regulatory governance compromise gsk effort filing engagement patent negatively impact reputation risk impact innate complexity interdependency potential impact risk include harm human subject regulatory filing particularly give global footprint reputational damage failure obtain necessary regulatory change increasingly stringent submission approval product governmental investigation legal requirement continue increase complexity worldwide proceeding bring group governmental product registration supply gsk medicine patient private plaintiff product liability suit claim damage dependent ongoing compliance maintenance loss revenue inadequate patent protection inability licence geography requirement supply gsk product regulatory action fine timeline differ secure management high volume penalty loss product authorisation lifecycle change licence renewal critical materially adversely affect financial result damage compliant supply failure maintain licence directly trust patient customer impact patient company revenue context wide variety biological material gsk research involve animal raise ethical concern discovery research development asset case research animal way convention biological diversity cbd nagoya investigate effect potential new medicine living protocol international community establish global body human animal research provide critical framework regulate access use genetic resource information cause mechanism disease nonhuman origin remain vital research continually support principle access benefit sharing seek way minimise use animal genetic resource outline cbd nagoya research development testing comply protocol recognise importance appropriate regulatory requirement reduce impact animal effective proportionate implementation measure national regional level human subject research include clinical trial healthy patent right award protect innovation play volunteer patient assess demonstrate important role provide competitive advantage investigational product efficacy safety evaluate market limited period time loss patent protection product approve disclose market gsk product develop research externally accord regulation ethical principle include reduce term availability scope patent right industry commitment materially adversely affect financial result work human biological sample market inadequate patent datum exclusivity protection fundamental discovery development safety lead example competition monitor product gsk commit ensure manufacturer generic biosimilar pharmaceutical product human biological sample manage accordance limit opportunity rely market future relevant law regulation ethical principle sale growth materially adversely impact manner respect interest sample donor financial result gsk annual report principal risk uncertainty continue research practice continue follow expiration certain intellectual property right enhance datum integrity control remain important generic biosimilar manufacturer lawfully produce priority datum integrity committee provide oversight compete copy product introduction generic product datum integrity quality assurance team conduct assessment typically lead rapid dramatic loss sale reduce provide independent business monitor internal revenue margin proprietary product control activity mitigate activity regulatory governance board serve global establish office animal welfare ethic regulatory risk management compliance board promote strategy oawes lead chief veterinary officer compliance regulatory requirement procedure support humane responsible care animal carry oversee groupwide write standard crossbusiness ethical review independent scientific review animal regulatory process significant programme underway study share knowledge advocate replace modernise regulatory information management application nonanimal alternative oawes provide system gsk framework animal welfare governance define provide establish access benefit sharing centre oversight animal care use training promote excellence oversee requirement enforcement measure replacement refinement reduction animal research acquisition use genetic material nonhuman conduct quality assessment manage programme origin line nagoya protocol external animal diligence develop deploy strategy reproducibility experiment translatability human organisation maintain control prepublication clinical end point procedure guard public disclosure advance filing patent application addition loss patent gsk chief medical officer oversee follow enterprise protection occur lack datum integrity prepare medical governance board patent application datum information legal expert human subject research board risk forum provide collaborate support review process new oversight human subject research sponsor patent application support ensure conform ethical medical research practice risk oversee enterprise scientific standard framework seeks ensure strengthen governance datum disclosure board risk forum oversee pharmaceutical vaccine consumer disclosure sponsor support human subject healthcare business research information available clinical leadership research practice enterprise risk study include summary result positive owner management risk take pragmatic approach negative information sharing streamline risk identification global human biological sample management escalation ensure ownership stay business hbsm governance framework oversee ethical lawful acquisition management human biological sample hbsm enterprise risk management team work minimise risk relate acquisition storage use transfer disposal human biological sample gsk annual report strategic report governance remuneration financial statement investor information environment health safety risk definition mitigate activity failure management corporate executive team responsible ehs governance risk oversight ensure effective execution hazardous activity control framework place use manage risk gsk physical asset infrastructure impact legal compliance issue relate ehs handle process hazardous chemical business include assign responsibility biological agent senior manager provide maintain control ensure tiere monitoring governance process control release substance harmful environment place business individual manager seek short long term ensure ehs control framework effective lead incident disrupt supply implement respective business area activity harm employee harm community harm fully compliant applicable law regulation local environment operate adequately resource maintain communicate monitor additionally employee personally risk impact responsible ensuring follow applicable local failure manage ehs risk lead significant harm standard operating procedure people environment community operate fine inability meet stakeholder expectation riskbase proactive approach articulate global regulatory requirement litigation regulatory action ehs policy detailed global ehs standard damage group reputation materially audit operation ensure compliance adversely affect financial result ensure hazards appropriately control safe design facility plant equipment follow context rigorous procedure help provide effective barrier gsk subject health safety environmental law protect employee health safety jurisdiction law impose duty protect people environment community despite extensive safety programme tragically operate potential obligation remediate experience employee fatality manufacturing contaminate site overall control framework site canada road traffic accident india manage ehs risk effective additional workrelate fatality belgium involve construction worker gsk direct supervision conduct extensive investigation cause fatality ensure action reduce risk similar tragic incident occur develop safety improvement plan strengthen exist safety practice gsk annual report principal risk uncertainty continue environmental sustainability risk definition mitigate activity failure management november gsk announce new commitment net zero climate impact net nature positive physical climate environmental risk goal build longterm ambition set current future regulatory requirement environmental reduce impact environment policy tax corporate executive team cet responsible delivery performance management environmental environmental sustainability governance risk oversight objective ensure effective framework place use lead reduce supply chain resilience product life cycle manage risk business deliver management issue loss trustreputation employee commitment gsk dedicated environmental investor customer regulator stakeholder sustainability enterprise risk plan place cet increase cost loss sale market access negative responsibility include appoint dedicated senior leader impact environment resource provide maintain risk control ensure governance process establish effective risk impact business gsk recognise way respond climate change manage environmental risk impact ability supply continue control antibiotic emission product patient consumer lead harm manufacturing effluent gsk facility environment impact reputation supplier follow good operational practice meeting emission limit define amr alliance manufacturing failure meet fastevolve regulatory requirement framework stakeholder expectation result litigation regulatory action materially adversely impact financial continuously assess business resilience climate result change task force climaterelate financial disclosure framework guideline context increasingly understand effect climate change ensure reduction carbon emission energy water nature loss interconnect waste deliver manage mature programme impact human health internal external expectation include ecodesign consideration product company address impact environment package increase effect climate change operational resilience regard access energy water natural resource product potential cost increase regulatory change environmental taxis gsk annual report strategic report governance remuneration financial statement investor information information security risk definition mitigate activity risk unauthorised disclosure theft unavailability global information security policy accompany corruption gsk information key information system standard process support dedicated lead harm patient workforce customer team programme activity gsk technology security disruption business andor loss commercial risk function provide strategy direction oversight strategic advantage damage reputation regulatory include active monitoring cybersecurity sanction enhance global information security capability ongoing programme investment risk impact follow significant investment mitigation activity failure adequately protect gsk information key continue advance come year information system cause harm patient workforce customer disruption business andor loss modernise cyber operation ensure timely detection commercial strategic advantage regulatory sanction response information security incident damage reputation modernise operational technology address age context complexity global footprint environment overall information security environment challenge manufacturing site difficulty keep pace increasingly optimise security architecture mitigate risk network sophisticated cyber threat factor user email externallyconnecte communication include complexity large regulate organisation removeable medium inappropriately intentionally wellresource nature hack activity increase unintentionally continue remediate demand accountability datum handle company improve control environment privileged elevated continue reassess gsk reliance interconnectivity user right gsk system party contractor partner supplier covid pandemic emerge significant external factor transfer party risk management manage impact information security manage gsk service partner organisation process gsk critical covidrelated threat include increase ransomware sensitive information support development attack healthcare sector hacker solution enable party opportunity disrupt critical healthcare operation access resource remotely secure case seize healthcare research relate covid environment vaccine treatment enable business performance high risk market gsk operate highlyconnecte information network assess datum information originate flow hold confidential research development manufacture international market local law norm represent commercial workforce financial datum mean heighten risk confidentiality integrity availability system information continue gsk operational system target cyberattack continue consolidate information system reduce attack point enable focused control gsks strategic approach digital analytic increase dependency digital asset distribute datum continue analysis assessment gsk critical data asset threat asset require continuous reevaluation emerge risk gsk mitigate action define area include secure deployment operation gsk resource highrisk market risk pose gsk datum cloud potential complexity result agile businessle development enterprise gsk annual report principal risk uncertainty continue supply continuity risk definition participate eus new reporting system failure deliver continuous supply compliant finish anticipate drug shortage introduce pandemic product inability respond effectively crisis incident proactively resolve supply issue potentially timely manner recover sustain critical operation impact hospital intensive care unit risk impact mitigate activity recognise important continuity supply supply chain model adopt pharmaceutical product patient consumer rely vaccine consumer healthcare business unit design material interruption supply lead litigation ensure far possible supply quality security regulatory action include exclusion healthcare product world programme financial penalty adversely affect supply chain governance committee business unit group financial result gsk international presence closely monitor inventory status delivery product partner expose workforce facility aim ensure customer product operation potential disruption natural event need improved link commercial forecasting storm earthquake manmade event manufacturing possible core commercial cycle imposition trading barrier short notice civilpolitical time reduce risk associate demand unrest terrorism cyberattack public health fluctuation impact ability supply cost emergency global covid pandemic writeoff product exceed expiry date vital robust crisis management node supply chain periodically review ensure recovery plan place manage event adequate safety stock balance work capital context endtoend supply chain particular attention place supply chain operation subject review approval mitigate supply risk associate medicallycritical regulatory agency effectively provide highrevenue product key new product launch licence operate failure manufacturing distribution routinely monitor compliance external manufacturing network deliver product lead litigation regulatory supplier service provider identify manage risk action product recall seizure interruption supply base practical minimise dependence supply delay approval new product suspension single source supply critical item alternative manufacture operation pende resolution manufacture source arrangement possible certain material logistic issue inventory strategy aim limit impact ultimately rely material service provide party protect supply chain unanticipated disruption supplier product include active continue implement anticounterfeit system like product pharmaceutical ingredient antigen intermediate serialisation accordance new emerge supply chain commodity component develop manufacturing requirement world falsify packaging pharmaceutical vaccine consumer medicine directive healthcare product thirdparty oversight include outsource operation contract manufacture corporate policy require business functional area clinical research organisation provide manufacture head ensure effective crisis management business support development key product behalf continuity plan include authorised response recovery strategy key area responsibility clear communication undertake risk mitigation recognise route place business disruption occur certain event result delay service interruption corporate security support business coordinating use effective crisis management business continuity crisis management business continuity training facilitating planning ensure health safety people simulation exercise assess preparedness recovery minimise impact supply maintain functional capability provide assurance oversight gsk central operation event natural manmade disaster repository plan support critical business process public health emergency drug shortage report appropriate regulatory authority food business unit perform risk oversight drug administration transparency solicit feedback respective risk management compliance board assure risk mitigation adequate risk mitigation include identify new emerge threat example take coordinated approach supply performance expectation increase evaluate managing implication gsk brexit covid pandemic government seek secure supply key medicine vaccine prioritise align activity help ensure maintain appropriate manufacture supply pandemic level readiness response capability develop medicine supplier leverage strategic stock maintain partnership external body include modify supply route avoid disrupt availability business continuity institute international strategy finish product disaster risk reduction help improve business continuity initiative disasterprone area support development community resilience disaster gsk annual report strategic report governance remuneration financial statement investor information transformation risk definition mitigate activity failure deliver plan successful transformation future ready office fro establish fourth separation gsk competitive standalone company quarter accountable monitoring progress new gsk biopharma company new consumer performance risk associate create new healthcare lead company report monthly corporate executive team cet ensure enterprise oversight risk impact plan key performance risk indicator addition failure manage increase macro level risk gsk chief executive officer ceo chief financial officer covid relation delivery transformation plan chief strategy officer head fro meet leader materially adversely affect ability deliver gsk consumer healthcare input approval key design strategy longterm priority choice new company require overall balance context transformation separation uphold clear february gsk announce new future ready governance joint new gsk consumer healthcare programme prepare separation company coordination rigorous progress track set new gsk biopharma company approach clear parameter focus science relate immune system use gsk board regularly inform future ready genetic new technology new leader consumer programme lead indicator ceo board report healthcare gsk increase investment new board meeting transformation separation product launch twoyear separation programme aim committee establish board level support drive common approach innovation modality advise management work transform separate improve capital allocation align improve capability group committee chair gsk chairman efficiency global support function support new include senior independent director chair gsk optimise supply chain portfolio audit risk remuneration corporate responsibility include divest noncore asset prepare consumer committee healthcare operate standalone company complete outlook company fundamentally strengthen make efficient modern automate future skill capability extend transition timeline gsk annual report shareholder information share capital control detail issue share capital number share interest voting right hold treasury december found state far aware note financial statement share capital share person significant direct indirect holding premium account company information provide company pursuant financial conduct authoritys disclosure guidance ordinary share list london stock exchange transparency rule dtr publish regulatory lse quote new york stock exchange information service company website nyse form american depositary share ad wwwgskcom ad represent ordinary share detail list debt list refer note financial statement company receive notification accordance net debt dtr follow notifiable interest voting right company issue share capital holder ordinary share ad entitle receive dividend declare company annual report december march entitle attend speak appoint proxy percentage percentage exercise voting right general meeting company total voting total voting voting right right voting right right restriction transfer limitation blackrock inc hold ordinary share ad requirement dodge cox obtain approval prior transfer ordinary share percentage total voting right date notification company ad carry special right regard control comprise indirect interest ordinary share company restriction vote right major holding qualify financial instrument contract shareholder voting right share difference shareholder know arrangement comprise indirect interest ordinary share financial right hold person holder american depositary share share know agreement restriction share company acquire disposed interest transfer vote right share period review share acquire group employee share plan exception transfer treasury satisfy award rank equally share issue special group employee share plan right trustee employee share ownership plan share buyback programme trust waive right dividend share hold board authorise issue allot ordinary trust share article company article association exchange control limitation affect holder power article authority company certain economic sanction purchase share subject shareholder force time time currently applicable law authority seek annual basis annual decree regulation force restrict import general meeting agm share purchase export capital restrict remittance dividend company cancel hold treasury share payment holder company share satisfy share option grant group nonresident similarly certain economic employee share plan sanction force time time programme cover purchase share cancellation limitation relate nonresident english hold treasury share accordance law company article association right authority renewed shareholders agm holder vote respect company share company authorise purchase maximum million share detail share purchase cancel hold treasury share subsequently transfer treasury satisfy awards group employee share plan disclose note financial statement share capital share premium account determine specific share repurchase level company consider development free cash flow year share purchase company confirm currently intend market purchase company review potential future share buyback line usual annual cycle subject return rating criterion gsk annual report strategic report governance remuneration financial statement investor information shareholder information continue share capital control continue market capitalisation market capitalisation base share issue exclude treasury share gsk december billion date gsk large company market capitalisation ftse index share price january december increasedecrease high year low year table set middle market closing price companys share price decrease compare increase ftse index share price ad price year middle market closing share price march nature trading market follow table set period indicate high low middle market closing price company ordinary share lse ad nyse ordinary share ad share share high low high low march february january december november october september quarter end december quarter end september quarter end june quarter end march quarter end december quarter end september quarter end june quarter end march year end december year end december year end december year end december march gsk annual report shareholder information continue analysis shareholding december number total total number account account share share hold share hold institutional corporate holder individual corporate body guaranty nominee limit hold treasury share glaxosmithkline morgan chase bank depositary company american depository receipt adr programme company ad list nyse ordinary share represent company adr programme manage depositary register guaranty nominee limit march guaranty nominee limit hold ordinary share represent issue share capital exclude treasury share date march number holder ordinary share holding ordinary share number register holder ad holding ad certain ordinary share ad hold broker nominee result number holder record register holder representative number beneficial holder residence beneficial holder dividend company pay dividend quarterly continue return board intend maintain dividend cash shareholder dividend policy dividend current level share subject material change remain essential component total shareholder return external environment performance expectation gsk recognise importance dividend shareholder implement new distribution policy dividend company aim distribute regular dividend payment detail dividend declare amount payment determine primarily reference free cash flow date give note financial statement generate business funding investment dividend necessary support group future growth dividend calendar dividend share quarter exdividend date record date payment date table set dividend share ad february february april year dividend ad translate july dollar applicable exchange rate august august october november november january year dividend pence february february april ordinary dividend receivable ad holder calculate base exchange rate april annual fee ad ad quarter charge depository cumulative dividend receivable ad holder gsk annual report strategic report governance remuneration financial statement investor information shareholder information continue financial calendar result announcement event date result announcement issue lse available quarter result announcement april news service send security annual general meeting exchange commission sec nyse issue biopharma investor update june media available website quarter result announcement july quarter result announcement october financial report preliminaryquarter result announcement february company publish annual report annual report publication februarymarch available website date publication annual report distribution march shareholder elect receive notification email publication annual report register information company include share ad wwwshareviewcouk elect receive price available website wwwgskcom information print copy annual report contact registrar available website constitute equiniti limited annual report copy previous annual report available website print copy obtain registrar contact detail annual general meeting annual general meeting agm hold investor hold share nominee service time wednesday great west arrange nominee service appoint proxy road brentford middlesex company respect shareholding order attend vote register office meeting electronically agm broadcast online register office ad holder wish attend meet electronically line government covid restriction refer agm notice detail request proxy physical attendance shareholder permit appointment depositary morgan chase bank shareholder invite attend meeting electronically enable attend ask question vote agm company principal forum communication electronically business transact meeting private shareholder addition formal agm ad holder remind instruct business presentation ceo depositary way share represent performance group future development ad vote complete return opportunity question ask board voting card provide depositary share chair board committee workforce vote engagement director available question document display relate role article association company director detail access agm ask question service contract applicable letter appointment vote electronically find notice annual director company subsidiary general meeting agm notice available letter relate severance term pension website wwwgskcom arrangement available inspection company register office appointment gsk annual report shareholder information continue tax information shareholder summary certain tax federal income tax inheritance tax consequence holder share ad citizen individual ukdomicile shareholder set complete liable inheritance tax transfer share ad analysis possible tax consequence purchase tax charge value ownership sale security intend shareholder estate reduce result transfer general guide holder advise consult adviser way lifetime gift disposal market respect tax consequence purchase ownership value case bequest death tax charge sale share ad consequence state value share date shareholder death local tax law implication current gift disposal subject ukus tax convention inheritance tax estate gift tax estate gift tax convention generally provide tax pay holder ad generally treat owner credit tax payable underlie share purpose current ukus double taxation convention relate income gain stamp duty stamp duty reserve tax income tax convention estate gift taxis estate gift stamp duty andor stamp duty reserve tax sdrt tax convention purpose internal revenue subject certain exemption payable transfer code amend share rate round near case stamp duty consideration transfer shareholder notwithstanding provide instrument execute summary apply resident shareholder pursuance agreement give rise charge hold share capital asset sdrt instrument stamp year agreement include stamp exempt sdrt taxation dividend charge cancel sdrt tax year resident individual pay repay entitle dividend tax allowance dividend receive tax year free shareholder tax dividend excess allowance tax summary apply shareholder citizen basic rate taxpayer high rate taxpayer resident domestic corporation person additional rate taxpayer subject federal income tax net income resident shareholder corporation taxpayer basis respect share ad hold share ad note dividend payable ordinary share generally capital asset resident tax purpose entitle exemption corporation tax hold share purpose trade profession vocation carry branch taxation capital gain agency resident shareholder liable tax gain disposal share ad summary address tax treatment holder subject special tax rule bank disposal individual tax year taxexempt entity insurance company dealer security taxable capital gain accrue disposal share ad currency person hold share ad tax basic rate taxpayer integrate investment include straddle comprise allowable deduction individual taxable income share ad position person year exceed basic rate income tax banding note directly indirectly company stock follow use exemption available individual vote value address tax treatment taxpayer annual exempt applicable result international income tax treaty corporation taxpayer entitle indexation allowance apply reduce capital gain extent gain arise inflation indexation allowance reduce chargeable gain create allowable loss asset acquire january legislation finance act freeze level indexation allowance give calculate company chargeable gain value apply disposal asset december asset acquire january onwards legislation finance act remove indexation allowance disposal gsk annual report strategic report governance remuneration financial statement investor information shareholder information continue tax information shareholder continue taxation dividend taxation capital gain gross dividend receive treat foreign generally holder subject capital gain source dividend income tax purpose eligible tax subject tax capital gain realise dividend receive deduction allow corporation sale disposal share ad gain dividend ad payable dollar dividend longterm capital gain subject reduce rate taxation ordinary share payable sterling dividend pay individual holder share ad hold sterling include income dollar year date share vestedrelease calculate reference exchange rate day shortterm capital gain subject taxation rate dividend receive holder subject certain longterm capital gain subject exception shortterm hedge position individual rate state local tax rate capital gain eligible holder subject taxation maximum apply federal rate plus applicable state local tax information report backup withholding respect qualified dividend qualified dividend define dividend payment proceed sale share internal revenue service irs dividend ad pay certain usrelated financial meet follow criterion intermediary subject information reporting issued corporation corporation subject backup withholding holder incorporate possession corporation corporation exempt recipient provide taxpayer eligible benefit comprehensive income tax treaty identification number certifie loss exemption deem satisfactory publish irs occur nonus holder generally subject dividend type list irs dividend information report backup withholding qualify require provide certification nonus status connection payment receive amount withhold require dividend hold period meet allow refund credit holder federal share own day income tax liability provide require information furnish hold period define day irs period begin day exdividend date day stock trade dividend price estate gift taxis example stock exdividend date october estate gift tax convention shareholder share hold day period generally subject inheritance tax august november year order holder subject federal estate gift tax count qualified dividend stamp duty dividend qualified subject taxation stamp duty andor sdrt subject certain exemption federal graduate tax rate maximum rate payable transfer share ad custodian type dividend automatically exclude depository rate consideration qualified dividend meet requirement provide transfer sale value transfer include limited consideration capital gain distribution stamp duty sdrt payable dividend bank deposit transfer agreement transfer ad dividend hold corporation employee stock ownership plan esop dividend pay taxexempt corporation state local tax rate qualify nonqualified dividend vary assess addition federal tax rate communicate gsk annual report statutory disclosure shareholder service contact registrar company registrar equiniti limited aspect house spencer road lance wwwshareviewcouk tel tel outside equiniti provide range service shareholder service offer participate dividend reinvestment plan alternative receive cash dividend choose drip election form download drip reinvest dividend buy gsk share wwwshareviewcouk request contact equiniti dividend payment direct bank dividend pay directly bank building society dividend bank mandate form account bank mandate account receive cash dividend provide download wwwshareviewcouk equiniti bank building society account detail request contact equiniti quick secure method payment dividend payment direct bank equiniti convert dividend local currency detail service cost account overseas shareholder send direct local bank account service available involve contact equiniti country worldwide electronic communication shareholder elect receive electronic notification register wwwshareviewcouk company communication include annual report dividend payment dividend confirmation availability online vote general meeting time gsk publish shareholder document receive email contain link document relevant website shareview portfolio service enable create free online portfolio view register wwwshareviewcouk share balance movement update address dividend payment instruction register vote general meeting deduplication publication mailing receive duplicate copy mailing contact equiniti account contact equiniti arrange account merge convenience avoid waste unnecessary cost share deal service shareholder trade share hold certificate online transaction log note market trading hour form corporate sponsor nominee online wwwshareviewcoukdeale time telephone postal dealing service provide equiniti telephone transaction monday friday exclude public financial service limit holiday england wale outside line open time monday friday exclude public holiday postal transaction request deal form corporate sponsor nominee account convenient way manage share require application form request share certificate service provide facility hold wwwshareviewcouk share nominee account sponsor company contact equiniti continue receive dividend payment attend vote company general meeting shareholder name appear publicly available share register service free join individual saving account isas company arrange equiniti financial service detail available wwwshareviewcouk limited provide gsk corporate isa hold gsk share request telephone equiniti line open deal enquiry monday friday exclude public holiday england wale line open monday friday exclude public holiday england wale provision share deal detail intend invitation inducement engage investment activity advice share dealing obtain stockbroker independent financial adviser gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue shareholder service contact continue ad depositary contact adr programme administer morgan investor relation chase bank investor relation contact follow regular correspondence shareowner services great west road box brentford middlesex paul tel delivery stock certificate overnight mail shareowner services crescent drive centre point curve suite philadelphia mendota heights tel toll free wwwshareowneronlinecom tel outside general gsk response center outside tel toll free depository provide global invest direct direct share scam alert ad purchasesale dividend reinvestment plan ad receive unsolicited telephone offering sell buy holder detail enrol visit wwwadrcom share extra care caller helpline number obtain enrolment pack highly organise financial scam donate share save child shareholder contact financial gsk embark ambitious global partnership conduct authority wwwfcaorgukconsumer save child share expertise resource consumer helpline aim help save live million child tel shareholder small number share value make uneconomical sell wish consider donate tel outside save child donate share aggregate line open time monday friday public sell save child use fund raise holiday saturday help reach goal obtain share donation form contact registrar equiniti manage donation sale share save child free charge provision share deal detail intend invitation inducement engage investment activity advice share dealing obtain stockbroker independent financial adviser stock exchange announcement notification provide shareholder service receive automatic email notification publish stock exchange announcement receive email notification sign announcement wwwgskcom investor section gsk annual report statutory disclosure continue law regulation number provision law regulation apply section corporate responsibility company share quote nyse financial report form ad sarbanesoxley require ceo cfo complete formal certification confirm nyse rule general nyse rules permit company follow review annual report form corporate governance practice instead apply base knowledge annual report form provide explain significant variation contain material misstatement omission explanation contain form base knowledge financial statement access sec edgar database website financial information fairly present material respect nyse rule require file annual interim write financial condition result operation cash flow affirmation concern audit risk committee arc date period present annual report statement significant difference corporate form governance responsible establish maintain sarbanesoxley act disclosure control procedure ensure material follow number corporate accounting scandal information know evaluate congress pass sarbanesoxley act effectiveness control procedure year sarbanesoxley wideranging piece legislation end result evaluation contain concerned largely financial report corporate annual report form governance responsible establish maintain internal recommend sec company establish control financial reporting provide reasonable disclosure committee committee report ceo assurance reliability financial reporting cfo arc chair company secretary preparation financial statement external purpose member consist senior manager finance legal accordance generally accept accounting principle corporate communication investor relation disclose annual report form external legal counsel external auditor internal expert change internal control financial reporting invite attend disclosure committee meeting period cover annual report form periodically committee responsibility consider materially affect reasonably likely affect materially materiality information timely basis determine company internal control financial reporting disclosure information responsibility disclose base recent evaluation timely filing report sec formal review internal control financial report external auditor annual report form committee meet arc significant deficiency material time weaknesse design operation internal control sarbanesoxley require annual report form financial reporting reasonably likely affect contain statement member arc adversely company ability record process audit committee financial expert define rule summarise report financial information fraud sarbanesoxley statement relevant member regardless materiality involve person arc judy lewent charles bancroft include significant role company internal control financial board committee information area corporate reporting governance report biography group carry evaluation supervision page additional disclosure requirement arise participation management include ceo section section sarbanesoxley cfo effectiveness design operation respect disclosure control procedure internal group disclosure control procedure control financial reporting december inherent limitation effectiveness system disclosure control procedure include possibility human error circumvention override control procedure accordingly effective disclosure control procedure provide reasonable assurance achieve control objective gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue law regulation continue ceo cfo expect complete certification group export certain pharmaceutical vaccine report conclusion effectiveness disclosure consumer product iran sale nonus entity control procedure march follow subsidiary entity privately hold iranian certification file sec group distributor form group regularly receive information section management annual report internal identity distributor downstream customer control financial reporting intermediary iran possible party accordance requirement section include entity governmentowne hospital sarbanesoxley follow report provide pharmacy own directly indirectly iranian management respect company internal control government person entity sanction connection financial reporting define rule terrorism proliferation activity securities exchange act amend group regularly receive information exchange act identity distributor downstream customer management responsible establish maintain establish proportion gross revenue sale adequate internal control financial report potentially attributable entity affiliate iranian group internal control financial reporting design government party sanction disclosable activity provide reasonable assurance reliability result group report entire gross revenue financial reporting preparation financial statement million net loss million group sale external purpose accordance ifrs iran management conduct evaluation effectiveness group aware hospital medical internal control financial reporting base facility lebanon affiliate control framework internal control integrate framework hezbollah group designate united issue committee sponsor organisation state pursuant executive order group treadway commission coso deal directly hospital facility instead sell distributor group unable change group internal control establish proportion gross revenue sale potentially financial reporting materially attributable reportable activity result group affect reasonably likely affect materially report entire gross revenue million net group internal control financial reporting profit million group sale lebanon management assess effectiveness internal control financial reporting december note group intends continue activity conclusion file group form describe addition section exchange act law deloitte llp audit consolidated financial generally restrict dealing person dealing statement group year end december subject jurisdiction certain country assess effectiveness group territory subject comprehensive sanction currently internal control financial reporting auditing crimea cuba iran north korea syria standard public company accounting oversight government venezuela country board united states audit report file venezuela group business nonus group form entities own control entity section exchange act certain jurisdiction believe group complie applicable sanction material respect section exchange act require issuer law complex continue evolve rapidly specific disclosure annual report certain type dealing iran include transaction dealing governmentowne entity dealings entity sanction activity relate terrorism proliferation weapon mass destruction activity prohibit law involve person gsk annual report statutory disclosure continue donation political organisation political expenditure ensure consistent approach political contribution result definition cover legitimate business group global policy introduce activity ordinary sense consider political voluntarily stop corporate political contribution donation political expenditure design support political party independent election candidate period january december group political donation notwithstanding policy noneu organisation intend donation political party organisation incur political expenditure notwithstanding introduction policy accordance annually seek shareholder authorisation inadvertent federal election campaign act continue expenditure support employeeoperate political action committee pac facilitate voluntary political donation eligible authority precautionary measure ensure gsk employee company subsidiary inadvertently breach legislation pac control gsk decision amount recipient contribution authorisation process expenditure participate employee exercise legal right pool year date agm hold follow resource political contribution introduction political party election subject strict limitation total referendum act authority donate political organisation renew annually gsk employee pac english law require prior shareholder approval political contribution political party independent election candidate political expenditure definition political donation political expenditure political organisation legislation broad particular definition political organisation extend body concern policy review law reform representation business community special interest group concern environment company subsidiary wish support gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company accordance section company act list subsidiary associate joint venture joint arrangement address register office effective percentage equity own december disclose state share capital disclose comprise ordinary share indirectly hold glaxosmithkline plc percentage hold class share state state subsidiary company register office tax resident country incorporation security register address wholly own subsidiary alberta ulc common street calgary canada action potential venture capital limit ordinary great west road brentford middlesex england adechsa gmbh ordinary prv provide treuhandgesellschaft dorfstrasse baar switzerland affymax research institute common corporation service company gateway oak drive suite sacramento california united states allen hanburys limited ordinary great west road brentford middlesex england allen hanburys pharmaceutical nigeria limited ordinary abimbola way ilasamaja isolo lagos nigeria allen farmaceutica ordinary severo ochoa parque tecnologico madrid tres cantos madrid spain allen pharmazeutika gesellschaft mbh ordinary wagenseilgasse euro plaza gebude stock vienna austria beecham group plc shares share great west road brentford middlesex england beecham pharmaceutical pte limited ordinary quality road jurong industrial estate jurong singapore beecham portuguesaproduto farmaceuticos quimicos lda ordinary quota rua antonio loureiro borge arquiparque miraflore alge portugal beecham ordinary parc noire epine avenue fleming wavre belgium biovesta ilalari ltd sti nominative bykdere caddesi levent plaza blok levent istanbul turkey cascan gmbh partnership capital prinzregentenplatz munich germany castleton investment ltd liquidation ordinary dtos cybercity floor standard charter tower ebene mauritius cellzome gmbh ordinary meyerhofstrasse heidelberg germany cellzome inc merged glaxosmithkline llc dec common corporation service company little fall drive wilmington series preferred delaware united states series prefer series convertible prefer series convertible prefer charles midgley limited ordinary cumulative preference great west road brentford middlesex england clarge pharmaceutical trustee limited ordinary great west road brentford middlesex england colleen corporation common corporation service company little fall drive wilmington delaware united states corixa corporation common corporation service company little fall drive wilmington delaware united states coulter pharmaceutical inc common corporation service company little fall drive wilmington delaware united states dealcyber limited ordinary great west road brentford middlesex england desarrollo energia solar alternativa ordinary severo ochoa parque tecnologico madrid tres cantos madrid spain duncan flockhart australia pty limited ordinary mountain highway boronia vic australia etex farmaceutica ltda social capital avenue andre bello piso las conde santiago chile fipar thailand ltd liquidation ordinary floor wave place wireless road lumpini pathumwan bangkok thailand genelabs technologies inc common corporation service company gateway oak drive suite sacramento california united states glaxo group limit ordinary great west road brentford middlesex england glaxo kabushiki kaisha ordinary akasaka minatoku tokyo japan glaxo laboratories nigeria limited ordinary marine road apapa lagos nigeria glaxo laboratory limit liquidation ordinary baker street london england glaxo new zealand pension plan trustee limited ordinary level egenerator gridakl madden street wynyard quarter auckland new zealand glaxo operation limit ordinary great west road brentford middlesex england glaxo property ordinary van asch van wijckstraat amersfoort netherlands gsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue glaxo trustee limited liquidation ordinary baker street london england glaxo verwaltung gmbh ordinary industriestrasse bad oldesloe germany glaxo wellcome australia pty ltd ordinary mountain highway boronia vic australia glaxo wellcome farmaceutica limitada ordinary quota rua antonio loureiro borge arquiparque miraflore alge portugal glaxo wellcome international iii ordinary huis ter heideweg zeist netherlands glaxo wellcome manufacturing pte ltd ordinary pioneer sector jurong industrial estate jurong singapore glaxo wellcome production sas ordinary rue franois jacob rueilmalmaison france glaxo wellcome vidhyasom limited ordinary floor wave place wireless road lumpini pathumwan bangkok thailand glaxo wellcome ordinary poligono industrial allendeduero avenida extremadura aranda duero burgo spain glaxo ordinary severo ochoa parque tecnologico madrid tres cantos madrid spain glaxoallenburys nigeria limited ordinary creek road apapa lago pmb nigeria glaxochem pte ltd iii ordinary rochester park singapore glaxosmithkline produtos farmaceuticos limitada ordinary quota rua antonio loureiro borge arquiparque miraflore alge portugal glaxosmithkline cambodia ltd liquidation ordinary floor dksh building preah monivong boulevard corner street sangkat phsar deum thakov khan chamkarmon phnom penh cambodia glaxosmithkline china investment ltd ordinary room unit floor mid east ring road chaoyang district beijing china glaxosmithkline china company limited equity building huanke road pilot free trade zone shanghai china glaxosmithkline cyprus limited ordinary arch makariou iii capital center floor nicosia cyprus glaxosmithkline gsk srl ordinary costache negri street opera center floor zone district bucharest romania glaxosmithkline ireland limit ordinary riverwalk citywest business campus dublin ireland glaxosmithkline israel ltd ordinary basel street box petachtikva israel glaxosmithkline malta limit ordinary floor cruz avenue qormi qrm malta glaxosmithkline private limited ordinary unit anthony road msasa harare zimbabwe glaxosmithkline thailand limited ordinary floor wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline ordinary hemvarnsg solna sweden glaxosmithkline ordinary talstrasse muenchenbuchsee switzerland glaxosmithkline angola unipessoal limitada quota luanda bairro petrangol estrada cacuaco angola glaxosmithkline argentina ordinary tucumn piso buenos aire caaa argentina glaxosmithkline ordinary drammensveien oslo norway glaxosmithkline asia pvt limited equity patiala road nabha dist patiala punjab india glaxosmithkline australia pty ltd ordinary mountain highway boronia vic australia glaxosmithkline ordinary van asch van wijckstraat amersfoort netherlands netherlands glaxosmithkline beteiligung gmbh ordinary prinzregentenplatz munchen germany glaxosmithkline biological shanghai ltd ordinary niudun road pilot free trade zone shanhai china glaxosmithkline biological kft ordinary gdll homoki nagy istvn utca hungary glaxosmithkline biological sas ordinary rue des aulnois saintamand les eaux france glaxosmithkline biological ordinary preference rue rixensart belgium glaxosmithkline brasil limitada quotas estrada do bandeirante rio janeiro brazil glaxosmithkline capital inc common wilmington trust services inc north market street suite wilmington delaware united states glaxosmithkline capital plc ordinary great west road brentford middlesex england glaxosmithkline caribbean limited ordinary great west road brentford middlesex england glaxosmithkline chile farmaceutica limitada social capital avenue andre bello piso las conde santiago chile glaxosmithkline colombia ordinary avenida dorado bpiso bogota colombia glaxosmithkline consumer healthcare holding limit ordinary great west road brentford middlesex england glaxosmithkline consumer healthcare investment ireland ordinary knockbrack dungarvan waterford ireland limited iii liquidation glaxosmithkline consumer healthcare ireland limited iii ordinary knockbrack dungarvan waterford ireland liquidation glaxosmithkline consumer hold ordinary van asch van wijckstraat amersfoort netherlands gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company continue security register address wholly own subsidiary continue glaxosmithkline doo quota zmja bosne broj sarajevo bosnia herzegovina glaxosmithkline doo equity capital ulica damira tomljanovica gavrana zagreb croatia glaxosmithkline doo beograd ordinary omladinskih brigada new belgrade city belgrade serbia glaxosmithkline ecuador ordinary agosto naciones unidas edificio electroectuatoriana piso quito ecuador glaxosmithkline eesti ordinary ltsa tallinn estonia glaxosmithkline salvador ordinary municipio san salvador departamento san salvador salvador glaxosmithkline eood ordinary tsarigradsko shose blvd floor mladost region sofia bulgaria glaxosmithkline export limit ordinary great west road brentford middlesex england glaxosmithkline export panama ordinary panama city republic panama panama glaxosmithkline far east ordinary van asch van wijckstraat amersfoort netherlands glaxosmithkline finance plc ordinary great west road brentford middlesex england glaxosmithkline gmbh partnership capital prinzregentenplatz munchen germany glaxosmithkline guatemala ordinary zona torre citibank nivel guatemala city guatemala glaxosmithkline hold ordinary drammensveien oslo norway glaxosmithkline holdings americas inc common wilmington trust services inc north market street suite wilmington delaware united states glaxosmithkline holdings ireland limited ordinary defer great west road brentford middlesex england glaxosmithkline holding limited ordinary great west road brentford middlesex england glaxosmithkline holding limit ordinary great west road brentford middlesex england glaxosmithkline holdings pty ltd ordinary mountain highway boronia vic australia glaxosmithkline honduras ordinary tegucigalpa mdc honduras glaxosmithkline ihc limit ordinary great west road brentford middlesex england glaxosmithkline ilaclari sanayi ticaret nominative bykdere caddesi levent plaza blok levent istanbul turkey glaxosmithkline inc class common class preference mississauga road north mississauga canada glaxosmithkline insurance ltd ordinary parlaville road hamilton bermuda glaxosmithkline intellectual property limit ordinary great west road brentford middlesex england glaxosmithkline intellectual property development limit ordinary great west road brentford middlesex england glaxosmithkline intellectual property holding limit ordinary ordinary great west road brentford middlesex england glaxosmithkline intellectual property limit ordinary defer great west road brentford middlesex england glaxosmithkline intellectual property management limit ordinary great west road brentford middlesex england glaxosmithkline investigacin desarrollo ordinary severo ochoa parque tecnolgico madrid tres cantos madrid spain glaxosmithkline investment holdings limit liquidation ordinary baker street london england glaxosmithkline investment service limit liquidation ordinary baker street london england glaxosmithkline investments ireland limited iii liquidation ordinary riverwalk citywest business campus dublin ireland glaxosmithkline investments pty ltd ordinary mountain highway boronia vic australia glaxosmithkline ordinary akasaka minatoku tokyo japan glaxosmithkline korea limited ordinary yongsan tower hangangdaero yongsangu seoul republic korea glaxosmithkline latin america ordinary panama city republic panama panama glaxosmithkline latvia sia ordinary dunte iela riga latvia glaxosmithkline lietuva uab ordinary ukmerge vilnius lithuania glaxosmithkline limit ordinary tower gateway canton road tsimshatsui kowloon hong kong glaxosmithkline llc llc interest corporation service company little fall drive wilmington delaware united states glaxosmithkline manufacture spa ordinary alessandro fleming verona italy glaxosmithkline maroc ordinary angle rachidi abou ham glaza casablanca morocco glaxosmithkline medical healthcare product limit ordinary csorsz utca budapest hungary glaxosmithkline mercury limit ordinary great west road brentford middlesex england glaxosmithkline mexico ordinary ordinary calzada mexicoxochimilco colonia san lorenzo huipulco delegacion tlalpan mexico glaxosmithkline limit ordinary level madden street wynyard quarter auckland new zealand glaxosmithkline ordinary piispansilta box espoo fin finland glaxosmithkline peru ordinary javier prado oeste san isidro lima peru glaxosmithkline pharma ordinary nykaer brondby denmark gsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue glaxosmithkline pharma gmbh ordinary wagenseilgasse euro plaza gebude stock vienna austria glaxosmithkline pharmaceutical kenya limit ordinary likoni road nairobi kenya glaxosmithkline pharmaceutical nigeria limited ordinary industrial avenue ilupeju ikeja lagos nigeria glaxosmithkline pharmaceutical sdn bhd ordinary level quill jalan prof khoo kay kim petale jaya selangor malaysia glaxosmithkline pharmaceuticals pvt ltd ordinary galle road kaldemulla moratuwa sri lanka glaxosmithkline pharmaceuticals costa rica ordinary metros este rotonda betania mercede montes oca sabanilla montes oca san jose costa rica glaxosmithkline pharmaceuticals ordinary ordinary grunwaldzka poznan poland ordinary ordinary glaxosmithkline pharmaceutical ordinary site apollo avenue pascal wavre belgium glaxosmithkline pharmaceutical ukraine llc charter capital pavla tychyny avenue kiev ukraine glaxosmithkline pte ltd ordinary rochester park singapore glaxosmithkline puerto rico inc common prenticehall corporation system puerto rico inc fast solution llc ponce leon avenue floor san juan puerto rico glaxosmithkline republica dominicana ordinary blue mall tower floor ave winston churchill santo domingo dominican republic glaxosmithkline research development limit ordinary great west road brentford middlesex england glaxosmithkline ordinary severo ochoa parque tecnologico madrid tres cantos madrid spain glaxosmithkline spa ordinary viale dellagricoltura verona italy glaxosmithkline sro ordinary hvezdova prague czech republic glaxosmithkline services gmbh partnership capital prinzregentenplatz munchen germany glaxosmithkline services inc common corporation service company little fall drive wilmington delaware united states glaxosmithkline service unlimite ordinary great west road brentford middlesex england glaxosmithkline single member aebe ordinary kifissias avenue halandri athens greece glaxosmithkline llc llc interest corporation service company little fall drive wilmington delaware united states glaxosmithkline viii partnership great west road brentford middlesex england glaxosmithkline slovakia sro ordinary galvaniho bratislava slovakia glaxosmithkline south africa pty limited ordinary flush meadow build campus sloane street bryanston south africa glaxosmithkline trade ordinary leningradskiy prospect build floor premise room moscow russian federation glaxosmithkline trading services limit iii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline tunisia sarl ordinary immeuble les quatre rue lac lochness berge lac tunis tunisia glaxosmithkline limit ordinary great west road brentford middlesex england glaxosmithkline uruguay register share provisory stock salto montevideo uruguay glaxosmithkline trading limit ordinary great west road brentford middlesex england glaxosmithkline venezuela ordinary urbanizacion trinidad calle luis camoems edif apatado posta caracas venezuela glaxosmithkline vietnam limited liability company equity capital metropolitan dong khoi street district floor unit chi minh city viet nam glycovaxyn common prefer grabenstrasse schlieren switzerland preferred prefer groupe glaxosmithkline sas ordinary rue franois jacob rueilmalmaison france gsk australia nvd pty ltd ordinary mountain highway boronia vic australia gsk bangladesh private limited ordinary sweden tower harinnachala konabari gazipur bangladesh gsk biopharma argentina nominative non endorseable tucumn piso buenos aire caaa argentina ordinary share gsk business service centre sdn bhd ordinary level quill jalan prof khoo kay kim petale jaya selangor malaysia gsk capital incorporate iii ordinary great west road brentford middlesex england gsk capital ordinary akasaka minatoku tokyo japan gsk commercial ordinary rzymowskiego warsaw poland gsk doo ljubljana ordinary amerika ulica ljubljana slovenia gsk enterprise management ltd ordinary floor lane huanke road zhongke road shanghai china gsk equity investment limited unit corporation service company interstate drive suite harrisburg pennsylvania united states gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company continue security register address wholly own subsidiary continue gsk finance limit ordinary great west road brentford middlesex england gsk finance plc ordinary great west road brentford middlesex england gsk india global services private limited equity share prestige trade tower floor palace road sampangiramnagar bangalore karnataka india gsk kazakhstan llp participationparticipating interest furmanov street almaty medeu district kazakhstan gsk pharma vietnam company limited charter capital unit floor metropolitan tower dong khoi street ben nghe ward district chi minh viet nam gsk pharmaceutical trading ordinary costache negri street opera center floor discussion room district bucharest romania gsk service ordinary grunwaldzka poznan poland gsk vaccine ordinary hullenbergweg amsterdam netherlands gsk vaccine gmbh ordinary emilvonbehringstr marburg germany gsk vaccines institute global health srl quota fiorentina siena italy gsk vaccines srl quota fiorentina siena italy gsk vaccines vertriebs gmbh ordinary rudolfdieselre holzkirchen germany hgs france sarl ordinary rue belle feuille boulognebillancourt france horlick limited ordinary preference great west road brentford middlesex england human genome sciences inc common corporation service company little fall drive wilmington delaware united states biomedical corporation quebec common boul parc technologique qubec canada instituto luso farmaco limitada ordinary quota rua antonio loureiro borge arquiparque miraflore alge portugal interpharma dienstleistungen gmbh quotas wagenseilgasse euro plaza gebude stock vienna austria technologies llc interest corporation service company shockoe slip floor richmond united states laboratoire glaxosmithkline ordinary rue franois jacob rueilmalmaison france laboratoire pharmaceutique algrien lpa production spa ordinary zone industrielle est boudouaou boumerde algeria laboratoire pharmaceutique algrien spa ordinary zone industrielle est boudouaou boumerde algeria laboratoires paucourt ordinary rue franois jacob rueilmalmaison france laboratoire saintgermain ordinary rue franois jacob rueilmalmaison france laboratorios dermatologico darier ordinary calzada mexico xochimilco san lorenzo huipulco district federal ordinary mexico mexico laboratorios farmaceuticos stiefel portugal ltda ordinary quota rua antonio loureiro borge arquiparque miraflore alge portugal laboratorios stiefel venezuela ordinary calle luis camoens edificio glaxosmithkline urb trinidad caracas venezuela laboratorios stiefel ltda ordinary rua professor joao cavalheiro salem bairro bonsucesso municipality guarulhos sao paulo cep brazil laboratorios wellcome portugal limitada ordinary quota rua antonio loureiro borge arquiparque miraflore alge portugal mixis genetic limit liquidation ordinary ordinary euro baker street london england montrose pharma company limited ordinary quota csorsz utca budapest hungary okairos liquidation common prefer preferred obc suisse aeschenvorstadt basel switzerland penn labs inc common corporation service company little fall drive wilmington delaware united states international ordinary van asch van wijckstraat amersfoort netherlands setfirst limit ordinary preference great west road brentford middlesex england sitari pharma inc common stock corporation service company little fall drive wilmington delaware united states smith kline french portuguesaprodutos farmaceuticos ordinary quota rua antonio loureiro borge arquiparque miraflore alge lda portugal smithkline beecham bangladesh private limited ordinary topkhana road segunbagicha dhaka bangladesh smithkline beecham cork limit ordinary riverwalk citywest business campus dublin ireland smithkline beecham manufacturing limit ordinary riverwalk citywest business campus dublin ireland smithkline beecham swg limit liquidation ordinary baker street london england smithkline beecham biological partnership partnership interest corporation service company little fall drive wilmington delaware united states smithkline beecham egypt llc quotas amoun street salam city cairo egypt smithkline beecham farma ordinary severo ochoa parque tecnologico madrid tres cantos madrid spain smithkline beecham interamerican corporation common corporation service company little fall drive wilmington delaware united states gsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue smithkline beecham limit ordinary great west road brentford middlesex england smithkline beecham overseas limit ordinary great west road brentford middlesex england smithkline beecham pension plan trustee limited ordinary great west road brentford middlesex england smithkline beecham pension trustee limit liquidation ordinary baker street london england smithkline beecham pharma gmbh partnership capital prinzregentenplatz munchen germany smithkline beecham pharma verwaltung gmbh ordinary prinzregentenplatz munchen germany smithkline beecham pharmaceuticals pty limited ordinary flush meadow build campus sloane street bryanston south africa smithkline beecham pharmaceutical common corporation service company little fall drive wilmington delaware united states smithkline beecham port louis limited liquidation ordinary cim corporate services ltd les cascade build edith cavell street port louis mauritius smithkline beecham senior executive pension plan trustee ordinary great west road brentford middlesex england limited stiefel distributor ireland limited liquidation ordinary finisklin business park sligo ireland stiefel dominicana srl ordinary ave lope vega torre novocentro local santo domingo dominican republic stiefel farma ordinary severo ochoa parque tecnologico madrid tres cantos madrid spain stiefel gmbh partnership capital prinzregentenplatz munchen germany stiefel india private limited equity wing floorfloral deck plaza opp rolta bhavan central midc road mumbai andheri india stiefel laboratory maidenhead ltd liquidation ordinary baker street london england stiefel laboratory legacy ireland limited ordinary unit build avenue cork airport business park cork ireland stiefel laboratory limited ordinary eurasia headquarters concorde road maidenhead berkshire england stiefel laboratory pte limited ordinary pioneer sector singapore stiefel laboratories inc common corporation service company little fall drive wilmington delaware united states stiefel maroc sarl ordinary boulevard zerktouni casablanca morocco stiefel research australia holdings pty ltd ordinary mountain highway boronia vic australia stiefel research australia pty ltd ordinary mountain highway boronia vic australia stiefel west coast llc llc interest corporation service company little fall drive wilmington delaware united states strebor inc common corporation service company little fall drive wilmington delaware united states tempero pharmaceuticals inc series preference corporation service company little fall drive wilmington series preference common delaware united states tesaro bio austria gmbh liqu liquidation common fleischmarkt vienna austria tesaro bio gmbh ordinary poststrasse zug switzerland tesaro bio netherlands shares joop geesinkweg amsterdamduivendrecht netherland tesaro bio spain slu sharesparticipation quota severo ochoa parque tecnolgico madrid tres cantos madrid spain tesaro bio sweden common bdo malardalen skatt box stockholm sweden tesaro development limit share clarendon house church street hamilton bermuda tesaro inc common corporation service company little fall drive wilmington delaware united states sydney ross common corporation service company princeton south corporate center suite charle ewing blvd ewe new jersey united states wellcome foundation investment company limit limited guarantee great west road brentford middlesex england active proposal strike ucb pharma asia pacific sdn bhd ordinary floor menara symphony jalan prof khoo kay kim seksyen petale jaya malaysia wellcome consumer healthcare limited ordinary great west road brentford middlesex england wellcome consumer product limited ordinary great west road brentford middlesex england wellcome developments pty ltd ordinary mountain highway boronia vic australia wellcome limited ordinary great west road brentford middlesex england wellcome operations pty ltd ordinary mountain highway boronia vic australia gsk pharma vietnam company limited charter capital unit floor metropolitan tower dong khoi street ben nghe ward district chi minh viet nam glaxosmithkline limit ordinary likoni road box nairobi kenya gsk consumer healthcare export limit great west road brentford middlesex england gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company continue effective security ownership register address subsidiary effective interest alacer corp common corporate service company dba csclawyers incorp gateway oak drive suite sacramento california united states amoun pharmaceutical industry sae new monetary share salam city box cairo egypt beecham enterprises inc common corporation service company little fall drive wilmington delaware united states biddle sawyer limited equity annie besant road mumbai india block drug company inc common corporation service company princeton south corporate center suite charle ewing blvd ewe new jersey united states block drug corporation common corporation service company princeton south corporate center suite charle ewing blvd ewe new jersey united states british pharma group limited captial great west road brentford middlesex england consumer healthcare holding limit ordinary great west road brentford middlesex england consumer healthcare intermediate holding limit ordinary great west road brentford middlesex england duncan consumer healthcare philippines inc common floor finance centre street corner avenue bonifacio global city taguig city philippines duncan pharmaceuticals philippines inc common floor finance centre street corner avenue bonifacio global city taguig city philippines exlax inc common prentice hall corporation system puerto rico inc fast solution llc citi tower ponce leon avenue floor san juan puerto rico ferrosan aps share share nykaer brondby denmark ferrosan international aps ordinary nykaer brondby denmark ferrosan srl register capital calea turzii clujnapoca cluj county romania galvani bioelectronics inc common corporation service company little fall drive wilmington delaware united states galvani bioelectronic limit ordinary ordinary great west road brentford middlesex england glaxo saudi arabia limit ordinary box area warehouse city stage khomrah jeddah saudi arabia glaxo wellcome ceylon limit ordinary ordinary galle road kaldemulla moratuwa sri lanka glaxosmithkline tianjin ltd ordinary fifth avenue tai feng industrial park tianjin economic technolog tianjin china glaxosmithkline algrie spa ordinary zone industrielle est boudouaou wilaya boumerdes algeria glaxosmithkline brasil produtos para consumo saude quota das america floor room rio janeiro ltda brazil glaxosmithkline consumer healthcare china ltd ordinary floor xizangzhong road huangpu district shanghai china glaxosmithkline consumer healthcare hong kong ordinary tower gateway canton road tsimshatsui kowloon limited hong kong glaxosmithkline consumer healthcare ireland limit ordinary riverwalk citywest business campus dublin ireland glaxosmithkline consumer healthcare overseas limit ordinary great west road brentford middlesex england glaxosmithkline consumer healthcare thailand limited ordinary floor unit wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline consumer healthcare limit ordinary great west road brentford middlesex england glaxosmithkline consumer healthcare trading ordinary great west road brentford middlesex england limited glaxosmithkline consumer healthcare llc llc interest corporation service company little fall drive wilmington delaware united states glaxosmithkline consumer healthcare ordinary nykaer brondby denmark glaxosmithkline consumer healthcare ordinary nykaer brondby denmark glaxosmithkline consumer healthcare australia pty ltd ordinary hughes avenue ermington nsw australia glaxosmithkline consumer healthcare ordinary van asch van wijckstraat amersfoort netherlands glaxosmithkline consumer healthcare colombia sa ordinary carrera piso colombia glaxosmithkline consumer healthcare czech republic sro ordinary hvezdova prague czech republic glaxosmithkline consumer healthcare finance limit ordinary great west road brentford middlesex england glaxosmithkline consumer healthcare finance ordinary great west road brentford middlesex england limited glaxosmithkline consumer healthcare finland ordinary piispansilta fin espoo finland glaxosmithkline consumer healthcare gmbh ordinary wagenseilgasse euro plaza gebude stock vienna austria glaxosmithkline consumer healthcare gmbh partnership capital barthstr mnchen germany glaxosmithkline consumer healthcare hellas single ordinary kifissias avenue halandri athens greece member societe anonyme gsk annual report statutory disclosure continue group company continue effective security ownership register address subsidiary effective interest continued glaxosmithkline consumer healthcare holding preference great west road brentford middlesex england limited glaxosmithkline consumer healthcare holding llc llc interest corporation service company little fall drive wilmington delaware united states glaxosmithkline consumer healthcare investment ordinary knockbrack dungarvan waterford ireland ireland limited iii liquidation glaxosmithkline consumer healthcare investment ordinary knockbrack dungarvan waterford ireland ireland unlimited company iii liquidation glaxosmithkline consumer healthcare japan ordinary akasaka minatoku tokyo japan glaxosmithkline consumer healthcare korea ltd ordinary yongsan tower hangangdaero yongsangu seoul korea republic glaxosmithkline consumer healthcare llc llc interest corporation service company interstate drive suite harrisburg pennsylvania united states glaxosmithkline consumer healthcare mexico ordinary calzada mexicoxochimilco colonia san lorenzo huipulco delegacion tlalpan mexico mexico glaxosmithkline consumer healthcare new zealand ulc ordinary level zurich house queen street auckland new zealand glaxosmithkline consumer healthcare norway ordinary drammensveien lysaker norway glaxosmithkline consumer healthcare pakistan limit ordinary syke building dockyard road west wharf karachi pakistan glaxosmithkline consumer healthcare philippines inc common floor finance centre street corner avenue bonifacio global city taguig city philippines glaxosmithkline consumer healthcare pte ltd ordinary rochester park singapore glaxosmithkline consumer healthcare ordinary site apollo avenue pascal wavre belgium glaxosmithkline consumer healthcare ordinary severo ochoa parque tecnologico madrid tres cantos madrid spain glaxosmithkline consumer healthcare srl ordinary zambeletti sncbaranzate milan italy glaxosmithkline consumer healthcare saudi limited ordinary salamah tower floor madinah road alsalamah district jeddah saudi arabia glaxosmithkline consumer healthcare sdn bhd ordinary lot jalan enggang ampangulu kelang industrial estate ampang selangor darul ehsan malaysia glaxosmithkline consumer healthcare slovakia ownership interest galvaniho bratislava slovakia glaxosmithkline consumer healthcare south africa ordinary flush meadow build campus sloane street bryanston pty ltd south africa glaxosmithkline consumer healthcare spzoo ordinary grunwaldzka poznan poland glaxosmithkline consumer healthcare srl ordinary costache negri street opera center floor zone district bucharest romania glaxosmithkline consumer healthcare ulc class preference burrard street suite bentall centre box glaxosmithkline soin sante aux consommateurs sri common vancouver canada glaxosmithkline consumer healthcare vietnam company charter capital floor metropolitan dong khoi ben nghe ward district limited chi minh city viet nam glaxosmithkline consumer healthcare partnership capital corporation service company little fall drive wilmington delaware united states glaxosmithkline consumer healthcare produto para ordinary quota rua antonio loureiro borge arquiparque miraflore alge saude higiene lda portugal glaxosmithkline consumer nigeria plc ordinary industrial avenue ilupeju ikeja lagos nigeria glaxosmithkline consumer private limited equity patiala road nabha dist patiala punjab india glaxosmithkline consumer trading service limit ordinary great west road brentford middlesex england glaxosmithkline costa rica ordinary san jose este rotonda betania carretera sabanilla costa rica glaxosmithkline dungarvan limit ordinary knockbrack dungarvan waterford ireland glaxosmithkline healthcare ordinary premise iii room floor presnenskaya nab moscow russian federation glaxosmithkline healthcare gmbh ordinary barthstr mnchen germany glaxosmithkline healthcare ukraine ooo ownership interest pavla tychyny avenue kiev ukraine glaxosmithkline pakistan limit ordinary syke building dockyard road west wharf karachi pakistan glaxosmithkline panama ordinary urbanizacion industrial juan calles republic panama panama glaxosmithkline paraguay ordinary oficial gilberto aranda planta alta casi salvador del mundo asuncion paraguay glaxosmithkline pharmaceuticals limited equity annie besant road mumbai india glaxosmithkline philippines inc common floor finance centre street corner avenue bonifacio global city taguig city philippines gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company continue effective security ownership register address subsidiary effective interest continue glaxosmithkline sae ordinary boomerang office building land zone district town center tagammoe new cairo city egypt glaxosmithkline sante grand public sas ordinary rue franois jacob rueilmalmaison france glaxosmithkline technology taizhou ltd ordinary room building phase new drug innovation base taizhou jiangsu province china glaxosmithkline tuketici sagligi anonim sirketi nominative bykdere caddesi levent plaza blok levent istanbul turkey glaxosmithklineconsumer hungary limited liability membership csorsz utca budapest hungary company gsk canada hold company limit ordinary great west road brentford middlesex england gsk kazakhstan llp charter capital manasa str bostandyk district almaty kazakhstan gsk consumer health inc common corporation service company little fall drive wilmington delaware united states gsk consumer healthcare holding inc common corporation service company little fall drive wilmington delaware united states gsk consumer healthcare holdings llc iii unit corporation service company little fall drive wilmington delaware united states gsk consumer healthcare israel ltd ordinary basel street petech tikva israel gsk consumer healthcare levice sro ordinary priemyselny park gena sachsa levice slovakia gsk consumer healthcare ordinary route prangin switzerland gsk consumer healthcare schweiz ordinary suurstoffi rotkreuz switzerland gsk consumer healthcare services inc common corporation service company little fall drive wilmington delaware united states gsk consumer healthcare singapore pte ltd ordinary rochester park singapore gsk consumer healthcare trinidad tobago limited ordinary floor algico plaza stvincent street port spain trinidad incorporate jan tobago gsk new zealand hold company limit ordinary great west road brentford middlesex england gskgebro consumer healthcare gmbh ordinary bahnhofbichl fieberbrunn kitzbhel austria iodosan spa ordinary zambeletti sncbaranzate milan italy kuhs gmbh ordinary barthstr mnchen germany laboratorios viiv healthcare ordinary severo ochoa parque tecnologico madrid tres cantos madrid spain modern pharma trading company llc quotas amoun street box salam city cairo egypt nch nutrition consumer health ltd ordinary hamephalsim petach tikva israel smithkline beecham pharmaceuticals shares share pulobuaran raya kav iii kawasan industri pulogadung jakarta indonesia sterling product indonesia share shares graha paramita build jalan denpasar raya blok jakarta indonesia panadol gmbh ordinary barthstr mnchen germany consumer healthcare llc membership interest corporation service company little fall drive wilmington delaware united states consumer healthcare class class van asch van wijckstraat amersfoort netherlands consumer healthcare brazil importadora distribuidora quota barueri avenida ceci block iii tambore district medicamentos ltda sao paulo brazil consumer healthcare canada ulc soin common burrard street suite bentall centre box sante sri vancouver canada consumer healthcare hold ordinary van asch van wijckstraat amersfoort netherlands consumer healthcare poland spzoo ordinary rzymowskiego street warsaw poland consumer healthcare singapore pte ltd ordinary rochester park singapore consumer ireland company limit ordinary riverwalk national digital park citywest business park dublin ireland consumer taiwan llc interests orange street corporate trust center wilmington delaware united states pfizer biotech corporation ordinary sec zhong xiao taipei taiwan pfizer consumer healthcare ordinary vetenskapsvagen sollentuna sweden pfizer consumer healthcare gmbh ordinary linkstrasse berlin germany pfizer consumer manufacturing italy srl quota stock nettunese aprilia prov latin italy pfizer laboratory pfe pty ltd common flush meadow build campus sloane bryanston south africa pfizer pfe colombia sas common carrera piso colombia phivco jersey limited iii dissolve dec ordinary ifc helier jersey united kingdom phivco jersey limited iii dissolve dec ordinary ifc helier jersey united kingdom gsk annual report statutory disclosure continue group company continue effective security ownership register address subsidiary effective interest continued phivco llc llc interest corporation service company little fall drive wilmington delaware united states phivco llc llc interest corporation service company little fall drive wilmington delaware united states prism pch limited voting share non vote great west road brentford middlesex england share glaxo wellcome indonesia share share pulobuaran raya kav iii kawasan industri pulogadung timur jakarta indonesia gsk consumer healthcare indonesia ordinary graha paramita build jalan denpasar raya blok kuningan jakarta selatan indonesia bina dentalindo liquidation ordinary gedung graha ganesha lantai raya bekasi jakarta timur indonesia shionogiviiv healthcare llc common interest corporation service company little fall drive wilmington delaware united states sinoamerican tianjin smith kline french laboratory ordinary cheng lin zhuang industrial zone dong district tianjin ltd china smithkline beecham private limited ordinary world trade center level west tower echelon square colombo sri lanka smithkline beecham research limit ordinary great west road brentford middlesex england smithkline beecham ordinary ctra ajalvir alcala henares madrid spain smithkline beechambiome ooo participation interest leningradskiy prospect build floor premise xiv room moscow russian federation staffordmiller ireland limit ordinary clocherane youghal road dungarvan waterford ireland staffordmiller limit liquidation ordinary baker street london united kingdom noncumulative non redeemable preference sterling drug malaya sdn berhad ordinary lot jalan enggangampang hulu kelang industrial estate selangor darul ehsan ampang malaysia sterling products international incorporate common corporation service company little fall drive wilmington delaware united states stiefel consumer healthcare limit ordinary great west road brentford middlesex england stiefel egypt llc quota amoun street box salam city cairo egypt stiefel laboratory ireland limit ordinary finisklin business park county sligo ireland treerly health ltd capital contribution unit room east zhujiang road tianhe district guangzhou city prc china viiv healthcare south africa proprietary limited ordinary flush meadow build campus sloane street bryanston south africa viiv healthcare ordinary van asch van wijckstraat amersfoort netherlands netherlands viiv healthcare company common corporation service company little fall drive wilmington delaware united states viiv healthcare finance limit liquidation ordinary baker street london england viiv healthcare finance limit ordinary great west road brentford middlesex england viiv healthcare finance limit ordinary redeemable great west road brentford middlesex england preference viiv healthcare gmbh ordinary prinzregentenplatz munchen germany viiv healthcare gmbh ordinary talstrasse muenchenbuchsee switzerland viiv healthcare hong kong limited ordinary tower gateway canton road harbour city tsimshatsui kowloon hong kong viiv healthcare ordinary akasaka minatoku tokyo japan viiv healthcare limited class share defer great west road brentford middlesex england class share class share class class class cumulativepreference viiv healthcare pty ltd ordinary mountain highway boronia vic australia viiv healthcare puerto rico llc llc interest centro international mercadeo carr torre suite guaynabo puerto rico viiv healthcare srl quota viale dellagricoltura verona italy viiv healthcare sas ordinary rue franois jacob rueilmalmaison france viiv healthcare sprl ordinary site apollo avenue pascal wavre belgium viiv healthcare trading llc participation interest leningradskiy prospect build floor premise xiv room moscow russian federation gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company continue effective security ownership register address subsidiary effective interest continued viiv healthcare trading service limit ordinary great west road brentford middlesex england viiv healthcare limited liquidation ordinary ifc helier jersey united kingdom viiv healthcare limit ordinary great west road brentford middlesex england viiv healthcare limit ordinary great west road brentford middlesex england viiv healthcare limit ordinary great west road brentford middlesex england viiv healthcare limit ordinary great west road brentford middlesex england viiv healthcare limit ordinary great west road brentford middlesex england viiv healthcare ulc common street calgary canada viiv healthcare venture llc llc interest corporation service company little fall drive wilmington delaware united states viivhiv healthcare unipessoal lda quota rua antonio loureiro borge arquiparque miraflore alge portugal vog pty ltd ordinary redeemable hughe avenue ermington nsw australia preference winster pharmaceutical limited ordinary association avenue ilupeju industrial estate lago box nigeria wyeth consumer healthcare llc membership interest corporation system suite harrisburg pennsylvania united states wyeth pharmaceutical ltd register capital baodai west road suzhou jiangsu province china wyeth pharmaceutical company vii capital contribution state road kilometer guayama puerto rico associates apollo therapeutics llp partnership interest stevenage bioscience catalyst gunnel wood road stevenage hertfordshire england glaxosmithkline landholding company inc common chino roce avenue city makati philippines index ventures life jersey partnership interest esplanade helier jersey channel islands innoviva inc common share old bayshore highway suite burlingame united states kurma biofund fcpr partnership interest rue royale paris france longwood fund partnership interest prudential tower suite boylston street boston medicxi ventures partnership interest esplanade helier jersey channel island joint ventures chiron panacea vaccines private limited equity share floor wing sagar tech plaza saki naka andheri east mumbai maharashtra india qualivax pte limit ordinary robinson road singapore quell intellectual property corp llc membership interest corporation service company little fall drive wilmington delaware united states qura therapeutics llc unit corporation service company little fall drive wilmington delaware united states significant shareholding axon therapy inc common share coridea llc west street new york delaware series preference usa gladius pharmaceuticals corporation series share boulevard west cartier quest laval global farm share cazadore coquimbo piso munro argentina shares share share share shares longwood fund partnership interest prudential tower suite boylston street boston neuspera medical inc series preference daggett san jose united states series preference sanderle venture vii partnership interest camino real suite san mateo capital fund partnership interest corporation service company little fall drive city wilmington county new castle delaware vhsquare limited series preference shares copley hill farm cambridge babraham cambridge united kingdom gsk annual report statutory disclosure continue group company continue follow subsidiary advantage audit exemption set section company act period end december state undertaking list own directly indirectly glaxosmithkline plc company security register address number register subsidiary exempt audit burrough wellcome international limited ordinary great west road brentford middlesex england cellzome limited ordinary great west road brentford middlesex england clarge pharmaceutical limit ordinary preference great west road brentford middlesex england domantis limit ordinary great west road brentford middlesex england edinburgh pharmaceutical industry limit ordinary preference shewalton road irvine ayrshire scotland eskaylab limited ordinary great west road brentford middlesex england glaxo wellcome limit ordinary great west road brentford middlesex england glaxochem unlimite ordinary ordinary great west road brentford middlesex england ordinary glaxosmithkline consumer healthcare limit ordinary great west road brentford middlesex england glaxosmithkline consumer healthcare sri lanka holdings ordinary great west road brentford middlesex england limited glaxosmithkline intellectual property limit ordinary great west road brentford middlesex england glaxosmithkline intellectual property limit ordinary great west road brentford middlesex england glaxosmithkline intellectual property limit ordinary great west road brentford middlesex england glaxosmithkline international limited ordinary great west road brentford middlesex england gsk consumer healthcare export limit ordinary great west road brentford middlesex england gsk limited ordinary great west road brentford middlesex england gsk new zealand hold company limit ordinary great west road brentford middlesex england montrose fine chemical company ltd ordinary shewalton road irvine ayrshire scotland consumer healthcare limit ordinary great west road brentford middlesex england phivco limited ordinary great west road brentford middlesex england phivco limit ordinary great west road brentford middlesex england smith kline french laboratory limit ordinary great west road brentford middlesex england smithkline beecham export limit ordinary great west road brentford middlesex england smithkline beecham limited noncumulative great west road brentford middlesex england nonredeemable ordinary smithkline beecham investment limit ordinary great west road brentford middlesex england smithkline beecham marketing technical service ordinary great west road brentford middlesex england limited smithkline beecham nominee limit ordinary great west road brentford middlesex england stiefel laboratory ltd ordinary eurasia headquarters concorde road maidenhead berkshire england tesaro limited ordinary baker street london england wellcome foundation limit ordinary great west road brentford middlesex england viiv healthcare overseas limited ordinary great west road brentford middlesex england company effective ownership viiv healthcare overseas limited phivco limited phivco limited company effective ownership glaxosmithkline consumer healthcare limited glaxosmithkline consumer healthcare sri lanka holdings limited gsk consumer healthcare export limited gsk new zealand hold company limited accordance section company act company guarantee debt liability subsidiary undertaking december total sum debt liabilitie million million key directly own glaxosmithkline plc ormant entity iii resident entity expect disposed remove incorporate sweden consolidated subsidiary accordance section company act ground dominant influence vii principal business address puerto rico viii exempt provision regulation partnership account regulation accordance exemption note regulation regulation incorporate netherlands gsk annual report strategic report governance remuneration financial statement investor information glossary term term annual report equivalent brief description accelerate capital allowance tax allowance excess depreciation arise purchase fix asset delay charge payment tax equivalent tax depreciation american depositary receipt adr receipt evidence title ad gsk adr represent ordinary share american depositary share ad list new york stock exchange represent ordinary share basic earning share basic income share call share capital ordinary share issue fully pay cer growth growth constant exchange rate company glaxosmithkline plc currency swap exchange currency couple subsequent reexchange currency agree exchange rate date define benefit plan pension plan specific employee benefit call final salary scheme define contribution plan pension plan specific contribution level pension dependent growth pension fund derivative financial instrument financial instrument derives value price rate underlie item dilute earning share diluted income share employee share ownership plan trust trust establish group satisfy sharebase employee incentive plan equity shareholder fund shareholder equity finance lease capital lease freehold ownership absolute right perpetuity group glaxosmithkline plc subsidiary undertakings gsk glaxosmithkline plc subsidiary undertaking hedging reduction risk normally relation foreign currency interest rate movement make offset commitment intangible fix asset asset physical substance computer software brand licence patent knowhow marketing right purchase outside party novartis transaction threepart interconditional transaction novartis involve consumer healthcare vaccine oncology business complete march ordinary share fully pay ordinary share capital company profit income profit attributable shareholder net income share capital ordinary share capital stock common stock issue fully pay share option stock option share premium account additional paidup capital paidin surplus distributable share issue number share outstanding subsidiary entity gsk exercise control treasury share treasury stock turnover revenue corporate governance code require list authority company disclose annual report apply good practice corporate governance provision financial reporting council corporate governance code gsk annual report index remuneration policy summary investor relation accounting principle policy key accounting judgement estimate acquisition disposal key performance indicator adjustment reconcile profit tax operate legal proceeding cash flow major restructuring cost affordability availability modern employer annual general meeting movement equity approach tax net debt asset hold sale new accounting requirement associate joint ventures nomination committee report audit risk committee report noncontrolle interest business model noncontrolle interest viiv healthcare cash cash equivalent nonexecutive director fee cash generation conversion nonfinancial information statement ceo statement note financial statement chairman statement operate profit chairman governance statement intangible asset chairman remuneration annual statement investment climaterelate financial disclosure noncurrent asset commitment noncurrent liability consolidate balance sheet operating incomeexpense consolidate cash flow statement provision consolidate income statement culture consolidate statement change equity longterm priority consolidate statement comprehensive income pension postemployment benefit consumer healthcare performance consumer healthcare product competition pharmaceutical contingent consideration liability pharmaceutical product competition contingent liability intellectual property corporate executive team pipeline corporate governance post balance sheet event corporate responsibility committee report presentation financial statement critical accounting policy principal group company datum engagement principal risk uncertaintie director senior management property plant equipment director interest share quarterly trend director report reconciliation net cash flow movement net debt director statement responsibility registrar dividend relate party transaction donation political organisation reliable supply political expenditure remuneration governance earning share remuneration report employee cost report framework employee share scheme responsible business environment right use asset ethic value risk management exchange rate science technology finance expense science committee report finance income section statement financial calendar share capital control financial instrument relate disclosure share capital share premium account financial performance shareholder information financial position resource shareholder service contact financial statement glaxosmithkline plc prepare stakeholder engagement gaap taxation year record tax information shareholder glossary term board goodwill trade payable group company trade receivable group financial review transformation separation committee report impact brexit treasury policy independent auditor report trust industry trend turnover segment information innovation law regulation inventory vaccine investment associate joint venture vaccine product competition intellectual property viability statement gsk annual report gsk glaxosmithkline plc incorporate english brand name brand name appear italic report public limited company december trade mark own andor license gsk associate company trade mark form merger glaxo wellcome plc property respective owner smithkline beecham plc gsk acquire acknowledgement print english company december print sustainably pureprint carbonneutral company fsc chain custody iso merger arrangement certify environmental management system recycle dry waste share list london stock exchange paper print innovation premium fsc certify paper new york stock exchange pulp totally chlorine free manufacturing mill iso environmental management certification mill energy produce biomass fuel source local forestry read wwwgskcom fossil fuel carbon emission measure offset world land trust carbon balanced scheme download pdfs nnual report orm cautionary statement factor include limit discuss group guidance assume successful delivery forwardlooke statement principal risk uncertaintie page group integration restructuring plan assume group report file furnish annual report impact integration investment programme follow securities exchange commission sec include covid pandemic forwardlooke statement creation consumer healthcare joint venture document write information release behalf group speak pfizer deliver successfully material cost oral statement public future date base knowledge investment new product launch behalf group contain forwardlooke information available director date factor expectation give give potential statement forwardlooke statement group annual report development option group pipeline outlook eyr yse dtn wap loe dlt stt jsn ecy tco thc bis pot iie ecn etv nefs tct tone amb soo sif pou dro ero sfie tsd anh fea ntacy oni csa eut mgiy aid rge esd nai hda dul tea het gond uror arg odfi vnv eae nts nce word term similar meaning connection information document constitute constant currency basis discussion future operate financial offer sell invitation buy share glaxosmithkline notice limitation performance particular include statement plc invitation inducement engage director liability english law relate future action prospective product product investment activity past performance rely approval future performance result current guide future performance company act safe harbour limit anticipated product sale effort expense annual report construe profit forecast liability director respect statement outcome contingency legal proceeding omission director report dividend payment financial result assumption relate guidance strategic report remuneration report accordance legal regulatory obligation outline guidance group english law director liable include market abuse regulation certain assumption healthcare sector company party list rule disclosure transparency different market group operate report contain error result recklessness rule financial conduct authority group delivery revenue financial benefit current know misstatement dishonest concealment undertake obligation update forwardlooke portfolio pipeline restructuring programme material fact liable page statement result new information future inclusive comprise event reader consult group planning assumption director report page inclusive comprise additional disclosure group healthcare system consumer trend approach strategic report page inclusive comprise document publish andor file sec normality second half year expect remuneration report draw reader locate note turnover flat low single digit growth present accordance reliance disclosure accordingly assurance give pharmaceutical vaccine business low english company law liabilitie director particular expectation meet investor midsingle digit growth consumer healthcare exclude connection report shall subject caution place undue reliance forward brand divestedunder review planning assumption limitation restriction provide law look statement mll mar ias inu run svi gat website forwardlooke statement subject assumption product material merger acquisition disposal gsk website wwwgskcom give additional information inherent risk uncertaintie relate material litigation investigation cost company group notwithstanding reference factor group control precise save recognise annual report gsk website estimate group caution investor number provision share repurchase information available website constitute important factor include document company change group shareholding annual report shall deem cause actual result differ materially viiv healthcare assumption assume material incorporate reference express imply forwardlooke statement change healthcare environment guidance factor divestment product exit announce date include product divestment plan connection formation consumer healthcare joint venture pfizer noncore divestment plan fund cash cost separation preparation restructuring programmefront cover technology help find pattern genetic datum fast combine genetic tool like functional genomic artificial intelligence help understand cause disease help double success rate new treatment intervention image create anonymised realworld clinical trial datum format produce visualisation unexpected natural grouping pattern dataset new insight patient well respond new medicine search head office register office glaxosmithkline plc great west road brentford middlesex united kingdom tel register number wwwgskcom